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Abstract 
The studies contained in this thesis highlight key issues relating to knowledge, psychological 
aspects and quality of life among newly anticoagulated atrial fibrillation (AF) patients. In 
addition, it also included objective measures of the quality of vitamin K antagonist (VKA) 
therapy among atrial fibrillation and operated valvular heart disease (VHD) patients on long 
term VKA therapy. Three studies were conducted in separate cohorts to achieve these 
objectives. 
Study 1 (TREAT-2) examined self-report assessment of depression, anxiety, beliefs about 
medication and knowledge of AF, and quality of life among 139 newly anticoagulated AF 
patients at baseline and 105 patients at six months follow up. Findings suggest that patients 
appear to have low levels of depression and anxiety and had positive beliefs about medication. 
However, AF knowledge and quality of life was poor. These findings remained unchanged at 
6 months follow up. Nevertheless, more patients were aware of AF consequences and had 
improvements in AF symptoms. 
Study 2 (TTR in relation to ethnicity) investigated objective measures and predictors of quality 
of anticoagulation control (time in therapeutic range, TTR) and adverse clinical outcomes in 
991 AF patients on VKA therapy over 5.2 years. TTR was compared among patients in 
different ethnic groups, elderly (≥80 vs. <80 years), and patients with different categories of 
kidney disease (eGFR≥90 vs. 60-89 vs. ≤59ml/min/1.73m2). TTR was significantly lower in 
South-Asians [60.5% (95% CI 58.0-63.0)] and Afro Caribbeans [61.3% (95% CI 58.2-64.4)] 
compared to Whites [67.9% (95% CI 67.1-68.8); p<0.001] despite similar INR monitoring 
intensity. No significant difference in TTR was seen among the elderly or patients with different 
categories of kidney disease within this cohort. Non-white ethnicity was the strongest 
independent predictor of poor TTR after adjusting for demographics and clinical variables [OR 
2.62 (95% CI 1.67-4.10); p<0.001].  
Study 3 (TTR in operated VHD) examined TTR, predictors and adverse clinical outcomes 
among 456 operated VHD patients with and without AF over 6.2 years. Results showed that 
TTR was significantly poorer in operated VHD patients with AF (TTR 55.7%) compared to 
those without AF (TTR 60.1%; p=0.002). Independent predictors of poor TTR included female 
sex, AF and anaemia/bleeding history.  
Findings from Study 1 suggest that among newly anticoagulated AF patients, improvements 
are needed in AF knowledge.  Although their quality of life is reduced, they were not anxious 
or depressed and they hold positive beliefs about their medication. Interventions (educational 
 
 
2 
and motivational) are required so that enhancements in knowledge and quality of life can be 
achieved among newly anticoagulated AF patients. Studies 2 and 3 indicate that good 
anticoagulation control is more difficult to achieve in non-white AF patients and operated VHD 
patients with AF, respectively. This suggests that more frequent INR checks and closer 
examination of the individual reasons for poor anticoagulation among these patients is 
required to improve quality of anticoagulation control so that adverse events can be prevented. 
The findings and conclusions provide a platform for future research to develop interventions 
to improve quality of life among anticoagulated AF patients and to improve INR control, 
particularly among ethnic minority patients with AF and those with VHD.  
 
 
3 
Publications arising from thesis 
Papers 
1. Zulkifly H, Lip GY, Lane DA. Bleeding Risk Scores in Atrial Fibrillation and Venous 
Thromboembolism. Am J Cardiol 2017; 120 (7): 1139-1145 
2. Zulkifly H, Lip GY, Lane DA. Use of the SAMe-TT2R2 score to predict anticoagulation 
control in atrial fibrillation and venous thromboembolism patients treated with vitamin 
K antagonists: A review. Heart Rhythm. 2018; 15 (4): 615-623  
3. Zulkifly H, Lip GY, Lane DA. Epidemiology of AF. Int J Clin Pract. 2018; 73 (3): 
e13070.    
Abstracts 
1. Zulkifly H, Cheli P, Lutchman I, Bai Y, Lip GYH, Lane DA. Quality of and predictors of 
anticoagulation control among multi ethnic cohorts receiving VKA therapy for stroke 
prevention in atrial fibrillation: Heart Rhythm Congress, Birmingham, UK, 8 October 
2018 [Poster] 
2. Zulkifly H, Cheli P, Lutchman I, Bai Y, Lip GYH, Lane DA. Anticoagulation control in 
elderly AF patients receiving vitamin K antagonists for stroke prevention in atrial 
fibrillation: the West Birmingham AF Project: European Society of Cardiology, Munich, 
Germany, 27 August 2018 [Poster] 
3. Zulkifly H, Cheli P, Lutchman I, Bai Y, Lip GYH, Lane DA. Anticoagulation control in 
different ethnic-minority patients receiving vitamin K antagonists for stroke prevention 
in atrial fibrillation: the West Birmingham AF Project: Festival of Graduate Research, 
University of Birmingham, UK, 10 April 2018 [Poster] 
4. Zulkifly H, Cheli P, Lutchman I, Bai Y, Lip GYH, Lane DA. Anticoagulation control in 
different ethnic-minority patients receiving vitamin K antagonists for stroke prevention 
in atrial fibrillation: the West Birmingham AF Project: Midlands Cardiovascular 
Scientific Meeting, University of Leicester, 23 November 2017 [Poster] 
5. Zulkifly H, Cheli P, Lutchman I, Bai Y, Lip GYH, Lane DA. Anticoagulation control in 
different ethnic-minority patients receiving vitamin K antagonists for stroke prevention 
in atrial fibrillation: the West Birmingham AF Project. European Society of Cardiology, 
Barcelona, Spain 28 August 2017 [Poster] 
6. Zulkifly H. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial 
fibrillation and venous thromboembolism patients treated with vitamin K antagonists: 
A review. MySecon, London, 14th May 2017 [Poster] 
 
 
4 
Dedication  
I dedicate this thesis to my husband, Naza and my two daughters, Raina and Raisha. 
 
 5 
Acknowledgements  
I would like to say a very-very big thank you (‘terima kasih’) to both of my supervisors, Dr 
Deirdre Lane and Professor Gregory Lip for their guidance, patience and support over the past 
three years of my PhD journey. This would not have been possible without you. 
I am grateful to the staff of the Anticoagulant Clinic, Sandwell and West Birmingham Hospitals 
and University Hospital Birmingham for being very helpful and cooperative whilst I was 
recruiting patients from their clinics. Also, for giving me access to their anticoagulation 
management software to identify patients needed for all my studies. Not to forget to all the 
patients who participated in the TREAT-2 study, staff, doctors, nurses and others who helped 
me at the AF clinic. A big thank-you to you all.  
Special thanks to my friends whom I’ve met along this journey: Paola, Marco, Daniele, Ivana, 
Maria, Josemy, Reem, Mazaya, Aeron, Kazuo, and Amy. You have been incredible in giving 
me support, strength and motivation to finish this work.  
A very big thank you to my family, mum, dad, Hanani, Faiz, Faizal and Naufal for coming all 
the way from Malaysia for emotional support and inspiring me to persist in difficult times. To 
mom and dad, a very big thank you for keeping me in your prayers and always believing in 
me. To dad, special thanks for inspiring me to write in a better way. You have always been my 
strength. To Aunt Misbah, a very special thank you for always being there for me, right from 
the beginning until the end. You have supported me all the way and encouraged me to 
persevere throughout my ups and downs.  
Not to forget, a very big thank you to my sponsors, Universiti Teknologi MARA and 
Kementerian Pendidikan Tinggi for funding my PhD study as well as my family here in the UK. 
Last but not least, to my lovely husband, Naza and my two daughters, Raina and Raisha. A 
very-very big thank you to you all for being with me throughout this journey. You have been 
very patient with me, my shoulder to cry on and my pillar of strength! Thank you for your 
sacrifices, your prayers, your support and for keeping me sane! I could have not made it 
without you. 
 
 6 
List of tables 
Table 1.1: Incidence and prevalence of AF and AF- associated mortality rate with 95% 
uncertainty intervals (UI) (per 100,000) for males and females (data extracted from Chugh 
2014) (1) ............................................................................................................................. 19 
Table 1.2: Worldwide prevalence of AF by continent........................................................... 22 
Table 1.3: Prevalence of AF by ethnicity and race .............................................................. 26 
Table 1.4: Patterns of atrial fibrillation (taken directly from ESC guideline 2016) ................. 34 
Table 1.5: Modified European Heart Rhythm Association symptom scale (38).................... 35 
Table 1.6: Comorbid conditions/risk factors associated with AF (38) ................................... 35 
Table 1.7: Adjusted-dose warfarin versus placebo or no treatment, taken directly from Hart 
2007 (117) .......................................................................................................................... 46 
Table 1.8: Pharmacokinetics of warfarin versus NOACs and baseline characteristics for four 
randomised controlled trial cohorts comparing warfarin versus NOACs .............................. 48 
Table 1.9: Baseline characteristics of the four randomised controlled trial cohorts comparing 
warfarin versus NOACs ...................................................................................................... 48 
Table 1.10: Efficacy outcomes in the four major randomised controlled trials comparing 
warfarin versus NOACs in AF populations .......................................................................... 49 
Table 1.11: Safety outcomes in the four major randomised controlled trials comparing warfarin 
versus NOACs in AF populations ........................................................................................ 50 
Table 1.12: Meta-analysis of real word studies comparing dabigatran, rivaroxaban and 
apixaban to warfarin for efficacy and safety outcomes [from Ntaios et al(136)] ................... 52 
Table 1.13: Risk factors in stroke risk stratification schemes, updated from Lip et al 2015 (141)
 ........................................................................................................................................... 56 
Table 1.14: CHA2DS2-VASc score components .................................................................. 57 
Table 1.15: CHA2DS2-VASc score and thromboembolic risk taken directly from Lip et al from 
the European Heart survey (146)  and SPORTIF III and IV trial (147) ................................. 57 
Table 1.16: Guideline recommendations for stroke prevention in AF .................................. 60 
Table 1.17: Risk factors for bleeding included in each bleeding risk score .......................... 66 
Table 1.18: Baseline patient characteristics of the derivation cohorts for each bleeding risk 
score ................................................................................................................................... 68 
Table 1.19: Characteristics of the Derivation and Validation cohorts for each of the bleeding 
risk scores and composition of each score .......................................................................... 70 
Table 1.20: Risk factors, risk categories and bleeding events in the validation cohorts ....... 72 
Table 1.21: Demographic and clinical factors affecting anticoagulation control ................... 78 
Table 1.22: Non-clinical factors affecting anticoagulation control ........................................ 79 
 7 
Table 1.23: Major studies reporting anticoagulation control in different ethnic groups ......... 85 
Table 1.24: Scores to predict anticoagulation control .......................................................... 88 
Table 1.25: Mean TTR% in studies validating the SAMe-TT2R2 score................................. 95 
Table 1.26: Models of care and anticoagulation control and/or clinical events .................. 100 
Table 1.27: Studies assessing the SAMe-TT2R2 score in atrial fibrillation cohorts ............. 103 
Table 1.28: Baseline characteristics of all studies assessing the SAMe-TT2R2 score in AF 
population ......................................................................................................................... 106 
Table 1.29:  Predictive ability (C-statistics) of SAMe-TT2R2 for anticoagulation control and 
clinical events ................................................................................................................... 112 
Table 1.30: Classification of AF patients with valvular heart disease [taken directly from (356, 
358)] ................................................................................................................................. 113 
Table 1.31:Target INR values for VKA among patients with prosthetic valves [taken directly 
from (358, 368)] ................................................................................................................ 116 
Table 2.1: Components of the TREAT intervention ........................................................... 127 
Table 2.2: Baseline demographics and clinical characteristics of newly anticoagulated AF 
patients stratified by the SAMe-TT2R2 score ..................................................................... 143 
Table 2.3: Baseline and 6 months follow up psychological measures of AF patients overall and 
according to OAC groups (warfarin vs. NOACs) ............................................................... 147 
Table 2.4: Changes in psychological measures between baseline and 6 months follow up 
among overall AF patients (N=105) .................................................................................. 148 
Table 2.5: Baseline and 6 months follow up knowledge scale of AF patients overall and 
according to OAC groups (warfarin vs. NOACs) ............................................................... 153 
Table 2.6: Change in knowledge scale between baseline and 6 months follow up among 
overall AF patients (N=105) .............................................................................................. 153 
Table 2.7: Specific questions in the AF knowledge scale and percentages of patients with 
correct response at baseline and 6 months follow up (N=105) .......................................... 154 
Table 2.8: Baseline and 6 months follow up scores on beliefs about medication of AF patients 
overall and according to OAC groups (warfarin vs. NOACs) ............................................. 157 
Table 2.9: Change in score on beliefs about medication between baseline and 6 months follow 
up among overall AF patients (N=105).............................................................................. 158 
Table 2.10: Baseline and 6 months follow up quality of life scores of AF patients overall and 
according to OAC groups (warfarin vs. NOACs) ............................................................... 160 
Table 2.11: Change in quality of life scores between baseline and 6 months follow up among 
overall AF patients (N=105) .............................................................................................. 161 
Table 3.1: CHA2DS2-VASc, HAS-BLED, and SAMe-TT2R2 scores .................................... 177 
Table 3.2: Categories of chronic kidney disease from the NICE guidelines (424) .............. 180 
 8 
Table 3.3: Baseline characteristics of the study population overall and stratified by ethnicity 
and age (≥80 vs. <80 years) ............................................................................................. 186 
Table 3.4: Distribution of patients in the current cohort according to the categories of kidney 
disease, N=974 ................................................................................................................. 190 
Table 3.5: Baseline characteristics of overall population with eGFR results and according to 
three categories of kidney disease .................................................................................... 192 
Table 3.6: Measures of anticoagulation control overall and by ethnic group ...................... 197 
Table 3.7: Measures of anticoagulation control among overall population and in patients aged 
≥80 and <80 years ............................................................................................................ 200 
Table 3.8: Measures of anticoagulation control among different categories of kidney disease, 
N=974 ............................................................................................................................... 203 
Table 3.9: Unadjusted demographic and clinical predictors of time in therapeutic range (TTR) 
by the Rosendaal method (linear regression) .................................................................... 206 
Table 3.10: Adjusted demographic and clinical predictors of time in therapeutic range (TTR) 
by the Rosendaal method (linear regression) .................................................................... 207 
Table 3.11: Unadjusted demographic and clinical predictors of percentage of INRs in range 
using the PINRR method (linear regression) ..................................................................... 208 
Table 3.12: Adjusted demographic and clinical predictors of percentage of INRs in range using 
the PINRR method (linear regression) .............................................................................. 209 
Table 3.13: Logistic regression for significant predictors of TTR<70% and PINRR <70% (using 
Rosendaal and PINRR methods) ...................................................................................... 210 
Table 3.14: Major adverse clinical outcomes among patients receiving warfarin for stroke 
prevention for AF overall and by ethnic group ................................................................... 212 
Table 3.15: Patients experiencing a major adverse clinical event stratified by TTR (<70% vs. 
≥70% and <65% and ≥65%) ............................................................................................. 213 
Table 3.16: Patients experiencing a major adverse clinical event stratified by PINRR (<70% 
vs. ≥70% and <65% and ≥65%) ........................................................................................ 214 
Table 3.17: Cox proportional hazard regression analysis for thromboembolic, bleeding events, 
CV hospitalisations and composite outcomes of thromboembolic events, major bleed and 
clinically relevant non-major bleeding, cardiovascular hospitalisation and all-cause mortality 
(≥1 MACE) ........................................................................................................................ 217 
Table 3.18: Major adverse clinical outcomes among patients receiving warfarin for stroke 
prevention in AF overall and in patients ≥80 and <80 years .............................................. 220 
Table 3.19: Cox proportional hazard regression analysis for the impact of age (≥80 years) on 
all bleeding events, including major bleeding and clinically relevant non-major bleeding and 
≥1 MACE .......................................................................................................................... 221 
 9 
Table 3.20: Major adverse clinical outcomes among patients receiving warfarin for stroke 
prevention in AF overall and by different categories of kidney disease ............................. 222 
Table 4.1: Baseline characteristics of patients with operated valvular heart disease, with and 
without AF ......................................................................................................................... 248 
Table 4.2: Measures of anticoagulation control of patients with operated valvular heart 
disease, with and without AF ............................................................................................ 252 
Table 4.3: Measures of anticoagulation control of patients according to different target INRs
 ......................................................................................................................................... 255 
Table 4.4: Demographics and clinical characteristics associated with predictors of poor TTR 
(<70%), in univariate analysis among patients with operated valvular heart disease, with and 
without AF ......................................................................................................................... 257 
Table 4.5: Models of predictors of poor TTR (<70%) in the overall cohort of patients with 
operated valvular heart disease ........................................................................................ 259 
Table 4.6: Adverse clinical outcome among patients with operated valvular heart disease, with 
and without AF .................................................................................................................. 261 
Table 4.7: Adverse clinical outcome vs. TTR among patients with operated valvular heart 
disease, with and without AF ............................................................................................ 263 
  
 10 
List of figures 
Figure 1.1: AF associated mortality stratified by sex and region (developed and developing 
countries) ............................................................................................................................ 20 
Figure 1.2: Prevalence of AF by country ............................................................................. 24 
Figure 1.3: ABC pathway [taken directly from Lip 2016 (90)] ............................................... 39 
Figure 1.4: NICE-AF care management pathway taken from NICE-AF guideline 2014 (91, 92)
 ........................................................................................................................................... 40 
Figure 1.5: European Society of Cardiology integrated pathway adapted from the ESC AF 
Guidelines 2016 (3) ............................................................................................................ 41 
Figure 1.6: Mean TTR% among studies that validated the SAMe-TT2R2 score.................... 97 
Figure 1.7: Mean TTR vs. SAMe-TT2R2 categories in validation studies ........................... 108 
Figure 1.8: Predictive ability (C-statistics and 95% confidence intervals) of SAMe-TT2R2 
towards anticoagulation control in validation studies ......................................................... 111 
Figure 2.1: Study design and patient selection flow chart .................................................. 133 
Figure 2.2: Flowchart of patient’s inclusion and follow-up in the study .............................. 142 
Figure 2.3: Mean/median score at baseline and 6 months follow up for depression, anxiety, 
knowledge of AF, beliefs about medication and quality of life among overall AF patients who 
completed the questionnaire at both time points (N=105) ................................................. 149 
Figure 2.4: GAD-7 scores in categories among overall AF patients at baseline and 6 months 
follow up (N=105).............................................................................................................. 150 
Figure 2.5: PHQ-9 scores in categories among overall AF patients at baseline and 6 months 
follow up (N=105).............................................................................................................. 150 
Figure 2.6: Major depression (PHQ-9 ≥15) and generalised anxiety disorder (GAD-7≥10) 
among overall AF patients at baseline and 6 months follow up (N=105) ........................... 151 
Figure 2.7: Proportion of AF patients with correct answers in each specific question at baseline 
and 6 months follow up (N=105) ....................................................................................... 155 
Figure 2.8: Quality of life domain scores assessed by the AFEQT questionnaire in AF patients 
overall at baseline and 6 months follow up (N=105) .......................................................... 162 
Figure 3.1: Study design and patient selection flow chart .................................................. 176 
Figure 3.2: Measures of anticoagulation control (including TTR by Rosendaal and PINRR 
method) by ethnicity .......................................................................................................... 198 
Figure 3.3: Percentage of patients by ethnic group with a therapeutic (TTR≥70%) TTR by the 
Rosendaal and PINRR method ......................................................................................... 198 
Figure 3.4: Percentage of INRs within therapeutic range (PINRR), and below (INR<2.0) and 
above ................................................................................................................................ 199 
Figure 3.5: Percentage of patients with an INR >5.0 and >8.0 .......................................... 199 
 11 
Figure 3.6: Mean percentage TTR and PINRR and number of visits among patients aged ≥ 80 
and <80 years ................................................................................................................... 201 
Figure 3.7: Measures of anticoagulation control in different categories of kidney disease . 204 
Figure 3.8: The proportion of INRs within, below and above therapeutic range in different 
categories of kidney disease ............................................................................................. 204 
Figure 3.9: Impact of TTR on cardiovascular hospitalization ............................................. 218 
Figure 3.10: Impact of TTR on composite endpoints of thromboembolic events, major and 
clinically relevant non-major bleeding events, cardiovascular hospitalisation and all-cause 
mortality (≥1 MACE).......................................................................................................... 218 
Figure 3.11: Kaplan-Meier curve of bleeding events among patients age ≥80 and <80 years
 ......................................................................................................................................... 221 
Figure 4.1: Study design and patient selection flow chart .................................................. 243 
Figure 4.2: Percentage of patients with optimal TTR/PINRR among operated valvular heart 
disease patients with and without AF ................................................................................ 253 
Figure 4.3: Percentage of INRs within range, below the range and above the range among 
operated valvular heart disease, with and without AF ....................................................... 254 
Figure 4.4: Percentage of patients with INRs>5.0 and INRs >8.0 among operated valvular 
heart disease, with and without AF ................................................................................... 254 
Figure 4.5: Kaplan-Meier curves among operated VHD patients stratified by the presence of 
AF for all-cause mortality .................................................................................................. 262 
Figure 4.6: Kaplan-Meier curves among operated VHD patients stratified by categories of TTR 
(TTR <70% vs. TTR≥70%) for all-cause mortality ............................................................. 264 
Figure 4.7: Kaplan-Meier curves among operated VHD patients stratified by categories of TTR 
(TTR <70% vs. TTR≥70%) for composites of thromboembolic, bleeding event, cardiovascular 
hospitalisation and all-cause mortality (≥1 MACE) ............................................................ 264 
 
 12 
List of abbreviations 
AC Anticoagulant clinic 
ACCP American College of Chest Physicians 
ACV Anticoagulant variability 
AF Atrial fibrillation 
AFEQT Atrial Fibrillation Effect on Quality of Life 
ALP Alkaline phosphatase 
ALT Alanine transferase 
AV Atrioventricular  
AVR Aortic valve replacement 
BDI Black Depression Inventory 
BMQ Beliefs about medication 
CABG Coronary Artery Bypass Graft 
CAVD Calcific aortic valve disease 
CCS Canadian Society of Cardiology 
CDA Clinical data archive 
CI Confidence interval  
CKD Chronic kidney disease 
CrCl Creatinine clearance 
CRNMB Clinically relevant non-major bleed 
cTnT-hs High sensitive cardiac troponin 
CV Cardiovascular  
CYP2C9 Cytochrome P450 2C9 
DASS Depression Anxiety Stress Scale 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, 4th Edition 
ECG Electrocardiogram  
EF Ejection fraction 
eGFR Estimated glomerular filtration rate 
EHRA type 1 VHD Evaluated Heart valves, Rheumatic or Artificial type 1 valvular 
heart disease 
EHRA type 2 VHD Evaluated Heart valves, Rheumatic or Artificial type 2 valvular 
heart disease 
ESC European Society of Cardiology 
ESRD End stage renal disease 
GAD-7 Generalised Anxiety Disorder-7 
GDF-15 Growth differentiation factor 15 
GI Gastrointestinal  
HADS Hospital Anxiety and Depression Scale 
Hct Haematocrit  
HR Hazard ratio 
HRA Health Research Authority 
HRQoL Health related quality of life 
ICD International Classification of Diseases 
ICM Implantable cardiac monitoring 
INR International normalised ratio 
IQR Interquartile range 
ISTH International Society on Thrombosis and Haemostasis  
KDIGO Kidney Disease Improving Global Outcomes  
MACE Major adverse clinical events 
MD Mean difference 
mEHRA Modified European Heart Rhythm Association 
MI Myocardial infarction 
 13 
MTAC Medication Therapy Adherence Clinic 
MVR Mitral valve replacement 
NICE The National Institute for Health and Care Excellence 
NNT Number needed to treat 
NNH Number needed to harm 
NOAC Non-vitamin K antagonist oral anticoagulants 
NVAF Non-valvular atrial fibrillation 
NYHA New York Heart Association  
OAC Oral anticoagulant 
OR Odds ratio 
PAF Paroxysmal atrial fibrillation 
PCI Percutaneous coronary intervention 
PE Pulmonary embolism 
PHQ-9 Patient Health Questionnaire-9 
PINRR Percentage of INRs in range 
PMAS Pharmacist managed anticoagulant services 
POC Point of care 
PSM Patient self-monitoring 
PST Patient self-testing 
PTCA Percutaneous transluminal coronary angioplasty 
QoL Quality of life 
R&D Research and Development 
RCT Randomised controlled trial 
REC Research Ethics Committee 
RHD Rheumatic heart disease 
RR Relative risk 
SA Sinoatrial 
SD Standard deviation 
SE Systemic embolism 
SF-36 Short Form Health Survey 
STAI-S State-Trait Anxiety Inventory 
SWBH Sandwell and West Birmingham Hospitals 
TE Thromboembolism  
TIA Transient ischemic attack 
TTR Time in therapeutic range 
UC  Usual care  
UHB University Hospitals Birmingham 
UI Uncertainty intervals 
USA United States of America 
VHD Valvular heart disease 
VKA Vitamin K antagonist 
VKORC1 Vitamin K Epoxide Reductase Complex Subunit1 
VTE Venous thromboembolism 
  
  
  
  
  
  
  
  
  
  
  
 14 
Table of Contents 
Abstract _______________________________________________________________________ 1 
Publications arising from thesis ____________________________________________________ 3 
Dedication _____________________________________________________________________ 4 
Acknowledgements _____________________________________________________________ 5 
List of tables ___________________________________________________________________ 6 
List of figures __________________________________________________________________ 10 
List of abbreviations ____________________________________________________________ 12 
Table of Contents ______________________________________________________________ 14 
Chapter 1. Literature review _______________________________________________ 18 
1.1 Epidemiology of atrial fibrillation ___________________________________________ 18 
1.1.1 Incidence and prevalence of atrial fibrillation worldwide _______________________________ 18 
1.1.2 Prevalence of atrial fibrillation by continents ________________________________________ 21 
1.1.3 Ethnicity, age and prevalence of atrial fibrillation _____________________________________ 25 
1.1.4 Incidence and prevalence of atrial fibrillation in stroke patients _________________________ 28 
1.2 Overview of atrial fibrillation _______________________________________________ 30 
1.2.1 Pathophysiology of atrial fibrillation _______________________________________________ 30 
1.2.2 Pathophysiology atrial fibrillation related thromboembolism ___________________________ 31 
1.2.3 Diagnosis and detection of atrial fibrillation _________________________________________ 31 
1.2.4 Patterns of atrial fibrillation ______________________________________________________ 32 
1.2.5 Symptoms of atrial fibrillation ____________________________________________________ 34 
1.2.6 Risk of developing atrial fibrillation ________________________________________________ 35 
1.2.7 Treatment of atrial fibrillation ____________________________________________________ 36 
1.2.8 Pathways to management of atrial fibrillation _______________________________________ 38 
1.3 Psychological aspects in patients with atrial fibrillation and the impact on quality of life
 42 
1.3.1 Depression and anxiety _________________________________________________________ 42 
1.3.2 Anticoagulation and quality of life _________________________________________________ 43 
1.4 Stroke prevention in atrial fibrillation ________________________________________ 45 
1.4.1 Antithrombotic therapy in stroke prevention in atrial fibrillation _________________________ 45 
1.4.2 Assessing risk factors for stroke ___________________________________________________ 53 
 15 
1.4.3 Predicting stroke risk with clinical risk scores ________________________________________ 54 
1.4.4 Guidelines and recommendations for stroke risk stratification and antithrombotic therapy ____ 58 
1.4.5 Assessing bleeding risk in atrial fibrillation __________________________________________ 65 
1.5 Anticoagulation control in stroke prevention __________________________________ 78 
1.5.1 Factors affecting anticoagulation control ___________________________________________ 78 
1.6 Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation 
treated with vitamin K antagonists _______________________________________________ 101 
1.6.1 SAMe-TT2R2 score validation studies ______________________________________________ 102 
1.6.2 Importance of good anticoagulation control ________________________________________ 109 
1.6.3 Impact of different methods of calculating TTR _____________________________________ 110 
1.7 Antithrombotic therapy in atrial fibrillation associated with valvular heart disease __ 113 
1.7.1 Epidemiology of valvular heart disease with atrial fibrillation __________________________ 114 
1.7.2 Anticoagulation therapy in AF patients with valvular heart disease ______________________ 114 
1.8 Aims and objectives _____________________________________________________ 121 
Chapter 2. A prospective study examining non-vitamin K antagonist oral anticoagulants 
(NOACs) versus warfarin based on the SAMe-TT2R2 score strata in anticoagulant-naïve 
patients with atrial fibrillation: the TREAT-2 study ______________________________ 122 
2.1 Abstract _______________________________________________________________ 122 
2.2 Background and rationale ________________________________________________ 125 
2.2.1 Study objective_______________________________________________________________ 127 
2.3 Methods ______________________________________________________________ 128 
2.3.1 Procedure ___________________________________________________________________ 129 
2.3.2 Assessment of medication adherence _____________________________________________ 131 
2.3.3 Study outcomes ______________________________________________________________ 134 
2.3.4 Hypothesis __________________________________________________________________ 138 
2.3.5 Statistical analysis ____________________________________________________________ 139 
2.4 Results ________________________________________________________________ 141 
2.4.1 Baseline demographics and clinical characteristics of AF patients _______________________ 141 
2.4.2 Psychological measures, knowledge and beliefs about medication of AF patients overall and 
according to OAC groups (warfarin vs. NOACs) ____________________________________________ 146 
2.4.3 AF knowledge ________________________________________________________________ 152 
2.4.4 Beliefs about medication _______________________________________________________ 156 
2.4.5 Quality-of-life ________________________________________________________________ 159 
 16 
2.4.6 Time in therapeutic range, medication adherence and adverse clinical outcome at 6 months 
follow up __________________________________________________________________________ 163 
2.5 Discussion _____________________________________________________________ 164 
2.5.1 Limitations __________________________________________________________________ 168 
2.5.2 Clinical implications and future research ___________________________________________ 169 
2.6 Conclusion _____________________________________________________________ 170 
Chapter 3. Anticoagulation control in different ethnic groups receiving vitamin K 
antagonist therapy for stroke prevention in atrial fibrillation: the West Birmingham 
AF Project 171 
3.1 Abstract _______________________________________________________________ 171 
3.2 Introduction ___________________________________________________________ 173 
3.2.1 Study objectives ______________________________________________________________ 174 
3.3 Methods ______________________________________________________________ 174 
3.3.1 Study design _________________________________________________________________ 174 
3.3.2 Patient selection _____________________________________________________________ 175 
3.3.3 Procedure ___________________________________________________________________ 177 
3.3.4 Variables and definitions _______________________________________________________ 178 
3.3.5 Statistical analysis ____________________________________________________________ 182 
3.4 Results ________________________________________________________________ 184 
3.4.1 Baseline characteristics ________________________________________________________ 184 
3.4.2 Measures of anticoagulation control ______________________________________________ 196 
3.4.3 Predictors of time in therapeutic range (TTR) by the Rosendaal and PINRR methods ________ 205 
3.4.4 Major adverse clinical outcomes _________________________________________________ 210 
3.5 Discussion _____________________________________________________________ 223 
3.5.1 Anticoagulation control in the overall cohort _________________________________________ 223 
3.5.2 Predictors of anticoagulation control in the whole cohort _____________________________ 230 
3.5.3 Adverse clinical outcomes in the whole cohort ______________________________________ 231 
3.5.4 Strengths and limitations _______________________________________________________ 234 
3.5.5 Clinical implications ___________________________________________________________ 235 
3.5.6 Future research ______________________________________________________________ 236 
3.6 Conclusions ____________________________________________________________ 236 
Chapter 4. Anticoagulation control in operated valvular heart disease patients with and 
without atrial fibrillation receiving vitamin K antagonist _________________________ 238 
 17 
4.1 Abstract _______________________________________________________________ 238 
4.2 Introduction ___________________________________________________________ 240 
4.2.1 Study objectives ______________________________________________________________ 240 
4.3 Methods ______________________________________________________________ 241 
4.3.1 Study design _________________________________________________________________ 241 
4.3.2 Statistical analysis ____________________________________________________________ 246 
4.4 Results ________________________________________________________________ 247 
4.4.1 Baseline characteristics ________________________________________________________ 247 
4.4.2 Quality of anticoagulation control of patients with operated valvular heart disease, with and 
without AF _________________________________________________________________________ 251 
4.4.3 Predictors of poor anticoagulation control, TTR <70% ________________________________ 256 
4.4.4 Adverse clinical outcome _______________________________________________________ 260 
4.5 Discussion _____________________________________________________________ 265 
4.5.1 Strengths and Limitations ______________________________________________________ 270 
4.5.2 Clinical implications ___________________________________________________________ 270 
4.5.3 Future work _________________________________________________________________ 271 
4.6 Conclusion _____________________________________________________________ 272 
Chapter 5. General discussion and conclusions ________________________________ 273 
Appendix 1 __________________________________________________________________ 280 
Appendix 2 __________________________________________________________________ 282 
Appendix 3 __________________________________________________________________ 295 
Appendix 4 __________________________________________________________________ 299 
Appendix 5 __________________________________________________________________ 311 
References ___________________________________________________________________ 330 
 
 18 
 
Chapter 1. Literature review 
1.1 Epidemiology of atrial fibrillation  
This section summarises the literature on the epidemiology of atrial fibrillation (AF) worldwide 
according to continents, age and ethnicity/race, and also includes the prevalence of AF in 
stroke patients.  This has been published in the International Journal of Clinical Practice (1). 
Atrial fibrillation (AF), the most common form of arrhythmia with clinical significance, is a major 
global health burden worldwide (2). In the United States (US) and European countries, one in 
every four middle-aged adults will develop AF. Most importantly, AF is associated with a five-
fold greater risk of stroke, increased risk of death and development of heart failure, and a 
greater risk of hospital admission, with 10-40% of AF patients hospitalised annually. 
Additionally, irrespective of other cardiovascular-related conditions, AF patients have poorer 
quality of life and unfortunately, despite anticoagulation for stroke prevention, they can still 
develop vascular dementia and a decline in cognitive function (3).  
1.1.1 Incidence and prevalence of atrial fibrillation worldwide 
According to the Global Burden of AF(4), worldwide, the projected number of people with AF 
in 2010 was 33.5 million, consisting of 20.9 million males (UI, 19.5-22.2 million) and 12.6 
million females (UI, 12.0-13.7 million), with higher incidence and prevalence rates in 
developed countries (Table 1.1). Mortality associated with AF globally is higher in females, 
primarily driven by higher mortality among females in developing countries (Figure 1.1).  
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Table 1.1: Incidence and prevalence of AF and AF- associated mortality rate with 95% uncertainty intervals (UI) (per 100,000) for 
males and females (data extracted from Chugh 2014) (4) 
  1990 2010 1990 2010 
  Male Female  
Incidence of AF 
Globally, all ages 60.7 (49.2-78.5) 77.5 (65.2-95.4) 43.8 (35.9-55.0) 59.5 (49.9-74.9) 
Developed Countries 78.4 (67.5-91.9) 123.4 (107.6-141.5) 52.8 (45.0-62.9) 90.4 (77.8-104.5) 
Developing Countries 50.0 (33.8-76.8) 53.8 (38.7-79.8) 36.0 (24.5-54.7) 40.0 (27.2-62.6) 
 
Prevalence of AF 
Globally, all ages 569.5 (532.8-612.7) 596.2 (558.4-636.7) 359.9 (334.7-392.6) 373.1 (347.9-402.2) 
Developed Countries 608.2 (547.0-693.5) 660.9 (597.1-738.2) 362.5 (329.3-422.3) 387.7 (343.8-450.0) 
Developing Countries 546.6 (503.0-599.6) 656.7 (522.9-617.6) 358.2 (329.8-393.0) 366.1 (337.4-400.8) 
Mortality rate 
Globally, all ages 0.8 (0.5-1.1) 1.6 (1.0-2.4) 0.9 (0.7-1.2) 1.7 (1.4-2.2) 
Developed Countries 1.3 (0.9-1.9) 2.7 (1.9-4.3) 1.1 (1.0-1.3) 2.4 (2.0-3.0) 
Developing 
Countries 0.4 (0.2-0.8) 0.7 (0.4-1.3) 0.7 (0.4-1.4) 1.0 (0.6-1.7) 
AF=atrial fibrillation 
 20 
 
  
 
 
 
 
 
1.3
2.7
0.4
0.7
1.1
2.4
0.7
1
0
0.5
1
1.5
2
2.5
3
1990 2010 1990 2010
Developed Countries Developing Countries
M
or
ta
lit
y 
pe
r 1
00
,0
00
Male
Female
Figure 1.1: AF associated mortality stratified by sex and region (developed and 
developing countries) 
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1.1.2 Prevalence of atrial fibrillation by continents  
In Europe, AF currently affects eight million people and is expected to rise drastically, 2.3-fold 
by 2060 (5, 6). In the United Kingdom, projections from the Clinical Practice Research 
Database suggest that AF will affect between 1.3 and 1.8 million people by 2060 (7). In the 
United States, about 3-5 million people are currently affected by AF and by 2050 this figure is 
expected to be greater than 8 million people (8). In Australia, Europe and the USA, the current 
estimated prevalence of AF is between 1-4% (2, 5). Table 1.2 and Figure 1.2 illustrate the 
prevalence of AF in nine countries, stratified by continents worldwide. Australia has the highest 
prevalence of AF i.e., 5.4% followed by Africa 4.6%, (although the prevalence was lower 
(0.7%) in another African study) (9) then Iceland (2.4%) and lowest in Asian countries (0.49%-
1.9%).  
 
A recent review (10) on AF epidemiology of 58 studies from five Asian (China, Japan, South 
Korea, India, Malaysia) and eight Middle Eastern countries (Turkey, Bahrain, Qatar, Kuwait, 
Saudi Arabia, Oman, United Arab Emirates and Yemen)(10) reported the annual incidence of 
AF to be 5.38 per 1000 person-years. These are mainly from Chinese, Japanese and Korean 
studies (10 studies in total) (11-20) conducted from 1991-2012, with study populations ranging 
from 1485 (15) to 471,446 (13). Prevalence of AF varies between hospital-based and 
community-based studies; being higher in the latter (0.37%-3.56% vs. 2.8%-15.8%) (10). 
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Table 1.2: Worldwide prevalence of AF by continent 
Country Study 
-Years data 
obtained 
-Study design 
Sample size 
Study population Prevalence (%) total,  
(men and women) Data source Age (SD) years [Men, women (%)] 
Africa 
Africa Sliwa et al  2010 (21) 
-2006-2008 
-Prospective  
5328 cardiac 
cases 
Hospital-based, 
single centre, urban 
population 
59 (18) 
[39, 61% AF] 4.6 (†) 
Kenya  
 
Shavadia et al  
2013 (9) 
-2008-2010 
-Retrospective  44, 144 
One hospital 
admission in 
Nairobi 
≥18 
[56, 44% AF] 0.7 (†) 
Asia 
Malaysia 
 
Lim et al  
2016 (22) 
 
-2007-2014 
-Prospective 
10,805 
 
18 urban, 22 rural 
communities across 
Malaysia 
52.6 (11.6)  0.49 (†) 
Singapore 
 
Yap et al  
2008(23) 
 
† 
-Prospective 
1,839 
 
Community-based 
study 
≥55 1.4 (†) 
Thailand 
 
Phrommintikul et al 
2016 (24) 
† 
-Prospective  1,277 
 
Cross section of 
Maerim District, 
Chiang Mai 
 
≥65 
[45.8, 54.2% AF] 
1.9 (†) 
Australia 
Australia Ball et al  2015(25) -June 2014 6,140,651 
7 international 
epidemiology study ≥55  5.4 (5.97, 4.79) 
Australia 
 
Sturn et al  
2002 (26) 
 
 
-2000 
-Prospective 
14, 194 
 
50 consecutive 
patients at 321 
general practices 
≥30 
 
 
4.0 (6.0, 4.0) 
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Table 1.2 continued 
Country Study 
-Years data 
obtained 
-Study design 
Sample size 
Study population 
Prevalence (%) total,  
(men and women) Data source 
Age (SD) 
[Men, women 
(%)] 
Europe 
England 
Health & Social 
Care Information 
Centre 2014-2015 
(27) 
-2014-2015 
-Retrospective 56,939,507 
National primary 
care practice 
database 
† 1.6 (†) 
United 
Kingdom 
Lane et al  
2017 (7) 
-1998-2010 
-Retrospective 57, 818 
UK Clinical 
Practice 
Research 
Datalink (CPRD) 
≥18  
[51.7, 48.3% AF] 
1.26 (1.33, 1.18) per 1000 pt-
yrs [age-adjusted incidence] 
Iceland 
 
 
Stefansdottir et al 
2011(6) 
 
-1987-31 December 
2008 
-Retrospective 
4905-AF 
cases 
 
The National 
University 
Hospital of 
Iceland 
20–99  2.4-age and sex standardised 
North America 
USA Naccarelli et al 2009(28) 
-2004-2005 
-Retrospective 242, 903 
National 
databases of 
employer-funded 
insurance and 
Medicare 
≥20 1.1 (†) 
South America 
Brazil 
Marcolino et al 
2015(29) 
-Jan-December 
2011 
-Retrospective 
262 685 
658 
municipalities, 
primary Care 
50.3 (19.3) 
[40.4, 59.6] 1.8 (2.4, 1.3) 
† Not reported 
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Figure 1.2: Prevalence of AF by country 
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Differences in the incidence and prevalence rates between studies is likely dependent on the 
time the study was conducted, the design (nationwide studies, medical insurance databases 
etc., retrospective, prospective, cross-sectional) and the study population (age of patients, 
urban compared to remote areas as their risk factors may vary, for example the prevalence of 
rheumatic heart disease is higher in rural populations in India)(30) which in turn affect the  
quality of data obtained (5). 
1.1.3 Ethnicity, age and prevalence of atrial fibrillation 
The prevalence of AF across different ethnic groups differs, although most of the studies 
investigating these differences have been conducted in the United States. For the purpose of 
this thesis, ethnicity is classified as Whites, (Europeans, Americans) Afro-Caribbeans, 
(Blacks, Black British, African-American) East Asians, (Chinese, Japanese, Malaysian and 
other Asians) South Asians, (Indian, Pakistani, Bangladeshi) Hispanics, (Hispanic or Latino) 
and others, as reported in individual studies (31, 32).  
 
Table 1.3 shows the prevalence of AF by race and ethnicity according to 11 studies,(33-43) 
conducted in the United States and one (33) multicentre study conducted in North America, 
Europe and Asia. In all studies, the prevalence of AF was highest among the Whites compared 
to Afro-Caribbeans, East Asians and Hispanics, ranging from 42% (42) to 2.5% (41) among 
the Whites, and 21%(41) to 1.7% (40) among Afro-Caribbeans. Only three studies (33, 35, 
43) reported AF prevalence among East Asians which ranged from 3.9% (35) to 10.1% (33), 
while only one study reported AF prevalence  among  Hispanics (3.9%) (35). A meta-analysis 
of 10 studies examining the prevalence of AF among African-Americans compared to Whites 
in the United States, concluded that being African-American was associated with a ‘protective 
effect’ from AF [OR 0.51 (95% CI 0.44-0.59); p<0.001]. Despite the lower prevalence of AF, 
African-Americans in the US have twice the risk of first ever stroke compared to Whites and 
this might be due to higher risk factor burden of stroke, for example, hypertension (44). 
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Table 1.3: Prevalence of AF by ethnicity and race 
Country/State  Study  a) Study design  
b) Follow up 
c) Sample size 
Mean (SD) age  
study population  
Prevalence of AF (%) 
Whites Afro-
Caribbeans 
East 
Asians 
Hispanics 
North America, 
Europe, Asia 
Lau et al 
2013(33) 
a) Prospective  
b) 2.5 years 
c) 2580  
Europeans: 76.2 (6.6) 
Black African: 75.2 (6.2) 
Chinese: 76.2 (6.7) 
Japanese: 78.4 (7.0) 
18 8.3 10.1 
Chinese, 
9.5 
Japanese 
N/A 
 
Michigan,  
USA 
 
Lahiri et al 
2011(34) 
 
a) Retrospective 
b) N/A 
c) 1001 
 
African American: 33.0% 
≥70 
European American: 
35.4% ≥70 
 
 
29 
 
19 
 
N/A 
 
N/A 
USA Winkelmayer et al 
2011(43) 
a) Cross sectional 
b) 15 years 
c) 2,483,199 
70.9 (11.8) 14 6.5 9.0* N/A 
        
California,  
USA 
Shen et al 
2010(35) 
a) Cross-sectional 
b) N/A 
c) 430, 317  
White: 70 (64-77) 
Black: 68 (64-74) 
Asian: 67 (63-73) 
Hispanic: 67 (61-71) 
8 3.8 3.9 3.6 
 
15 U.S states, 
Washington, 
DC 
 
Marcus et al 
2010(36) 
 
a) Combination of CHS 
and ARIC study 
b) – 
c) 19, 784 
 
CHS 
African American: 73 (6) 
Whites: 73 (6) 
ARIC 
African Americans: 53 
(6) 
Whites: 54 (6) 
 
23 
 
15 
 
N/A 
 
N/A 
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Table 1.3 continued 
Country/State  Study  a. Study design 
b. Follow up 
c. Sample size 
Mean (SD) age  
study population  
Prevalence of AF (%) 
Whites Afro-
Caribbeans 
East 
Asians 
Hispanics 
Maryland, 
Minnesota, 
Mississippi, N. 
Carolina, USA 
Alonso et al 
2009(37) 
a) Prospective  
b) 228,976 person-years 
c) 15, 407 
Whites: 54.4 (5.7) 
African Americans: 53.6 
(5.8) 
7.9 4.8 N/A N/A 
Ohio,  
USA 
Smith et al 
2006 (38) 
a) Prospective 
b) - 
c) 9671 
N/A 24 17 N/A N/A 
California,  
USA 
Ruo et al 
2004 (39) 
a) Retrospective and 
prospective 
b) –  
c) 1373 
 
73 overall 38 20 N/A N/A 
Georgia,  
USA 
Upshaw et al 
2002(40) 
a) Retrospective  
b) – 
c) 2123 
14% age 70-79 7.8 2.5 N/A N/A 
California,  
USA 
Go et al 
2001(41) 
a) Cross sectional 
b) N/A 
c) 17, 974  
71.2 (12.2) whole cohort  2.5 1.7 N/A N/A 
 
Michigan, 
USA 
 
Afzal et al 
1999(42) 
a) Prospective  
b) 6 months 
c) 163 
Blacks: 63.8 (13.7) 
Whites: 70.8 (13.1) 
42 21 N/A N/A 
Pt-yrs = patient years; *Asian Americans; N/A = not applicable 
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In addition to ethnic differences, age distribution of AF diagnosis may also differ between 
regions. More than 70% of AF patients in Western Europe, Australia and North America were 
aged >65 years (2). A different pattern in the average age of AF diagnosis is evident from 
other regions. AF patients are younger from the Arabic (45), Ethiopian (46), South Korean (2) 
and South African (21) studies with mean age ranging from 41-65 years. Results from the RE-
LY AF registry which enrolled AF patients from the 164 emergency departments worldwide to 
evaluate the differences in the presentation and management of AF, also shows some regional 
variation in terms of age at AF diagnosis; patients from America and Europe countries were 
on average 10-12 years older than those from Africa, India and the Middle East (47). 
1.1.4 Incidence and prevalence of atrial fibrillation in stroke patients 
AF increases the risk of stroke approximately 5 times compared to those without AF (3). The 
presence of AF was 24.6% in patients [mean (SD) age 78.8 (13.3) years] with ischemic stroke 
in one Italian population-based study. In this study, AF was more frequent in women, elderly 
patients (>80 years), those with coronary heart disease and peripheral arterial disease. AF 
was also an independent predictor of 30-day and 1-year mortality in Cox regression analysis 
(48).  
 
Another prospective study in Germany reported an overall prevalence of AF slightly higher 
than the Italian study, i.e., 28.6% in patients (N=692) with ischemic stroke or transient ischemic 
attack, with prevalence increasing with age (49). The prevalence of AF in ischaemic stroke 
patients in the USA (i.e., 23% in acute ischaemic stroke patients from eight states) (50), two 
European studies (24.6 and 28.6% respectively) (29, 30) and one Australian study (25%; study 
population 26,960) (51) was similar to that reported by the Italian study. However, the 
prevalence of AF was reportedly lower in some Asian countries, approximately 10% in China 
(52), 5.8-6% in India (53, 54), but higher in Japan (32%) (55).  
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Sposato et al conducted a meta-analysis of 50 studies in 2015 (56) to estimate the proportion 
of newly diagnosed AF patients experiencing stroke or transient ischemic attack (TIA) after 
undergoing four sequential phases of cardiac monitoring; phase 1: electrocardiogram (ECG) 
at admission, phase 2: continuous inpatient ECG, phase 3: Holter monitoring and phase 4: 
mobile cardiac outpatient telemetry. In this study, they reported an overall presence of AF in 
23.7% (95% CI 17.2-31.0) of their post-stroke patients and an estimated prevalence of AF in 
post-stroke patients with either known or newly diagnosed AF of about 39.0%, higher than 
previously reported studies (56). 
 
The prevalence of AF worldwide is increasing steadily although large variation can be seen 
between studies and countries. A larger proportion of ischemic stroke patients are also found 
to have AF either during admission or upon investigation post-discharge that becomes a major 
concern as AF related to stroke has poorer outcomes and prognosis (3, 5). This increase in 
the prevalence of AF may be explained by the fact that better detection methods have been 
used to detect AF (2, 3, 57) and also greater awareness among physicians and other 
healthcare providers who are able to detect patients with AF during routine check-ups, flu 
injections and also during hospital admissions.  
 
Further epidemiological studies should be undertaken globally, especially in Asian and African 
countries, in urban and rural areas, so that a more accurate picture of the incidence and 
prevalence of AF can be captured, thereby allowing appropriate implementation of stroke 
prevention strategies to reduce stroke risk and burden.  
 
The next section summarises the pathophysiology, diagnosis, pattern and symptoms of risk 
and general treatment of AF.  
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1.2 Overview of atrial fibrillation 
Atrial fibrillation is a condition where there is an ineffective atrial contraction that results from 
an uncoordinated atrial activation. The sino-atrial (SA) node which sends electrical impulses 
to the atria for atrial contraction (thus forcing the blood to enter the ventricles) and is also 
responsible for controlling and coordinating the heart rate, is no longer functioning in an 
organised manner, thereby causing an irregular and rapid heart rate (58). 
1.2.1 Pathophysiology of atrial fibrillation 
 Atrial fibrillation occurs when the electrical signalling pathway is abnormal (3). The signals are 
generated from all over the atria causing a fibrillating or quivering atrial activity. The signals 
are no longer systematically triggered via the SA node (58). Specifically, the pulmonary veins 
located in the left atrium generate multiple impulses in majority of AF cases (3). The generated 
impulses can be fired at a very rapid rate of about 300-600 beats per minute, however, not all 
of the impulses can be filtered by the atrioventricular (AV) node (59). The signals originating 
from multiple areas within the atria are chaotic, fast and irregular, leading to inadequate atrial 
emptying. Excessive signals passing through the AV node causes the ventricular rate to be 
increased (59). The emptying of the ventricles is affected by the increase in ventricular activity 
(60-130 beats per minute) and if this continues, it leads to reduced general circulation of the 
blood causing symptoms of fatigue, light-headedness, breathlessness and chest pain (59).  
Hypertension, diabetes, heart failure, coronary artery disease, and ageing are among the 
factors that can lead to changes to the pathophysiology of the atria, including hypo-
contractility, inflammation, vascular remodelling, inflammation, fatty infiltration and ion channel 
dysfunction (3). These changes can cause conduction disturbances and thus lead to the 
development of AF. Some of these changes are also involved in the manifestation of a 
hypercoagulable state in AF.  
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1.2.2 Pathophysiology atrial fibrillation related thromboembolism 
Tissue factor exposure in the blood stream as a result of hypocontractility and ischemia 
induces inflammation and adds to the thrombogenic environment in the atria of AF patients, 
thus leading them to have an increased risk of thromboembolic events such as stroke or 
transient ischemic attack (TIA) (3). Along with the structural remodelling, the rhythm of AF 
itself predisposes the atrial myocardium to a prothrombotic state (60). Additionally, the 
myocardial damage within the atrium that develops within short periods of AF stimulates the 
release of prothrombotic factors onto the endothelial surface causing platelet aggregation. 
This could partly elucidate the reason of long-term stroke risk even in short episodes of AF 
(61, 62). 
1.2.3 Diagnosis and detection of atrial fibrillation 
AF diagnosis is made using the ECG that shows a typical pattern of AF involving irregular RR 
intervals and no distinct P waves. Any episode of AF lasting at least 30 seconds is considered 
as a diagnosis of AF (3). Patients with AF can be symptomatic or asymptomatic (‘silent AF’).  
Silent AF can have severe consequences such as stroke and death just as with symptomatic 
AF (63-65). Such events can be avoided or reduced with early detection and OAC initiation. 
Suggestions have been made to screen AF in a more widespread manner including within 
community healthcare practices (66) and using sophisticated diagnostic tools which could 
detect short and long episodes of AF. One systematic review (67) of eight trials (N=18,189) 
conducted in the GP/outpatient clinic and community setting identified a 1.4% incidence of 
undiagnosed AF using a single time point screening AF method (pulse palpation or ECG) of 
patients aged ≥65 years (67). The pulse palpation method was reported to have a sensitivity 
of 94% and a specificity of 72% in detecting AF (68) while the handheld single lead ECGs 
have higher sensitivity and specificity ranging from 94%-98% and 76%-97% respectively (69).  
Evidence has shown that detection of undiagnosed AF can be obtained by prolonged ECG 
monitoring (70, 71). In 2014, two trials (70, 72) were conducted to investigate whether long 
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term ECG monitoring is superior to conventional 24-hour monitoring in detecting AF in patients 
with cryptogenic stroke. The EMBRACE-AF trial (72) included 572 patients with cryptogenic 
stroke within the previous 6 months and investigated the benefits of longer monitoring periods 
(30 days) versus conventional 24-hour ECG monitoring. In the study, at least 16.2% of patients 
had AF for 30 seconds over 90 days of monitoring compared to just 3.2% for those undergoing 
24-hour monitoring (an absolute difference of 12.9 percentage points [95% CI (8.0 to 17.6); 
p<0.001])(72).  
The CRYSTAL AF trial (70), with a slightly lower number of participants (N=447), examined if 
‘conventional follow-up’ was better than continuous cardiac monitoring via implantable cardiac 
monitor (ICM) in detecting AF in patients with cryptogenic stroke after 3 months of the event. 
At 6 months, it was similarly shown that the rate of AF detection is higher in patients receiving 
ICM compared to the conventional group [8.9% vs. 1.4%, (HR 6.4; 95% CI 1.9 - 21.7; 
p<0.001)] (70). Essentially, the benefit of continuous monitoring was also seen at 12 months 
with a 12.4% AF detected in patients with ICM compared to 2.0% in the conventional group 
(70). Despite the available evidence to date, the best method for detecting and screening AF 
is still unclear.  
Evidence demonstrates the benefits of continuous ECG monitoring, the current guideline (3) 
recommends ECG rhythm strip and pulse palpation for primary prevention and at least 72 
hours of monitoring in post stroke/TIA patients.  
1.2.4 Patterns of atrial fibrillation  
In most cases, AF progresses from infrequent, short episodes to longer and more frequent 
episodes, and a sustained form of AF can develop eventually over time. Five types of AF are 
classified based on the presentation, duration, and spontaneous termination of AF episodes 
(Table 1.4). Currently, guidelines do not differentiate between types of AF and stroke 
prophylaxis as observational studies suggest that stroke risk is dependent on concomitant 
stroke risk factors regardless of AF type (73, 74). However, a recent meta-analysis (75) 
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suggests that the risk of stroke may differ between patients with paroxysmal AF and non-
paroxysmal AF. Twelve studies (10 RCTs and 2 prospective studies) involving almost 100, 
000 patients evaluated the impact of AF type (PAF vs. non-PAF) on thromboembolic (TE) 
events, bleeding and death. After adjustment for stroke risk factors (hypertension, heart failure, 
age, gender, previous thromboembolism and diabetes) the hazard ratio for TE events was 
1.38 (95% CI 1.19–1.61; p<0.001); bleeding events was 1.03 (95% CI 0.90–1.17; p=0.715) 
and all-cause mortality was 1.22 (95% CI 1.09–1.37; p<0.001) respectively in non-PAF vs. 
PAF patients (75). Results from this meta-analysis showed that thromboembolism and 
mortality were significantly higher in non-PAF compared to PAF patients (75).  
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Table 1.4: Patterns of atrial fibrillation (taken directly from ESC guideline 2016)  
AF pattern Definition 
First diagnosed AF Undiagnosed AF before, irrespective of duration of 
arrhythmia or presence and severity of AF-related 
symptoms 
Paroxysmal AF AF that self-terminates usually within 48 hours. Some 
paroxysms can occur for up to 7 days OR AF episodes that 
are cardioverted within 7 days 
Persistent AF AF episodes lasting longer than 7 days, including episodes 
terminated by cardioversion (pharmacological or direct 
current cardioversion), after 7 days or more 
Long-standing persistent AF Prolonged AF lasting for ≥1 year when a rhythm control 
strategy is adopted 
Permanent AF AF accepted by patients and physicians and rhythm control 
strategy is not pursued. If rhythm control therapy is to be 
adopted, AF should be classified as long-standing 
persistent AF 
 
1.2.5 Symptoms of atrial fibrillation 
Some AF patients (25-40%) report no symptoms or very minimal symptoms while others (15-
30%) report severe disabling symptoms. Symptoms include palpitations, lethargy, shortness 
of breath, chest tightness, sleeping difficulties and psychological distress. Symptomatic AF 
patients tend to report poorer quality of life than asymptomatic patients (3). The modified 
European Heart Rhythm Association (EHRA) symptom scale (Table 1.5) can be used to 
categorise the severity of AF symptoms.  
 
 
 
 
 35 
Table 1.5: Modified European Heart Rhythm Association symptom scale (3) 
Modified 
EHRA score 
Symptoms Description 
1 None No symptoms 
2a Mild Symptoms related to AF are not affecting normal daily 
activity 
2b Moderate Patients are troubled by symptoms of AF but normal daily 
activity is not affected 
3 Severe Symptoms related to AF are affecting normal daily 
activity 
4 Disabling Discontinuation of normal daily activity  
1.2.6 Risk of developing atrial fibrillation 
Many concomitant conditions and cardiovascular diseases increase the risk of AF 
development.  Table 1.6 lists the most common concomitant disease associated with AF. 
Identifying these risk factors and managing them is crucial to prevent AF and its burden of the 
disease (3).  
Table 1.6: Comorbid conditions/risk factors associated with AF (3) 
Comorbidities/risk factors 
• Genetic predisposition  • Obstructive sleep apnoea 
• Older age • Chronic kidney disease 
• Hypertension • Smoking  
• Heart failure • Alcohol consumption 
• Valvular heart disease • Vigorous exercise  
• Myocardial infarction  
• Thyroid disorder  
• Obesity   
• Diabetes mellitus   
• Chronic obstructive pulmonary 
disease 
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The original Framingham Heart Study (76) (38 years follow up) investigated the predictors of 
AF development has shown that men had 1.5 times higher risk of developing AF. Other risk 
factors identified from the study include: hypertension (OR 1.5 men and OR 1.4 women), 
congestive heart failure (OR 4.5 men and 5.9 women), myocardial infarction (OR 1.4 men), 
valvular heart disease (OR 1.8 men and OR 3.4 women), aging and diabetes (OR 1.4 men 
and 1.6 women) were all independent predictors of AF development (76). Other studies also 
showed that obesity (HR 1.37) (77), thyroid dysfunction (78), COPD (FEV1<60%: RR 2.53) 
(79), chronic kidney disease (stage 4/5: OR 3.52) (80), current smoker (RR 2.05) (81) and >21 
drinks of alcohol per week (RR 1.39)(82) were also associated with AF development.  
1.2.7 Treatment of atrial fibrillation 
Essentially, there are five targets of treatment in AF patients: 1) acute rate and rhythm control 
to achieve hemodynamic stability, 2) managing precipitating factors which involves lifestyle 
changes and treating underlying conditions for the purpose or cardiovascular risk reduction, 
3) assessing stroke risk and offering oral anticoagulants (OAC) therapy in patients with stroke 
risk factors (this will be discussed in more detail in section 1.4), 4) assessing heart rate with 
rate control therapy and lastly symptoms assessment with anti-arrhythmic drugs, 
cardioversion or catheter ablation. These targets are set for the benefits of patients to improve 
life expectancy, quality of life autonomy and social functioning (3). 
1.2.7.1 Rate and rhythm control therapy 
Essentially, rate control therapy is often offered to patients to improve AF-related symptoms. 
Very little evidence exist that showed the best type and intensity of rate control therapy 
compared to stroke prevention. Most data were derived from observational studies and short-
term cross over trials (83-86).  Medical treatment options for rate control therapy for acute or 
long-term rate control are beta blockers (bisoprolol, carvedilol), non- dihydropyridine calcium 
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channel blockers (diltiazem and verapamil), digoxin and some rhythm control agents which 
have rate control properties, for example amiodarone, dronedarone and sotalol (3).  
Another part of AF management involves restoring and maintaining sinus rhythm either with 
pharmacological agents or with catheter ablation or in combination. At the moment, rhythm 
control therapy is indicated in patients who are still symptomatic despite on adequate rate 
control therapy (3). When anti-arrhythmic drugs are ineffective, electrical cardioversion is 
usually offered in symptomatic AF patients. Evidences comparing rate and rhythm control 
therapy versus rate control therapy alone have shown neutral outcomes (87-89). 
Pharmacological rhythm control therapy options include amiodarone, flecanide and 
propafenone. However, long term use of rhythm control therapy should be considered based 
on the safety of each agent. For example, amiodarone could cause QT prolongation so it 
should be avoided (if possible) with drugs causing the same effect. In addition, dronedarone 
is contraindicated in patients with decompensated heart failure or patients with NYHA class 
IV heart failure as these patients are prone to negative inotropic action and ventricular 
proarrhythmic effects of anti-arrhythmic drugs (3). 
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1.2.8 Pathways to management of atrial fibrillation 
1.2.8.1 The ABC pathway 
Recently, ‘The Atrial Fibrillation Better Care (ABC)’ pathway was introduced for the 
management of AF patients in an integrated manner (90) (Figure 1.3). The ‘A’ in the ABC 
pathway stands for ‘Avoid’ stroke, which can be achieved by implementing the ‘Birmingham 3 
step’ approach (Figure 1.3). The ‘B’ acronym stands for ‘Better management of symptoms’ 
including offering rate or rhythm control therapy and lastly ‘C’ stands for managing 
cardiovascular and other Comorbidities. Simply, the ‘Birmingham 3 step approach’ involves: 
1) Identifying low risk patients 
2) Offering appropriate stroke prevention (OAC) to patients not in the ‘low risk group and 
assessing bleeding risk (using the HAS-BLED score)  
3) Deciding on OAC therapy either with a NOAC or VKA, emphasising anticoagulation 
control (TTR ³70%) in those receiving VKA 
1.2.8.2  National Institute for Health and Care Excellence (NICE) AF care 
pathway and European Society of Cardiology (ESC) integrated pathway 
Similarly, the NICE AF care pathway (91, 92) (Figure 1.4) and the ESC integrated pathway 
(3) (Figure 1.5) suggest offering stroke prevention strategy to all AF patients at risk of stroke 
and better management of AF symptoms with either rate or rhythm control strategy. The ABC 
pathway (90) and the ESC integrated pathway (3) adds the ability to manage cardiovascular 
risk factors and other comorbidities. The ESC integrated pathway necessitates changes in 
lifestyle that will result in a better quality of life and improved life expectancy. All three 
pathways were created to guide physicians to manage AF patients in a more integrated and 
efficient manner.   
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NOAC: Non-vitamin K antagonist oral anticoagulant; OAC: oral anticoagulation; TTR: time in therapeutic range; 
VKA: vitamin K antagonist  
Figure 1.3: ABC pathway [taken directly from Lip 2016 (90)]  
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Poor 
control  
Anticoagulation contraindicated 
Assess stroke risk stratification 
using CHA2DS2-VASc 
Assess bleeding risk stratification 
using HAS-BLED 
Discuss risk and benefits of anticoagulation 
Identify low risk patients i.e., CHA2DS2-VASc =0 (men) or 1 (women) 
Individual who decline treatment 
No anticoagulation therapy 
CHA2DS2-VASc =1 (men) 
consider anticoagulation 
CHA2DS2-VASc ≥2 offer 
anticoagulation 
Discuss the options for anticoagulation with the person and base the choice 
on their clinical features and preferences 
VKA (assess anticoagulation 
control, TTR≥70%) NOACs 
Left atrial appendage occlusion 
Annual review for all patients 
Rate and rhythm control strategies Left atrial ablation strategies  
Low risk 
NOACs 
contraindicated 
or not tolerated 
Symptomatic 
Symptomatic 
AF: atrial fibrillation; NOACs: non-Vitamin K antagonist oral anticoagulants; TTR: time in therapeutic range; VKA: vitamin K antagonist 
Figure 1.4: NICE-AF care management pathway taken from NICE-AF guideline 2014 (91, 92) 
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Acute rate and 
rhythm control 
Manage 
precipitating 
factors
•Lifestyle changes, 
treatment of 
underlying CV 
conditions
Assess 
stroke risk
•Oral anticoagulation in 
patients at risk of 
stroke
Assess 
heart rate 
•Rate control 
therapy
Assess 
symptoms 
Antiarrhythmic 
drugs, cardioversion, 
catheter ablation, AF 
surgery 
Treatment  Desired outcome  
Hemodynamic stability   
CV risk reduction  
Stroke prevention  
Symptom improvement, 
preservation of LV 
function  
Symptom improvement 
Patient benefit   
Improved life expectancy  
Improved quality of life, 
autonomy, social 
functioning  
Figure 1.5: European Society of Cardiology integrated pathway adapted from the ESC AF Guidelines 2016 (3)  
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1.3 Psychological aspects in patients with atrial fibrillation and the 
impact on quality of life 
1.3.1 Depression and anxiety 
Studies have reported psychological distress among patients with AF (93). Five studies (94-
98) have reported the prevalence of depression in AF cohorts which ranged from 10%-38% 
measured using validated questionnaires [Beck Depression Inventory (BDI) (3-5) and Hospital 
Anxiety and Depression Scale (HADS)] (94, 98). Meanwhile, the prevalence of state and trait 
anxiety is reported as between 28-35% and 35%-38%, respectively, among AF patients, in 
other studies, using the State-Trait Anxiety- Inventory (STAI-S) questionnaire (96, 99).  
Recently, one Greek study of 170 permanent AF patients (94) found that depression and 
anxiety were associated with patients’ age and number of years since diagnosis; those aged 
>70 years who had the disease for 6-10 years were more anxious and depressed than those 
aged <70 years who had AF for less than 6 years. Elderly AF patients are likely to be more 
anxious and depressed perhaps due to various factors like cognitive impairment, physical 
impairment, and poor treatment adherence (100, 101). In this study, poor/no knowledge of the 
state of their health and having moderate/poor relationship with medical staff were also 
associated with depression. Patients may be more depressed if they are unsure about the 
disease, their prognosis and management. However, with adequate knowledge, patients tend 
to have better control of their disease, present with fewer symptoms and are emotionally less 
distressed (102, 103). In this study, females were also found to be more anxious compared to 
males. This could be due to the differences in the type of AF and severity of symptoms and 
outcomes of cardiac disease, as well as daily living or health behaviours (94, 104). For 
example, females may be more prone to distress after facing an emotional trauma (example 
divorce or death of family members) and perhaps this added stress would further cause 
negative impact to their current comorbid condition. 
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Research has shown that quality of life (QoL) is poorer among AF patients with anxiety and 
depression. Thrall et al (96) compared 101 AF and 97 hypertensive patients (age and sex 
matched) and reported that AF patients were significantly more anxious (mean trait anxiety 
score 37.4 vs. 33.3; p=0.02 in AF vs. hypertensive patients) than hypertensive patients at 
baseline and this persisted 6 months later (mean trait anxiety score 36.9 vs. 32.6; p=0.03 in 
AF vs. hypertensive patients). Symptoms of depression were also present in 38% of AF 
patients at baseline and this also persisted at 6 months. Furthermore, symptoms of depression 
and anxiety were independently related to health related quality of life (HRQoL) at baseline 
but at 6 months, only symptoms of depression predicted HRQoL (96). In this study, AF patients 
were more anxious and depressed than hypertensive patients probably because AF is an 
illness associated with symptoms and an increased risk of stroke whereas hypertension is 
without any specific symptoms and patients may have the perception of hypertension being a 
benign condition. Studies (105-107) have shown that AF patients with greater severity of 
symptoms (106, 107) and with recurrence of AF (108) have higher rates of depression and/or 
anxiety.  
Similarly in 2009, Lane et al (99) reported that lone AF patients presented with more anxiety 
symptoms (38% state and 41% for trait anxiety) and had poor QoL, however, depression level 
was low [median score 2.0 (0-3.0)] at baseline. In contrast to Thrall et al, (who did not 
investigate the beliefs about medication)(96), Lane et al (99) reported that beliefs about 
medication and number of AF symptoms predicted their physical quality of life.  
1.3.2 Anticoagulation and quality of life  
Despite the marked improvement in the prevention of stroke with the use of oral 
anticoagulation therapy, studies (109, 110) have shown that the QoL among patients with VKA 
therapy is affected as it requires behaviour and lifestyle modification.  
Several studies (109, 111-113) from Brazil, Argentina and Spain among anticoagulated 
patients (N=72 to 905) mainly for AF and mechanical heart valves, have assessed QoL using 
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the SF-36 tool. They reported overall SF-36 scores ranging from 54-62 indicating poor QoL. 
These studies (109, 111-113) reported that patients have more limitations in daily activity 
compared to emotional health evident by lower scores in physical domain compared to 
emotional domains. This indicates that anticoagulated patients appear to have greater 
impairment in their physical health rather than emotional health. 
However, other studies (109, 111, 114, 115) from Brazil, Turkey, Malaysia and Spain (N=72 
to 339) among mostly anticoagulated AF patients using VKA showed a relatively better QoL 
with scores ranging from 67-86 with the Duke Anticoagulation Satisfaction Scale (DASS) (109, 
111-113). Three studies (109, 111, 114) showed that patients were more limited and had 
higher burden in their physical activity, however, only one study (115) showed patients were 
more psychologically affected by their anticoagulation therapy. Although the studies differed 
methodologically (small sample size, cross-sectional study), they suggest that anticoagulated 
patients are more likely to be affected by treatment inconvenience rather than by their 
emotional health.  
Another Turkish study (116) compared HRQoL using the SF-36 tool among 182 NOAC and 
warfarin patients (91 patients in each group). They showed that even after adjustment for age, 
gender, adherence, and duration of OAC therapy, warfarin treated patients had significantly 
lower HRQoL scores in all domains (p<0.05); self-reported symptoms of anxiety (HADS-A: 6.2 
vs. 4.6; p<0.001) and depression (HADS-D: 4.9 vs. 3.6; p<0.001) were significantly higher 
among warfarin treated patients compared to NOAC patients respectively. (116) This may be 
expected given that NOACs have fewer drug interactions, no known food interactions and do 
not require frequent INR monitoring, which have all been shown to impact patient’s QoL (109, 
111, 114, 115). 
The next section discusses stroke prevention in AF including identifying stroke risk factors, 
different treatment strategies (VKA vs. NOACs) and guideline recommendations.  
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1.4 Stroke prevention in atrial fibrillation 
1.4.1 Antithrombotic therapy in stroke prevention in atrial fibrillation 
Currently, there are five types of OAC therapy available for stroke prevention in AF patients, 
including Vitamin K antagonists (VKA e.g., warfarin) and non-VKA oral anticoagulants 
(NOACs e.g., dabigatran, rivaroxaban, apixaban and edoxaban) (3). 
1.4.1.1 Vitamin K antagonist (VKAs) 
The principal priority in managing patients with AF is stroke prevention. Warfarin and other 
types of VKAs (for example acenocoumarol, phenprocoumon) were among the first 
anticoagulants used in AF patients.  Clinical trials (117) have shown that compared to placebo, 
dose-adjusted VKA reduces the risk of stroke and systemic embolism by 64% (95% CI 49-74) 
(Table 1.7) and all-cause mortality by 26% (95% CI 3-43) (117). Compared to antiplatelet 
therapy, dose-adjusted VKA was also more efficacious in a reduction of TE complication 
[relative risk reduction 39% (95% CI 22-52) from 12 trials, 12, 963 participants] (117). 
However, VKAs have a narrow therapeutic index requiring dose adjustments and frequent 
monitoring of the international normalised ratio (INR) to achieve maximum therapeutic effect 
and minimise harm. Furthermore, individual response to VKA can be influenced by many 
factors (see section 1.5, pages 78-100 for more detail) (3). Nonetheless, VKA is still the 
recommended OAC of choice in AF patients with severe renal impairment (CrCl<15ml/min) 
and patients with valvular heart disease requiring mechanical valve prosthesis (3). When VKA 
is used, attention needs to be given on the quality of anticoagulation reflected by the time in 
therapeutic range (TTR) of the INR (3). To maximise effectiveness and safety of VKA, the 
European guidelines (3) have recommended a TTR of ≥70% while the NICE guideline (118) 
recommended TTR of ≥65%. Several studies (119-122) have also shown that TTR 
independently predict thromboembolic (120, 122), bleeding events (120, 121) and improves 
survival (119, 122) in AF patients prescribed with VKA therapy.  
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Table 1.7: Adjusted-dose warfarin versus placebo or no treatment, taken directly from 
Hart 2007 (117)  
Study, year Patients, 
N 
Target INR Strokes/patients, n/n 
a. warfarin  
b. placebo or control 
Relative risk 
reduction  
(95% CI), % 
AFASAK I, 
1989(123), 
1990(124) 
671 2.8-4.2 a. 9/335  
b. 19/336 
54 * 
BAATAF, 1990(125) 420 1.5-2.7 a. 3/212  
b. 13/208 
78*  
SPAF 1, 1991(126) 421 2.0-4.5 a. 8/210  
b. 19/211 
60* 
CAFA, 1991(127) 378 2.0-3.0 a. 6/187  
b. 9/191 
33* 
SPINAF, 1992(128) 571 1.4-2.8 a. 7/281  
b. 23/290 
70* 
EAFT, 1993(129) 439 2.5-4.0 a. 20/225  
b. 50/214 
68* 
6 trials 2900 - a. 53/1450  
b. 133/1450 
64 (49-74) 
INR: international normalized ratio; * 95% CI not stated in the Hart 2007 meta-analysis (117) 
1.4.1.2 Non-vitamin K antagonist oral anticoagulants (NOACs) 
With the emergence of non-VKA oral anticoagulants (NOACs), the practice of antithrombotic 
management has shifted toward prescribing NOACs for stroke prevention in patients with AF 
given the relative efficacy, safety and convenience of NOACs compared to VKAs (26). Four 
NOACs including the direct thrombin inhibitor, dabigatran and factor Xa inhibitors rivaroxaban, 
apixaban and edoxaban are suitable alternatives to VKAs for stroke prevention in AF.  Table 
1.8 list the different characteristics of warfarin and the four NOACs and Table 1.9 summaries 
the baseline characteristics of the four major NOAC trials.  NOACs have a more targeted mode 
of action, shorter time to reach the maximum anticoagulant effect, shorter half-life, less drug-
drug interactions and no food restrictions compared to warfarin. Tables 1.10 and 1.11 present 
the efficacy and safety results, respectively, from the four NOAC trials. Compared to warfarin, 
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dabigatran 150mg twice daily [RR 0.66 (95% CI 0.53-0.82)] and apixaban 5mg twice daily [RR 
0.79 (95% CI 0.66-0.95)] are associated with a lower risk of ischemic stroke and systemic 
embolism.  All four NOACs significantly reduced the risk of haemorrhagic stroke [dabigatran 
150 mg RR 0.26 (95% CI 0.14-0.49); rivaroxaban 20 mg RR 0.59 (95% CI 0.37-0.93); 
apixaban 5 mg RR 0.51 (95% CI 0.35-0.75); edoxaban 60 mg RR 0.54 (95% CI 0.38-0.77)] 
and intracranial haemorrhage [dabigatran 150 mg RR 0.40 (95% CI 0.27-0.60); rivaroxaban 
20 mg RR 0.67 (95% CI 0.47-0.93); apixaban 5 mg RR 0.42 (95% CI 0.30-0.58); edoxaban 
60 mg RR 0.47 (95% CI 0.34-0.63)] compared to warfarin. A meta-analysis (3) of the four 
major Phase 3 NOAC trials have also concluded that compared to warfarin, NOACs 
significantly reduced the risk of stroke and systemic embolism by 19% [RR 0.81 (95% CI 0.73-
0.91; p<0.0001)], and this is largely due to a significant reduction in haemorrhagic stroke [RR 
0.49 (0.38-0.64; p<0.0001)] (130). NOACs also significantly reduce intracranial haemorrhage 
[RR 0.48 (0.39-0.59; p<0.0001)] and all-cause death [RR 0.90 (0.85-0.950; p=0.0003)] but 
were also associated with increased risk of GI bleeding [RR 1.25 (1.01-1.55); p=0.04)] when 
compared to warfarin (3). 
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Table 1.8: Pharmacokinetics of warfarin versus NOACs and baseline characteristics for four randomised controlled trial cohorts comparing 
warfarin versus NOACs 
 Warfarin (131) Dabigatran (132) Rivaroxaban (133) Apixaban (134) Edoxaban (135) 
Mechanism of 
action 
Interfere with synthesis 
of vitamin K dependent 
clotting factors by 
inhibiting VKORC1 
Direct thrombin inhibitor Activated factor Xa inhibitor  Activated factor Xa 
inhibitor 
Activated factor Xa 
inhibitor 
Bioavailability, %  98 3-7 66 without food 
100% with food 
50 62 
Time to reach peak 
level, hours 
1.5-3 days 3 2-4 3 1-2 
Half-life, hours 20-60 12-17 5-13 9-14 10-14 
Clearance  Renal  80% renal 66% liver, 33% renal 27% renal  50% 
Dosing in AF Variable dose, once 
daily  
150mg or 110mg twice 
daily 
20mg or 15mg once daily 5mg or 2.5mg twice daily 60mg or 30mg or 15mg 
once daily 
Not recommended if  - CrCl<30ml/min CrCl<15ml/min CrCl<15ml/min CrCl<15ml/min 
Antidote Vitamin K Idarucizumab Not available Not available Not available 
 
 
Table 1.9: Baseline characteristics of the four randomised controlled trial cohorts comparing warfarin versus NOACs 
 Dabigatran (132) Rivaroxaban (133) Apixaban (134) Edoxaban (135) 
Patients, N 18,113 14,264 18,201 21,105 
Mean/median age 71.5 (8.7) 73 (65-78) 70 (63-76) 72 (64-78) 
Male, %  63.6 60.3 64.5 61.9 
Follow up, years 2 1.9 1.8 2.8 
CHADS2 score (mean) 2.1 3.5 2.1 2.8 
Median individualised TTR  67 (54-78) 58 (43-71) 66 (52-77) 68 (57-77) 
AF: atrial fibrillation; CrCl: creatinine clearance; CHADS score: 1 point each for congestive heart failure, hypertension, age >75 years, diabetes mellitus, and 2 points for stroke/TIA; TTR: time in therapeutic range; 
VKORC1: vitamin K epoxide reductase 
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Table 1.10: Efficacy outcomes in the four major randomised controlled trials comparing warfarin versus NOACs in AF populations 
 Dabigatran (132) 
(RE-LY) 
Rivaroxaban (133) 
(ROCKET-AF) 
Apixaban (134) 
(ARISTOTLE) 
Edoxaban (135) 
(ENGAGE AF-TIMI 48) 
Efficacy Outcomes 
 Dabigatran 
150mg 
N=6076 
Warfarin, 
 
N=6022  
Rivaroxaban 
20mg  
Warfarin Apixaban  
5mg  
N=9120† 
Warfarin,  
 
N=9081† 
Edoxaban 
60mg, 
N=7035† 
Warfarin,  
 
N=7036† 
Stroke/ systemic 
embolism, N (%/yr) 
134 (1.11) 199 (1.69) 269/7081† 
(2.1) 
306/7090† 
(2.4) 
212 (1.27) 265 (1.60) 296 (1.57) 337 (1.80) 
Relative risk (95% CI)  0.66 (0.53-0.82); p<0.001  0.88 (0.75-1.03); p=0.12* 0.79 (0.66-0.95); p=0.01* 0.87 (0.73-1.04)§; p=0.08 
Ischemic stroke, N 
(%/yr) 
111 (0.92) 142 (1.20) 149/7061‡ 
(1.34) 
161/7082‡  
(1.42) 
162 (0.97) 175 (1.05) 236 (1.25) 235 (1.25) 
Relative risk (95% CI)  0.76 (0.60-0.98); p=0.03* 0.94 (0.75-1.17); p=0.581* 0.92 (0.74-1.13); p=0.42 1.00 (0.83-1.19); p=0.97 
Haemorrhagic stroke, N 
(%/yr) 
12 (0.10) 45 (0.38) 29/7061‡  
(0.26) 
50/7082‡   
(0.44) 
40 (0.24) 78 (0.47) 49 (0.26) 90 (0.47) 
Relative risk (95% CI)  0.26 (0.14-0.49); p<0.001* 0.59 (0.37-0.93); p=0.0248 0.51 (0.35-0.75); p=<0.001* 0.54 (0.38-0.77); p<0.001 
All-cause mortality, N 
(%/yr) 
438 (3.64) 487 (4.13) 208/7061‡  
(1.87) 
250/7082‡  
(3.53) 
603 (3.52) 669 (3.94) 773 (3.99) 839 (4.35) 
Relative risk (95% CI)  0.88 (0.77-1.00); p=0.051* 0.85 (0.70-1.02); p=0.073* 0.89 (0.80-0.998); p=0.047* 0.92 (0.83-1.01); p=0.08 
* p for superiority; † based on intention to treat population; ‡based on safety on-treatment population; §97.5%CI was used  
 
  
 50 
Table 1.11: Safety outcomes in the four major randomised controlled trials comparing warfarin versus NOACs in AF populations 
 Dabigatran  
(RE-LY) (132) 
Rivaroxaban  
(ROCKET-AF) (133) 
Apixaban  
(ARISTOTLE) (134) 
Edoxaban (135) 
(ENGAGE AF-TIMI 48) 
Safety outcomes 
 Dabigatran 
150,  
N=6076 
Warfarin, 
 
N=6022  
Rivaroxaban 
20,  
N=7111 
Warfarin,  
 
N=7125 
Apixaban  
5,  
N=9088 
Warfarin,  
 
N=9052 
Edoxaban 60,  
 
N=7012 
Warfarin,  
 
N=7012 
Major bleeding N (%/yr) 375 (3.11) 397 (3.36) 395 (3.6) 386 (3.4) 327 (2.13) 462 (3.09) 418 (2.75) 524 (3.43) 
Relative risk (95% CI)  0.93 (0.81-1.07); p=0.31 1.04 (0.90-1.20); p=0.58 0.69 (0.60-0.80); p<0.001 0.80 (0.71-0.91); p<0.001 
Intracranial 
haemorrhage, N (%/yr) 
36 (0.30) 87 (0.74) 55 (0.5) 84 (0.7) 52 (0.33) 122 (0.80) 61 (0.39) 132 (0.85) 
Relative risk (95% CI)  0.40 (0.27-0.60); p<0.001 0.67 (0.47-0.93); p=0.02 0.42 (0.30-0.58); p<0.001 0.47 (0.34-0.63); p<0.001 
GI bleed, N (%/yr) 182 (1.51) 120 (1.02) 224 (3.15%) ¶ 154 (2.16%)¶  105 (0.76) 119 (0.86) 232 (1.51) 190 (1.23) 
Relative risk (95% CI)  1.50 (1.19-1.89); p<0.001 - 0.89 (0.70-1.15); p=0.37 1.23 (1.02-1.50); p=0.03 
Net clinical outcome, N 
(%/yr) 
832 (6.91)† 901 (7.64)† - - 1009 (6.13)‡ 1168 (7.20)‡ 1323 (7.26)§ 1462(8.11)§ 
Relative risk (95% CI)  0.91 (0.82-1.00); p=0.04 - 0.85 (0.78-0.92); p<0.001 0.89 (0.83-0.96); p=0.003 
 
 
†composite of stroke, systemic embolism, pulmonary embolism, myocardial infarction, death or major bleeding, ‡ composite of stroke, systemic embolism, major bleeding or all-cause death; §composite of stroke, systemic 
embolic event, major bleed, all-cause death;¶ percentage not %/yr and p<0.001 
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Another meta-analysis of ‘real-world’ high quality studies (28 studies included only from 
nationwide or health insurance claims database with adjusted or matched findings) of 
dabigatran, rivaroxaban and apixaban compared to warfarin for stroke prevention in AF has 
produced findings consistent with the RCTs (Table 1.12)  (136).  Dabigatran, rivaroxaban and 
apixaban all reduced the risk of intracranial bleed compared to warfarin, with similar risk of 
ischemic stroke and ischemic stroke/systemic embolism.  Mortality risk was lower with 
dabigatran and apixaban. There was less gastrointestinal (GI) bleeding and major bleeds with 
apixaban but higher risk of GI bleed with dabigatran and rivaroxaban, and similar risk of 
myocardial infarction with dabigatran and rivaroxaban compared to warfarin (Table 1.12). 
(136) Edoxaban was not included in this meta-analysis as no real world studies assessing 
edoxaban was published at the time of the searches.  
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Table 1.12: Meta-analysis of real word studies comparing dabigatran, rivaroxaban and apixaban to warfarin for efficacy and safety outcomes [from 
Ntaios et al(136)] 
 
Efficacy outcomes Dabigatran vs. warfarin Rivaroxaban vs. warfarin Apixaban vs. warfarin 
Ischemic stroke  (HR, 0.96; 95% CI, 0.80–1.16) (HR, 0.89; 95% CI, 0.76–1.04) (HR, 0.95; 95% CI, 0.75–1.19) 
Number of 
studies 
No of patients 9 476, 924 5 108, 810 3 48, 549 
Ischemic stroke/systemic 
embolism 
(HR, 1.17; 95% CI, 0.92–1.50) (HR, 0.73; 95% CI, 0.52–1.04) (HR, 1.07; 95% CI, 0.87–1.31) 
Number of 
studies 
No of patients 7 234, 739 4 54, 577 1 24, 993 
Any stroke/systemic embolism (HR, 0.93; 95% CI, 0.77–1.14) HR, 0.87; 95% CI, 0.71–1.07 (HR, 0.67; 95% CI, 0.46–0.98) 
Number of 
studies 
No of patients 2 66, 992 2 50, 620 1 15, 390 
Myocardial infarction (HR, 0.96; 95% CI, 0.77–1.21) (HR, 1.02; 95% CI, 0.54–1.89) - 
Number of 
studies 
No of patients 5 316, 180 2 24, 621 - - 
Safety outcomes 
 
Intracranial haemorrhage (HR, 0.42; 95% CI, 0.37–0.49) (HR, 0.64; 95% CI, 0.47–0.86) (HR, 0.45; 95% CI, 0.31–0.63) 
Number of 
studies 
No of patients 12 606, 855 7 136, 221 4 66, 482 
Gastrointestinal bleed (HR, 1.20; 95% CI, 1.06–1.36) (HR, 1.24; 95% CI, 1.08–1.41) (HR, 0.63; 95% CI, 0.42–0.95) 
Number of 
studies 
No of patients 10 537, 770 4 71, 368 2 33, 323 
Major bleed (HR, 0.83; 95% CI, 0.65–1.05) (HR, 1.00; 95% CI, 0.92–1.08) (HR, 0.55; 95% CI,0.48–0.63) 
Number of 
studies 
No of patients 13 348, 896 8 167, 532 4 89, 036 
Death  (HR, 0.63; 95% CI, 0.52–0.76) (HR, 0.67; 95% CI, 0.35–1.30) (HR, 0.65; 95% CI, 0.56–0.75) 
Number of 
studies 
No of patients 6 319, 486 2 51, 795 1 41, 785 
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1.4.2 Assessing risk factors for stroke 
Assessing risk factors for stroke in AF patients is essential before starting anticoagulation 
treatment. Stroke risk factors related to AF have been reported in various systematic reviews 
(137, 138). History of stroke/TIA [RR 2.5 (95%CI 1.8-3.5)], increasing age [RR 1.5 per decade; 
(95% CI 1.3-1.7)], history of hypertension [RR 2.0 (95% CI 1.6-2.5)] and diabetes mellitus [RR 
1.7 (95%CI 1.4-2.0)] were the most consistent risk factors for stroke as reported by the Stroke 
in AF Working group study (137). Female sex, vascular disease and heart failure have been 
less consistently associated with stroke risk in AF. One systematic review and meta-analysis 
reported an increased risk of strokes among females with AF [RR 1.31 (95%CI 1.18-1.46)] 
(139), while in another non-anticoagulated AF population, only females ≥75 years were at 
increased the risk of stroke [HR 1.20 (95%CI 1.12-1.28)] (140). Stroke risk in women is age-
dependent where women age <65 with no other stroke risk factors are classified as being at 
low risk of stroke (141).  Recently, another nationwide registry showed that female and male 
(with no additional risk factor) AF patients have similar thromboembolic risk. In addition, female 
gender acts as a ‘risk modifier’ rather than a risk factor whereby risk of TE is only higher in 
females with ≥2 non-gender stroke related risk factors with the acronym CHA2DS2-VA (heart 
failure, hypertension, aged 75 years, diabetes, stroke, vascular disease and age 65-74). 
Furthermore, in this registry, the risk of stroke differs by different score categories; the risk 
increases significantly with a score ≥2 (but not 3) thus modifying the stroke risk.  [CHA2DS2-
VA score 2: HR 1.21 (1.08-1.34); score 3: HR 1.03 (0.93-1.13); score 4: HR 1.25 (1.14-1.36); 
score 5: HR 1.41 (1.27-1.56)] (142). 
In terms of vascular disease, the OPTIMAL trial showed increased risk of stroke [adjusted HR 
of 14.6 (95% CI 5.87-36.3)] among new-onset AF patients 30 days after acute myocardial 
infarction (143), while another Danish study also reported increased risk of stroke among 
patients with peripheral arterial disease [HR 1.93 (95% CI 1.70-2.19)] (144). Left ventricular 
dysfunction (moderate to severe) was also seen as risk factor for stroke (RR 2.5 95% CI 1.5-
4.4) in one study (92) while another study showed no difference in the risk of stroke or 
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thromboembolism between different categories of ejection fraction (EF) [HR 0.75 (95% CI 
0.44-1.30) for EF <35% and HR 1.25 (95% CI 0.83-1.93) for EF 35-49% (145).  
1.4.3 Predicting stroke risk with clinical risk scores 
Various clinical risk scores to predict stroke, TIA or thromboembolism (TE) in AF patients have 
been developed since the 1990’s (Table 1.13). The risk scores were developed based on 
common demographic and clinical factors found in AF patients (141). Table 1.13 presents 
eleven risk scores to predict stroke in AF population. The most common risk factors present 
in these risk scores are prior thromboembolic events and diabetes mellitus (present in all 
eleven risk scores). Increasing age and hypertension were present in ten of the risk scores 
followed by female sex and heart failure (in 6 scores), and vascular disease (5 scores).  
1.4.3.1 CHA2DS2-VASc score  
Among all the risk scores mentioned in Table 1.13, only the CHA2DS2-VASc score will be 
discussed in more detail as it is the most widely validated risk score and is recommended by 
most major AF clinical guidelines (see next section). The CHA2DS2-VASc score (Table 1.14) 
was developed in 2010 (146), almost a decade after the development of CHADS2 score. 
Compared to the CHADS2 score, it included three additional stroke risk factors:  female sex, 
age 65 to 74 and vascular disease.  In addition, the CHA2DS2-VASc score more clearly defined 
the ‘congestive heart failure’ factor to include those with moderate to severe LV dysfunction 
(ejection fraction<40%), recent decompensation of heart failure either with preserved or 
reduced ejection fraction. Furthermore, 2 points was awarded for those aged ≥75 years (146) 
as increasing age is a strong predictor of stroke (137). 
The CHA2DS2-VASc score was first validated in the Euro Heart Survey cohort of 1084 non-
valvular, non-anticoagulated AF patients (146). In this study, increasing rates of TE can be 
seen as the CHA2DS2-VASc score increases (Table 1.15). The same trend was also seen 
when it was validated in the SPORTIF III and IV cohort (147) but lower TE rates from the 
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anticoagulated cohort were evident compared to the non-anticoagulated cohort. Slight 
improvement in the ability to predict stroke with the CHA2DS2-VASc score compared to the 
CHADS2 score were shown in both studies [C index 0.60 vs. 0.56 in Euro Heart Survey cohort 
(146) and C index 0.65 vs. 0.64 for in the SPORTIF III and IV cohort (147) for CHA2DS2-VASc 
and CHADS2 respectively]. 
The CHA2DS2-VASc score was further validated in several other cohorts (118, 144, 148, 149) 
including in non-Western cohorts (150, 151). Compared to the CHADS2 score, the CHA2DS2-
VASc score was able to predict stroke events in two Chinese studies [C index: 0.53 (150) and 
0.72, respectively] (151). 
 56 
Table 1.13: Risk factors in stroke risk stratification schemes, updated from Lip et al 2015 (141) 
 Risk factors  Other factors  
Scores  Age, y Female sex Prior TE 
event 
Hypertension  Heart failure Diabetes 
mellitus  
Vascular 
disease  
 
AFI, 1994(152) 65-75, >75  ü ü  ü   
SPAF, 1999(153) >75† ü† ü ü  ü   
CHADS2, 2001(154) ≥75  ü ü ü ü   
Framingham, 2003 (155) ü ü ü ü  ü   
vanWalraven, 2003(156)   ü ü  ü ü  
Rietbrock, 2008 (157) ü ü ü   ü   
CHA2DS2-VASc, 
2010(146) 
65-74, ≥75 ü ü ü ü ü ü  
QStroke, 2013(158) ü ü ü ü ü ü ü Many other‡ 
ATRIA, 2013(159) ü ü ü ü ü ü ü Proteinuria, eGFR 
CHADS2, 2013, 
Japan(160) 
≥65  ü ü ü ü ü Cardiomyopathy  
CHADS65, 2014 (161) ≥65  ü ü ü ü   
eGFR: estimated glomerular filtration rate; TE: thromboembolism; vascular disease: prior myocardial infarction, aortic plaque or peripheral arterial disease 
†age and female sex is combined as a single factor; ‡ ethnicity (self-assigned), smoking status, ratio of total serum cholesterol to high density lipoprotein, cholesterol concentrations, body mass index, 
family history of coronary heart disease in first degree relative under 60 years, Townsend deprivation score, treated hypertension, diabetes type I and II, renal disease, rheumatoid arthritis, valvular 
heart disease and atrial fibrillation 
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Table 1.14: CHA2DS2-VASc score components 
CHA2DS2-VASc components   
CHF or LVEF ≤40% 1 
Hypertension 1 
Age ≥75 years 2 
Diabetes 1 
Stroke/TIA/ thromboembolism 2 
Vascular Disease* 1 
Age 65-74 1 
Female sex 1 
Total score: 9 
Low risk: 0 male 
1 female 
High risk:  ≥ 1 male 
≥2 female 
LVEF: left ventricular ejection fraction*prior myocardial infarction, peripheral artery disease or aortic plaque 
 
Table 1.15: CHA2DS2-VASc score and thromboembolic risk taken directly from Lip et 
al from the European Heart survey (146)  and SPORTIF III and IV trial (147)  
CHA2DS2-
VASc score 
European Heart survey cohort (146) SPORTIF III and IV cohort (147) 
TE rate at 1 year 
(95% CI) 
Adjusted 1 year 
TE rate, %# 
TE rate at 1 year 
(95% CI) 
Adjusted 1 year 
TE rate, %† 
0 0 0 0 0 
1 0.6 (0.0-3.4) 0.7 0.46 (0.10-1.34) 1.3 
2 1.6 (0.3-4.7) 1.9 0.78 (0.44-1.29) 2.2 
3 3.9 (1.7-7.6) 4.7 1.16 (0.79-1.64) 3.2 
4 1.9 (0.5-4.9) 2.3 1.43 (1.01-1.95) 4.0 
5 3.2 (0.7-9.0) 3.9 2.42 (1.75-3.26) 6.7 
6 3.6 (0.4-12.3) 4.5 3.54 (2.49-4.87) 9.8 
7 8.0 (1.0-26.0) 10.1 3.44 (1.94-5.62) 9.6 
8 11.1 (0.3-48.3) 14.2 2.41 (0.53-6.88) 6.7 
9 100 (2.5-100) 100 5.47 (0.91-27.0) 15.2 
TE: thromboembolic events # Theoretical TE rates without therapy: corrected for the % of patients receiving aspirin within each 
group, assuming that aspirin provides a 22% reduction in TE risk, based on Hart et al. (1) †Theoretical TE rates without therapy: 
assuming that warfarin provides a 64% reduction in TE risk, based on Hart et al. (1); CI indicates confidence interval. 
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All of the ‘clinical factor’ based risk scores have modest predictive ability (C-index 
approximately 0.6) for identifying ‘high risk’ groups thus addition of biomarkers (such as D-
dimer, natriuretic peptides, von Willebrand factor) has been shown to improve the predictive 
ability of identifying the high-risk group (141, 162-164). However, despite addition of several 
biomarkers, only slight improvement in the predictive abilities of the scores can be seen 
changing the C-index to 0.65-0.70 (162-164). Measurement of biomarkers results in additional 
cost and loss of simplicity in risk score calculation making such scores less easy to use in 
everyday clinical practice (141).   
1.4.4 Guidelines and recommendations for stroke risk stratification and 
antithrombotic therapy  
Previously, the focus of the older risk scores was to divide patients into low risk, moderate risk 
and high risk of stroke. However, evidence has shown that identifying ‘high risk’ patients leads 
to under treatment with OAC in these groups (165, 166). Thus, the focus now has shifted 
towards identifying ‘low risk’ patients (CHA2DS2-VASc =0 in males or 1 in females). Many 
studies (167-169) have demonstrated that the CHA2DS2-VASc score is best at identifying the 
‘truly low risk’ patients for whom the risk of stroke or systemic embolism is <1% per year. Due 
to this, the latest European Society of Cardiology (ESC)(3), the National Institute for Health 
and Care Excellence (NICE) (118), American (170), Australian (150) and Asia Pacific (171) 
guidelines (Table 1.16) have recommended using the CHA2DS2-VASc score to stratify stroke 
risk.  The Canadian Cardiovascular Society (CCS) 2016 (172) recommends the modified 
CHADS65 score, although it acknowledges that other risk factors (also present in CHA2DS2-
VASc score) such as age >65, prior myocardial infarction, aortic plaque and peripheral arterial 
disease.  
All of the latest AF guidelines recommend OAC, with either a NOAC or well-controlled VKA 
(TTR ≥70%), for all AF patients who are not deemed ‘low risk’, with preference for a NOAC in 
most guidelines (1, 28-30). The recommendation for no antithrombotic therapy for low risk 
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patients and use of OAC in high-risk patients (those with ≥2 stroke risk factors) is consistent 
in all guidelines (except in the Australian guideline (150), where the recommendation is no 
antithrombotic or aspirin in the low risk group). However, AF guidelines (3, 150, 170, 173) 
have conflicting recommendations for patients in the intermediate risk groups with a single 
stroke risk factor where some (3, 173) considered OAC based on patient preferences and 
others (150, 170) with the recommendation of ‘No antithrombotic therapy or treatment with 
OAC or aspirin may be considered’. 
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Table 1.16: Guideline recommendations for stroke prevention in AF  
 Risk score   Risk categories (scores) Recommendations  
APHRS 2017(171) CHA2DS2-VASc Asia pacific CHA2DS2-VASc =0 or 1 in female No antithrombotic therapy 
CHA2DS2-VASc=1 in male NOAC preferred (D, R, A, E) or well 
controlled VKA 
CHA2DS2-VASc ≥2  NOAC preferred (D, R, A, E)  
 
ESC 2016 (3) 
 
CHA2DS2-VASc 
 
European  
 
CHA2DS2-VASc =0 or 1 in female 
 
No antithrombotic therapy 
CHA2DS2-VASc = 1 in male and 2 in 
female 
OAC should be considered depending on 
individual characteristics or patient 
preference  
CHA2DS2-VASc ≥2 in male ≥3 in female NOAC (preferred) or well controlled VKA 
 
CCS 2016 (172) 
 
CHADS65 
 
Canada 
 
Age <65 without CHADS2 risk factors, 
CAD/ coronary, aortic or peripheral 
vascular disease  
 
No antithrombotic therapy  
 
Age <65, no CHADS2 risk factor but have 
CAD/coronary, aortic or peripheral 
vascular disease  
 
OAC- NOAC preferred over to VKA 
 
Age <65 and one of CHADS2 risk factors 
-Heart failure 
-Hypertension 
-Diabetes Mellitus 
-Stroke/TIA/peripheral embolism 
 
OAC- NOAC preferred over to VKA 
 
Age ≥65 
 
OAC- NOAC preferred over to VKA 
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Table 1.16 continued  
NICE 2014 (118) CHA2DS2-VASc United 
Kingdom 
Low risk  
(0 male) 
(1 female) 
No antithrombotic therapy 
High risk 
(1 male) 
(≥2 female) 
 
Well controlled VKA or NOAC 
2014 AHA/ACC/HRS 
Guideline 
for the Management 
of Patients 
With Atrial Fibrillation 
(170) 
CHA2DS2-VASc America  CHA2DS2-VASc =0 No antithrombotic therapy 
CHA2DS2-VASc score =1 
 
No antithrombotic therapy or treatment with 
oral anticoagulant or aspirin may be 
considered 
With prior stroke, TIA, or CHA2DS2-VASc 
score ≥2 
 
CHA2DS2-VASc score ≥2 and end stage 
CKD (CrCL<15ml/min) or on 
haemodialysis 
 
CHA2DS2-VASc score ≥2 moderate to 
severe CKD  
VKA, D, R, A 
 
 
VKA 
 
 
 
Reduced doses of direct thrombin or factor 
Xa inhibitors may be considered 
 
CCS 2014 (161) 
 
CHADS65 
 
Canada  
 
Age <65 without CHADS2 risk factors, 
CAD/ coronary, aortic or peripheral 
vascular disease  
 
No antithrombotic therapy  
 
Age <65, no CHADS2 risk factor but have 
CAD/coronary, aortic or peripheral 
vascular disease  
 
ASA  
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Table 1.16 continued  
    
Age <65 and one of CHADS2 risk factors 
-Heart failure 
-Hypertension 
-Diabetes Mellitus 
-Stroke/TIA/peripheral embolism 
 
OAC- NOAC preferred over to VKA 
Age ≥65 OAC- NOAC preferred over to VKA 
Atrial Fibrillation 
Information for the 
Health Practitioner 
(2014)(150) 
CHA2DS2-VASc 
 
Australia  Age <65 without CHADS2 risk factors, 
CAD/ coronary, aortic or peripheral 
vascular disease 
No antithrombotic therapy or aspirin only 
CHA2DS2-VASc=1 
1 clinically relevant non-major risk factor  
Evidence of treatment is limited but options 
include: 
-No antithrombotic treatment, aspirin 75-
300mg daily or OAC. Aspirin and OAC is 
unlikely to have a net clinical benefit unless 
HAS-BLED score is low 
CHA2DS2-VASc ≥2 
1 ‘major’ risk factor or ≥ 2 clinically 
relevant non-major risk factor 
-New OAC is preferred to warfarin (target 
INR 2.5) 
 
APHRS 2013 (174) 
 
CHA2DS2-VASc 
 
Asia pacific 
 
CHA2DS2-VASc =0 
 
No antithrombotic therapy  
CHA2DS2-VASc 1 NOAC (D/A) 
W/R (alternative) 
CHA2DS2-VASc ≥2 OAC (D/R/A/W) 
 
ESC 2012 (173) 
 
CHA2DS2-VASc 
 
European 
 
CHA2DS2-VASc =0 No antithrombotic therapy 
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Table 1.16 continued  
   CHA2DS2-VASc= 1 Well controlled VKA or NOAC  
OAC should be considered, based upon an 
assessment of the risk of bleeding 
complications and patient preferences. 
CHA2DS2-VASc ≥2 Well controlled VKA or NOAC  
When patient refuse any form of OAC, 
antiplatelet therapy with combination of ASA 
and clopidogrel or less effectively ASA  
ESC 2010(173) CHADS2 score European Low risk  
-No risk factor (<65 with lone AF) 
ASA or no antithrombotic 
 
 
Intermediate risk   
1 ‘clinically relevant non-major’ 
-Heart failure (moderate to severe LV 
systolic dysfunction, LVEF <40%)  
-Hypertension and/or diabetes mellitus 
-Female sex and/or age 65-74 years 
-Vascular disease 
 
Adjusted dose VKA (target INR 2.5) OR ASA 
75-325 mg daily 
 
 
 
 
 
    
High risk (CHADS2≥2) OR 1 ‘major’ or 
≥2 ‘clinically relevant non-major’ 
 
Major risk factor 
-Previous stroke, TIA, systemic embolism 
-Age ≥75 
 
 
VKA with target INR 2.5 
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Table 1.16 continued  
NICE 2006 (175) NICE  United 
Kingdom 
Low risk  
Age <65 with no moderate or high-risk 
factors 
ASA 75-300 mg daily 
Moderate risk 
-Age ≥65 with no high-risk factors 
-Age <75 with hypertension, diabetes, 
vascular disease 
Consider anticoagulation or ASA 75-300mg 
daily 
High risk 
-Previous thromboembolic event 
-Age ≥75 with hypertension, diabetes, 
vascular disease 
-Clinical evidence of valve disease, heart 
failure or impaired LV function 
VKA with target INR 2.5 
ACC/AHA/ESC 2006 
Guidelines for the 
Management of 
Patients With Atrial 
Fibrillation(58) 
 America No risk factors ASA 81 to 325 mg daily 
One moderate-risk factor 
-Age ≥75 
-hypertension 
-heart failure (EF ≥35%) 
-Diabetes mellitus 
ASA 81 to 325 mg daily, or warfarin (INR 2.0 
to 3.0, target 2.5) 
Any high-risk factor or more than 1 
moderate-risk factor 
High risk factors 
Previous stroke. TIA, embolism 
Prosthetic heart valves 
VKA (target INR 2.5) 
AF: atrial fibrillation; ASA: Aspirin; A: apixaban; D: dabigatran; E: edoxaban; R: rivaroxaban; CAD: coronary artery disease; CHADS score: 1 point each for congestive heart failure, hypertension, age 
>75 years, diabetes mellitus, and 2 points for stroke/TIA; CHA2DS2-VASc score: 1 point each congestive heart failure/left ventricular ejection fraction ≤40%, hypertension, age 65-74, diabetes mellitus, 
vascular disease and 2 points each for age>75 years and prior stroke/TIA; CrCl: creatinine clearance; EF: ejection fraction; INR: international normalised ratio; HAS-BLED: 1 point each for uncontrolled 
hypertension, abnormal renal or  liver function, stroke, prior bleeding labile INR,  age >65, interacting drugs and alcohol excess; LV: left ventricular; NOAC: non-vitamin K antagonist; TIA: transient 
ischemic attack; TTR: time in therapeutic range; VKA: vitamin K antagonist 
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1.4.5 Assessing bleeding risk in atrial fibrillation 
This section will summarise bleeding risk and the various bleeding risk scores developed for 
AF. The review has been published in the American Journal of Cardiology (176). 
Assessing bleeding risk is also important before prescribing OAC therapy to AF patients. Over 
the last decade, several risk scores have been proposed to predict bleeding events in AF 
patients on anticoagulant therapy. These scores have been tested and validated worldwide in 
many cohorts of AF (177-185) to support physicians in assessing bleeding risks (186). 
Recently, the ESC Guidelines on the management of AF 2016 has summarised bleeding risks 
(into modifiable and non-modifiable) and encouraged prompt attention to common modifiable 
bleeding risk. This includes hypertension (especially when systolic blood pressure is >160 
mmHg), labile INR or TTR <60% (in patients on VKA), medications predisposing to bleeding 
such as antiplatelet and non-steroidal anti-inflammatory drugs and lastly excessive alcohol 
consumption (≥8 drinks/week) (3, 141). 
1.4.5.1 Risk factors of bleeding 
Many risk factors of bleeding are included in the various bleeding scores shown in Table 1.17. 
The number of risk factors included in the bleeding risk scores ranges from three (177) to 12 
(181). All bleeding scores (177-182, 187) include common clinical factors that influence the 
risk of bleeding for example age, utilising different age ranges and cut-offs (ranging from above 
50 years old to above 85 years old) to indicate greater risk of bleeding; three scores include 
age ≥75 (178, 179, 181). After age, the most common bleeding risk factors included in the 
scores are as follows: (i) previous/remote bleeding (reported in 7 scores) (177-182, 187), (ii) 
renal disease (included in 5 scores) (178-181, 187), and (iii) anaemia (in 5 scores) (178, 179, 
181, 182, 187), hypertension (179-181), stroke (180, 181, 187), combined antiplatelet therapy 
(178, 180, 182) and alcohol excess (180-182) (all included in 3 scores). Two scores included 
diabetes (182, 187) and liver disease (180, 181) and one score included malignancy (181), 
reduced platelet count (181) and female sex (182).  
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Table 1.17: Risk factors for bleeding included in each bleeding risk score 
Risk factor ABC (177) ORBIT(178) ATRIA (179) HAS-BLED (180) HEMORR2HAGES(181) Shireman (182) OBRI (187) Total 
Age≥75 
 
✓ ✓ 
 
✓ 
  
3 
Age≥70 
     
✓ 
 
1 
Age≥65 
   
✓ 
  
✓ 2 
Age≥50 ✓ 
      
1 
Biomarkers ✓ 
      
1 
Previous/remote bleed ✓ ✓ ✓ ✓ ✓ ✓ ✓ 7 
Recent bleed 
     
✓ 
 
1 
Anaemia 
 
✓ ✓ 
 
✓ ✓ ✓ 5 
Renal disease 
 
✓ ✓ ✓ ✓ 
 
✓ 5 
Liver disease 
   
✓ ✓ 
  
2 
Hypertension 
  
✓ ✓ ✓ 
  
3 
Myocardial infarction 
      
✓ 1 
Diabetes 
     
✓ ✓ 2 
Malignancy 
    
✓ 
  
1 
Stroke 
   
✓ ✓ 
 
✓ 3 
Combined antiplatelet therapy 
 
✓ 
 
✓ 
 
✓ 
 
3 
Labile INR 
   
✓ 
   
1 
Alcohol excess 
   
✓ ✓ ✓ 
 
3 
Excessive fall risk 
    
✓ 
  
1 
Genetic factors 
    
✓ 
  
1 
Reduced platelet count 
    
✓ 
  
1 
Female sex 
     
✓ 
 
1 
Total risk factors 3 5 5 9 12 8 7  
ICU/CCU: intensive coronary care unit/ coronary care unit; INR: international normalised ratio; PE: pulmonary embolism 
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Two bleeding risk scores, HEMORR2HAGES (181) and the ABC bleeding score, (177) 
included factors that are not routinely available in daily clinical practice. HEMORR2HAGES 
included genetic testing, although this was not available in their cohort, and the ABC score 
included 3 biomarkers, GDF-15, cTnT-hs and haemoglobin.  
1.4.5.2 Derivation and validation studies for the bleeding risk scores 
Seven bleeding  (177-182, 187) risk scores have been developed and validated between 1989 
to 2016. Six were developed in AF patients (177-182), and one in a mixed disease cohort of 
patients (valvular heart surgery, mitral valve disease, AF, stroke, TIA, pulmonary embolism 
(PE), deep vein thrombosis (DVT), and other thromboembolism) (187). 
The mean/median age of study population in the derivation cohort ranged from 61(187) to 80.2 
years(181) (Table 1.18). Almost half of the population in the derivation studies were female 
and only three studies (178, 179, 187) reported ethnicity, which was predominantly White.  
Five out of six (177-180, 182) studies from the AF cohort reported hypertension as the 
common co-morbid disease present in their population whereas one study from the mixed 
cohort (187) reported kidney disease to be more prevalent in their patient population.  
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Table 1.18: Baseline patient characteristics of the derivation cohorts for each bleeding risk score 
CAD: coronary artery disease; CHF: congestive heart failure; GI: gastrointestinal; hb: haemoglobin; hct: haematocrit; MI: myocardial infarction; NOACs: newer oral anticoagulant;  
† warfarin users only; ‡ major bleed; # CAD; α<30ml/min; § renal failure; ¥ hepatic/renal failure; (-) not reported 
 Patients, % ABC ORBIT ATRIA HAS-BLED HEMORR2HAGES† Shireman OBRI  
Number of patients  14,537 7411 6123 3456 1604 19,875 556 
Mean age (SD)/median 
(IQR) 
70 (19-97) 75(68-82) - 66.8(12.8) 80.2 88% ≥70 years 61 (14) 
Sex (female) 36 42.4 41.8 39.3 57 52.5 53 
White ethnicity - 89.6 86.6 - - - 93 
History/ diagnosis of 
cancer 
- 23.9 15.2 - 4.8 2.5 - 
Anaemia/abnormal Hb/Hct - 36.6 12.4 - 8.5 7.5 - 
Hypertension  87 84.9 62.0 65.6 0.4 72 - 
Diabetes  25 30.6 20.6 18 - 29.6 8 
CHF 31 34.7 - 29.5 - 59.8 - 
MI 13 15.8 0.4 34.6# - 68.5# 4 
Prior stroke/TIA 19 9.5 12.6 10.4 37.2 32.1 12 
GI bleed - 8.0 7.1 1.8‡ - 11.9 10 
eGFR <60ml/min -  32.1 2.9α 5.3§ - 0.6¥ 18 
Antiplatelet  - 37.9 1.0 - - 22.3 - 
Warfarin  - 93.5 - - 42.3 28.7 - 
NOACs - 6.5 - - - - - 
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Table 1.19 presents the characteristics of derivation and validation studies of bleeding risk 
scores for AF. A prospective study design was used in three (177, 178, 180) out of six scores 
for AF populations. Two (179, 182) studies used a retrospective analysis and one study (181) 
derived their score from the previous bleeding score available in AF, while one  retrospective 
study design was used in mixed population (187). 
Most had follow-up for at least 1 year except by the first score developed by Shiremen et al 
(182) which followed their patients for the first 90 days following hospital discharge following 
AF diagnosis. All studies derived their risk score using bleeding risk factors from large cohorts 
of patients ranging from 3456 (180) to almost 20,000 (182) patients, apart from one study, 
Landefield et al which only included 556 patients (187).    
All bleeding risk scores stratified patients into three categories of bleeding risk (low, 
intermediate and high) except for the HAS-BLED score which initially categorised bleeding 
risk as high (score ≥3) and low-moderate risk (0-2) (141). These bleeding risk scores showed 
major bleeding rates ranging from 0.6%-3% in the low risk group and 4.9%-30% in the high-
risk group in the validation cohorts (Table 1.20).  
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Table 1.19: Characteristics of the Derivation and Validation cohorts for each of the bleeding risk scores and composition of each 
score 
Author, year, 
country 
Derivation cohort 
a. Study design 
b. Sample size 
c. Length of follow up 
d. Indication of 
anticoagulation 
Validation cohort 
a. Study design 
b. Sample size 
c. Length of follow up 
d. Indication of 
anticoagulation 
Major Bleed definition 
 
ABC (177) 
2016 
Sweden 
a. Prospective 
b. 14, 537 
c. 1.7 years (median) 
d. AF  
a. Prospective 
b. 8468 
c. 1.9 years (median) 
d. AF 
ISTH criteria: clinically overt bleeding with at least one of (i) 
decrease haemoglobin concentration 2 g/L or more; (ii) transfusion 
of 2 or more units of packed RBC; (3) that was fatal or occurred in 
critical area or organ (intracranial, intraspinal, intraocular, 
pericardial, intra-articular, intramuscular with compartment 
syndrome or retroperitoneal)  
 
ORBIT (178) 
2015 
USA 
 
 
a. Prospective 
b. 7411 
c. 2 years 
d. AF 
 
a. Prospective  
b. 14264 
c. Median 1.9 year 
d. AF 
 
 
(i) fatal bleeding and/or (ii) symptomatic bleeding in a critical area 
or organ (intracranial, intraspinal, intraocular, retroperitoneal,  
intra-articular or pericardial, or intramuscular with compartment 
syndrome), and/or (iii) bleeding causing haemoglobin level to fall of 
20 g/L (1.24 mmol/L) or more, or leading to transfusion of two or 
more units of whole blood or red cells. 
 
ATRIA (179) 
2011 
USA 
 
a. Retrospective  
b. 6123 
c. 6 years 
d. AF 
 
 
 
 
a. Retrospective  
b. 3063 
c. 6 years 
d. AF 
 
 
Fatal, requiring transfusion of 2 U packed blood cells, or 
haemorrhage into a critical anatomic site (e.g., intracranial, 
retroperitoneal) 
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Author, year, 
country 
Derivation cohort 
 
Validation cohort 
 
Major Bleed definition 
 
 
HAS-BLED 
(180) 
2010 
UK 
 
a. Prospective  
b. 3456 
c. 1 year 
a. AF 
 
 
a. Prospective  
b. 3071 
c. 1 year 
d. AF 
 
Any bleeding requiring hospitalization and/or causing a decrease in 
haemoglobin level of >2 g/L and/or requiring blood transfusion that 
was not a haemorrhagic stroke 
 
HEMORR2HAG
ES (181) 
2006 
USA 
 
a. Score derived from 3 
previously published 
bleeding scheme   
 
a. Retrospective  
b. 3791 
c. 36 months 
d. AF 
 
Any hospitalisation for haemorrhage determined by Medicare 
claims 
 
Shireman et al 
(182) 
2006  
USA 
 
a. Retrospective  
b. 19,875 
c. 3 months 
d. AF 
 
a. Retrospective  
b. 6,470 
c. 3 months 
d. AF 
 
 
Hospital admission for either a GI haemorrhage 
or intracranial haemorrhage according to the DRG and ICD-9 CM 
codes 
 
OBRI (187) 
1989 
USA 
 
 
a. Retrospective 
b. 556 
c. 48 months 
d. Valvular heart surgery, 
mitral valve disease, 
AF, stroke, TIA, PE, 
DVT, other 
thromboembolism  
 
a. Prospective 
b. 264 
c. 48 months 
d. VTE, prosthetic heart 
valve, others 
 
Overt bleeding that led to the loss of at least 2.0 units in 7 days or 
less, or was otherwise life-threatening 
 
 
 
 
 
 
AF: atrial fibrillation; DRG and ICD-9 CM codes:  Diagnosis Related Group and International Statistical Classification of Disease and Related Health Problems; GI: gastrointestinal; ISTH: International 
Society on Thrombosis and Haemostasis; PE: pulmonary embolism; RBC: red blood cell; TIA: transient ischemic attack; U: units; VTE: venous thromboembolism 
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Table 1.20: Risk factors, risk categories and bleeding events in the validation cohorts 
 Risk factors and points awarded Risk categories Bleeding events in validation cohort (per 100 patient years) 
ABC Age    
Biomarkers  Low: <1%  0.62  
GDF-15 Medium: 1-2% 1.67   
cTnT-hs High: >3% 4.87   
Haemoglobin   
Clinical history (previous bleeding)   
     
ORBIT Older age ≥75 years 1 Low : 0-2 2.4a 
Reduced haemoglobin/ hct/anaemia 2 Medium : 3 4.7  
Bleeding history 2 High : ≥4 8.1  
Insufficient kidney function 1 
  
Treatment with antiplatelet 1 
  
Total  7 
  
    
ATRIA Anaemia 3 Low : 0-3 0.83  
Renal disease 3 Intermediate : 4 2.41  
Age ≥75 years 2 High : 5-10 5.32  
Prior bleeding 1 
  
Hypertension 1 
  
Total  10 
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Table 1.20 continued  
 Risk factors and points awarded Risk categories Bleeding events in validation cohort (per 100 patient years) 
HAS-BLED Elevated systolic Hypertension 1 Low : <3 0=1.13  
Abnormal renal and liver function (1 pt 
each) 
1/2 High : ≥3 1=1.02   
Stroke 1 
 
2=1.88   
Bleeding 1 
 
3=3.74   
Labile INR 1 
 
4=8.70   
Elderly >65 years 1 
 
5=12.50   
Drugs or alcohol (1 pt each) 1/2 
 
6=0.0 
Total  9 
 
7=-    
8=-    
9=-    
Any score=1.56   
    
HEMORR2HAGES Hepatic or renal disease 1 Low : 0-1 1.9-2.5  
Ethanol abuse 1 Intermediate : 2-3 5.3-8.4  
Malignancy 1 High : ≥4 10.4-12.3  
Older age >75 years 1   
Reduced platelet count or function 1   
Re-bleeding risk 2   
Hypertension (uncontrolled) 1   
Anaemia 1   
Genetic factors 1   
Excessive fall risk 1   
Stroke 1   
Total  12   
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Table 1.20 continued  
 Risk factors and points awarded Risk categories Bleeding events in validation 
cohort (per 100 patient years) 
Shireman et al Age ≥70 years 0.49 Low: ≤1.07 0.9% Within 90 days 
Female 0.31 Moderate : >1.07 but <2.19 2.0% within 90 days 
Remote bleeding 0.58 High : ≥2.19 5.4% within 90 days 
Recent bleeding 0.62   
Alcohol/drug abuse 0.71   
Diabetes 0.27   
Anaemia 0.86   
Antiplatelet 0.32   
Total  4.16 
 
 
 
 
OBRI 
  
Age ≥65 years 1 Low : 0 3% at 12 month 
History of stroke 1 Intermediate: 1-2 8% at 12 months 
History of GI  bleed 1 High : 3-4 30% at 12 months 
Recent MI, anaemia, DM, 
creatinine>1.5mg/dl 
1 
  
Total  4     
cTnT-hs: Troponin T; DM: diabetes mellitus; GDF-15: growth differentiation factor-15; GI: gastrointestinal; hct: haematocrit; INR: international normalised ration; MI: myocardial 
infarction; PE: pulmonary embolism; P/Y: person years; pt: point 
a bleeding event in original derivation cohort; b clinically important bleeding: sum of major bleed and clinically relevant non-major; (-) not available 
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The earliest bleeding score developed by Landefeld et al (187) in 1989 derived five predictive 
factors of major bleeding in a mixed population. One of the original risk factors was AF but this 
was later removed when the score was validated in 1989, as its association with major 
bleeding in the derivation cohort was no longer significant in the validation cohort.  Diabetes 
mellitus was substituted instead of AF as a new predictor of major bleeding.  
1.4.5.3 Performances of bleeding risk scores 
The ability of the bleeding risk scores to predict bleeding risk has been validated in both similar 
cohort where the score was derived (3 studies) (179, 180, 182) and in independent validation 
cohort (4 studies) (177, 178, 181, 188). In the validation and comparison study by Hijazi et al 
(177),  the ABC score statistically outperformed the HAS-BLED and ORBIT scores in 
predicting major bleeding in both the derivation cohort [0·68 (95% CI 0·66–0·70) vs. 0·61 
(0·59–0·63) vs. 0·65 (0·62–0·67) respectively; ABC-bleeding vs. HAS-BLED p<0·0001 and 
ABC-bleeding vs. ORBIT p=0·0008] and the external validation cohort [0·71 (95% CI 0·68–
0·73) vs. 0·62 (0·59–0·64) for HAS-BLED vs. 0·68 (0·65–0·70) for ORBIT; ABC-bleeding vs. 
HAS-BLED p<0·0001 and ABC-bleeding vs. ORBIT p=0·0016](177). Although the ABC score 
performed better than the HAS-BLED and ORBIT scores in this report, the complexity of the 
algorithm and testing for biomarkers which are not routinely performed in daily clinical practice, 
may make it difficult and costlier, for physicians to apply routinely.  
One recent meta-analysis (189) compared the diagnostic accuracy between HAS-BLED and 
HEMORR2HAGES, ATRIA, CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with 
AF. The findings revealed that the HAS-BLED score performed better than the 
HEMORR2HAGES and ATRIA bleeding scores, as well as being superior to CHADS2 or 
CHA2DS2-VASc in predicting bleeding.  Despite having better performance when compared 
to HEMORR2HAGES, ATRIA and ORBIT, an additional advantage of the HAS-BLED score 
over the other five bleeding scores is the inclusion of quality of anticoagulation control (the ‘L’ 
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acronym for labile INR or poor TTR<65%). TTR reflects anticoagulation control in patients 
taking a VKA; a target TTR of ≥70% is optimal for efficacy and safety (173).  
In a post-hoc analysis evaluating the performance of HAS-BLED, ATRIA and ORBIT bleeding 
risk scores in the AMADEUS trial (190), TTR was strongly correlated with clinically relevant 
bleeding events in patients using the ATRIA and ORBIT score, thus demonstrating that 
incorporating TTR in bleeding scores improves their ability to predict future bleeding events.  
Another comparison of four bleeding risk scores (HAS-BLED, ORBIT, ATRIA and 
HEMORR2HAGES) in the SPORTIF cohort (191)  also investigated whether the addition of  
‘labile INR’ (TTR<65%) improved bleeding risk prediction (with the exception of the HAS-BLED 
score which already contains labile INR). Addition of  ’labile INR’ to ORBIT, ATRIA and 
HEMORR2HAGES bleeding risk scores, significantly improved the predictive performance of 
each score for major bleeding [integrated discriminatory improvement (IDI) 0.0023, p=0.0092 
vs. IDI 0.0020, p=0.00014 vs. IDI 0.0015, p=0.0016 respectively](191). 
Apostolakis et al (192) compared the predictive performance of HAS-BLED with 
HEMORR2HAGES and ATRIA in the AMADEUS trial and demonstrated that the HAS-BLED 
score performed better than HEMORR2HAGES and ATRIA score in predicting any clinically 
relevant bleeding, with only the HAS-BLED score demonstrating significant improvement for 
intracranial haemorrhage(192). In another ancillary analysis of the same trial (193), the HAS-
BLED score performed better than the ORBIT score in predicting any clinically relevant bleed 
in a non-oral anticoagulant (idraparinux)(193). 
More recently the predictive ability of the HAS-BLED score was also investigated in patients 
receiving NOAC therapy, with rivaroxaban, in a small retrospective case-control study(194); 
the HAS-BLED score demonstrated some diagnostic ability to predict major bleeding events 
although this was not  statistically significant (C statistics=0.68; p=0.07) (194). Analyses have 
demonstrated that the HAS-BLED score not only performs well in predicting bleeding events 
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in VKA treated patients with AF, it can also be used to predict bleeding events in non-VKA 
treated patients which is very useful as more AF patients are being treated with NOACs.  
 
The next section will summarise factors affecting anticoagulation control in stroke prevention 
in AF. 
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1.5 Anticoagulation control in stroke prevention  
Studies (119, 122, 195) have shown that good anticoagulation control is associated with 
reduction of thromboembolic complications while the risk of intracranial haemorrhage is 
significantly higher in patients with high INR values (INR>4.0) (196). Therefore, it is important 
to identify factors that might affect anticoagulation control in patients taking oral 
anticoagulants. 
1.5.1 Factors affecting anticoagulation control 
These factors can be divided to demographic and clinical factors (Table 1.21) and non-clinical 
factors (Table 1.22).  
Table 1.21: Demographic and clinical factors affecting anticoagulation control 
†continuous variable; * hypertension, diabetes mellitus, coronary artery disease/myocardial infarction, peripheral arterial disease, 
congestive heart failure, previous stroke (ischemic or haemorrhagic), pulmonary disease, and hepatic or renal disease, venous 
thromboembolism, thrombocytopenia, anaemia; ¥lack of participation (no access or plan) in a dedicated anticoagulation 
management when VKA is initiated  
Demographic factors Lab parameters 
Sex (female) (197-203)  Albumin, g/dL†  (204) 
Age † (198-200, 204-207)  Neutrophil, %†  (204) 
Younger age (<50 years) (198-200, 204-207)  Red blood cell count, x106/mcL† (204) 
Tobacco use (within 2 years) (199, 205, 208) Red blood cell distribution width, %† (204) 
Ethnicity (non-white)(195, 198, 209, 210)  
Alcohol  (204)   
Clinical factors 
Warfarin naïve (195) Non-standardised target INR (201) (211) 
Medical history* (200, 201) (131, 204, 212)  Changes in gut flora (131) 
Pneumonia (213) Numerous drug interaction (e.g., 
amiodarone, antibiotics, pain medications, 
aspirin) (131, 199, 204, 213) 
Bleeding history (213) Genetics (214-217) 
Hospital stays ≥7days (213) Uncontrolled systolic blood pressure, mm 
Hg†  
No enhanced anticoagulation care¥ (213) Body mass index kg/m2 † (204) 
Paroxysmal AF (195)  
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Table 1.22: Non-clinical factors affecting anticoagulation control 
Patient factors Physician factor Health care system factors 
Knowledge and behavioural 
factors (218-220) 
Bleeding risk(221) Hospital based vs. community-
based vs. clinical trial (206, 
222, 223) 
Adherence (224-227)  Lower targeted INR range  
(1.6-2.5) (221) 
Models of care (228-232) 
 
Socioeconomic status (200, 
233) 
Different treatment priorities 
(221) 
 
Dietary and herb interaction  
(234, 235)  
  
Fasting (236, 237)   
 
1.5.1.1 Demographic and clinical factors affecting anticoagulation control 
1.5.1.1.1 Female sex 
Differences in the quality of anticoagulation therapy between males and females have been 
observed in some studies while other studies have not confirmed this. Seven studies (197-
203) investigating predictors of TTR have demonstrated that women have poorer 
anticoagulation control compared to men although the precise mechanism remains unclear 
and should be investigated further (199). Poor anticoagulation control can be translated to 
poorer clinical outcomes among women. The SPORTIF trial comparing warfarin vs. 
ximelagatran (238) has shown that compared to males, females with AF were older, had more 
stroke risk factors and had higher risk of stroke and thromboembolic events [2.08%/year, (95% 
CI 1.60–2.56%/year vs. 1.44%/year, 95% CI 1.18–1.71%/year in men; p=0.016)] (238). A 
meta-analysis (139) has also shown that female patients have higher residual risk of stroke 
and systemic embolism despite the use of warfarin [OR 1.3, (95% CI 1.11 to 1.47); p=0.001] 
as compared to the male patients (239). It can be speculated that maybe females have more 
interruptions (238) (probably due to menopausal transitions), have more stroke risk factors 
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(238) and have the fear of the bleeding complications while on anticoagulation therapy leading 
to poorer anticoagulation control compared to males. 
1.5.1.1.2 Younger age (<50-60 years)  
Some studies (198-200, 204-207) have shown that younger patients, in particular those <50 
years old (206, 207, 240), have poorer anticoagulation control compared to older patients, 
although the precise mechanism remains uncertain. It could be speculated that perhaps 
younger patients have more active lifestyle, are less motivated to manage their AF due to 
competing demands on their time (job, less leisure time) (199, 200) and have medication 
adherence issues which might impact their quality of anticoagulation control.   
1.5.1.1.3 Older age  
Although studies have shown that younger patients have poorer anticoagulation control with 
VKA therapy, the quality of anticoagulation control among the very elderly (aged ≥80 years) is 
also perceived to be low (241-244). This perception leads to a lower prescription rate among 
the very elderly patients (241, 245, 246). The ageing population with AF is increasing; they 
too require effective anticoagulation therapy. However, anticoagulation in the elderly is not a 
simple matter due to the increased risk of bleeding associated both with age per se and the 
greater risk of co-morbidities and polypharmacy (241, 247, 248). Also, VKA therapy may be 
more difficult among the elderly due to the frequency of INR monitoring required (which may 
be more problematic if it requires travel to an anticoagulant clinic), dietary intake and drug 
interactions (249).  
Among the studies in the elderly anticoagulated population, few report anticoagulation control 
with the exception of the WASPO (250) and BAFTA (251) trials with mean TTR 67 and 69 
respectively. Good anticoagulation control (mean TTR 71% in both studies) was seen in 
another two Italian studies of their elderly cohort of ≥80 (247) and ≥75 (252) years. However, 
a much lower TTR (mean age 77, mean TTR 58%) can be seen in another study (241) of  
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elderly patients in the inception warfarin period. None of these studies (241, 247, 252) 
investigated the association of age with TTR but two studies (241, 247) showed that increasing 
age (age ≥80 years for both studies) was significantly associated with bleeding events 
[adjusted OR 2.0 (1.1-4.0); p=0.05 (247) and unadjusted incidence rate 2.75 (1.27-5.95) 
(241)].  
1.5.1.1.4 Medical history  
Numerous studies have shown that comorbid diseases influence patients’ quality of 
anticoagulation with warfarin therapy.  Poorer anticoagulation control is associated with heart 
failure (197-202, 253-255), diabetes (197-200, 202, 205, 256), kidney disease (198, 199, 201, 
213, 257), liver disease (198, 199, 254, 257), lung disease (199, 201, 204, 205), coronary 
artery disease (199, 201), peripheral vascular disease (199, 201), stroke (199, 204), 
pneumonia (205, 213), cancer (201, 258), major depression (201, 259), venous 
thromboembolism (204, 258), previous bleeding (213),  thrombocytopenia (204), bipolar 
disorder (259), and psychosis (259). The exact mechanism of this relationship is unclear but 
perhaps this reflects greater illness burden and complexity, more medications leading to 
increased risk of non-adherence, polypharmacy and drug interactions (will be described in 
more detail in section 1.5.1.1.9 page 86), poorer quality of life which all might lead to poorer 
anticoagulation control (200).  
1.5.1.1.5 Chronic kidney disease (CKD)  
Among all the other comorbid disease affecting anticoagulation control, the impact of CKD 
towards anticoagulation control will be discussed in more detail. This is because studies have 
shown an increased risk of bleeding among AF patients with CKD (especially those with 
severe renal impairment and on dialysis) while using OACs (260-262). Nonetheless, studies 
(263-266) have also shown that good anticoagulation control while on VKA therapy among 
CKD patients is associated with reduced risk of stroke [HR 0.60 (95%CI 0.39-0.93)], major 
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bleeding [HR 0.58 (95%CI 0.42-0.80)] and mortality [HR 0.61 (95% CI 0.46-0.82). (264) To 
date, eight studies (263-270) have presented information on anticoagulation control among 
AF patients with CKD.  All studies showed a decrease in TTR as the kidney function worsened. 
Indeed, the presence of CKD was negatively associated with achieving good TTR [OR 0.75 
(0.67-0.92)] in the SPORTIF III and V trial cohort (264). Similarly, CKD was also as 
independent predictor of TTR in the Current Perspective of Anticoagulation in Clinical Practice 
in the Primary Care Setting (PAULA) study [unstandardized coefficient -3.4 (95% CI -5.51 to -
1.29); p=0.002] (270).  
The exact mechanism of poor TTR among CKD patients in unknown but studies have shown 
(270-272) patients with CKD are usually at risk for under- or over- anticoagulation; among the 
latter this is a result of reduced clearance of S-warfarin in CKD patients (273). Indeed, patients 
with end stage renal disease (ESRD) have a 50% increase in plasma warfarin S/R ratio 
compared to patients with normal renal function (274). This could perhaps reflect a decrease 
in CYP2C9 activity in patients with renal failure, thus necessitating a lower dose in these 
patients (274). Following that, Limdi et al (268, 275) showed that after accounting for clinical 
and genetic factors, patients with reduced kidney function were able to maintain therapeutic 
anticoagulation with lower warfarin dosage (average dose 3.9mg/day in severe group vs. 
4.8mg/day in normal group; p=0.0002) (268, 275).  
1.5.1.1.6 Treatment with interacting drug (e.g.: amiodarone) 
Pharmacological rhythm control strategies in AF, particularly with amiodarone, are known to 
have some effect on INR readings. Amiodarone, a potent inhibitor of both the S-enantiomer 
and R-enantiomer of warfarin (276) is known to inhibit the metabolism of warfarin thus 
potentiating an enhanced anticoagulant effect of warfarin  (277). In addition, amiodarone has 
a long half-life thus causing this potential drug interaction to occur for several weeks or months 
after cessation of amiodarone (277). This might lead to an increase in INR values in patients 
taking warfarin together with amiodarone thus translating into poorer TTR among these 
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patients. Apostolakis et al (199), in the original cohort of the SAMe-TT2R2 score, reported 
14.3% of patients were prescribed Amiodarone (for rhythm control) and this was associated 
with low TTR (ß=-0.03 95%CI (-0.06 to 0.0); p=0.05) (199). 
1.5.1.1.7 Smoking history 
Smoking is not only a predictor of poor anticoagulation control in three studies (199, 205, 208); 
it also has also been shown to predict severe bleeding in patients treated with warfarin therapy 
[HR 1.32; (95%CI 1.04-1.67; p=0.02)] in the Loire Valley AF Project (278). Meanwhile, a meta-
analysis of 13 studies (279) assessing the interaction between smoking and warfarin has 
shown that warfarin clearance might be enhanced by the effects of smoking, which in return 
leads to a reduction in the effects of warfarin. This meta-analysis also found that a significantly 
higher dose of warfarin was required in active smokers compared with non-smokers to achieve 
a therapeutic INR (279) which might explain the increased risk of bleeding among smokers.  
The exact relationship between smoking and anticoagulation control is unclear but it may 
reflect less interest in maintaining good health (among smokers) that may translate into poorer 
adherence to OACs, thus resulting in poor TTR. 
1.5.1.1.8 Ethnicity 
Studies have shown that ethnic minority groups (Blacks, Hispanics and Asians) have poorer 
anticoagulation control compared to Whites. Three studies (198, 209, 210) conducted in the 
United States and two trials (280, 281) comparing TTR among the Blacks and Whites have 
shown that mean TTR among Blacks was lower compared to Whites (Table 1.23). Similarly, 
in the SPORTIF III and IV trials (195), the proportion of patients from Black/African Americans 
was greater in the poor anticoagulation control group compared to moderate and good 
anticoagulation control group  (Table 1.23). 
These observations may be due to various reasons for example differences comorbid disease, 
socioeconomic status, poor understanding of therapy, adherence issue and genetic 
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background. Ethnic differences in anticoagulation control were evident in a cohort of 98,053 
patients (210) receiving warfarin therapy for various indications (AF, VTE and other mixed 
conditions), with lower mean TTR among the Blacks compared to Whites. Blacks were 
younger and lived in areas of highest quartile of poverty, had higher illness burden including 
more comorbid disease, requiring more medications and hospitalisations to manage those 
conditions compared to White patients (210). After accounting for all these factors, which are 
mostly non-modifiable, Black patients still had a recorded TTR 2.3% lower than White patients 
(210)  (Table 1.23). 
In terms of pharmacogenetics, warfarin metabolism and dose requirements might differ 
between ethnic groups. Studies have shown that warfarin dosage requirements are higher in 
Blacks compared to Whites partly due to racial differences in genotype frequencies (216). 
Blacks have been found to have additional CYP2C9 alleles which are associated with reduced 
function of the CYP2C9 activity and thus might contribute to dose variability (216). In addition, 
issues like health literacy, adherence to medication might also contribute to the differences in 
quality of anticoagulation therapy among different ethnic groups (210). 
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Table 1.23: Major studies reporting anticoagulation control in different ethnic groups 
 
Patients Study design 
Follow 
up Ethnicity 
Mean TTR, 
% 
Poor INR 
control 
(TTR≤60) 
Moderate 
INR control 
(TTR 60-75) 
Good 
INR 
control 
(TTR≥75) 
SPORTIF III and IV trial, 
USA (195) 
3587 AF RCT 16.6 (6.3) 
months 
White - 87.3 93.7 96.1 
Asian - 9.6 4.5 3 
Black/African 
American 
- 2.5 1.6 0.8 
IMPACT trial, North 
America, Europe, 
Australia (280, 281) 
2718 but 229 
with INR results 
RCT 2 years White  55 - - - 
Black  44 - - - 
Asian  68 - - - 
Non-Hispanic 54 - - - 
Hispanic  48 - - - 
VARIA study,  
USA (198) 
98,053 AF, VTE, 
others 
Retrospective 2 years White 62.3 - - - 
Black 55.8 - - - 
TREAT-AF study,  
USA (209) 
184, 161 AF Retrospective 90 days White 59 (18) - - - 
Black 52 (20) - - - 
Asian 59 (18) - - - 
ORBIT-AF,  
USA (210) 
10, 132 AF Prospective 2.1 years White 68 (53-80) - - - 
Black 59 (41-75) - - - 
Hispanic 62 (46-78) - - - 
AF: atrial fibrillation; INR: International normalised ratio; RCT: randomised controlled trial; TTR: Time in therapeutic range; VTE: venous thromboembolism 
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1.5.1.1.9 Other clinical factors affecting anticoagulation control 
As seen in Table 1.21 there are other clinical factors that may affect anticoagulation control. 
Seven studies (199, 200, 204, 205, 208, 213, 254) have demonstrated that numerous drug 
interactions with warfarin such as amiodarone, aspirin, pain medications, and antibiotics might 
impact the quality of anticoagulation therapy. This can be explained by the fact that these 
medications are inhibitor (amiodarone, analgesics, antibiotics, ex macrolides, quinolones and 
azoles groups) or inducer of CYP2C9 (carbamezipine) enzyme that is involved in warfarin 
metabolism, thus concomitant use of these drugs might cause potentiation or inhibition of the 
warfarin effect (282). The concomitant use of these medications with warfarin should be 
avoided but if essential, they should be used with caution (dose adjustment of warfarin 
required) and with careful, regular monitoring of INR (277, 282). 
Warfarin is mainly metabolised in the liver by the enzyme cytochrome-P450 2C9 (CYP2C9) 
and it exerts its anticoagulant effect by inhibiting the protein VKORC1. Anticoagulant effects 
of warfarin have been found to be influenced by the effect of three single nucleotide 
polymorphism (SNPs); two in the CYP2C9 gene (CYP2C9*2 and CYP2C9*3) and one in the 
VKORC1 gene. Patients with CYP2C9*2 (more commonly in Whites), CYP2C9*3 and 
VKORC1 variants will metabolise warfarin less efficiently thus require lower doses of warfarin 
(216). Although patients with  CYP2C9*2, CYP2C9*3 and VKORC1 variants are at risk of over 
anticoagulation during the initiation phase, (214, 215) the impact on TTR among the 
maintenance phase remains debatable  (217). 
Combining common clinical and demographic predictors of INR control together, Apostolakis 
et al (199) developed a scoring system, known as  the SAMe-TT2R2 score. In 2017, Lin et al 
(213) and Williams et al (204) published two  novel scoring systems; the former with seven 
factors known as the PROSPER score (213), the latter (204) with 15 and the SAMe-TT2R2 
score (199) with six predictors of anticoagulation control (Table 1.24).  
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All three scores (199, 204, 213) included concomitant medical history and potential drug 
interaction as predictors of anticoagulation control. Both SAMe-TT2R2 score (199) and 
Williams et al (204) included demographic factors of age, whereas SAMe-TT2R2 score 
included additional demographic factors such as tobacco use and ethnicity while Williams et 
al (204) included body mass index and alcohol. PROSPER score and Williams et al included 
more clinical factors where there might be an overlap between pneumonia and prescription of 
antibiotics in the PROSPER score (213) and the latter included more laboratory variables 
(204) as compared to the SAMe-TT2R2 score (Table 1.24).  
In the SAMe-TT2R2 (199) and PROSPER (213) score, if patients had a score of >2, they are 
predicted to have poor TTR with the latter (213) being emphasized for the geriatric population. 
Whereas in the model by Williams et al (204), if patients have ≥4 and ≥7 poor TTR factors, 
their estimated TTR will be <60% and <50% respectively (Table 1.24). NOAC is the preferred 
anticoagulant of choice rather than VKAs if patients had high scores in all three scores (199, 
204, 213). These scores were developed to identify patients at risk of having good/poor 
anticoagulation control with warfarin and thus can aid physicians to choose the appropriate 
anticoagulant therapy for stroke prevention in AF. Although the two new scores (204, 213) 
seem very comprehensive, they are very complex and are not ‘user friendly’ especially in a 
busy clinical setting. 
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Table 1.24: Scores to predict anticoagulation control 
SAMe-TT2R2  Points  PROSPER Points Williams et al  
Sex (female)  1 Pneumonia  1 Age, y¥  
Age (<60 years)  1 Renal dysfunction† 2 Systolic BP, mmHg¥  
Medical history*  1 Oozing blood (bleeding history) 1 Body mass index, kg/m2¥  
Treatment (interacting drugs, e.g., 
amiodarone)  
1 Staying in hospital ≥7 days 1 Albumin, g/dL¥  
Tobacco use (within 2 years)  2 Pain medications 1 Neutrophil, %¥  
Race (non-white)  2 No enhanced anticoagulation care‡ 4 Red blood cell count, x 106/mcl¥  
  Prescription for antibiotics 1 Red blood cell distribution width, %¥  
    Alcohol problem£  
    Anaemia£  
    Lung disease£  
    Stroke haemorrhagic£  
    Thrombocytopenia£  
    Venous thromboembolism£  
    Any antiarrhythmic£  
    Aspirin£  
Cut offs      
Scores 0-2 Good 
INR 
control§ 
Scores 0-2 Good 
INR 
control§ 
≥4 poor factors TTR 
<60% 
Scores >2 Poor 
INR 
control§ 
Scores >2 Poor INR 
control§ 
≥7 poor factors TTR 
<50% 
*Two or more of the following: hypertension, diabetes mellitus, coronary artery disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, 
and hepatic or renal disease. ¥continuous variable; £binary variables; †Having records of acute kidney injury, chronic kidney disease, or end stage kidney disease prior 180 days 
‡lack of participation (no access or plan) in a dedicated anticoagulation management service when initiating a VKA; § on probability 
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1.5.1.2 Non-clinical factors 
1.5.1.2.1 Patient factors 
 
Studies have shown that patient’s comprehension and acceptance of the complex regimen 
required with warfarin therapy might also affect the quality of VKA treatment (283). Evidences 
have shown that in the general AF population, patients have minimal knowledge about their 
medical condition (284-289), poor understanding of the benefits and risk of specific treatment 
in particular OAC therapy (285-291), and are usually not aware of factors that can influence 
the effectiveness and safety of the treatment (284-287). However, one recent survey 
conducted in eight European countries showed different results (292). Most of their patients 
(91-94%) have good knowledge of anticoagulation (in terms of indication and INR target 
range). Furthermore, patients with college or university grades had lower frequent deviations 
of their target INR range (2.8% vs. 5.1%, p<0.05) and had higher awareness (57% vs. 38.5%, 
p<0.05) of the anticoagulation related risk of bleeding compared to those without schooling 
respectively (292). However, this survey did not indicate the proportions of patients with 
different education level thus this might affect their results (probably they had higher 
proportions of patients with college or university grades).   
 
Recently, the ESC guideline has recommended a tailored patient education in all phases of 
AF management (3). Patient education is important to ensure accurate information is delivered 
about AF and its treatment. Apart from that,  obtaining feedback from patients regarding any 
concerns or barriers (for example food and drug interactions, the need to modify lifestyle habits 
and the risk of bleeding complications) that prevent them from taking warfarin (283) are also 
crucial. The concerns should be addressed so that any barriers to medication taking can be 
avoided and thus optimal outcome of anticoagulation therapy can be achieved. In the recent 
years, several patient information tools (for example phone apps or structured face to face 
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educational session) have been developed focusing on oral anticoagulation therapy (293, 
294). Evidences have shown that these educational tool or intervention was effective at 
improving the quality of anticoagulation therapy (219, 293, 295, 296). The TREAT (219) 
educational intervention (an educational-behavioural intervention), was effective at improving 
the quality of anticoagulation therapy (TTR) among patients receiving it compared to usual 
care (TTR at 6 months 76.2% vs. 71.3%, p=0.035 respectively) (293). Two recent surveys 
conducted in Serbia (218) and Singapore (220) demonstrated that better knowledge, quality 
of life, adherence rate and higher satisfaction to VKA therapy resulted in good TTR at follow 
up; however these studies were not designed to measure the impact of an educational 
intervention on TTR. 
 
Despite overwhelming evidence showing the effectiveness of oral anticoagulation in stroke 
prevention in AF, the demonstrable benefits of the OACs, in terms of stroke prevention, will 
not be translated if patients do not adhere to, or fail to persist with their medications (226). A 
recent extensive review of 30 studies (226) assessing adherence and persistence towards 
OACs reported that within the five NOAC trials (132-135, 297), the discontinuation rate for 
patients who were on warfarin was similar to each of the NOACs ranging between 13-34%. 
(132-135, 297) In the same review, 13 ‘real-world’ [9 NOACs (298-306) and 4 warfarin (227, 
307-309)] studies were also included (226). The adherence rate to warfarin was lower (40-
56%) in three of the warfarin studies (227, 307, 308), compared to 63-99% adherence in the 
nine NOAC studies (298-306). Among all these studies, only two studies (227, 300) 
demonstrated the impact of non-adherence on treatment outcomes. Although retrospective 
and with a relatively short duration of follow up (median 0.67 years), Shore et al (300) 
demonstrated that even a 10% decrease in adherence to dabigatran therapy was associated 
with 13% increase in the combined outcome of all-cause mortality and stroke. In a larger 
number of population (N=64, 661), with a slightly longer follow up (median 1.1 year), Yao et al 
(227) showed an increased risk of stroke in patients with CHA2DS2-VASc score of ≥2 not taking 
OACs for ≥6 months.  
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Other patient-related factors that might influence anticoagulation control are socioeconomic 
status. Rose et al (200) has demonstrated that patients living in the poorest area (based on 
the zip code of residence) was predicted to have poor TTR control compared to the wealthiest 
during the first 6 months of warfarin therapy. This relationship persisted even after 6 months 
being on warfarin therapy (200). In another population based study of 166,742 patients, lower 
socioeconomic status (based on the median neighbourhood income quantiles) was also a risk 
factor for bleeding and bleeding related to mortality among older individuals taking warfarin 
therapy (233).  
 
Common concerns among patients receiving VKA relate to food and drug interactions. 
Patients receiving warfarin are advised to reduce intake of food that is rich in vitamin K, for 
example, green leafy vegetables (spinach, broccoli etc.) as this might impact INR stability. 
Vitamin K-rich food might counteract the anticoagulant effects of warfarin and dose adjustment 
is required in patients presenting with low or high INR values after drastic changes in dietary 
intake of vitamin K. A recent systematic review (234) (two intervention trials and nine 
observational studies) summarising current evidence on the interaction between dietary 
vitamin K intake and warfarin concluded that the evidence available does not support the 
restriction of dietary intake of vitamin K but encourages patients to have a stable dietary habit 
and avoidance of dramatic changes in dietary vitamin K  (234).  
 
Due to the narrow therapeutic index of warfarin, concomitant use of warfarin and herbal 
remedies results in a major safety concern (235). Warfarin accounted for 26% of cases of 
drug-herb interaction from clinical cases (310). A review on clinical evidences of herb and 
warfarin interaction has highlighted clinical effects, severity of interaction and quality of clinical 
evidences (235). They have identified thirty-eight selected herbs, four were evaluated with 
Level I evidence as ‘highly probable’ to interact with warfarin, three were ‘probable interaction’ 
with Level II evidence, ten were ‘possible’ (Level III evidence) and twenty-one were ‘doubtful 
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interaction’ (Level IV evidence). The concomitant use of warfarin should be strongly avoided 
in ‘highly probable’ (Cranberry, Soya, St John’s wort and Danshen) and ‘probable herbs’ 
(coenzyme Q10, Chinese Angelica, Ginger). Whereas for ‘possible’ (for example Ginko and 
Chamomile) and ‘doubtful’ (for example Fenugreek and Parsley) interaction, for safety reason, 
close monitoring of INR is recommended (235). For example, Cranberry juice commonly used 
for blood and digestive disorder has been found to be linked to a major bleeding and high INR 
(due to potentiation of warfarin effect) in a case report in the US involving a man who took 
warfarin after drinking 710 ml of cranberry juice (311). Despite the available case reports about 
warfarin and herb interaction, the intensity of the interaction might be overestimated. Future 
studies or trials are needed to ascertain the magnitude and the clinical impact of these 
interactions. 
 
The impact of fasting on anticoagulant control is debatable. A prospective Singaporean (236) 
study investigated the effect of fasting among 32 patients taking warfarin pre-Ramadhan, 
during Ramadhan, and post Ramadhan. Although underpowered, a decrease in TTR was 
seen from 81.0% to 69.6% before Ramadhan to during Ramadhan, respectively. In contrast, 
another recent study (237) showed that TTR was better during the Ramadhan period 
compared to pre-Ramadhan period (TTR 82.1% vs. 70%; p<0.001). More studies with larger 
sample size are needed to ascertain the impact of fasting towards anticoagulation control 
among warfarinised patients.  
 
1.5.1.2.2 Physician factors  
Bleeding risk is the most commonly cited (221) reason for not initiating or delaying warfarin 
treatment. In some older patients, some physicians prefer to target a lower INR range (INR 
1.6-2.5) to avoid bleeding complications as elderly (>65 years in HAS-BLED score) is a risk 
factor for bleeding complications.  
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The benefit of oral anticoagulation in an elderly population has been demonstrated in several 
studies. Focks et al (312) reported the rate of major bleeding and ischemic stroke of 2.8 and 
2.3 per 100 patient years respectively, in his cohort of the very elderly (≥80years) AF patients. 
Based on number needed to treat (NNT: 91) and number needed to harm (NNH: 22) a total of 
four strokes/TIAs can be prevented based on every major bleed caused by VKA. Meanwhile, 
Friberg et al (313) has shown a positive net clinical benefit from treatment with warfarin 
(adjusted net clinical benefit >6%/y) in nearly all AF patients except those at lowest risk of 
stroke as the benefit of preventing a stroke far outweighs the smaller risk of bleeding even in 
patients with high HAS-BLED scores.  
Bleeding risk should not be used as a reason to withhold anticoagulant treatment; instead 
anticoagulation treatment should be used with caution and strict control even in patients at 
high risk of bleeding complications (3, 314). Some physicians would prefer to avoid a major 
bleeding event than to prevent stroke, whereas patients are prepared to accept the risk of 
bleeding rather than to suffer from a stroke (221, 315). Currently there are five options for OAC 
therapy for stroke prevention in AF (VKAs, dabigatran, apixaban, edoxaban, rivaroxaban). The 
availability of NOACs allows physicians to choose the best NOAC that would fit into their 
patient’s criteria. In the case of patients with high risk of bleeding (HAS-BLED>3), dabigatran 
110 mg, apixaban 5mg or edoxaban 60 mg can be offered to patients (316). 
1.5.1.2.3 Health care system factors 
1.5.1.2.3.1 Hospital vs. community-based vs. clinical trial 
To date, 16 studies have validated the SAMe-TT2R2 score in AF cohorts. These studies are 
described in detail in the next section (section 1.6, page 101). In these studies (Table 1.25 
and Figure 1.6), seven (199, 317-322) used hospital anticoagulation clinics to monitor 
patient’s INR, four (323-326) stated hospital monitoring without specifying whether it was 
performed by an anticoagulation clinic or not, three (199, 280, 327) were from clinical trial 
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settings and one from primary care (328) and cardiology outpatient clinic each. (329) 
Anticoagulation control was highest in patients monitored by hospital anticoagulation clinics, 
with TTRs ranging from 58% (319) to 78% (322). In the hospital setting (without information 
on anticoagulant clinic involvement), TTR ranged from 38.2% (325) to 58% (326). In the 
clinical trial settings, TTR was 53.6% (280) to 68.5%(327) and lastly, TTR was 69%(328) in 
primary care.  
A 2006 meta-analysis of 67 studies (222) compared the effect of study setting on 
anticoagulation control in a mixed group of patients (on OAC for AF, valvular disease, VTE, 
cerebrovascular disease, peripheral vascular disease) and showed that anticoagulation 
control was significantly lower in the community setting compared to those from 
anticoagulation clinic and in RCTs [unadjusted mean TTR 56.7 (51.5-62.0) vs. 65.6 (63.7-
67.7) vs. 66.4 (59.4-73.3), p>0.0001 respectively]. Similarly, another meta-analysis of eight 
studies from 14 participating centres in the United States reported that AF patients who are 
managed in the community setting had a lower mean TTR (51%) compared to those managed 
by the anticoagulant clinic i.e. TTR 63% (223). In contrast, in the Auricula registry of 18,391 
patients in 67 different centres, found no significant difference in the mean TTR among 
hospital based centres versus community based centres (TTR 75.7% vs. 80.3% respectively) 
and their mean TTR in the entire population was 76.2%, higher than reported in clinical trials 
(206). 
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Table 1.25: Mean TTR% in studies validating the SAMe-TT2R2 score 
 
a.  Study design 
b.  Length of follow-up 
Population Method INR 
monitoring 
Mean (SD)/  
Median (IQR) TTR 
Pivatto Junior, 2017, Brazil 
(317) 
a. Retrospective  
b. 1 year  
263 
 
Anticoagulant clinic-
hospital 
62.5 (44.2-79.5) 
Bernaitis, 2016, Singapore 
(326) 
a. Retrospective  
b. - 
1137  
 
Hospital based 58.0 (34.3) 
Chan, 2016, Hong Kong (325) a.  Retrospective 
b.  4.7 ± 3.6 years (mean) 
1428  
  
Hospital based 38.2 (24.4) 
Gorzelak-Pabis, 2016, Poland 
(324) 
a. Prospective  
b. - 
104  Hospital based 51 (32) 
Lip, 2016, USA (280) a. Prospective  
b. 438 days on OAC 
229  Trial setting 53.6 (23) 
Lobos-Bejarano, 2016, Spain 
(328) 
a.  Retrospective 
b.  >12 months  
1524  
 
Primary care 69 (17.7) 
Proietti, 2016, Europe, Asia, 
Australasia(327) 
a. Prospective  
b. 563 days (median) 
3665  
 
Clinical trial centre 68.5 (55.17-79.32) 
Szymanski, 2016, Poland (323) 
 
a.  Retrospective 
b.  N/A 
211  Hospital 51.8 (25.0-71.2) 
Abumuaileq, 2015, Spain (319) 
 
a.  Retrospective  
b.  10 months (mean) 
911 Anticoagulant clinic-
hospital 
PINRR 58 (18) 
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Table 1.25 continued 
 a.  Study design 
b.  Length of follow-up 
Population Method INR 
monitoring 
Mean (SD)/  
Median (IQR) TTR 
Roldán, 2015, Spain (318) a.  Prospective 
b.  6 months 
459  
 
Anticoagulant clinic-
hospital 
64 (17) 
Ruiz-Ortiz, 2015, Spain (329) 
 
a.  Retrospective 
b.  27 months (median)  
1056  
 
Cardiology outpatient 
clinic-hospital 
63.8 (25.9) 
Gallego, 2014, Spain (322) a.  Prospective  
b.  952 days (median) 
972  
 
Anticoagulant clinic-
hospital 
78 (19.98) 
Lip, 2014, France (330) 
 
a.  Prospective 
b. 1016±1018 days 
(mean) 
8120  
 
Clinicians -hospital - 
Poli, 2014, Italy (321) 
 
a.   Prospective 
b.   4.6 years (mean) 
1089  
 
Anticoagulant clinic-
hospital 
73 (62.5-82.0) 
Skov, 2014, Denmark (320) 
 
a.  Prospective 
b.  1 year 
182  Anticoagulant clinic-
hospital 
76 (-) 
Apostolakis, 2013, UK (199) 
 
a. Retrospective and 
prospective  
b.  3.5 years (mean) 
1305  
 
Derivation- clinical trial  
Internal-clinical trial 
External: anticoagulant 
clinic-hospital 
Derivation cohort 64.2 
(18) 
Internal validation 63.0 
(19) 
External validation 66 
(16) 
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Figure 1.6: Mean TTR% among studies that validated the SAMe-TT2R2 score 
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1.5.1.2.3.2 Models of care 
A variety of models of care known as usual care (UC) model, anticoagulant clinic (AC) model 
and patient self-testing (PST) model (also known as home monitoring) were developed due to 
the complexity of managing patients on warfarin therapy. In the UC model, patients are 
managed by physicians without formal systematic monitoring procedures or policies to focus 
on dose management. In the AC model, patients are usually managed by specialised nurses 
or pharmacist under physicians’ supervision with systematic policies and procedures on 
initiating, optimising and maintaining warfarin therapy. Lastly in PST model, patients self-
manage their own INR test at home using a portable point of care (POC) instrument.  Patients 
either receive instruction on dose from a healthcare provider or self-managed their own dose 
(PSM) (331). 
Studies have shown that different models of care might influence patient’s quality of 
anticoagulation therapy and impact adverse clinical outcome. A recent systematic review (228) 
of 25 studies (3 RCTs and 22 non-RCTS) involving 12,252 participants evaluated the quality 
of anticoagulation control among pharmacist-managed anticoagulant services (PMAS) 
compared with routine medical care. Quality of anticoagulation therapy was significantly better 
in the PMAS group (TTR 66.9%) compared to usual care (TTR 56.7%), evidenced by a higher 
TTR in the former compared to the latter in 23 of 25 studies. Adverse clinical outcomes were 
also lower in the PMAS group compared to routine medical care, evidenced by lower or equal 
risk of major bleeding (N=10 of 12 studies) and lower rates of thromboembolic events (in nine 
out of 10 studies). (228) Another meta-analysis of eight RCTs (229) comparing the 
effectiveness of PMAS versus other models of care (including UC by physicians, nurses and 
other healthcare professional) in a mixed group of patients also showed better TTR in standard 
therapeutic range for patients in the PMAS compared to UC group. However, safety and 
mortality data were inconclusive; instead patients in PMAS group were most satisfied (229) 
(Table 1.26). The findings from the two meta analyses showed the benefits of PMAS over UC 
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towards improving TTR however more studies are needed to confirm the benefits of PMAS in 
terms of adverse clinical outcomes.  
Evidence has shown that more frequent INR testing results in a reduction of thromboembolic 
and bleeding events (332). With the difficulties associated with frequent INR visits to an 
anticoagulant clinic in short interval of time, the concept of patient self-testing (PST) was 
introduced. Since 2004, the American College of Chest Physicians (ACCP) have 
recommended PST to be implemented ‘for patients who are motivated and can demonstrate 
competency’ (Grade 2B) (333). Several meta-analyses of clinical trials showing the 
advantages of PST/PSM have been conducted in 2011 (232) and 2012(231) (Table 1.26). 
Bloomfield et al (232) demonstrated that in highly motivated adult patients requiring long term 
anticoagulation therapy with warfarin, PST alone or in combination of PSM was associated 
with significantly reduced risk of thromboembolic events (42%) and deaths (26%) without an 
increased risk of major bleeding events compared to patients receiving UC (232). Similarly, 
Heneghan et al (334) conducted a systematic review including 28 trials in 2016  also showed 
a significant reduction of TE events in the PSM or PST groups [RR 0.58, (95% CI 0.45 to 0.75)]; 
but no significant reduction in major bleeding [RR 0.95, (95% CI, 0.80 to 1.12)] or all-cause 
mortality [RR 0.85, (95% CI 0.71 to 1.01)] (231). Results from the two meta-analyses suggest 
the benefits of PST and/or PSM towards reducing TE and mortality compared to UC. 
Another small randomised trial (N=159) performed in the Netherlands reported that PST and 
PSM patients had a significantly improved quality of life compared to PST patients or UC 
(managed in the hospital) only (335). 
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Table 1.26: Models of care and anticoagulation control and/or clinical events 
 No of 
studies 
Populati
on, N 
Population  Models TTR and/or clinical events 
Manzoor 
2017(228) 
25 studies 
3 RCT 
22 non RCT 
12, 252 AF, VTE PMAS vs. 
UC 
TTR higher in PMAS 
(66.9%) vs. UC (56.7%) in 
23 of 25 studies 
 
Zhou 2016 
(229) 
 
8 RCTs 
 
1493 
 
AF, VTE, valvular 
heart disease, 
CVA, 
cardiomyopathy, 
mural thrombus 
and others 
 
PMAS vs. 
UC 
 
TTR PMAS vs. UC: MD 
3.66 95% CI (2.2-5.11) for 
INR 2.5 ± 0.5 (standard INR 
range) 
TTR PMAS vs. UC: MD 
2.85 95% CI (-0.56 to 6.26) 
for INR 2.5 ± 0.7 (expanded 
INR range) 
 
Heneghan 
2016 (334)  
 
28 trials 
 
8950 
 
AF, valve 
replacement, 
DVT 
 
PST and/or 
PSM vs. UC 
 
TE: 
PST or PSM: (RR 0.58, 
95% CI 0.45-0.74; 
participants = 7594; 18 
studies)  
Mortality: 
PST or PSM: (RR 0.85, 
95% CI 0.71-1.01; 6358 
participants, 11 studies) 
 
Bloomfield 
2011(232) 
22 trials 8413 AF, mechanical 
heart valve 
replacement 
PST and/or 
PSM vs. UC 
TE: OR 0.58, 95% CI (0.45-
0.75, =<0.001) 
Mortality: OR 0.74 95%CI 
(0.63-0.87, p<0.001) 
CI: confidence intervals; MD: mean difference; PMAS: pharmacist-managed anticoagulant service; PST: patient self-
testing; PSM: patient self-monitoring; UC: usual care 
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1.6 Use of the SAMe-TT2R2 score to predict anticoagulation control in 
atrial fibrillation treated with vitamin K antagonists 
 
The section summarises studies which have assessed and/or validated the SAMe-TT2R2 
score in patients treated with VKA for AF. This section has been published in the Heart Rhythm 
Journal (336). 
 
The original purpose of developing the SAMe-TT2R2 score was to produce a simple clinical 
schema which could be used routinely in everyday practice to help assess the likelihood of an 
AF patient being able to achieve and maintain good anticoagulation control on VKA therapy, 
using patient-related clinical parameters which are readily available. The availability of NOACs 
worldwide has resulted in increased usage due to their advantages. These include faster 
onset-of-action [average maximum effect approximately three hours after intake (337) 
compared to VKA (onset 36-72 hours)], greater reduction in stroke/systemic embolism [+19% 
compared to VKA(3)], avoidance of INR monitoring with NOACs(338), and absence of 
achieving/maintaining adequate TTR (as with warfarin). Achieving a therapeutic INR can take 
2-4 weeks and often longer (131). After termination of study drug in the NOAC trials, of those 
patients switching to warfarin, <40% achieved a therapeutic INR within 15 days, and <80% 
after 30 days(339); more strokes occurred during that period in the patients who went from 
study drug to VKA than from VKA to VKA (339, 340). This strong argues for using NOACs 
over VKAs where possible, however, VKAs are still widely used globally and will not disappear 
from use especially for AF patients with severe renal impairment, moderate to severe mitral 
stenosis or mechanical heart valves (3). In addition, in low- and middle-income countries 
where cost plays an important role in options available for OAC treatment VKA is still the first-
line antithrombotic agent of choice, therefore the SAMe-TT2R2 score will remain an important 
decision-making tool, currently and in the future, to guide physicians choice of anticoagulant 
treatment (341).  
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1.6.1 SAMe-TT2R2 score validation studies 
 
Current studies (N=16) assessing the SAMe-TT2R2 score in AF patients are summarised in 
Table 1.27 and the baseline patient characteristics of these cohorts are presented in Table 
1.28. The majority of the studies (N=9) (199, 280, 318, 320-322, 324, 327, 330) were 
performed prospectively, with a follow-up duration ranging from six months (318) to 4.7 years 
(325). Eleven of the studies were performed in European populations (199, 318-324, 327, 328, 
330), three in Asian populations (325, 326, 342) and one in the American populations (280).  
Proietti et al (327) studied a mixed indication clinical trial cohort including patients from Europe, 
Asia and Australasia. 
 
Most studies to date were performed in elderly (mean or median age ranging from 61 years to 
76 years old) Western Caucasian populations, which mainly used warfarin (10 studies) (199, 
280, 320, 321, 323, 325-327, 330, 342) as their OAC of choice. The majority of the patients 
had multiple comorbidities with hypertension being the most common, except for the study by 
Lip et al (330) where congestive heart failure was most common. All of the studies reported a 
low prevalence of smoking status and use of amiodarone for rhythm control, with the exception 
of Lip et al (330), with 35% of patients using amiodarone. As shown in Figure 1.7, as the 
SAMe-TT2R2 score categories increase, the mean TTR of their study population decreases.  
 
Five studies (280, 319, 325, 328, 343) investigated the relationship between components 
included in the SAMe-TT2R2 score and TTR. Three studies (280, 319, 328) showed that female 
sex was associated with poor anticoagulation control; one (319) showed that having ≥2 
comorbidities was related to poor TTR and one (280) showed that black ethnicity (as well as 
NYHA IV) was associated with poorer anticoagulation control. Chan et al (325) also reported 
that having heart failure and diabetes mellitus independently predicts poor anticoagulation 
control. 
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Table 1.27: Studies assessing the SAMe-TT2R2 score in atrial fibrillation cohorts 
  a. Study design 
b. Mean follow-up  
c. Method INR monitoring  
Population 
a.  Number 
b. Mean (SD)/median (IQR) age 
(range, years) 
c.  Race/ethnicity 
d.  OAC used 
SAMe-TT2R2 score distribution 
(%); mean (SD) TTR (%)  
Percentage of 
patients with 
dichotomised TTR 
(%)  
Pivatto Junior(317) 
2017 
Brazil 
a. Retrospective  
a. 1 year  
b. Hospital OAC clinic 
a. 263 AF 
a. 71.2 (64.1-78.5) 
b. White 
c. 97.3% Warfarin 
0-1: 138 (52.5); 69.2 
≥2: 125 (47.5); 56.3 
- 
 
Bernaitis(326) 
2016 
Singapore  
 
a. Retrospective  
b. - 
c. Hospital  
 
a. 1137 AF 
b. 71 (63-77) 
c. Asian 
d. Warfarin  
 
0-1:0 
2: 339; 63.2 (34.1) 
>2:798; 55.8 (34.1) 
- 
 
Chan(325) 
2016 
Hong Kong 
  
a. Retrospective 
b.  4.7 ± 3.6 years 
c.  Hospital  
  
 
a. 1428 NVAF 
b.  76.2 (8.7) 
c.  Chinese 
d.  Warfarin 
 
2: 22 (14.3); 70† 
3: 80 (51.9); 70 
4: 41 (26.6); 70 
5: 7 (4.5); 70 
6: 4 (2.6);70 
 
TTR≥70: 11 
TTR<70: 89 
  
 
Gorzelak-Pabis(324) 
2016 
Poland  
 
a. Prospective  
b. - 
c. Hospital  
 
a. 104 AF with cognitive 
impairment 
b. 75 (10) 
c. White 
d. 61% Acenocoumarol 
 
0-1: 64 (26) 
≥2: 50 (28) 
 
- 
 
Lip(280) 
2016 
USA 
 
a. Prospective  
b. 438 days 
c. Trial setting  
 
a. 229 AF 
b. 66.7 (11) 
c. 80.3% White 
d. Warfarin  
 
0-1:0.571 (0.22) 
≥2: 0.498 (0.24) 
- 
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 a. Study design 
b. Mean follow-up  
c. Method INR monitoring 
 
a.  Number 
b.  Mean (SD)/median (IQR) 
age (range, years) 
c.  Race/ethnicity 
d.  OAC used 
SAMe-TT2R2 score distribution  
(%); mean (SD) TTR (%)  
Percentage of 
patients with 
dichotomised TTR 
(%)  
Lobos-Bejarano(328) 
2016 
Spain 
a.  Retrospective 
b.  >12 months  
c.  Primary care  
a.  1524 NVAF 
b.  77.4 (8.7) 
c.  White 
d.  94.8% Acenocoumarol 
0-1: 69.6% (17.4) 
≥2: 66.6% (18.5) 
TTR≥65: 60.6 
TTR<65: 39.4 
Proietti(327) 
2016 
Europe, Asia, 
Australasia 
a. Prospective  
b. Median 563 days  
(IQR 483-651) 
c. Trial setting 
a. 3665 AF 
b. 72(66-77) 
c. Mixed‡ 
d. Warfarin  
0-2: 2914 (80.4);  
69.05 (55.63-79.89) 
>2: 710 (19.6);  
66.55 (52.83-77.46) 
TTR>70: 46.9 
TTR≤70: 53.1 
 
Szymanski (323) 
2016 
Poland 
 
a.  Retrospective 
b.  - 
c.  Hospital 
 
a.  211 AF 
b.  57.1 (10.2) 
c. White 
d. 75.4% warfarin  
 
0-1: 114 (54); 52.3 
≥2: 97 (46); 51.3 
 
TTR>70: 25.2 
TTR≤70: 74.8 
Abumuaileq(319) 
2015 
Spain 
a.  Retrospective  
b.  10 months 
c.  Hospital OAC clinic 
a.  911 NVAF  
b.  73 (11) 
c.  White 
d.  93% Acenocoumarol 
0-1:672 (74); 59 (18)¶ 
≥2: 239 (26); 54 (19)¶ 
PINRR>65:44 
PINRR≤65:55 
Roldán (318) 
2015  
Spain 
a.  Prospective 
b.  6 months 
c.  Hospital OAC clinic 
a.  459 NVAF 
b.  76 (70-82) 
c.  White 
d.  Acenocoumarol 
<2: 253 (55); 67 (18) 
≥2: 206 (44.8); 61 (16) 
TTR>65:54 
TTR≤65:46 
Ruiz-Ortiz(329) 
2015 
Spain 
a.  Retrospective 
b.  Median 27 months  
c.  Cardiology clinic 
a.  1056 NVAF  
b.  73.6 (9.8) 
c.  White 
d.  Acenocoumarol 
0-1:613 (58); 65.6 (26.2) 
≥2: 443 (42); 61.3 (25.3) 
TTR≥65:52.7 
TTR<65:47.3 
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Table 1.27 continued 
 a. Study design 
b. Mean follow-up  
c. Method INR monitoring 
 
a.  Number 
b.  Mean (SD)/median (IQR)age  
c.  Race/ethnicity 
d.  OAC used 
SAMe-TT2R2 score distribution  
(%); mean (SD)TTR (%) 
Percentage of 
patients with 
dichotomised TTR 
(%)  
Gallego(322) 
2014 
Spain 
a.  Prospective  
b.  Median 952 days 
c.  Hospital OAC clinic 
a.  972 NVAF  
b.  76 (70-82) 
c.  White 
d.  Acenocoumarol 
0-1:431 (44); 79.67 (19.46) 
≥2: 332 (34); 78.4 (20.28) 
>2:208 (21); 74.25 (20.24) 
- 
Lip(330) 
2014 
France 
a.  Prospective 
b.  1016±1018 days 
c.  Clinicians -hospital 
a.  8120 AF†† 
b.  70 (15) 
c.  White 
d.  Warfarin  
0-1: 4504 (55); 77(1.7)§ 
≥2: 2252 (28); 52(2.3)§ 
>2:1364 (17); 43(3.2)§ 
- 
Poli(321) 
2014 
Italy 
a.    Prospective 
b.   4.6 years 
c.    Hospital OAC clinic 
a.  1089 AF 
b.  75 (30-94) 
c.  White 
d.  Warfarin  
0-1:624 (57); 72.3 (15.3) 
2: 288 (26); 72.0 (15.6) 
>2:177 (16); 68.2 (16.4) 
- 
Skov(320) 
2014 
Denmark 
a.  Prospective 
b.  1 year 
c.  Hospital OAC clinic 
a.  182 AF 
b.  70.2# 
c.  White 
d.  Warfarin  
0-1:105 (58); 76 
≥2: 77 (42); 76 
- 
 
Apostolakis(199) 
2013 
United Kingdom 
  
a. Retrospective and 
prospective  
b.  3.5 years 
c. Clinical trial (internal-
validation)/Hospital OAC 
clinic (external-validation) 
 
a. 1305 AF 
b.  69(8)/74(10) 
c.  8.7%, 19.3 % non-white 
(internal/external-validation) 
d.  Warfarin   
 
(Internal/External validation) 
0: 242 (18); 0.66±0.16/0.7±0.13 
1: 413 (31);0.65±0.18/0.66±0.17 
2: 303 (23);0.63±0.17/0.66±0.16 
3:185 (14); 0.59±0.22/0.65±0.17 
 
Internal validation 
TTR>70:35.7 
TTR≤70:64.3 
External validation 
TTR>70:44.1 
TTR≤70:55.9 
AF: atrial fibrillation; CV: cardiovascular; INR: international normalised ratio; IQR: interquartile range; Max: maximum; MI: myocardial infarction; NVAF: non-valvular atrial fibrillation; OAC: oral 
anticoagulant/anticoagulation; ROC: area under curve; SD: standard deviation; SAMe-TT2R2 score: sex (female), age (<60 years, medical history (≥2 of the following: hypertension, diabetes, coronary 
artery disease or myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary, hepatic, or renal disease), treatment with interacting drugs (e.g. amiodarone[all 
1 point],  current tobacco use and race (non-white) [2 points]; TTR: time to therapeutic; TE: thromboembolism; VTE: venous thromboembolism †TTR presented as ≥70% and <70% not mean TTR; 
‡mixed population: White, Black, Asian, other; §number of patients with labile INR, (%); ¶PINRR % (mean ± SD); #no SD or IQR reported;  †† n=4637 on VKA; - not reported  
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Table 1.28: Baseline characteristics of all studies assessing the SAMe-TT2R2 score in AF population 
 
N (%)  Female Age 
<60  
Hypertension Diabetes  HF Prior 
stroke/TIA 
PAD Renal 
diseas
e 
CAD COPD Smoking Previous 
bleeding 
Amiodaron
e 
Pivatto(317) 113 
(43.0) 
41  
(15.6) 
231 
(87.8) 
108 
(41.1) 
149 
(56.7) 
96 
(36.5) 
25 
(9.5) 
7 
(2.7) 
76 
(28.9) 
36 
(13.7) 
37 
(14.1) 
24 
(9.1) 
26 
(9.9) 
Bernaitis 
(326) 
448 
(39.4) 
172 
(15.1) 
677 
        (59.5) 
343 
(30.2) 
88 
(7.7) 
45 
(4.0) 
- 156 
(13.7) 
271 
(23.8) 
- 84 
(7.4) 
- 78 
(6.9) 
Chan(325) 671 
(52.5) 
48.0 
(3.4) 
922 
(64.6) 
387 
(27.1) 
367 
(25.7) 
496 
(34.7) 
102 
(7.1) 
2.9 
(2.0) 
407 
(28.5) 
- 71.0 
(5.0) 
- 94 
(6.6) 
Gorzelak-
Pabis(324) 
63 
(60.6) 
- 92 
(88.5) 
30 
(28.8) 
72 
(69.2) 
15 
(14.0) 
- - - - 20 
(19.2) 
- 8 
(7.7) 
Lip(280) 47 
(20.5) 
57 
(24.9) 
206 
(90.0) 
106 
(46.3) 
208 
(90.8) 
26 
(11.4)/ 
14 (6.1) 
31 
(13.5) 
- 178 
(77.7) 
- - - 46 
(20.1)# 
L.Bejarano 
(328) 
741 
(48.6) 
66 
(4.3) 
1223 
(80.2) 
473 
(31.0) 
392.0 
(25.7) 
209.0 
(13.7) 
99 
(6.5) 
92 
(6.0) 
286 
(18.8) 
- 100 
(6.6) 
134 
(8.8) 
100 
(6.6) 
Proietti(327) 1116 
(30.5) 
72§ 
(66-77) 
2812 
(76.7) 
860 
(23.5) 
1372 
(37.4) 
753 
(20.5) 
- - 1619 
(44.2) 
- 334 
(9.1) 
208 
(5.7) 
- 
Szymanski 
(323) 
79 
(37.4) 
108 
(51.2) 
194 
(91.9) 
27 
(12.8) 
8.0 
(3.8) 
16 
(7.6) 
- - - - 31.0 
(14.7) 
- 17 
(8.1) 
Abumuaileq 
(319) 
306 
(33.6) 
- 678 
(74.4) 
220 
(24.1) 
343 
(37.7) 
103 
(11.3) 
92 
(10.1) 
36¶ 
(4) 
127 
(13.9) 
183 
(20.1) 
77 
(8.5) 
115 
(12.6) 
- 
Roldán(318) 237 
(53.0) 
38 
(8.0) 
368 
(80.0) 
141 
(31.0) 
87 
(19.0) 
67 
(15.0) 
- 51 
(11.0) 
70 
(15.0) 
50 
(11.0) 
38 
(8.0) 
37 
(8.0) 
72 
(16.0) 
Ruiz-
Ortiz(329) 
443 
(42.0) 
- 884 
(83.7) 
321 
(30.4) 
235 
(22.2) 
150 
(14.2) 
- 153  
(14.5) 
215 
(20.3) 
176 
(16.7) 
76 
(7.2) 
56 
(5.3) †† 
102 
(9.7) 
Gallego 
(322) 
494 
(51.0) 
66 
(7.0) 
796 
(82.0) 
249 
(26.0) 
350 
(36.0) 
182 
(19.0) 
- 94 
(10.0) 
182 
(19.0) 
- 136 
(14.0) 
79 
(8.0) 
- 
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Table 1.28 continued 
N (%)  Female Age 
<60  
Hypertension Diabetes  HF Prior 
stroke/TI
A 
PAD Renal 
disease 
CAD COPD Smoking Previous 
bleeding 
Amiodaro
ne 
Lip(330) 3,129 
(39) 
- 3,405 
(42.0) 
1,244 
(15.0) 
4,466 
(55.0) 
674 
(8.0) 
- 734 
(9.0) 
2,434 
(30.0) 
870 
(11.0) 
1,053  
(13.0) 
- 1,670 
(35.0) 
Poli(321) 412 
(37.8) 
61 
(5.6) 
745 
(68.7) 
216 
(19.9) 
268 
(24.7) 
313 
(28.8) 
143 
(13.2) 
- 239 
(22.1) 
- 181  
(16.6) 
- 200 
(18.4) 
Skov 
(320) 
54 
(29.6) 
23 
(12.6) 
- - - - - - - - 41 
(22.5) 
- 27 
(14.8) 
Apostola
kis(199)† 
382 
(37.5) 
147 
(14.4) 
692 
(67.9) 
200 
(19.6) 
197 
(19.3) 
130 
(12.8) 
57 
(5.6) 
53 
(5.2)‡ ‡ 
173 
(17.0)
§§ 
- 64.0 
(6.3) 
- 129 
(12.7) 
Apostola
kis(199)‡ 
157 
(67.1) 
30.0 
(10.5) 
234 
(81.8) 
64 
(22.4) 
45 
(15.7) 
30.0 
(12.8) 
8 
(2.8) 
2.0 
(0.7)‡ ‡ 
44 
(15.4)
§§ 
- 140 
(49.0) 
- 26 
(9.1) 
 
CAD: Coronary artery disease; HF: Heart failure; COPD: chronic obstructive pulmonary disease; eGFR: estimated glomerular filtration rate; MI: myocardial infarction; TIA: 
transient ischemic attack; PAD: peripheral arterial disease  
*internal validation †external validation; ‡ median age; § eGFR 30 ml/min/1.73m2; || antiarrhythmic; ¶ Major bleed; # hepatic/renal disease; ** history of MI 
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Figure 1.7: Mean TTR vs. SAMe-TT2R2 categories in validation studies 
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Six of the studies (199, 317, 319, 328-330) reported the predictive ability of the SAMe-TT2R2 
score using C-statistics (Figure 1.8). Taken together, these validation studies suggest that the 
SAMe-TT2R2 score is able to predict good or poor anticoagulation control among AF patients 
better than chance, with C-statistics ranging from 0.56 (328) to 0.72. (199) Many risk scores 
based on clinical factors such as CHADS2, CHA2DS2-VASc, Killip and TIMI scores show 
broadly similar modest C-indexes (approx. 0.6) when used to predict patients categorised at 
‘high risk’ who actually sustain clinical events (193, 314). 
 
Six studies (319, 321, 322, 325, 327, 330) also examined if the SAMe-TT2R2 score could 
discriminate AF patients with clinical events. Five (319, 322, 325, 327, 330) demonstrated 
some positive associations for SAMe-TT2R2 score predicting clinical events, with C-statistics 
ranging from 0.55 (330) to 0.62 (322) (Table 1.29). As seen in most of the studies, (199, 280, 
318, 319, 321-330, 342) increasing SAMe-TT2R2 score demonstrated poorer TTR values 
which might also translate into poorer outcomes. This can be evidenced by studies that 
showed the SAMe-TT2R2 score relating to severe bleeding (322) and major bleeding (defined 
by the Bleeding Academic Research Consortium) (330), stroke/TE (330), adverse 
cardiovascular event (322) and death (322, 330) during follow up. In an observational study 
performed in 911 non-valvular AF Spanish patients, the SAMe-TT2R2 score also successfully 
predicted the composite outcome of major bleeding, TE complications and death (319). A 
Chinese study also demonstrated that a SAMe-TT2R2 score of ≤2 vs. SAMe-TT2R2 of 3 vs. 
SAMe-TT2R2 ≥4 is associated with lower annual stroke risk (3.49%/year vs. 4.56% per year 
vs. 6.41%/year, respectively) (325) . 
1.6.2 Importance of good anticoagulation control 
Achieving good anticoagulant control (i.e. TTR≥65-70%) as recommended by guidelines (3, 
344) is essential for managing AF patients treated with VKA. Indeed, numerous studies have 
demonstrated that a high TTR translates into lower risk of stroke and bleeding (119, 120, 122, 
195, 345). A systematic review demonstrated that a 7% and 12% improvement in TTR can 
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lead to a reduction in major bleeding and thromboembolic event, respectively, by 1 event per 
100 patient years (120). A real-world study (119) of 27,458 warfarin treated patients for AF 
(with at least 3 INR measurements) showed that in patients with good anticoagulation control 
(TTR ≥70%), stroke risk was reduced to 79% compared to patients with poor INR control (TTR 
≤30%). However, achieving and maintaining a therapeutic INR can be difficult to accomplish 
and therefore, NOACs are preferred to VKA in the majority of patients requiring OAC initiation 
(3). 
1.6.3 Impact of different methods of calculating TTR 
Fauchier and colleagues (346) have raised concern about the different methods used to 
calculate TTR, whether to use TTR based on the Rosendaal method, percentage of INRs in 
range (PINRR) (traditional method) or percentage of visits in range on a given date (cross-
sectional method), as these methods are not interchangeable. Overall, 14 studies (199, 280, 
318, 320-329, 342) reported TTR using the Rosendaal method, only one study (319) utilised 
PINRR method and another one reported ‘labile INR’ as their measure of anticoagulation 
control (330). At the moment, there is no evidence showing which method of calculating 
percentage of INR in range is best, as each method has its own unique strengths and 
weaknesses (347). While TTR via the Rosendaal method calculates the exact percentage of 
days the INR falls within range; its calculation is more complex than the others and is based 
on linear extrapolation. In contrast, calculating TTR via the PINRR method is simpler as it only 
looks at the number of INRs that fall within the therapeutic range divided by the total number 
of INR tests undertaken. However, the PINNR method does not consider the actual number 
of days of anticoagulant treatment and thus might underestimate control in patients with 
inconsistent INR monitoring, patients who have temporary discontinued therapy and patients 
with a long gap between each INR test, in contrast to the Rosendaal method where these 
factors will be accounted for, resulting in a lower TTR.  
The next section discusses about antithrombotic therapy in patients with valvular heart 
disease. 
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Figure 1.8: Predictive ability (C-statistics and 95% confidence intervals) of SAMe-TT2R2 towards 
anticoagulation control in validation studies 
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Predictive ability of SAMe-TT2R2 score on anticoagulation control with C-statistics (95% CI) 
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Table 1.29:  Predictive ability (C-statistics) of SAMe-TT2R2 for anticoagulation control and clinical events 
 
Anticoagulation control, c-statistics (95% CI) Clinical events, c-statistics (95% CI) 
Pivatto Junior (317) TTR≥65: 0.612 (0.544-0.681; p=0.002) - 
Chan (325) - Stroke: 0.54 (0.52-0.57)  
Abumuaileq (319) PINRR ≤70: 0.60 (0.56-0.64; p<0.01) Composite major bleeding, thromboembolic complication or 
death:  
0.57 (0.51-0.62); p=0.03 
Ruiz-Ortiz (329) TTR≥65: 0.57 (0.53-0.60; p<0.0005) - 
Gallego (322) - Adverse CV event: 0.62 (0.57-0.68; p<0.001)  
Bleeding: 0.55 (0.49-0.62; p=0.117)  
All-cause mortality: 0.62 (0.55-0.68; p<0.001) 
Lip (330) Labile INR: 0.589 (0.574-0.603) Stroke/TE: 0.561 (0.547-0.575) 
Severe bleeding: 0.552 (0.537-0.566) 
Major BARC bleeding:0. 574 (0.560-0.589)  
Death: 0.544 (0.530-0.559) 
Apostolakis (199) TTR 31% internal 0.72 (0.64-0.795)  
TTR 36% external 0.70 (0.57-0.82) 
- 
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1.7 Antithrombotic therapy in atrial fibrillation associated with valvular 
heart disease 
AF and valvular heart disease (VHD) often coincide and are present in about 2.5% of patients 
in industrialized countries (348-350). However, the management of patients with both 
conditions have not been well addressed in large clinical trials.  Patients with valvular heart 
disease are often excluded from most of the clinical trials due to the complexity of their 
management strategy. Due to this, there is a lack of definitive guidance on how best to manage 
this group of patients (349, 351).  
Recently, new definition to ‘valvular AF’ has been proposed based on the type of oral 
anticoagulation to be used in AF patients with valvular heart disease. The term valvular AF is 
outdated; the new term is Evaluated Heart valves, Rheumatic or artificial (EHRA) type I VHD 
and EHRA type II VHD (Table 1.30) (349, 351). These new terms will be used throughout the 
thesis except when it is cited as ‘valvular AF’ from original studies.  
Table 1.30: Classification of AF patients with valvular heart disease [taken directly 
from (356, 358)] 
Definition  OAC therapy Valve type  
Evaluated Heart valves, 
Rheumatic or artificial (EHRA) 
type I VHD  
VKA only • Moderate to severe mitral 
stenosis of rheumatic origin 
• Mechanical prosthetic valve 
replacement 
Evaluated Heart valves, 
Rheumatic or artificial (EHRA) 
type II VHD considering 
CHA2DS2-VASc score 
VKA or NOAC • Mitral regurgitation 
• Mitral valve repair 
• Aortic stenosis 
• Aortic regurgitation  
• Tricuspid regurgitation 
• Tricuspid stenosis 
• Pulmonary regurgitation 
• Pulmonary stenosis 
• Bio prosthetic valve 
replacement 
• Transaortic valve 
intervention (TAVI) 
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1.7.1 Epidemiology of valvular heart disease with atrial fibrillation 
Large differences can be seen in the epidemiology of VHD across different types of VHD and 
between low and high income countries (352). Rheumatic heart disease (RHD) is the most 
common cause of morbidity and mortality in low income countries while calcific aortic valve 
disease (CAVD) carries the greatest burden of VHD in high income countries (352). A review 
reported the prevalence of RHD between 46 per 100,000 in northern India while higher 
prevalence can be seen in the Solomon Islands, 2400,000 per 100,000 (353). In contrast, in 
the United States, aortic stenosis (a spectrum of CAVD) accounts for 45% of all deaths from 
VHD and was the main driver of VHD-related deaths over the past 30 years (354). The risk of 
ischaemic stroke can be up to 17 times greater in AF patients with rheumatic heart disease 
compared to patients with AF alone without any significant valvular heart disease (355). 
However, limited information is available on the prevalence and incidence of AF associated 
with VHD. The RELY-AF registry (enrolled AF patients at 164 sites in 46 countries) reported 
the presence of RHD among AF patients as 31.5% in India, 21.5% in Africa and 2.2% in North 
America (356). Whereas the ORBIT-AF registry, a multicentre, prospective, outpatient hospital 
registry included 176 US practices with 9748 AF patients, demonstrated a prevalence of 
27.7% with significant VHD in this population. Among them, 4.1% had mitral 
stenosis/mechanical valve, 4.7% had bioprosthetic valves or balloon valvuloplasty or prior 
valve repair while a higher prevalence (18.9%) of patients with aortic regurgitation/aortic 
stenosis, mitral regurgitation or tricuspid regurgitation (357) was found, consistent with other 
high income countries (354).  
1.7.2 Anticoagulation therapy in AF patients with valvular heart disease 
Thrombotic events are the most common cause of mortality and morbidity especially after 
surgery for VHD. This risk is especially higher within the first 3 months, for both bioprosthetic 
and mechanical devices (348). Therefore, antithrombotic therapy is required to prevent 
thrombotic events in VHD patients after surgical intervention. Effective measures should also 
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be made to control modifiable risk factors (for example effective blood pressure control in 
hypertensive patients) to reduce the risk of thromboembolism, together with the prescription 
of antithrombotic drugs (358). Anticoagulation therapy is required lifelong in patients receiving 
a mechanical valve as this confers a life-long thrombotic risk. In addition, AF, a common 
arrhythmia in VHD, also requires life-long anticoagulation (3, 348, 349, 358). Thus, patients 
with both AF and mechanical/bioprosthetic device are at risk of thromboembolic and bleeding 
complications if their anticoagulation therapy is not well optimised (348). 
1.7.2.1 Anticoagulation therapy in mechanical heart valves 
Exposure to the artificial valve and tissue injury caused by the presence of a prosthetic valve 
activates the intrinsic and extrinsic coagulation pathways thus inducing the formation of 
thrombin which in turn facilitates thrombus generation (349, 351). This condition is more 
pronounced in AF patients, patients with mild to severe stenosis and aortic stenosis, as all 
these conditions affect the blood flow turbulence thus triggering the coagulation cascade, 
intensifying the propensity to thrombosis (349, 351). VKA antagonists prevent the coagulation 
cascade at both the intrinsic and extrinsic pathways thus preventing the formation of thrombin. 
The European guidelines (3, 349, 351) recommend the use of VKA in patients undergoing 
mechanical valve transplantation (regardless of presence of AF) and AF patients with 
moderate to severe mitral stenosis with good anticoagulation control, TTR >65-70% (3, 349, 
351). The use of VKA should be monitored according to the INR range and targets based on 
the prosthesis thrombogenicity and patient-related risk factors (Table 1.31). Treatment 
duration with anticoagulation therapy depends on several factors. Patients with mechanical 
valves and those with bioprosthetic valves or native valve disease (aortic and mitral stenosis, 
aortic, mitral and tricuspid regurgitation) with additional (≥2) stroke risk factors require lifelong 
anticoagulation treatment (Class 1 recommendation) (3, 351). However, the current ACC/AHA 
guideline (359) recommends VKA therapy with the addition of aspirin (at least 75-100 mg/day) 
to all patients receiving mechanical valves (Class 1A recommendation), whereas ACCP (360) 
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recommends addition of aspirin only in high-risk patients with careful monitoring of the 
bleeding risk (359, 360).  
Table 1.31:Target INR values for VKA among patients with prosthetic valves [taken 
directly from (358, 368)] 
Prosthesis 
thrombogenicity  
Valve type INR target in 
patients with 
related factors 
≥1*(351) 
INR target in 
patients without 
risk factor  (361) 
Low Carbomedics. Medtronic 
Hall, St Jude Medical, ON-
X 
3.0 2.5 
Medium Other bileaflet valves 3.5 3.0 
High Lillehei-kaster, 
omniscience, Starr-
Edwards, Bjork-Shiley and 
other tilting-disc valves 
4.0 3.5 
*Risk factors: mitral or tricuspid valve replacement, previous thromboembolism, AF, mitral stenosis of any degree, 
left ventricular ejection fraction <35% 
 
A meta-analysis from 1994 (362) of 13,088 patients on antithrombotic therapy vs. no 
antithrombotic therapy investigated thromboembolic and bleeding complications among 
patients receiving a mechanical heart prosthesis. In this study, the incidence of major 
embolism (causing death, residual neurological deficit or peripheral ischemia causing surgery) 
without any antithrombotic therapy was 4.0 per 100 patient-years (95% CI 2.9-5.2) while this 
incidence was further reduced to 1 per 100 patient-years (95% CI 1.0-1.1) in patients with VKA 
and 2.2 per 100 patient-years (95% CI 1.4-3.1) for those on antiplatelet therapy (362). For 
bleeding complications, OAC therapy increased the incidence of total bleeding (cerebral, 
intracranial, bleeding causing death or hospitalisation and minor bleeding); 1.9 per 100 patient-
years (95% CI 1.7-2.0) and the addition of antiplatelet therapy further increased the incidence 
of total bleeding; 4.6 (95% CI 3.1-6.4) (362). 
Another more recent meta-analysis of RCTs by Massel et al (363), comparing VKA alone vs. 
combination VKA and antiplatelet, of 4122 mechanical valve replacement patients found a 
reduced risk of TE event [OR 0.43 (0.32-0.59, p<0.00001] and mortality [OR 0.57 (0.42-0.78; 
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p=0.0004)] in patients with the combination therapy compared to VKA alone. However there 
was increased risk of major bleeding with the addition of antiplatelet therapy [OR 1.58 (1.14-
2.18); p=0.006)] compared to anticoagulation therapy (363).  
The use of NOACs in patients with mechanical valve prosthesis is contraindicated (351, 358). 
There is only one trial, the RE-ALIGN trial, a phase 2 dose study (364) of patients with 
mechanical heart prosthesis (aortic and mitral) that evaluated the use of dabigatran versus 
warfarin. Based on the kidney function, the selection dose of dabigatran was 150, 220 or 
300mg twice daily to achieve a trough level of 50ng/ml which is based on the pharmacokinetic 
model from the RE-LY trial. Unfortunately, the trial was terminated early after randomisation 
of 252 of 405 patients because there was an excess of thromboembolic and bleeding events 
in the dabigatran group (364). Several explanations have been suggested including 
inadequate concentration of dabigatran in plasma, varied pharmacodynamics properties of 
dabigatran and warfarin and over reactive contact coagulation pathway in the early 
postoperative period induced by the sewing ring (351). No other studies of NOACs (factor Xa) 
has been tested subsequently. Due to this, currently all patients with mechanical valve 
prosthesis should be anticoagulated with a VKA (3, 349, 351). 
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1.7.2.2 Anticoagulation therapy in bioprosthetic valves 
Reports have shown that thromboembolism associated with bioprosthetic valves ranged from 
0.2%-3.3% per year (360, 365, 366) whereas higher risk can be found among the valves in 
the mitral, compared to the aortic, position. Similar to that seen in mechanical prostheses, but 
to a lower extent, TE risk is also higher within the first 3-months post-surgery (367, 368). Due 
to that, compared to OACs, the use of low dose aspirin is now favoured for those with surgical 
aortic bioprosthesis (without other indications for OAC, for example AF) for the first three 
months post-surgery; however, this is based on a low-level of evidence (class IIa, level C) 
(358). OACs may be considered for the first 3 months after surgery in aortic bioprosthesis 
patients with class IIB, level C evidence (358, 369-371). In contrast, those with mitral or 
tricuspid valve replacement with bioprosthesis should still be considered for OAC therapy for 
the first 3 months after surgical intervention (358). 
Lifelong anticoagulation therapy is required in patients with bioprosthesis and with additional 
risk factors such as venous thrombosis, AF, hypercoagulable state and severely impaired left 
ventricular function with low evidence (class I, level C) (351, 358). When long term 
anticoagulation therapy is needed, VKA should be favoured in patients with bioprosthesis 
(358). Despite the lack of RCT, (351, 372-374) NOACs can be used instead of warfarin in AF 
patients with bioprosthesis after the third month of the post-operative period (351, 358).  
The Dabigatran Versus Warfarin After Bioprosthesis Valve Replacement for the Management 
of Atrial Fibrillation Postoperatively (DAWA) pilot study (375) compared dabigatran vs. 
warfarin post bioprosthetic valve replacement in AF patients however due to low enrolment 
(N=27; 15 dabigatran and 12 warfarin), the trial was terminated earlier and no concrete 
conclusion was made.  One patient from the warfarin group and no patient from the dabigatran 
group developed intra cardiac thrombus and ischaemic stroke respectively after 90 days of 
randomisation (375). Other small studies (373, 374) also suggested NOACs as reasonable 
alternatives to VKA therapy in patients with AF and VHD, but more studies are needed to 
confirm its efficacy and safety profile (351). 
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The ARISTOTLE (376) and ENGAGE-AF (373) trials included 82 and 191 patients with a 
bioprosthesis, respectively. In both trials, the incidence of stroke/systemic embolism was 
similar; between 1.19-2.9%/year for those receiving either apixaban or low/high dose 
edoxaban compared to 1.7%/year incidence with warfarin therapy (351, 373, 376). Compared 
to warfarin, edoxaban low and high dose was associated with similar risk of stroke/SE [HR 
0.37 (0.10-1.42) and HR 0.53 (0.16-1.78) respectively compared to warfarin]; however only 
low dose edoxaban was associated with a lower risk of major bleeding [HR 0.12 (0.01-0.95)]; 
low and high dose of edoxaban with lower risk of all-cause mortality [high dose edoxaban vs. 
warfarin: HR 0.46 (0.23-0.91) and low dose edoxaban vs. warfarin: HR 0.43 (0.21-0.88) 
respectively] (351, 373, 376). 
1.7.2.3 Anticoagulation control in patients with valvular heart disease (VHD) 
To date, only four (377-380) studies evaluated anticoagulation control by TTR in patients 
undergoing valve replacement therapy. Two studies from Italy and Denmark (377, 378) that 
evaluated TTR among mechanical heart valve patients showed relatively low TTR ranging 
from 55-60% while very good TTR of 71-73% can be seen in another two Swedish studies 
(379, 380). 
Meanwhile, in 2002 one study (381) assessed the effect of anticoagulation control on long 
term survival after valve replacement with a Medtronic Hall valve among 1532 patients 
receiving single valve replacement at either the aortic or mitral position. Anticoagulation control 
variability (ACV) was used and defined as the percentage of INRs outside the 2.0-4.0 range 
[patients with aortic valve replacement (AVR) had a range of 2.0-3.0 while patients with mitral 
valve replacement (MVR) had a higher range of 3.0-4.0]. The ACV was further divided into 3 
equal sized groups: low (0-19.9% ACV), intermediate (20-29.9% ACV) and high ACV (≥30% 
ACV); with higher ACV reflecting poor anticoagulation control. Overall, 75.5% of the collected 
INRs were within the target range. Of those INRs outside of the therapeutic range, 12.0% were 
below 2.0 and 12.5% were above 4.0. Survival at 15 years was reduced in the high ACV group 
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with AVR but was similar among the low and intermediate group (28% vs. 59% vs. 55%; 
p<0.001, respectively). Similarly, as with MVR at 15 years, the survival rate was 56%, 42% 
and 24%; p<0.001 for the low, intermediate and high ACV groups, respectively; also, 
significantly reduced in the high ACV group. On multivariate analysis, ACV per 20% increase 
was associated with increased mortality [HR 1.8, coefficient 0.595; p=0.001]. In this study, 
although the quality of anticoagulation control was not assessed via the Rosendaal or the 
percentage of INRs in range methods, better quality of anticoagulation assessed by ACV was 
associated with reduced mortality (381).  
In essence, VHD patients, particularly those with surgical prostheses (regardless of AF), are 
at increased risk of thromboembolic complications. Long term anticoagulation therapy with 
VKA is recommended for those with a mechanical prosthesis; whereas those with a 
bioprosthesis (without additional risk factors) require at least three months of anticoagulation 
therapy (VKA/NOACs) after surgical intervention. Measures should be taken to ensure the 
quality of anticoagulation control is optimised level to prevent TE and bleeding complications.  
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1.8 Aims and objectives 
 
This thesis will include three studies with the main objective of examining anticoagulation 
control in AF patients from different cohorts. Specific objectives are outlined below. Secondary 
objectives will be mentioned in each specific study.  
 
1. The original aim was to assess the impact of at behavioural-educational intervention 
(TREAT-2) on TTR, among patients identified as less likely to establish and maintain 
adequate TTR (SAMe-TT2R2 score >2), receiving warfarin and comparing these 
patients against those receiving warfarin and usual care alone (SAMe-TT2R2 score 0-
2). However, due to a change in clinical practice regarding the prescription of NOACs 
instead of warfarin since 2015, the original aim of this study changed with the focus on 
assessing depression, anxiety, knowledge about AF, beliefs about medication, and 
quality of life among newly anticoagulated AF patients in this cohort [see Chapter 2].  
2. To examine the quality of VKA control (measured by TTR), predictors of 
anticoagulation control, and the relationship between INR control and adverse clinical 
outcomes [thromboembolic (stoke/TIA and systemic embolism), bleeding events, 
cardiovascular hospitalisation, all-cause mortality and ≥1 composite endpoints 
(MACE)] in AF patients in a multi-ethnic cohort [see Chapter 3].  
3. To examine the quality of VKA control (measured by TTR), predictors of 
anticoagulation control, and the relationship between INR control and adverse clinical 
outcomes [thromboembolic (stoke/TIA and systemic embolism), bleeding events, 
cardiovascular hospitalisation, all-cause mortality and ≥1 composite endpoints 
(MACE)] in patients with operated valvular heart disease (VHD), with and without AF 
[see Chapter 4].  
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Chapter 2.  A prospective study examining non-vitamin K antagonist 
oral anticoagulants (NOACs) versus warfarin based on the SAMe-
TT2R2 score strata in anticoagulant-naïve patients with atrial 
fibrillation: the TREAT-2 study 
 
2.1 Abstract  
Introduction: 
To ensure efficacy and safety of OAC therapy with VKA (for example warfarin), the therapeutic 
range of INR 2.0-3.0 must be achieved. In clinical practice, this is often poorly controlled and 
could be due to poor adherence, inadequate knowledge and awareness of the importance of 
OAC therapy. The TREAT intervention (219, 382), a one-off educational-behavioural session, 
demonstrated a significant improvement in the TTR compared to patients receiving usual care 
alone. 
 
Objective:  
The original aim of this study was to examine the impact of a behavioural-educational 
intervention (TREAT-2) on TTR among warfarin patients with SAMe-TT2R2 score >2 (those 
predicted to have poor response to warfarin therapy) and compare their TTR among patients 
with SAMe-TT2R2 score 0-2 (those predicted to have good response warfarin therapy).  
Medication adherence via pill count method was assessed for patients receiving NOAC 
therapy. Secondary endpoints included assessment of patients’ depression, anxiety, 
knowledge of AF and its treatment, beliefs about medication and quality of life using validated 
questionnaires at baseline and six months follow up. Due to a change in clinical practice 
regarding the prescription of NOACs instead of warfarin since 2015, there were insufficient 
patients initiated on warfarin therapy within the Trust.  Therefore, the comparison of the impact 
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of the TREAT-2 intervention on TTR among warfarin-treated patients could not be examined.  
Instead the results focus on the secondary outcomes.  
 
Methods:  
Prospective, observational and longitudinal study design was employed among patients 
newly-initiating OAC therapy for stroke prevention in AF (either warfarin or a NOAC). The 
Patient Health Questionnaire-9 (PHQ-9), Generalised Anxiety Disorder-7 (GAD-7), AF 
knowledge scale, Beliefs about medication (BMQ) and Atrial Fibrillation Effect on Quality of 
Life (AFEQT) questionnaires were completed among 139 newly anticoagulated AF patients at 
baseline and 105 patients at six months follow up. The parameters were compared 
descriptively between warfarin and NOACs patients at both time points. The change in scores 
between baseline and follow-up were analysed in those who completed the questionnaires at 
both time points (N=105). 
 
Results:  
At baseline the overall median (IQR) depression and anxiety scores were 4.0 (1.0-8.0) and 
1.0 (0-5.0) respectively. The mean (SD) AF knowledge score was 5.7 (1.7). Patients had 
positive perceptions about their medications evident by the mean (SD) positive necessity-
concern differential 5.8 (4.1) and poor overall quality of life score, 66.7 (53.7-77.8). There were 
no significant differences in the depression, anxiety and beliefs about medication scores over 
time. However, significantly higher proportions of patients answered correctly in the question 
assessing the consequences of AF (88.6% vs. 50.5%; p<0.001) and symptoms score from 
the quality of life questionnaire has significantly improved at follow up compared to baseline 
(83.3 vs. 79.2; p=0.02)] respectively. Median (IQR) TTR at follow up for patients on warfarin 
was 77.3% (54.4-84.7) and adherence for 70% of NOAC patients via pill count method was 
100%. 
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Conclusion: 
Newly anticoagulated AF patients appear to have low levels of anxiety, depression, poor AF 
knowledge, positive perceptions about their medication and poor overall quality of life at 
baseline and these parameters remained the same after six months of follow up. However, 
significantly more patients were aware of the consequences of AF and symptoms of AF (by 
the AFEQT questionnaire) improved at follow up. Future research is required in order to 
determine the impact of educational and behavioural interventions towards improving 
knowledge, emotional health, quality of life and thus preventing adverse clinical outcomes in 
patients receiving different types of OAC therapy.  
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2.2 Background and rationale 
Adequate OAC, either with VKA or NOAC is essential for effective stroke prevention in patients 
with AF with ≥1 additional stroke risk factor (173). NOACs offer efficacy, safety and relative 
convenience compared to the VKAs (130). However, cost considerations result in variable 
policies regarding NOACs in different healthcare systems, ranging from unrestricted 
reimbursement at one end of the spectrum to full payment by AF patients at the opposite end. 
Some healthcare systems have even adopted ‘conditional authorisation’ of NOACs 
prescription, based on (say) 6 months of low quality of anticoagulation with VKAs, as 
measured by the TTR during a pre-defined period of VKA trial, whilst others still search for 
optimal criterion for patient selection in the local setting. Indeed, the SAMe-TT2R2 score could 
help aid individual decision-making regarding the choice between VKAs or NOACs in routine 
clinical practice. 
 
Previous studies by the Birmingham group (284, 383, 384) and others (385, 386) have found 
that many AF patients possess very little knowledge of their disease and do not understand 
the risks and/or benefits of anticoagulant therapy, particularly among ethnic minority patients 
(383, 384).  This may contribute to poor INR control, given the complexity of the warfarin 
regimen, with dosing adjustments, drug-, food- and alcohol- interactions. Few studies have 
intervened to improve adherence with, and understanding of, warfarin therapy. Thus, a more 
structured education intervention among patients who are predicted to be less likely to achieve 
good INR control (SAMe-TT2R2 score of >2) may be an alternative treatment strategy which 
could help improve their TTR. 
 
Patient education has been found to improve INR control (296). Indeed, an earlier pilot study 
of a brief educational intervention (284) demonstrated a significant improvement in the 
awareness of target therapeutic INR (p<0.0001) and factors which may affect INR levels 
(p=0.005), with a trend towards improvement in awareness of the benefits of anticoagulants 
 
 
126 
and bleeding risks. Further, the TREAT intervention (see Table 2.1 for the components of the 
intervention), a one-off educational-behavioural session, delivered by a health psychologist, 
demonstrated a significant improvement in the TTR compared to patients receiving usual care 
alone (76.2% vs. 71.3% respectively; p=0.035) (219, 382).  
 
However, a recent Cochrane systematic review (387) assessing the impact of knowledge and 
behavioural intervention on TTR showed equivocal results. The mean difference of TTR 
between patients receiving educational and self-monitoring interventions compared to usual 
care was 6.31 (95% CI -5.63 to 18.28). This suggest that although TTR appears to be higher 
in the intervention group vs. usual care, analysis of the pooled data was not in favour 
(statistically) of the former compared to the latter. Nonetheless, these results were based on 
only two trials (N=69) with very low quality of evidence, assessing the impact of self-monitoring 
and education intervention vs. usual care on TTR.  Thus, further trials are needed to 
investigate the benefits of similar interventions (both educational and behavioural) on 
anticoagulation control in AF patients.    
 
Improving understanding about a disease and its treatment allows patients to make informed 
decisions about the management of their condition and treatment may make a significant 
difference to clinical outcomes. Whilst NOACs are a valid alternative to warfarin, the latter will 
still continue to be used as a treatment for AF, and interventions that can improve 
anticoagulation control are essential to reduce the risk of adverse events.  
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 Table 2.1: Components of the TREAT intervention 
 Content 
Educational Booklet • AF causes and consequences 
• Warfarin and its metabolism 
• Stroke risk and risk of bleeding on treatment 
• Lifestyle changes (diet, alcohol, lifestyle changes) 
 
Patient DVD 
 
Delivered by ‘expert 
patient’ narratives 
and consultant Q&A 
 
• AF: causes, consequences, side effects, treatment options 
• Warfarin: INR monitoring, lifestyle changes 
• Patient barriers: psychological, physical 
• Consultant Q&A: common questions and answers 
Patient worksheet  Including: Calculate your own risk of stroke; personal barriers to 
warfarin uptake; and discussion of personal goals for lifestyle 
changes 
Self-monitoring diary Two-week diary monitoring including: Diet; Alcohol intake (in units); 
Medications; and INR outcomes 
 
2.2.1 Study objective 
The initial objective of this study was to perform a prospective observational intervention of 
NOAC versus warfarin based on SAMe-TT2R2 score strata in anticoagulant-naïve patients with 
AF. In addition, to evaluate the impact of the TREAT-2 educational and behavioural 
intervention on TTR among patients identified as less likely to establish and maintain adequate 
TTR (SAMe-TT2R2 score >2) receiving warfarin and comparing these patients against those 
receiving warfarin and usual care alone (those with a SAMe-TT2R2 score ≤2).  
Secondary objectives included assessment of patients’ depression, anxiety, knowledge of AF 
and its treatment, beliefs about medication and quality of life using validated questionnaires 
at baseline and six months follow up.   
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2.3 Methods 
Study design 
Prospective observational study with a 16-month inclusion period and a 6-month follow-up.  
 
Patients  
Anticoagulant-naïve AF patients referred for OAC therapy (see Figure 2.1), were recruited 
from three different sources: (1) OAC clinic at Sandwell and West Birmingham Hospitals 
(SWBH), (2) AF/Cardiology Clinic at SWBH and (3) OAC clinic, University Hospitals 
Birmingham (UHB).  
 
Inclusion criteria 
Male and female adult (aged ≥18 years) patients with electrocardiographically documented 
AF without Evaluated Heart valves, Rheumatic or Artificial (EHRA) type 1 VHD, and at least 
one additional risk factor for stroke (based on the CHA2DS2VASc score)(146), who were OAC-
naïve (having never taken OAC) and eligible for OAC were considered for inclusion. Men with 
a CHA2DS2VASc score of ≥1 and women with a CHA2DS2VASc score of ≥2 were eligible for 
OAC therapy. 
 
Exclusion criteria 
The exclusion criteria were: (1) aged <18 years old, (2) any contraindication to OAC, (3) 
prosthetic cardiac valve or significant VHD with an indication for heart surgery, (4) likelihood 
of intermittent or permanent discontinuation of OAC during follow-up (e.g., due to major 
surgery or post-AF ablation), (5) active malignancy, (6) cognitive impairment, (7) any disease 
likely to cause their death within 6 months and (8) unable to provide written informed consent. 
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Ethical approval 
This study involved patients from two NHS sites, thus REC approval was applied for. Ethical 
approvals were obtained from the West Midlands South Birmingham Research Ethics 
Committee [REC; (REC reference: 16/WM/0339)], the Health Research Authority [HRA; (IRAS 
ID: 193145); 26th September 2016), and also SWBH Research and Development (R&D; R&D 
reference: 16CARD06;13th October 2016). The University Hospitals Birmingham was added 
as a site later and approval from the REC and UHB R&D was obtained (Reference number 
RRK6149; 12th December 2017). Approval letters can be found in Appendix 5. The University 
of Birmingham acted as the sponsor for this study. 
 
Patient recruitment 
Recruitment of patients lasted for 16 months starting from 15th October 2016 to 3rd March 
2018. However, the process of obtaining ethical approval at the UHB site began later on and 
was a lengthy process. Thus, in the 3-month period of recruitment at the UHB site (3rd January 
– 3rd March 2018), only a limited number of patients were recruited (25 patients were screened 
for eligibility and only nine patients agreed to participate) (Figure 2.1). 
 
2.3.1 Procedure 
After initiation of OAC (either warfarin or a NOAC) therapy, patients were seen by an 
anticoagulant nurse/healthcare professional for an educational session regarding their AF and 
anticoagulation therapy as per usual care. After that, patients were approached by the 
researcher to discuss the study and if the patient agreed to participate, written informed 
consent was obtained and the baseline questionnaire was administered. Individual baseline 
SAMe-TT2R2 score was calculated and patients were allocated to one of four groups on the 
basis of their SAMe-TT2R2 score and OAC (warfarin or NOAC) (see Figure 2.1). Patients with 
a SAMe-TT2R2 score ≤2 who were prescribed warfarin (dose-adjusted to achieve a target INR 
of 2.0 to 3.0) were assigned to Group 1 and patients with a SAMe-TT2R2 score ≤2 who were 
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prescribed NOAC were assigned to Group 2. Patients with a SAMe-TT2R2 score >2 who were 
prescribed warfarin were assigned to Group 3, to receive the intensive education (TREAT-2). 
Patients with a SAMe-TT2R2 score >2 who were prescribed NOAC (apixaban, dabigatran, 
edoxaban, or rivaroxaban) were assigned to Group 4. Baseline demographic and clinical 
information, including medical, medication history and laboratory information was recorded 
from the hospital records onto a proforma (Appendix 1, A1.1). All patients were informed 
about AF and the need for anticoagulant therapy by a healthcare professional using the 
standard warfarin or NAOC-specific education checklist at baseline as per usual care. All 
patients on warfarin also received the standard Yellow book to identify that they were on 
warfarin.   
 
Patients in Group 3 would receive a group intervention (between 2-4 patients plus carer/family 
member) based on the session developed for the TREAT study delivered by the researcher 
within 4 weeks of warfarin initiation. In addition, patients would receive an educational booklet, 
self-monitoring diary, worksheet and alert card.  
 
INR monitoring 
INR monitoring was performed by the Anticoagulation Services at SWBH and UHB. All 
patients who received warfarin (usual care and intensive education arms) attended the 
anticoagulant outpatient clinic at the respective hospital to have their INR checked using a 
capillary sample. The frequency of the INR visits was at the discretion of the OAC clinic (the 
OAC clinic staff were blinded to the intervention arm the patient is allocated to enable as 
‘naturalistic’ as possible follow-up and monitoring). Every INR result from baseline to the end 
of the study (6-months) was recorded. The proportion of time each patient spent in the 
therapeutic INR range (2.0 to 3.0) (TTR) was calculated by the Rosendaal (using linear 
interpolation method between two consecutive INR values) and the percentage of INR in 
range (PINRR) methods (dividing the number of INRs that falls in range by the total number 
of INR tests). INR data was utilised from months 1 to 6 follow-up (to allow attainment of the 
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correct dose of warfarin during the first four weeks). More details of the calculation of TTR can 
be seen in section 3.3.4.1.1, page 178. 
 
Six-month follow-up 
All patients were followed up via phone call at 6 months. Patients receiving NOACs were 
asked to post back all their pill boxes and blister packs to the researcher. Medication 
adherence of patients in Groups 2 and 4 were reviewed at 6- months via pill count.   
 
The battery of questionnaires (PHQ-9, GAD-7, AF knowledge scores, BMQ and AFEQT) was 
posted to all participants at follow up with a stamped addressed envelope for return. If returned 
questionnaires were not fully completed, the researcher contacted the patient by telephone to 
facilitate 100% completion of the questionnaires. Patients were sent a reminder questionnaire 
at both baseline and follow up if they did not respond within 2-3 weeks of receiving the original 
set of questionnaires.  
 
2.3.2 Assessment of medication adherence 
Medication adherence was assessed among patients receiving NOAC therapy via the pill 
count method. Patients were asked to keep their NOAC boxes and blisters from the point they 
were recruited into the study until six months of follow up. They were also given stamped-
addressed envelopes to return their empty pill boxes and blister packages. Upon receiving the 
packages, the number of pills remaining in the blister packages were counted. In addition to 
pill counting, the patients were also asked two questions to assess adherence via a phone 
call: 1. ‘Do you sometimes forget to take your blood-thinning pills?’ (yes/no answer); 2. ‘Over 
the past 2 weeks, were there any days when you did not take your blood-thinning medicine?’ 
(yes/no answer). These two questions were adapted from the self-report questions from the 
Morisky Green Levine adherence scale, which showed concurrent and predictive validity on 
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blood pressure control in majority of patients with good adherence to antihypertensive 
medications (388). Although the pill count method is an indirect measure of adherence, it has 
higher accuracy compared to other subjective methods (389), cost effective (389) and is 
commonly used in clinical trials (390, 391).  
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 Figure 2.1: Study design and patient selection flow chart 
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2.3.3 Study outcomes  
The primary outcome was the proportion of time spent in the therapeutic INR range, 2.0 to 
3.0, at 6 months for the two groups commencing warfarin and medication adherence (via pill 
count) for patients receiving a NOAC. The following secondary outcomes were examined: (1) 
depression, (2) anxiety, (3) patients’ knowledge of AF, (4) beliefs about medication and (5) 
quality of life.  
Ancillary descriptive analyses explored the incidence of bleeding, stroke/TIA, cardiovascular 
hospitalisation and death (given that the study was not powered to detect these differences). 
Exploratory analyses determined whether the incidence of bleeding, stroke/TIA, 
cardiovascular hospitalisation, death and composites (≥1) of these events were similar in 
patients with SAMe-TT2R2 0-2 compared to SAMe-TT2R2 >2. 
The number of patients with strokes/TIA, bleeding, thromboembolic, CV hospitalisations and 
death events were determined from hospital records. Stroke was defined as a focal neurologic 
deficit, from a non-traumatic cause, lasting at least 24 hours and further categorized as 
ischemic (with or without haemorrhagic transformation), haemorrhagic, or of uncertain type (in 
the case of patients who did not undergo brain imaging or in whom an autopsy was not 
performed). Systemic embolism was defined as a thromboembolic event outside the brain, 
retina, heart or lungs. Stroke and systemic embolism were later combined as thromboembolic 
events (TE). Major bleeding was classified according to the ISTH criteria (392): fatal bleeding, 
and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment 
syndrome, and/or bleeding causing a fall in haemoglobin level of 20 g/L or more, or leading to 
transfusion of two or more units of whole blood or red cells) (392). Clinically relevant non-
major bleeding (CRNMB) was defined as clinically overt bleeding that did not satisfy the criteria 
for major bleeding and that led to hospital admission, physician guided medical or surgical 
treatment, or a change in antithrombotic therapy (392). Major bleeding and CRNMB were 
combined as bleeding events. Cardiovascular hospitalisation was defined as a hospitalisation 
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with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, 
ventricular arrhythmia,  uncontrolled AF/atrial flutter, supraventricular arrhythmia, ii) valve 
surgery, coronary artery bypass graft (CABG) surgery, percutaneous transluminal coronary 
angioplasty (PTCA) surgery, pacemaker/ implantable cardioverter-defibrillator (ICD) insertion, 
carotid endarterectomy, peripheral angioplasty/surgery, limb amputation (393) AND as 
recorded in patient’s medical records.  
2.3.3.1 Questionnaires  
The following questionnaires were given to the patients to complete at baseline and 6-months 
later to assess depression and anxiety, knowledge of AF, beliefs about medication, and quality 
of life (see Appendix 2 for full questionnaires). These questionnaires were chosen as they 
are validated questionnaires and have been used in other cohorts of chronic diseases 
including asthma, diabetes and cardiovascular diseases including AF (394-396) (397) (398) 
(399).  
2.3.3.1.1 Patient Health Questionnaire (PHQ-9) 
Depression was assessed using the Patient Health Questionnaire (PHQ-9) (400).  The PHQ-
9 is a 9-item scale that contains the diagnostic criteria for depression based on the DSM-IV 
criteria. It is calculated by assigning scores of 0 to 3 to the response categories of “not at all,” 
“several days,” “more than half the days,” “and nearly every day,” respectively; scores range 
from 0-27. Scores of 0 indicated no depression and ≥15 signify the presence of major 
depression. Scores of 5, 10, 15, and 20 represents thresholds demarcating the lower limits of 
mild, moderate, moderately severe and severe depression, respectively (400).  
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2.3.3.2.1 The Generalised Anxiety Disorder 7-item (GAD-7) 
The Generalised Anxiety Disorder 7-item (GAD-7) questionnaire was used to assess anxiety. 
It is a 7-item scale and is calculated by assigning scores of 0 to 3 to the response categories 
of “not at all,” “several days,” “more than half the days,” “and nearly every day,” respectively, 
and adding the scores together. A total score for the 7 items ranges from 0 to 21. Scores of 0 
indicated no anxiety and ≥10 represents the presence of generalised anxiety disorder (GAD). 
Scores of 5, 10 and 15 are taken as the cut off points for mild, moderate and severe anxiety, 
respectively (401). The GAD-7 and PHQ-9 scores were chosen because they were 
recommended by the NICE guidelines as one of the valid measures of anxiety and depression 
severity (400, 401) among primary care patients (402, 403). Furthermore, both scales have 
been validated in patients with cardiovascular diseases, (394-396) with good sensitivity and 
specificity to detect major depressive disorder (81% and 77%, respectively) (395) and 
generalised anxiety disorder (75% and 89%, respectively) (404).  
2.3.3.3.1 Knowledge of AF 
Patients’ knowledge of AF was assessed using the Atrial Fibrillation Knowledge scale. (397) 
This scale consists of 11-items concerning AF in general (3-items), symptoms recognition, (3-
items) treatment (3-items) and general attitudes towards AF (2-items). For each question, 
patient can choose one of three options; only one answer is correct. Scores range from 0 to 
11 or 0-100%, with higher correct scores denoting better knowledge of AF(397). This scale 
has a border line reliability score with Cronbach α of 0.58 in its original derivation cohort. This 
scale combines three important aspects of AF knowledge: AF management, symptoms and 
antithrombotic therapy. It can also be used to detect gaps in knowledge and attitude towards 
AF management (397). 
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2.3.3.4.1 Beliefs about Medicine Questionnaire (BMQ)  
To assess patients’ beliefs about medication, the Beliefs about Medicine Questionnaire (BMQ) 
was used (398). This is an 18-item questionnaire consisting of two parts, one assessing 
patients’ belief about their own medicine (BMQ-specific) and the other assessing patients’ 
beliefs about medicine in general (BMQ-general). The BMQ-specific covers two themes the 
specific-necessity theme evaluates patients’ view about the importance and necessity of their 
medicines, whilst specific-concern theme comprises patients’ beliefs about potential harm and 
adverse effect of their own medicines. Each sub-scale has a score ranging from 5 to 25. 
Patients can choose if they ‘strongly disagree’, ‘disagree’, ‘uncertain’, ‘agree’ and ‘strongly 
agree’ with the statements regarding their view of medicines. A high score on the ‘necessity’ 
theme indicates that patients think their medicines are important to them; a high score on the 
‘concern’ theme means that patients are worried and concerned about their own medicines. 
The difference between the necessity and concern domain is obtained by subtracting the two 
values. Positive values indicate that patients perceive their medication as more important than 
their concerns about potential side effects of the medication and vice versa for negative 
values. Likewise, BMQ-general part has two themes as well; general overuse theme assesses 
how patients perceive the extent of medicine usage, and the general harm theme represents 
patients’ beliefs about the harmful nature of medicines in general. The scores of the last two 
themes range from 4 to 20; a high score in each theme means negative perception about 
medicines in general (398). This scale is valid, reliable and has been validated in AF and other 
cardiovascular diseases, renal, and diabetic populations (398). 
 
2.3.3.5.1 The Atrial Fibrillation Effect on Quality–of-life (AFEQT)  
The Atrial Fibrillation Effect on Quality–of-life (AFEQT) questionnaire was used to assess AF 
patients’ quality of life (405). It is a 20-item scale that is further divided to assess symptoms 
(4-items), daily activities (8-items), treatment concern (6–items) and lastly treatment 
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satisfaction (2–items). Responses were expressed using a 7-point Likert scale ranging from 
the most severe limitations/symptoms to no limitation/symptom. The raw score of 1 to 7 was 
transformed to a 0 to 100 scale. A score of 0 indicates lowest quality of life and a score of 100 
indicates highest quality of life. Thus, higher scores on the AFEQT instrument indicate better 
health status. The responsiveness of this instrument is its ability to detect clinically meaningful 
changes in a patients’ health status over time. Changes in the AFEQT overall and domain 
scores from baseline to subsequent 6 months were used to evaluate responsiveness to 
change over time (405). The AFEQT questionnaire was shown to adequately assess quality 
of life in AF populations evident by demonstrating robust content validity in one systematic 
review (399).  
2.3.4 Hypothesis 
It was originally hypothesised that patients with a SAMe-TT2R2 score >2 receiving warfarin 
who received the TREAT-2 intervention (Group 3) would have a significant improvement in 
TTR compared to those patients with a SAMe-TT2R2 score 0-2 receiving warfarin only. 
Secondly, it was hypothesised that patients with a SAMe-TT2R2 score >2 would have more 
depression and anxiety symptoms, poor knowledge of AF, negative beliefs or perception 
towards medication and have poorer quality of life than those with SAMe-TT2R2 score 0-2.  
 
Unfortunately, due to the change in clinical practice during the study, where prescription rates 
for NOACs for stroke prevention in AF increased sharply from 2015, there were only 13 
patients (Group 1 and 3) prescribed with warfarin therapy of which only four (Group 3) were 
eligible for the TREAT-2 intervention. However, these four patients did not agree to participate 
in the TREAT educational intervention within 4 weeks of warfarin initiation; but only agreed to 
do the questionnaire (Figure 2.2). Therefore, the planned analysis of comparing TTR between 
Group 1 (warfarin and usual care) and Group 3 (warfarin and TREAT-2 educational 
intervention) could not be undertaken. Hence the analyses focus on the secondary outcomes 
from the questionnaire data, adverse events and medication adherence in NOAC patients. 
 
 
139 
Patients were grouped according to the type of OAC they received (warfarin or NOAC) for the 
questionnaire analyses. 
 
Research questions 
• Do patients with a SAMe-TT2R2 score >2  
o Have poorer TTR?  
o Have more depression and anxiety symptoms, poorer knowledge of AF and 
quality of life and negative perceptions of medication? 
o Have more thromboembolic and bleeding events, CV hospitalisations, death 
and a composite of these events than those with SAMe-TT2R2 score 0-2? 
 
Power calculations  
Power for the primary endpoint of INR control, evidenced by TTR was calculated based on 
the results of the TREAT (219) study. In the TREAT study, patients receiving the intensive 
educational intervention (N=43) and usual care (N=54) had a mean (SD) TTR of 78.5% (20.1) 
and 66.7% (21.8), respectively. Therefore, a sample size of 54 patients in each of the warfarin 
groups will provide at least 90% power to detect similar differences at a significance level of 
0.05. The same number of patients were recruited for the NOAC groups. To allow for a 20% 
attrition rate, 64 patients per group were needed, resulting in a total sample size of 256 
patients. Data was analysed using IBM SPSS for Windows (Version 23.0) (406). 
2.3.5 Statistical analysis 
Following a test of statistical normality, by histogram plot method and the Kolmogorov-Smirnov 
test where a bell-shaped distribution in the former and p-values >0.05 in the latter were 
indicative of normally distributed data. Continuous variables were presented as mean (SD) 
and for non-parametric data, median with interquartile range (IQR, 25th to 75th quartile) were 
reported. Categorical variables were reported as counts with percentages. Descriptive 
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statistics were presented for baseline demographic and clinical information. Categorical 
variables were analysed using the chi-square statistic or the Fisher exact test (where expected 
frequencies are less than five in any cell).  
All data were analysed by intention-to-treat. The primary endpoint, TTR, was determined by 
the method of linear interpolation using the Rosendaal and the PINRR methods, with INR data 
from months 1 to 6. Overall TTR was also calculated incorporating all available INRs. 
Differences in the overall TTR and TTR excluding the inception period (INR value from day 1 
to day 30) were examined using the Wilcoxon-signed ranked test and were reported as median 
(IQR) as they were not normally distributed. P-values <0.05 were considered statistically 
significant. 
Data for the secondary endpoints of (1) depression, (2) anxiety, (3) patients’ knowledge of AF, 
(4) beliefs about medication and (5) quality of life at the two time-points (baseline, 6- months) 
were presented descriptively and graphically to illustrate the change in these variables over 
time. In this section, patients were grouped according to the type of OAC they received, either 
warfarin or NOAC, instead of the original SAMe-TT2R2 groups. As mentioned previously, there 
were too few patients in Groups 1 and 3 (N=9 and N=4, respectively) compared to Groups 2 
and 44 (N=102 and N=24, respectively), thus making the comparison between SAMe-TT2R2 
groups inappropriate. However, the results arranged by the original groupings are provided in 
Appendix 3. Paired t-test and Wilcoxon-signed ranked test were used for normally and non-
normally distributed data, respectively, to investigate the changes for the questionnaire 
variables over time for patients who completed the questionnaires at both baseline and six 
months (N=105).  
The number of patients with thromboembolism, major bleeding, CV hospitalisation and all-
cause death at 6- months follow up were presented as absolute numbers and percentages. 
The events were also compared in relation to the SAMe-TT2R2 score categories (0-2 vs. >2) 
and were presented as proportions.  
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2.4 Results 
During the period of patient recruitment, 598 AF patients (573 SWBH and 25 UHB) were 
screened for eligibility. One hundred and seventy-four patients refused to participate and 255 
patients were not eligible due to OAC-experience (N=123), did not attend appointment 
(N=111), no documented evidence of AF (N=14), cancer (N=4), and cognitive impairment 
(N=3) (Figure 2.2). Of those eligible to participate (N=343), 169 (49.2%) agreed and gave 
written informed consent.  However, only 139 (40.5%) (SWBH 132 and UHB 7) patients 
returned the baseline questionnaires. At six months follow up, 105 (75.5%) patients returned 
their questionnaires, with only 67 (70%) NOAC patients returning the empty pill boxes and 
blister packs (Figure 2.2). 
2.4.1 Baseline demographics and clinical characteristics of AF patients 
Table 2.2 presents the demographics and clinical characteristics of 139 AF patients who were 
prescribed OAC therapy at baseline stratified by their baseline SAMe-TT2R2 score. There were 
111 patients (79.9%) with the SAMe-TT2R2 score of 0-2, of which 9 patients were prescribed 
warfarin (Group 1) and 102 patients were prescribed NOACs (Group 2). Only 28 patients 
(20%) had a SAMe-TT2R2 >2, of which only 4 patients were prescribed warfarin (Group 3) and 
24 patients received a NOAC (Group 4). 
 
In the overall population, the mean (SD) age was 72.0 (8.5), 56.1% were male, the majority 
were white (88.8%), married (55.4%), and had secondary school level education (76.3%).  
Slightly more than half experienced no AF symptoms (54.7%) according to the modified 
European Heart Rhythm Association (mEHRA) classification system and most (77.0%) had 
paroxysmal AF. Hypertension (75.5%) was the most common co-morbidity followed by 
diabetes (28.8%) and chronic kidney disease (26.6%) [defined as creatinine clearance (CrCl) 
<60ml/min or as stated in the medical notes].  The overall mean (SD) CHA2DS2-VASc and 
HAS-BLED scores were 3.3 (1.5) and 1.9 (1.1) respectively (Table 2.2).  
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Answered baseline questionnaire, N=139  
(132 SWBH; 7 UHB) 
 
Did not return 
baseline 
questionnaire, 
N=30 
Group 1: 
N=9 
Group 2: 
N=102 
Group 3: 
N=4 
Group 4: 
N=24 
Answered 6-month questionnaire, 
N=105 
NOACs 
N=96 
Screened for eligibility N=598 (SWBH= 573; UHB =25) 
Excluded, N=255: 
• Not OAC naïve: 123 
• Did not attend appointment: 111 
• No AF: 14 
• Cancer: 4 
• Cognitive impairment: 3 
 
Returned pill counts for NOAC 
patients only, N=67  
Warfarin 
N=13 
NOACs 
N=126 
Warfarin 
N=9 
SAMe-TT2R2 0-2 SAMe-TT2R2 >2 
Number of patients eligible: 343 
• Agreed to participate and gave consent, N=169  
(160 SWBH; 9 UHB) 
• Rejected: 174 
 
 Figure 2.2: Flowchart of patient’s inclusion and follow-up in the study 
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 Table 2.2: Baseline demographics and clinical characteristics of newly anticoagulated AF patients stratified by the SAMe-TT2R2 
score 
 SAMe-TT2R2 0-2 SAMe-TT2R2 >2 
  Overall 
N=139 
Group 1 
N=9 
Group 2 
N=102 
Group 3 
N=4 
Group 4 
N=24 
Age at OAC 
initiation  
Mean age (SD) 72.0 (8.5) 72 (6.2) 73.8 (7.9) 68.5 (13.3) 67.2 (9.0) 
Age groups  ≤64 21 (15.1) 0 10 (9.8) 1 (25.0) 10 (41.7) 
65-74 65 (46.8) 7 (77.8) 48 (47.1) 2 (50.0) 8 (33.3) 
≥75 53 (38.1) 2 (22.2) 44 (43.1) 1 (25.0) 6 (25.0) 
Sex  Female 61 (43.9) 4 (44.4) 41 (40.2) 2 (50.0) 14 (58.3) 
Ethnic groups White 123 (88.8) 8 (88.9) 102 (100) 2 (50.0) 11 (45.8) 
South-Asian 7 (5.0) 1 (11.1) 0 0 6 (25.0) 
Afro-Caribbean 9 (6.5) 0 0 2 (50.0) 7 (29.2) 
Marital status Married  77 (55.4) 5 (55.6) 55 (53.9) 2 (50.0) 15 (62.5) 
Single   19 (13.7) 1 (11.1) 16 (15.7) 1 (25.0) 1 (4.2) 
Divorced/separated 12 (8.6) 1 (11.1) 7 (6.9) 1 (25.0) 3 (12.5) 
Widowed  31 (22.3) 2 (22.2) 24 (23.5) 0 5 (20.8) 
Educational 
status 
Primary school 5 (3.6) 0 3 (2.9) 0 2 (8.3) 
Secondary school 106 (76.3) 8 (88.9) 75 (73.5) 4 (100) 19 (79.2) 
College  28 (20.1) 1 (11.1) 24 (23.5) 0 3 (12.5) 
Age leaving 
education 
Mean age (SD) 16.7 (5.8) 16.7 (3.6) 17.2 (6.2) 15.5 (0.6) 15.9 (4.7) 
Alcohol intake Alcohol>14unit/day 23 (16.5) 0 20 (19.6) 1 (25.0) 2 (8.3) 
Smoking status Smoking/ex-smoker 17 (12.2) 0 4 (3.9) 2 (50.0) 11 (45.8) 
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Table 2.2 continued  
  Overall 
N=139 
Group 1 
N=9 
Group 2 
N=102 
Group 3 
N=4 
Group 4 
N=24 
Modified EHRA 
class 
Class 1 (none) 76 (54.7) 5 (55.6) 52 (51.0) 4 (100) 15 (62.5) 
Class 2 (mild) 40 (28.8) 3 (33.3) 31 (30.4) 0 6 (25.0) 
Class 3 (severe) 23 (16.5) 1 (11.1) 19 (18.6) 0 3 (12.5) 
AF type Paroxysmal  107 (77.0) 7 (77.8) 77 (75.5) 3 (75.0) 20 (83.3) 
Persistent 9 (6.5) 0 7 (6.9) 0 2 (8.3) 
Permanent  23 (16.5) 2 (22.2) 18 (17.6) 1 (25.0) 2 (8.3) 
Past medical 
history 
Heart failure 10 (7.2) 1 (11.1) 7 (6.9) 1 (25.0) 1 (4.2) 
Hypertension 105 (75.5) 6 (66.7) 76 (74.5) 4 (100.0) 19 (79.2) 
Diabetes 40 (28.8) 3 (33.3) 28 (27.5) 2 (50.0) 7 (29.2) 
Stroke/TIA 23 (16.5) 3 (33.3) 13 (12.7) 0 7 (29.2) 
Vascular disease* 21 (15.1) 1 (11.1) 13 (12.7) 1 (25.0) 6 (25.0) 
Lung disease# 26 (18.7) 3 (33.3) 15 (14.7) 1 (25.0) 7 (29.2) 
Kidney disease† 37 (26.6) 4 (44.4) 24 (23.5) 2 (50.0) 7 (29.2) 
Anaemia  29 (20.9) 1 (11.1) 25 (24.5) 0 3 (12.5) 
Previous bleeding 7 (5.0) 0 6 (5.9) 0 1 (4.2) 
CHA2DS2-VASc 
score 
Mean (SD) 3.3 (1.5) 3.6 (1.9) 3.2 (1.3) 3.5 (2.6) 3.4 (1.7) 
CHA2DS2-VASc 
score categories 
Low risk  0 0 0 0 0 
Intermediate  22 (15.8) 2 (22.2) 13 (12.7) 1 (25.0) 6 (25.0) 
High risk  117 (84.2) 7 (77.8) 89 (87.3) 3 (75.0) 18 (75.0) 
HAS-BLED score Mean 1.9 (1.1) 1.9 (0.8) 2.0 (1.1) 1.8 (0.5) 1.8 (1.2) 
HAS-BLED score 
categories 
Low risk (0-2) 108 (77.7) 7 (77.8) 79 (77.5) 4 (100) 18 (75.0) 
High risk (≥3) 31 (22.3) 2 (22.2) 23 (22.5) 0 6 (25.0) 
SAMe-TT2R2 
score 
Mean (SD) 1.7 (1.2) 1.3 (0.7) 1.1 (0.7) 3.5 (0.6) 3.7 (0.8) 
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Table 2.2 continued 
  Overall 
N=139 
Group 1 
N=9 
Group 2 
N=102 
Group 3 
N=4 
Group 4 
N=24 
Current 
medications 
Warfarin  13 (9.4) 9 (100) 0 4 (100) 0 
NOACs 126 (90.6) 0 102 (100) 0 24 (100) 
Beta-blocker 77 (55.4) 5 (55.6) 53 (52.0) 3 (75.0) 16 (66.7) 
ACEI/ARB 72 (51.8) 3 (33.3) 54 (52.9) 2 (50.0) 13 (54.2) 
Diuretics  44 (31.7) 3 (33.3) 29 (28.4) 2 (50.0) 10 (41.7) 
Amiodarone 3 (2.2) 0 1 (1.0) 0 2 (8.3) 
Concurrent antiplatelet 7 (5.0) 0 2 (2.0) 0 5 (20.8) 
Digoxin  12 (8.6) 2 (22.2) 8 (7.8) 0 2 (8.3) 
Calcium channel 
blocker  
54 (38.8) 3 (33.3) 39 (38.2) 2 (50.0) 10 (41.7) 
Statins  98 (70.5) 7 (77.8) 68 (66.7) 3 (75.0) 20 (83.3) 
Group 1: SAMe-TT2R2 score 0-2 + warfarin; Group 2: SAMe-TT2R2 score 0-2 +NOAC; Group 3: SAMe-TT2R2 score >2 +warfarin; SAMe-TT2R2 score >2+NOAC 
ACEI/ARB: angiotensin converting enzyme inhibitor/ angiotensin receptor blockade; AF: atrial fibrillation; CHA2DS2-VASc score - Congestive heart failure/left ventricular dysfunction, Hypertension, 
Age ≥75years [2 points], Diabetes, Stroke [2 points], Vascular disease, Age 65–74 years, and Sex category (female). Total scores range between 0-9; low risk CHA2DS2-VASc score:  0 male; 1 female, 
intermediate: 1male, ≥2 female, high risk CHA2DS2-VASc score: ≥2 male; ≥3 female; TIA: transient ischemic attack; eGFR: estimated glomerular filtration rate, ml/min/1.73 m2; HAS-BLED score – 
uncontrolled Hypertension: systolic ≥160 mmHg, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR ratio/TTR <60, Drugs/alcohol concomitantly. Total scores range 
between 0-9; low risk of bleeding range between 0-2 and high risk of bleeding ≥3; modified European Heart Rhythm Association symptom scale (mEHRA): 1 no symptoms, 2 mild and moderate, 3 
severe, 4 disabling; SAMe-TT2R2 score – Sex female, Age<60, Medical history (more than two comorbidities), Treatment (interacting drug, e.g. Amiodarone), Tobacco use (doubled) and Race (non-
white, doubled). Total scores ranged from 0-8; probable good response to VKA therapy range between 0-2 and probable poor response to VKA therapy ranged from ≥3; SD: standard deviation 
* Vascular disease: prior myocardial infarction, peripheral artery disease or aortic plaque; # Lung disease: obstructive and restrictive diagnosed lung conditions; †eGFR <60ml/min or as noted in 
medical notes 
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2.4.2 Psychological measures, knowledge and beliefs about medication of 
AF patients overall and according to OAC groups (warfarin vs. NOACs)  
2.4.2.1 Depression and anxiety 
At baseline, the median (IQR) depression and anxiety scores in the whole cohort were 4.0 (1.0-
8.0) and 1.0 (0-5.0), respectively (Table 2.3). Most patients had none or minimal symptoms of 
depression (57.6%) or anxiety (71.9%) (Table 2.3). The median (IQR) depression and anxiety 
scores were higher in patients receiving a NOAC than those receiving warfarin, [depression [4.0 
(1.0-8.0) vs. 2.0 (0-4.5)] and anxiety [1.0 (0-5.0) vs. 0 (0-4.5)], respectively.  
At the 6-month follow-up, the overall median (IQR) scores of PHQ-9 and GAD-7 were the same 
[depression 4.0 (0-9.0) and anxiety 1.0 (0-5.0), respectively] (Table 2.3). There were no significant 
differences in the median (IQR) depression and anxiety scores (Table 2.4 and Figure 2.3) and 
the proportion of AF patients in different categories of depression (Figure 2.4) and anxiety (Figure 
2.5) across the two time points.    
The prevalence of major depression (PHQ-9 ≥15) at baseline and follow-up was 6.7% (Table 
2.4). Meanwhile, the prevalence of generalised anxiety disorder (GAD-7 ≥10) was 11.4% at 
baseline but declined slightly to 9.5% at follow up (Table 2.4). There was no significant difference 
between the proportion of patients with major depression and generalised anxiety disorder over 
time (Table 2.4 and Figure 2.6).  
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 Table 2.3: Baseline and 6 months follow up psychological measures of AF patients overall and according to OAC groups 
(warfarin vs. NOACs) 
 Baseline (N=139) Follow up (N=105) 
Median (IQR) Overall, 
N=139 
Warfarin  
N=13 
NOACs 
N=126 
Overall, 
N=105 
Warfarin  
N=9 
NOACs 
N=96 
PHQ-9 (9 items; scores range from 0-27)    
Total score 4.0 (1.0-8.0) 2.0 (0-4.5) 4.0 (1.0-8.0) 4.0 (0-9.0)  3.0 (0-6.0) 4.0 (0.3-9.0) 
Minimal 0-4, N (%)  80 (57.6) 10 (76.9) 70 (55.6) 56 (54.4) 7 (77.8) 51 (53.1) 
Mild 5-9, N (%) 31 (22.3) 2 (15.4) 29 (23.0) 25 (24.3) 1 (11.1) 24 (25.0) 
Moderate 10-14, N (%) 20 (14.4) 0 20 (15.9) 15 (14.6) 0 15 (15.6) 
Moderately severe 15-
19, N (%) 
5 (3.6) 0 5 (4.0) 6 (5.8) 1 (11.1) 5 (5.2) 
Severe depression 20-
27, N (%) 
3 (2.2) 1 (7.7) 2 (1.6) 1 (1.0) 0 1 (1.0) 
GAD-7 (7 items; scores range from 0-21)    
Total score  1.0 (0-5.0) 0 (0-4.5) 1.0 (0-5.0) 1.0 (0-5.0) 0 (0-5.0) 1.0 (0-5.0) 
Minimal 0-4, N (%) 100 (71.9) 10 (76.9) 90 (71.4) 68 (66.0) 6 (66.7) 64 (66.7) 
Mild 5-9, N (%) 23 (16.5) 1 (7.7) 22 (17.5) 25 (24.3) 2 (22.2) 23 (24.0) 
Moderate 10-14, N (%) 8 (5.8) 2 (15.4) 6 (4.8) 6 (5.8) 0 6 (6.3) 
Severe anxiety 15-21, 
N (%) 
8 (5.8) 0 8 (6.3) 1.0 (1.0) 1 (11.1) 3 (3.1) 
GAD-7: The Generalised Anxiety Disorder 7-item; IQR: interquartile range; NOACs: non-vitamin K oral anticoagulants; OAC: oral anticoagulants; PHQ-9: Patient 
Health Questionnaire 
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 Table 2.4: Changes in psychological measures between baseline and 6 months follow up among overall AF patients 
(N=105) 
Median (IQR) change in score Baseline 
N=105 
Follow up 
N=105 
Changes in score 
over time 
Differences over time 
p- value* 
PHQ-9 (9 items) 
Median (IQR) score  4.0 (1.0-8.5) 4.0 (0-9.0) 0 (-2.5 to 1.5) 0.53 
Major depression PHQ-9≥15, N (%) 7 (6.7) 7 (6.7) - 1.00 
GAD-7 (7 items) 
Median (IQR) score  1.0 (0-5.0) 1.0 (0-5.0) 0 (-1.0 to 1.0) 0.67 
Major anxiety disorder, GAD-7≥10, N 
(%) 
12 (11.4) 10 (9.5) - 0.822 
*Wilcoxon-signed ranked test; AF: atrial fibrillation; PHQ-9: Patient Health Questionnaire; GAD-7: The Generalised Anxiety Disorder 7-item; IQR: interquartile range 
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*N=86 
*p=0.02 
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 Figure 2.3: Mean/median score at baseline and 6 months follow up for depression, anxiety, knowledge of AF, beliefs about 
medication and quality of life among overall AF patients who completed the questionnaire at both time points (N=105) 
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 Figure 2.5: PHQ-9 scores in categories among overall AF patients at baseline and 6 
months follow up (N=105) 
 Figure 2.4: GAD-7 scores in categories among overall AF patients at baseline and 6 
months follow up (N=105) 
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2.4.3 AF knowledge 
At baseline, the overall mean (SD) score, for AF knowledge was low at 5.7 (1.7) with warfarin 
patients obtaining slightly higher mean scores overall compared to NOAC patients (Table 2.5). 
At follow up, the overall mean (SD) score for AF knowledge was similar to the score at 
baseline, at 5.9 (1.9) (Table 2.5). There were no significant differences in the overall mean AF 
knowledge scores between baseline and 6-months (Table 2.6). 
 
Each question of the AF knowledge scale was also analysed specifically among patients who 
answered the questionnaires at both time points (N=105) (Table 2.7 and Figure 2.7). The 
majority of patients correctly answered the ‘reason for OAC prescription’ (90.5%) and on the 
question ‘regarding physical activity’ (91.4%) at baseline. However, significantly fewer patients 
correctly answered the ‘reason for OAC prescription’ at follow up (74.3%) compared to 
baseline (p=0.002). Conversely, significantly higher proportions of patients were aware of ‘the 
consequences of AF’ at follow up (88.6%) compared to baseline (50.5%; p<0.001) (Table 2.7 
and Figure 2.7). 
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 Table 2.5: Baseline and 6 months follow up knowledge scale of AF patients overall and according to OAC groups (warfarin vs. 
NOACs) 
AF knowledge scale (11 items; scores range from 0-100%) 
 Baseline (N=139) Follow up (N=105) 
Mean (SD), % Overall 
N=139 
Warfarin  
N=13 
NOACs 
N=126 
Overall 
N=105 
Warfarin  
N=9 
NOACs 
N=96 
Total overall scores 
(min-max: 0-11) 
5.7 (1.7) 6.8 (1.2) 5.6 (1.7) 5.9 (1.9) 7.0 (1.3) 5.8 (1.9) 
Total overall scores, %  52.0 (15.4) 61.5 (11.2) 51.0 (15.4) 53.9 (16.9) 63.6 (11.1) 52.9 (17.0) 
AF: atrial fibrillation; NOACs: non-vitamin K oral anticoagulants; OAC: oral anticoagulants; SD: standard deviation  
 
  
 Table 2.6: Change in knowledge scale between baseline and 6 months follow up among overall AF patients (N=105) 
AF knowledge scale  
(11 items; scores range from 0-
100%) 
Baseline 
N=105 
Follow up 
N=105 
Changes in score 
over time 
Differences over time p- 
value* 
Total overall score  
(min-max: 0-11) 
5.8 (1.7) 5.9 (1.9) -0.1 (2.0) 0.50 
Total overall score, %  52.6 (15.5) 53.9 (16.9) -1.2 (18.3) 0.50 
*Paired t-test; AF: atrial fibrillation 
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 Table 2.7: Specific questions in the AF knowledge scale and percentages of patients with correct response at baseline and 6 months 
follow up (N=105) 
Questions in AF knowledge score  Baseline  Follow up p-value* 
AF in general    
1. If AF is identified without any complaints, patients should immediately visit hospital 18 (17.1) 17 (16.2) 1.00 
2. It is risky if patients do not feel his/her AF 45 (42.9) 33 (31.4) 0.06 
3. AF is a rare condition 8 (7.6) 8 (7.6) 1.00 
Symptoms recognition    
1. What are the trigger factors for AF 47 (44.8) 58 (55.2) 0.07 
2. Why is it important to take my medications properly 50 (47.6) 44 (41.9) 0.43 
3. What is atrial fibrillation? 64 (61.0) 69 (65.7) 0.53 
AF treatment    
1. Why patients using oral anticoagulation should be careful with the use of alcohol  71 (67.6) 72 (68.6) 1.00 
2. What is the function of anticoagulation clinic 61 (58.1) 57 (54.3) 0.61 
3. Why is oral anticoagulation prescribed in certain patients with AF 95 (90.5) 78 (74.3) 0.002 
AF general attitude    
1. Statements regarding physical exercise 96 (91.4) 93 (88.6) 0.61 
2. Statements regarding the danger associated with AF 53 (50.5) 93 (88.6) <0.001 
*chi-square; AF: atrial fibrillation 
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2.4.4 Beliefs about medication 
At baseline, the overall mean (SD) score in the general overuse and general harm domains were 
10.5 (2.9) and 8.6 (2.9), respectively. In terms of patients’ specific beliefs about their 
anticoagulation therapy, the mean (SD) specific-necessity score was higher [19.0 (3.0)] than the 
specific-concern score [13.3 (3.5)], with a positive necessity-concern differential [5.8 (4.1)]. This 
indicates that patients perceived their medications are being more important than their concerns 
regarding medications. NOAC patients obtained slightly higher scores on the general harm and 
specific-concerns domains at baseline compared to warfarin patients (Table 2.8).  
At six months follow up, the scores in the general and specific domains remained the same. 
Similar scores were seen among warfarin and NOAC patients in the general overuse and general 
harm domains, while NOAC patients achieved slightly higher scores on the specific necessity and 
necessity-concern differential (Table 2.8).  There was no significant difference in either the 
general and specific domains over time (Table 2.9). 
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 Table 2.8: Baseline and 6 months follow up scores on beliefs about medication of AF patients overall and according to 
OAC groups (warfarin vs. NOACs) 
 Baseline scores (N=139) Follow up scores (N=105) 
Baseline scores, 
mean (SD) 
Overall, 
N=139 
Warfarin  
N=13 
NOACs 
N=126 
Overall, 
N=105 
Warfarin  
N=9 
NOACs 
N=96 
Beliefs about medication (BMQ; 18 items)    
BMQ general (scores range from 4-20)    
General overuse  
(4-20)  
10.5 (2.9) 10.5 (2.9) 10.5 (2.9) 10.7 (2.9) 10.8 (1.4) 10.7 (3.0) 
General harm  
(4-20)  
8.6 (2.9) 7.4 (1.7) 8.7 (2.9) 8.2 (2.4) 8.4 (1.2) 8.2 (2.5) 
 
BMQ specific (scores range from 5-25)    
Specific necessity  
(5-25)  
19.0 (3.0) 19.2 (2.4) 19.0 (3.1) 19.1 (3.1) 18.8 (1.4) 19.1 (3.2) 
Specific concern  
(5-25) 
13.3 (3.5) 12.2 (2.7) 13.4 (3.6) 12.9 (3.8) 13.3 (4.3) 12.9 (3.8) 
Necessity-concern 
differential 
5.8 (4.1) 6.9 (3.9) 5.7 (4.2) 6.1 (4.4) 5.4 (4.2) 6.2 (4.4) 
BMQ: Beliefs about medication; NOACs: non-vitamin K oral anticoagulants; OAC: oral anticoagulants; SD: Standard deviation 
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 Table 2.9: Change in score on beliefs about medication between baseline and 6 months follow up among overall AF 
patients (N=105) 
BMQ (18 items) 
mean (SD) score 
Baseline 
N=105 
Follow up 
N=105 
Changes in score 
over time 
Differences over 
time p- value* 
BMQ general‡     
General overuse  10.4 (3.0) 10.7 (2.9) -0.4 (2.8) 0.20 
General harm 8.3 (2.8) 8.2 (2.4) 0.1 (2.4) 0.78 
BMQ specific‡     
Specific necessity 19.2 (3.0) 19.1 (3.1) 0.1 (2.4) 0.54 
Specific concern 13.0 (3.5) 12.9 (3.8) 0.0 (3.5) 0.91 
Necessity-concern differential 6.2 (4.0) 6.1 (4.4) 0.1 (3.9) 0.78 
*paired t-test; AF: atrial fibrillation; BMQ: Beliefs about medication; SD:  standard deviation 
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2.4.5 Quality-of-life 
The overall global median (IQR) baseline score for quality of life was 66.7 (53.7-77.8). Patients 
scored lowest in the daily activity domain [60.4 (39.6-79.2)] and highest in the AF symptoms 
domain [79.2 (58.3-95.8)]. NOAC patients had higher scores in the AF symptoms and treatment 
satisfaction domains and the overall global score compared to warfarin patients (Table 2.10). 
At follow up, the median (IQR) global score was also 66.7 (49.1-81.9) and patients continued to 
score lowest in the daily activity domain (Table 2.10). Similarly, NOAC patients had higher scores 
in the AF symptoms and treatment satisfaction domains compared to warfarin patients. Among 
patients who completed the questionnaires at both time-points, there was a significant increase 
in AF symptoms score at follow-up [83.3 (64.6-100) vs. 79.2 (54.2-95.8); p=0.02], with no 
significant change in the other domains over time (Table 2.11 and Figure 2.8).  
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 Table 2.10: Baseline and 6 months follow up quality of life scores of AF patients overall and according to OAC groups 
(warfarin vs. NOACs) 
AFEQT (20 items; scores range from 0-100)  
 Baseline measures (N=139) Follow up measures (N=105) 
Median (IQR) Overall, 
N=139 
Warfarin  
N=13 
NOACs 
N=126 
Overall, 
N=105 
Warfarin  
N=9 
NOACs 
N=96 
AF symptoms (0-100) 79.2 (58.3-95.8) 58.3 (41.7-97.9) 79.2 (58.3-95.8) 83.3 (64.6-100) 75.0 (54.2-97.9) 83.3 (66.7-100) 
Daily activity (0-100) 60.4 (39.6-79.2) 68.8 (31.3-82.3) 60.4 (39.6-77.6) 54.2 (34.4-77.1) 66.7 (21.9-82.3) 54.2 (35.4-76.6) 
Treatment concern  
(0-100) 
75.0 (52.8-86.1) 75.0 (68.1-83.3) 75.0 (52.8-88.9) 72.2 (58.3-88.9) 72.2 (52.8-88.9) 72.2 (58.3-88.9) 
Treatment Satisfaction
†
 
(0-100) 
75.0 (66.7-83.3) 66.7 (56.3-85.4) 75.0 (66.7-83.3) 83.3 (66.7-91.7) 75.0 (66.7-91.7) 83.3 (66.7-89.6) 
Overall global score  
(0-100) 
66.7 (53.7-77.8) 60.2 (50.9-80.1) 66.7 (53.7-77.8) 66.7 (49.1-81.9) 75.0 (47.2-81.5) 66.2 (48.6-82.2) 
† N=111; AFEQT: Atrial Fibrillation Effect on Quality–of-life; AF: atrial fibrillation; OAC: oral anticoagulants; IQR: interquartile range; NOACs: non-vitamin K oral 
anticoagulants 
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 Table 2.11: Change in quality of life scores between baseline and 6 months follow up among overall AF patients (N=105) 
Median (IQR) change in 
score 
Baseline 
N=105 
Follow up  
N=105 
Changes in score 
over time 
p- value* 
AFEQT (20 items)     
Median (IQR) AF 
symptoms 
79.2 (54.2-95.8) 83.3 (64.6-100) -4.8 (22.2) 0.02 
Median (IQR) daily activity 58.3 (38.5-80.2) 54.2 (34.4-77.1) 2.8 (18.9) 0.33 
Median (IQR) treatment 
concern 
75.0 (52.8-86.1) 72.2 (58.3-88.9) -0.90 (23.2) 0.57 
Median (IQR) treatment 
satisfaction
†
   
75.0 (66.7-83.3) 83.3 (66.7-83.3) -4.3 (22.2) 0.07 
Median (IQR) overall 
global score 
66.7 (51.9-78.0) 66.7 (49.1-81.9) -0.3 (16.2) 0.65 
†
 N=86 at both time points; *Wilcoxon-signed ranked test; AFEQT: Atrial Fibrillation Effect on Quality–of-life; AF: atrial fibrillation; IQR: interquartile range 
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p=0.02 
 Figure 2.8: Quality of life domain scores assessed by the AFEQT questionnaire in AF patients overall at baseline and 6 
months follow up (N=105) 
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2.4.6 Time in therapeutic range, medication adherence and adverse 
clinical outcome at 6 months follow up 
The overall median (IQR) TTR for warfarin patients at 6 months using the Rosendaal and 
PINRR methods were 62.6 (49.0-70.3) and 43.1 (33.0-50.0), respectively. When the inception 
period (the first 4 weeks of warfarin treatment) was excluded, TTR and PINRR were 
significantly better, 77.3 (54.4-84.7; p=0.004) and 56.4 (45.8-66.7; p=0.004), respectively. 
Among the 126 patients on NOACs at baseline, 96 patients reached the six months follow up. 
Among them, 67 patients (70%) returned their pill boxes and blister packages at follow up and 
the pill count demonstrated 100% adherence. Six patients had their medications prepared 
from the pharmacy as weekly blister packs thus they are not able to keep their empty NOAC 
packages/boxes. Moreover, upon questioning, majority of patients (86.5%) claimed that they 
never forget to take their NOAC medication and only one patient claimed they have forgotten 
to take it over the past two weeks. 
At follow up, there were only 13 patients with ≥1 of the composites of bleeding, CV 
hospitalisations and death. No thromboembolic events occurred, three patients experienced 
bleeding events (2 major bleed and 1 CRNMB bleed), 8 patients had CV hospitalisation and 
3 patients died.  When the events were stratified according to the SAMe-TT2R2 score 
categories (0-2 vs. >2), a non-significant higher proportion of patients with SAMe-TT2R2 >2 
experienced CV hospitalisation (7.1% vs. 5.4%), death (3.6% vs. 1.8%) and ≥1 of the 
composites of bleeding, CV hospitalisations and death (10.7% vs. 9.0%) compared to those 
with SAMe-TT2R2 0-2 respectively. However, all bleeding events (2.7%) occurred among those 
with SAMe-TT2R2 0-2.  
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2.5  Discussion 
 
AF patients who were newly anticoagulated with either warfarin or NOACs for stroke 
prevention do not appear to have significant depressive or anxiety symptoms at baseline. 
However, patients had poor knowledge of AF and its treatment, perceived that OAC 
medication is important and this outweighed their medication concerns, and they also had 
poor quality of life. At six months, there were no significant changes in depression, anxiety, 
beliefs about medication and quality of life. However, more patients were aware of the 
consequences of AF but fewer patients understood the reason of OAC prescription and 
patients had improvements in AF symptoms at follow up compared to baseline.  
 
In this study, few patients reported depressive and anxiety symptoms at baseline and follow 
up; consistent with previous studies in the West Midlands assessing depression and anxiety 
among AF patients using validated questionnaires (99, 407) (219). In the overall population, 
more patients experienced symptoms of generalised anxiety rather than major depression at 
baseline (11.4% vs. 6.7%, respectively) and follow up (9.5% vs. 6.7%, respectively). This 
finding is consistent with studies by Lane et al (99) and Clarkesmith et al (219). Both studies 
(99, 219) reported a higher prevalence of anxiety (38.5-41.5%) than depression (25.5%) 
among their AF cohorts at baseline, but were limited by smaller sample sizes (N=70 to 97) 
and used different questionnaires to assess symptoms of depression and anxiety (BDI, STAI 
and HADS) than the present study. Taken together, these results suggest that anxiety is the 
predominant affective trait among AF patients, which might influence the patient’s quality of 
life (96, 99, 219).  The presence of higher anxiety symptoms rather than depressive symptoms 
in the current cohort is difficult to explain but may be influenced by the presence of 
comorbidities as well as AF symptoms and commencing OAC therapy. A recent systematic 
review (408) of eight studies (AF vs. control group) assessed the role of psychological factors 
in AF using validated questionnaires. From the five studies (95, 96, 409-411) assessing the 
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role of depression in AF patients included in the review, only one study (409) showed a 
significant difference in the depression level among AF patients compared to healthy controls 
(effect size 3.08; 95% CI 2.63-3.57) (409). For trait anxiety, two studies (96, 410) showed 
higher levels of trait anxiety in AF patients compared to hypertensive patients (96) and patients  
with supraventricular tachycardia (410), although the differences were small for both studies 
[0.34; 95% CI 0.07-0.61 and 0.41 (0.02-0.80) respectively].  As a result, no clear conclusion 
was made due to small number of studies and methodological differences (408). For example, 
types of AF patients studied were different (paroxysmal vs. persistent vs. permanent), different 
type of questionnaires were used to assess depression and anxiety and conclusions from 
each study were inconsistent. Hence, future studies in this area are needed to draw a clear 
conclusion on the involvement of psychological distress in AF patients. 
 
In general, patients in the current study have positive perception towards OAC medication 
evidenced by high mean (SD) specific-necessity scores [19.0 (3.0)] and a positive necessity-
concern differential [5.8 (4.1)] at baseline. This remained unchanged at follow up indicating 
that patients perceive their OAC medication as more important than their concerns about it. 
This finding is similar to the TREAT study (219) in the UK and in another study in Palestine 
(412). Both studies showed higher specific-necessity beliefs than specific-concern beliefs and 
this was associated with better treatment adherence in both studies (219, 412) and better TTR 
in the TREAT education intervention group compared to the usual care group (219). In this 
cohort, patients also disagreed that their medications are harmful. This further strengthens the 
positive beliefs that patients have towards the importance of taking their medication which 
could potentially impact their adherence level. In the adherence assessment among patients 
receiving NOACs via the pill count method at six months, 70% of the patients reported 100% 
adherence. However, the remainder (N=29) did not return any boxes/blister packages as they 
had forgotten to keep them for the study purposes. In contrast, one study from Saudi Arabia 
(413) among patients with multiple chronic diseases (diabetes, hypertension, asthma; N=408) 
showed higher general harm score [13.6 (2.3)] than the current study and this was significantly 
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more prevalent among non-adherent patients compared to high adherent patients. This 
suggests that where patients have negative thoughts about their medication, they are more 
likely to become non-adherent. In this study, no significant differences were seen in both the 
general and specific domains of the BMQ over time. Although the available evidence 
demonstrates consistent results with the current studies, caution must be exercised as there 
could be differences in terms of medication beliefs, usage and cultural differences between 
studies conducted in Western countries compared to Middle Eastern countries (412) (413).  
 
In terms of AF knowledge, AF patients in this cohort had poorer knowledge about AF and its 
treatment reflected by an average score of 5.7 (1.7) and 5.9 (1.9) at baseline and follow up, 
respectively. There were no significant differences in the AF knowledge score over time. 
Nevertheless, on assessing each specific question on the AF knowledge questionnaire, more 
patients were aware of the consequences of AF at follow-up but fewer understood the reasons 
of OAC prescription at follow up compared to baseline. Clearly, there is a gap in AF knowledge 
among patients which changes over time in terms of the need of OAC therapy for stroke 
prevention. These findings are in keeping with other studies investigating knowledge among 
AF patients (283, 284, 286, 287). Studies showed that AF patients have inadequate 
knowledge of their condition (284-287), poor understanding of the benefits and risk of their 
treatment, (285-287) specifically anticoagulation therapy and not aware of the factors that 
could impact the effectiveness and safety of treatment (284-286). Thus, this could influence 
their ability to make informed choices of the treatment options and prevent them from being 
actively involved in management of their own treatment. Lane and colleagues (283) have 
included strategies to improve knowledge among AF patients entailing: greater awareness 
among the public of what is AF and the repercussions, better patient support and provisions 
of educational materials, enhanced understanding of the patients’ needs among medical 
professions, improved communication between physicians and patients and including 
patients’ preferences during the discussion of treatment options (283). Studies (219, 386) 
have also shown that with better education, emotional distress can be reduced, adherence 
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and concordance can be enhanced (219, 284, 289) and quality of life can be improved 
resulting in better treatment outcomes (219, 386). 
 
Overall, AF patients had poor quality of life evident by a median score of 66.7% for the overall 
global score and this remained the same at 6 months follow up; similar to other studies (99, 
219). In contrast, one trial (386) in the Netherlands (N=712) showed higher baseline QoL score 
in AF patients randomised to the nurse-led group (72%) (with psychosocial support and 
education intervention at 3,6 and 12 months) but similar QoL scores in the usual care group 
(68%) compared to the current study. In their study, QoL, including anxiety and depression, 
improved significantly after 1 year of follow up, irrespective of treatment group. However, 
patients in the nurse-led group had better knowledge at follow up and quality of life was 
significantly correlated with knowledge. Taken together, these findings suggest the benefits of 
a structured educational intervention (involving educational reinforcement and psychosocial 
support) in promoting better knowledge, emotional health and quality of life. In the current 
cohort, patients seem to have the greatest limitation in their physical health compared to 
emotional and clinical health at both baseline and follow up (evident by lowest score in the 
daily activity domain). Multiple observational studies worldwide (109, 111-113, 116) have 
shown similar results where AF patients appear to have the greatest impairment in their 
physical health compared to their emotional health. This could be influenced by ageing, 
symptoms severity, number of comorbidities, all of which could affect the patients’ ability to 
conduct physical activity and thereby reduce their quality of life (QoL) (386) (109, 111-113, 
116). In this study, significant improvement was only seen in the AF symptoms domain at 
follow up, suggesting that patients were less affected by their symptoms at this point. This 
could probably be influenced by effective symptom management with either pharmacological 
or non-pharmacological interventions (cardioversion or ablation) although this is purely 
speculative. Another explanation is that maybe patients had had time to come to terms with 
their diagnosis and were therefore less bothered by their symptoms.  
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There were only thirteen patients on warfarin therapy and their overall median (IQR) TTR at 
six months was suboptimal at 62.6% (49.0-70.3) however, TTR was significantly better and at 
the optimal level after excluding the inception period (the first four weeks of therapy to allow 
attainment of warfarin dose) with 77.3% (54.4-84.7; p=0.004); a finding similar to previous 
study(219). In terms of adverse events, there were no TE events, however, three patients had 
bleeding events (2 major bleed and 1 CRNMB), eight patients were hospitalised for CV reason 
and two patients died at follow up. All adverse events occurred among NOAC patients. 
2.5.1 Limitations  
This study has several limitations. Firstly, the study contained only 13 patients on warfarin and 
no patients attended the TREAT educational intervention thus the original planned analyses 
and hypothesis testing were not possible, due primarily to a change in clinical practice 
regarding NOAC prescription over warfarin for AF patients newly initiating OAC.  The 
recruitment target was not achieved (N=256) based on the pre-specified SAMe-TT2R2 groups 
(N=64 in each group). Thus, the results for patients on warfarin or NOAC were presented 
descriptively and no significance testing was undertaken. Secondly, although two centres 
were utilised for patient recruitment, the overall number of patients included was low compared 
to other longitudinal studies assessing psychological measures, knowledge and quality of life 
among AF patients (108, 386, 414). However, the results from the current study are in keeping 
with previous studies within the West Midlands reporting low levels of anxiety, depression and 
knowledge among AF patients (99, 407). In addition, there were only 16 non-white patients, 
thus the results may not be applicable to all AF participants. Thirdly, only 105 (76%) patients 
completed the 6-month questionnaires; the study had 24% attrition rate at 6 months. It is 
possible that those who did not return the 6-month questionnaires may have experienced 
more health problems and/or worsening emotional health and quality of life. The results may 
have been different if all respondents completed the 6-month questionnaires. However, the 6-
month response rate was 76%, which is higher than many previous questionnaire studies (96, 
219, 415, 416).  Fourth, among the 96 NOAC patients who reached the follow up only 70% 
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returned their empty pill boxes/packages. The pill count method is not the most robust method 
of assessing adherence as patients may not have taken all the pills but simply returned the 
empty boxes and blister packs, however this method is simple, low cost and used in many 
clinical trials (389). To date, direct measures of adherence including measurement of drugs in 
plasma or urine were considered the most accurate way to assess adherence however it is 
expensive, difficult to perform, is dependent on the test used and drug metabolism (389). 
2.5.2 Clinical implications and future research 
This study will add to the existing literature on the psychological health, quality of life and AF 
knowledge of patients with AF who receive OAC. Whilst NOACs have sought to overcome the 
inherent difficulties experienced by patients prescribed with warfarin, the psychological impact 
on patients (as well as warfarin patients) has not been thoroughly investigated to date. 
Together, these results will provide important insights into patient’s feelings, beliefs and 
awareness about the OAC, and the impact on their QoL. This information can be used to 
create innovative strategies to improve health outcomes in AF patients receiving OAC therapy 
for stroke prevention. 
 
More in-depth studies investigating the psychological impact of OAC therapy in AF patients 
are needed. Validated questionnaires to collect data on the emotional impact (anxiety and 
depression) and quality of life could be routinely included as endpoints in large 
RCTs/multinational registries so that this information is available alongside other endpoints.  
 
Furthermore, the TREAT-2 intervention could be extended to other developing countries like 
Malaysia where warfarin is the main OAC of choice for stroke prevention in AF. In Malaysia, 
the majority of VKA patients are being managed by clinical pharmacist in the hospital setting 
in the Medication Therapy Adherence Clinic (MTAC) (417). This clinic aims to optimise 
medication therapy, improve medication adherence and prevent/reduce problems related to 
medication with a pre-specified protocol that incorporates a patient education checklist, INR 
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testing interval, dosage adjustment and warfarin dispensing (417). To date, no trials are 
available in Malaysia to determine the impact of MTAC towards TTR however, one 
retrospective cohort study (418) of mainly AF patients showed that TTR was significantly 
better in the MTAC compared to usual care group (TTR 65.1 vs. 48.3; p<0.05 respectively) 
while another study (419) of AF patients showed no difference in TTR between the two 
respective groups. It would be of interest to incorporate the components of TREAT-2 
intervention into the MTAC protocol and design a trial to examine TTR in the TREAT-2 
intervention group + MTAC (N=50) vs. usual care group (N=50) in Malaysia. The outcome of 
this study could determine the benefits of the added TREAT-2 intervention into the current 
MTAC protocol and the impact of such interventions towards psychological health, quality of 
life and knowledge among patients receiving it.  
2.6 Conclusion 
Newly anticoagulated AF patients appear to have low levels of anxiety, depression, poor AF 
knowledge, positive perceptions about their medication and poor overall quality of life at 
baseline which remains unchanged at six months follow up. However, more patients were 
aware of the consequences of AF and AF symptoms (by the AFEQT questionnaire) improved 
significantly at follow up.  
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Chapter 3. Anticoagulation control in different ethnic groups 
receiving vitamin K antagonist therapy for stroke prevention in 
atrial fibrillation: the West Birmingham AF Project 
 
3.1 Abstract  
Introduction: Efficacy and safety of VKAs is optimised in AF patients when the INR is 2.0-
3.0. Anticoagulation control comparing different ethnic groups has not been well-assessed, 
although epidemiological studies suggest poorer INR control in non-white cohorts. 
Objective: To examine the quality of VKA control (TTR), predictors of anticoagulation control 
and the prevalence of adverse clinical outcomes [thromboembolic (stoke/TIA and systemic 
embolism), bleeding events, cardiovascular hospitalisation and all-cause mortality] in AF 
patients in a multi-ethnic cohort at one acute Trust in the West Midlands, United Kingdom.  
Ancillary analysis was also undertaken to investigate TTR among elderly (≥80 vs. <80 years) 
and patients with different categories of kidney disease (eGFR≥90 vs. 60-89 vs. 
≤59ml/min/1.73m2) within this cohort. Exploratory analyses investigated the relationship 
between INR control and adverse clinical outcome. 
Methods: All demographic and clinical data were collected retrospectively from the electronic 
medical record database. VKA control was assessed retrospectively by TTR using the 
Rosendaal method and percentage INRs in range (PINRR), among 991 White, Afro-
Caribbean and South-Asian AF patients. Predictors included patient’s demographics, 
comorbidities and other clinical data and these were examined by multiple regression analysis. 
The relationship between INR control and adverse clinical outcome was investigated with chi-
square. 
Results: The overall mean (SD) age at warfarin initiation was 71.6 (9.4) years; 55% male; 
mean (SD) CHA2DS2-VASc score 3.4 (1.6) and patients were followed up over a median of 
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5.2 years. The cohort consisted of 807 Whites, 102 South-Asians and 82 Afro-Caribbean 
patients.  Compared to Whites, mean (SD) TTR and PINRR were significantly lower in South-
Asians [TTR 67.9% vs. 60.5%, p<0.001; PINRR 58.8% vs. 51.6%, p<0.001 respectively] and 
Afro-Caribbeans [TTR 67.9% vs. 61.1%, p<0.001; PINRR 58.8% vs. 53.1%, p<0.001 
respectively], despite similar INR monitoring intensity. Whites had better anticoagulation 
control, evidenced by a greater proportion with TTR ≥70% and PINRR ≥70%. Anticoagulation 
control was significantly more likely to be sub-therapeutic (INR<2.0) among South-Asians and 
Afro-Caribbeans compared to Whites (30.2%, 30.2%, and 24.7%, p<0.05 respectively).  
Ancillary analyses showed that TTR was similar (66.6%) in patients ≥80 vs. <80 years and 
there were no significant differences in TTR observed among patients with normal kidney 
function (eGFR≥90), mild (eGFR 60-89) and mild-moderate-severe kidney disease (eGFR 
≤59) [64.0% vs. 66.9% vs. 67.0%; p=0.053 respectively].  
Logistic regression revealed that non-white ethnicity [OR 2.62 95%CI (1.67-4.10); p<0.001 
and OR 3.47 (1.44-8.34); p=0.005] and anaemia [OR 1.65 95%CI (1.00-2.70); p=0.05 and OR 
6.27 95%CI (1.89-20.94); p<0.003] were independent predictors of both TTR<70% and 
PINRR<70%, respectively.  
At 5.2 years, 329 (33.2%) patients experienced ≥1 major adverse clinical outcome (MACE). 
Cardiovascular hospitalisations were significantly higher among South-Asians compared to 
Whites (32.3% vs. 21.3%; p<0.05). Patients with CV hospitalisations were significantly more 
likely to have poor TTR (TTR<70%, p=0.002 and TTR<65%, p=0.008).  
Conclusions: Ethnic disparities in the quality of anticoagulation control are evident with 
South-Asians and Afro-Caribbeans having poorer INR control compared to Whites.  There 
were no significant differences in TTR between elderly and younger patients (≥80 vs. <80 
years) or between different categories of kidney disease. Non-white ethnicity and anaemia 
remained the strongest independent predictor of poor TTR and PINRR. CV hospitalisations 
were more prevalent among South-Asians and were associated with poor TTR.  
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3.2 Introduction 
 
Vitamin K antagonists (e.g., warfarin) have been used for many decades for the prevention of 
stroke in patients with AF (131). The efficacy and safety of VKA is determined by achieving 
the target international normalised ratio (INR) of 2.0-3.0 in AF patients (131).  To summarise 
INR control over time, TTR can be calculated by various methods including Rosendaal’s (using 
linear interpolation to assign INR value to each day between two consecutive INR values) and 
the percentage of INRs within therapeutic range (PINRR) (420, 421). TTR is a significant and 
important predictor of thromboembolic and bleeding outcomes in AF patients on VKA (3, 131, 
173, 316). A recent European consensus document recommended an individual TTR of ≥70% 
for optimal efficacy and safety outcomes whilst on a VKA (3), whilst the NICE guidelines on 
AF recommend a TTR ≥65% (344).  
 
Many factors can influence the quality of anticoagulation control thus affecting TTR, (see 
Section 1.5.1, page 78 for a review  of predictors of anticoagulation control) (199).  Ethnicity 
has been identified as one of the determinants of anticoagulation control in patients with AF 
(199) and this has been incorporated in the SAMe-TT2R2 score (see Section 1.5.1.1.8, pages 
83-85 for more information on ethnicity and TTR). Apart from ethnicity, studies have also 
shown that increasing age (247, 252) and chronic kidney disease (263-270) were associated 
with poor anticoagulation control [see Section 1.5.1 for more information on the impact of age 
(pages 80-81) and kidney disease (pages 81-82 ) on TTR].   
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3.2.1 Study objectives 
 
Birmingham is a multi-ethnic city mainly comprised of White British (53.1%), Afro-Caribbean 
(4.4%), Pakistani (13.5%) and Indian (6%) citizens, and Sandwell and West Birmingham 
Hospitals NHS Trust serves this tri-ethnic population. The main aim of this study was first to 
investigate the quality of anticoagulant control; second, to examine predictors of 
anticoagulation control (TTR) and lastly, to examine the prevalence of adverse clinical 
outcomes in AF patients in a multi-ethnic cohort. Ancillary analyses were also undertaken to 
investigate anticoagulation control among elderly patients (≥80 vs. <80 years) and patients 
with different categories of kidney disease (eGFR≥90 vs. 60-89 vs. ≤59ml/min/1.73m2). 
Exploratory analyses also investigated the relationship between INR control and adverse 
clinical outcomes. 
3.3 Methods 
3.3.1 Study design  
This is a retrospective cohort analysis of a multi-ethnic cohort of AF patients receiving VKA 
therapy for stroke prevention at one acute Trust in the West Midlands, United Kingdom. Data 
collection was undertaken from February to December 2016. AF patients receiving VKA 
therapy for stroke prevention with a target INR range of 2.0-3.0 were selected from the DAWN 
AC® anticoagulation management software; used by the Trust Anticoagulation Service to 
manage anticoagulation therapy.  
The DAWN AC® anticoagulation management software, a computer assisted dosage 
program, is clinically validated software designed to manage large anticoagulation clinics in 
an effective and safe way (422). It contains a complete anticoagulation decision support 
package that includes induction, maintenance and bridging of warfarin therapy (422). It also 
contains demographic and clinical information including reasons for anticoagulation, types of 
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anticoagulant used, target INR range, and the start date of anticoagulation, plus the dosing 
algorithm, test interval and INR results including history and current INRs for VKA 
management.  
This study was considered as service evaluation by the SWBH Research and Development 
department and therefore did not require REC approval.  However, local R&D approval was 
obtained (see email confirmation from SWBH R&D Department, Appendix 5). 
3.3.2 Patient selection 
An alphabetical list of patients was generated (N=2478) from DAWN® AC and patients were 
selected at random by choosing every third, fifth and tenth patient from the patients list.  A total 
of 1070 patients were included constituting 43% of the whole population. The ethnic group 
distribution of the population in this Trust (AF patients on VKA therapy) generated from the 
DAWN database is as follows: 78% Whites, 7.4% South-Asian, 5.3% Afro-Caribbeans and 
9.5% unknown/other ethnic background. For the purpose of this analysis, the present cohort 
is representative of the whole AF and VKA cohort at the Trust, i.e., 81.4% White, 10.3% South-
Asian and 8.3% Afro-Caribbean. 
Patients with EHRA type 1 VHD (N=45), unknown ethnicity (N=21), or unknown medical history 
(N=13) were excluded from these analyses. EHRA type 1 VHD were defined as patients with 
a diagnosis of moderate-to-severe mitral stenosis, rheumatic valvular disease or valve 
replacement requiring VKA therapy. Thus, the final cohort comprises 991 patients (807 White, 
102 South-Asian, and 82 Afro-Caribbean). Figure 3.1 presents the study design flow chart. 
 
 
176 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Ancillary analysis 1; †Ancillary analysis 2; CDA: clinical data archive; CV: cardiovascular; INR: international 
normalised ratio; TTR: time in therapeutic range; PINRR: percentage of INRs in range; SWBH: Sandwell and West 
Birmingham Hospitals; VKA: vitamin K antagonist 
 
Atrial fibrillation patients on VKA therapy 
selected from SWBH DAWN AC® Database 
(N=2478) 
Random patient’s selection according to 
alphabetical order (N=1070) 
Patient’s baseline demographic characteristics, past, 
current medical and medication history recorded from 
CDA and DAWN AC® databases 
Final cohort, N=991 
 
Patients excluded, N=79: EHRA type 1 VHD 
(N=45), unknown ethnicity (N=21), unknown 
medical background (N=13) 
 
Measure of 
anticoagulation 
control 
Adverse clinical 
outcomes 
Time to therapeutic 
range (TTR) by 
Rosendaal 
Percentage of INR 
within range (PINRR) 
Thromboembolic and bleeding 
events, CV hospitalization, 
death 
Predictors of 
anticoagulation 
control 
Outcome  
Ethnic groups: 
White, South-Asian, Afro-
Caribbean population 
 
Elderly: * 
≥80 years vs. <80 years 
 
Chronic kidney disease: † 
Group 1: eGFR ≥90  
Group 2: eGFR 60-89  
Group 3: eGFR ≤59  
 Figure 3.1: Study design and patient selection flow chart 
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3.3.3 Procedure 
A proforma (see Appendix 4, Table A4.1) was used to collect all baseline demographic and 
clinical characteristics of patients including medical history, medication, laboratory results and 
also information on outcomes of interest, INR results and adverse clinical outcomes. All 
demographics and clinical information were gathered from the Clinical Data Archive (CDA), an 
electronic medical record database. The CHA2DS2-VASc score (146),  HAS-BLED score (180) 
and SAMe-TT2R2 score (199) were calculated for each patient based on the available 
information and used to predict stroke, bleeding and anticoagulant control, respectively (see 
Table 3.1).  
Table 3.1: CHA2DS2-VASc, HAS-BLED, and SAMe-TT2R2 scores 
CHA2DS2-VASc   HAS-BLED   
CHF or LVF ≤40% 1 Uncontrolled Hypertension†  1 
Hypertension 1 Abnormal kidney/liver function 1/2 
Age ≥75 years 2 Stroke 1 
Diabetes 1 Bleeding‡  1 
Stroke/TIA/ thromboembolism 2 Labile INR§ 1 
Vascular Disease* 1 Elderly ≥65 years 1 
Age 65-74 1 Drugs/alcohol excess|| 1/2 
Female sex 1   
    
Total 9   9 
    
SAMe-TT2R2      
Sex (female) 1   
Age (<60 years) 1   
Medical history¶  1   
Treatment strategy# 1   
Tobacco use**  2   
Race (non-Caucasian) 2   
    
Total  8 
CHF: congestive heart failure; INR: international normalised ration; LVF: left ventricular function; TIA: transient ischemic attack; * 
prior myocardial infarction, peripheral artery disease or aortic plaque; †systolic blood pressure ≥160mmHg; ‡ bleeding history, 
anaemia or predisposition for bleeding;  §poor time in therapeutic range (<60%); ||concurrent antiplatelet /non-steroidal anti-
inflammatory drugs, ≥8units alcohol/week; ¶Two or more of the following: hypertension, diabetes mellitus, coronary artery 
disease/myocardial infarction, peripheral arterial disease, congestive heart failure, previous stroke, pulmonary disease, and 
hepatic or renal disease; #interacting drugs, e.g., amiodarone; **within 2 years  
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3.3.4 Variables and definitions 
3.3.4.1 Primary dependent/outcome variables:  
3.3.4.1.1 Time in therapeutic range (TTR) 
All available INR values from inception to 31st December 2016 or cessation of OAC therapy or 
death were obtained from the CDA and DAWN AC® databases. The quality of anticoagulation 
control was calculated as the proportion of TTR (INR 2.0-3.0), using the Rosendaal method 
(421) (which uses linear interpolation to assign an INR value to each day between two 
consecutive INR values) and PINRR, calculated by dividing the number of INR in range with 
the total INR values (420, 423). TTR values were further dichotomized into TTR ≥70% and 
TTR <70%, according to a recent European consensus document for optimal efficacy and 
safety outcomes (3) whilst on a VKA, and ≥65% and <65% based on the NICE guidelines 
(118). The proportion of sub-therapeutic (INR <2.0) and supra-therapeutic (INR >3.0) INRs 
was also calculated. Years of follow up is defined as the duration of warfarin therapy denoted 
from the first available INR on the DAWN AC® system until the present.  
3.3.4.1.2 Adverse clinical outcome 
The adverse clinical outcomes of interest were stroke, transient ischemic attack (TIA), 
systemic embolism (SE), bleeding events [combination of major and non-clinically relevant 
non-major bleeding (CRNMB)], cardiovascular (CV) hospitalization and all cause death and 
these were obtained from the patients’ medical records, CDA. All analysis pertaining to 
adverse clinical outcome were exploratory in nature. A composite endpoint of major adverse 
clinical event (MACE) encompassed ≥1 of the following: stroke/TIA, systemic embolism, 
bleeding, cardiovascular hospitalisation or death. Definitions of each outcome can be found in 
Section 2.3.3, pages 134-135.  
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3.3.4.2 Independent variable: Ethnicity 
Self-reported ethnicity was identified directly from the electronic medical records, CDA/DAWN® 
AC, where available. The different ethnic groups identified were White British, White Irish, 
White others, Asian British Indian, Asian British Pakistani, Asian British Bangladeshi, other 
Asians, Black British Caribbean and Black British African, according to the UK Census. These 
were then recoded into the three main ethnic groups; White, South Asian and Afro-Caribbean 
respectively. Those without information on ethnicity were excluded from the study (N=21). 
Ethnicity was an independent variable for the first part of the analysis examining the quality of 
anticoagulation control among the different ethnic groups. However, for the second part of the 
analysis, investigating the predictors of TTR, ethnicity was a covariate along with the other 
demographics and clinical characteristics.  
3.3.4.3 Predictors: Patient demographic and clinical factors 
Patients’ age was calculated according from the date of the first of INR available from the VKA 
therapy. Elderly patients were defined as patients who are ≥80 years. Information on gender 
(male and female), smoking (smoking within 2 years and non-smoking) and alcohol history (no 
alcohol, alcohol within recommended units i.e.; 14 units per week for both men and women or 
above recommended units) were obtained directly from CDA. Smoking history was available 
for 717 patients (72.4%). For calculation of the SAMe-TT2R2 score, that required information 
on smoking status, all missing information on smoking status was coded as non-smoker 
(N=274).  Information on alcohol intake was only available for 58.0% patients, thus this variable 
was excluded from further analysis. Comorbid conditions at baseline including hypertension, 
heart failure, coronary artery disease/ischemic heart disease, stroke/TIA, prior bleeding history 
and anaemia were obtained directly from CDA.  
Other comorbid diseases like kidney disease, liver disease and anaemia were also assumed 
based on available laboratory results at baseline. A correction factor to eGFR values was 
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made for Afro-Caribbean patients by multiplying the eGFR obtained from CDA by 1.21 (424). 
Assumption of CKD was made if patients had eGFR <60ml/min or serum creatinine 
>200umol/L; liver disease if abnormal liver function tests were reported; if alanine 
transaminase/alkaline phosphatase (ALT/ALP) >x3 upper limit of normal (ULN), and anaemia 
if the haemoglobin level was <135 g/L for males and <115 g/L for females. Laboratory results 
and medications taken at baseline were obtained directly from the CDA.  
3.3.4.3.1 Chronic kidney disease (CKD) 
Further categorisation of kidney disease was made according to the ‘Kidney Disease 
Improving Global Outcomes’ (KDIGO) GFR categories adapted by the NICE guidelines, with 
five categories of kidney disease for the ancillary analysis (Table 3.2) (424).  
 Table 3.2: Categories of chronic kidney disease from the NICE guidelines (424) 
GFR category GFR (ml/min) Terms 
G1 ≥90 Normal or high 
G2 60-89 Mildly decreased 
G3a 45-59 Mild to moderately decreased 
G3b 30-44 Moderate to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
GFR: glomerular filtration rate 
3.3.4.4 Other patient clinical factors (not included as predictors of 
anticoagulation control) 
Type of AF, including paroxysmal, persistent, long-standing persistent and permanent, was 
obtained from the medical notes. If this information was not available, an assumption was 
made based on the length of time since AF diagnosis and the pattern of ECG recordings 
available with confirmation from a medical doctor and according to the ESC AF guidelines (3). 
For example, if the available ECG showed multiple episodes of AF which lasted less than 48 
hours, this was categorised as paroxysmal AF. If AF lasted longer than 7 days, including those 
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terminated by cardioversion (either with drugs or direct current cardioversion), this was 
categorised as persistent AF. Whereas for long-standing persistent AF, the AF was 
continuous, lasting ≥1 year and a decision had been made to adopt a rhythm control strategy. 
Lastly permanent AF was defined when AF was accepted by both physician and patient and 
a decision has been made to not continue with rhythm control therapy (3). Calculation of stroke 
risk, bleeding risk and quality of anticoagulation control was made according to the CHA2DS2-
VASc score, HAS-BLED score, and TTR (Rosendaal and PINNR methods), respectively. 
The individual CHA2DS2-VASc score (to predict stroke risk) was calculated as follows: one 
point each for the presence of congestive heart failure, hypertension, diabetes mellitus, 
vascular disease (defined as peripheral vascular disease, myocardial infarction or aortic 
plaque), age 65-74 and female sex, and two points each for the presence of age≥75 years and 
previous stroke/TIA (Table 3.1).  
The individual HAS-BLED score (to predict bleeding risk) was calculated as follows: one point 
each for the presence of uncontrolled hypertension (for all cases blood pressure was assumed  
to be controlled as this is a requirement when on VKA therapy), abnormal kidney was defined 
as serum creatinine >200umol/L, abnormal liver function as ALT/ALP >x3 ULN) and from the 
past medical history (i.e., cirrhosis), previous stroke, prior bleeding within 12 months (including 
recent diverticulitis, gastric ulcer or anaemia defined as haemoglobin level of <135 g/L for male 
and <115 g/L for female and from the medical history), labile INR or TTR<60%, elderly >65 
years and drugs (concurrent antiplatelet or NSAIDs) and/or alcohol (>14 units/week, 
recommended by the current guidelines; modified from the original HAS-BLED score of >8 
units/week). There was insufficient information about alcohol intake, and therefore this variable 
was not included in the calculation of HAS-BLED score; the maximum HAS-BLED score was 
eight. A HAS-BLED score of 0-2 was denoted as low risk of bleeding and ≥3 as high risk of 
bleeding (Table 3.1). 
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The individual SAMe-TT2R2 score (to predict quality of anticoagulation control) was calculated 
as follows: one point each for female sex; presence of ≥2 of the following medical conditions: 
hypertension, diabetes mellitus, coronary artery disease or myocardial infarction, peripheral 
artery disease, congestive heart failure, previous stroke, pulmonary disease, hepatic disease 
or renal disease; treatment with interacting drugs e.g. amiodarone for rhythm control; and two 
points each for tobacco use within 2 years (tobacco use is a combination of current smoking 
and ex-smoking but with unknown duration as this information is not available); and race (non-
white), giving a possible score ranging from 0-8.  Patients with SAMe-TT2R2 score of 0-2 were 
defined as being likely to do well on VKA therapy and those with a SAMe-TT2R2 score >2 were 
classified as at risk of suboptimal anticoagulation control (TTR<65%) (Table 3.1). 
3.3.5 Statistical analysis 
Normality tests were performed by histogram plot method and the Kolmogorov-Smirnov test 
where a bell-shaped distribution in the former and p-values >0.05 in the latter were indicative 
of normally distributed data. Normally distributed data were expressed as mean (standard 
deviation, SD) and non-parametric data are presented as median (interquartile range, IQR). 
Categorical variables were compared using the chi-square test or the Fisher’s Exact test (as 
appropriate) and reported as counts with percentages. Continuous variables comparing >2 
groups used the analysis of variance (ANOVA) test for normally distributed data, with post-hoc 
tests as appropriate (e.g., Bonferroni), while, the Kruskal-Wallis test was utilised for non-
parametric data. Independent t-tests and Wilcoxon signed ranked tests were utilised for 
comparing continuous variables within two groups for normally and non-normally distributed 
data, respectively.   
For baseline demographics, clinical characteristics and adverse clinical outcomes, data were 
presented as descriptive statistics. Pearson correlation was utilised to investigate the 
correlation between TTR and PINRR (normally distributed).  
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Linear regression analysis was conducted to investigate the predictors of TTR and PINRR as 
a continuous variable. Logistic regression analysis was also used to investigate predictors of 
poor TTR (TTR<70%) and PINRR (PINRR <70%) as categorical variables as this cut off 
reflects poor anticoagulation control recommended by the European Guidelines (1). The 
relationship between INR control (TTR<70% and TTR<65%) and adverse clinical outcomes 
was investigated using the Chi-squared test and these analyses were exploratory. Predictors 
of MACE events and composite endpoints (≥1 MACE) were examined using Cox proportional 
hazard regression models. Survival analysis was also displayed using Kaplan-Meier curves. 
P-values <0.05 were considered statistically significant. All analyses were confined to 
complete cases only (except for smoking history) and were conducted using SPSS version 
23.0 (IBM, NY, USA) (425). 
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3.4 Results  
3.4.1 Baseline characteristics 
3.4.1.1 By ethnicity 
The final cohort included 991 AF patients receiving warfarin for stroke prevention, with a 
median (IQR) length of follow up of 5.2 (3.2-7.0) years. The majority of the population were 
White (N=807, 81.4%), with 10.3% South-Asian (N=102) and 8.3% Afro-Caribbean (N=82). 
The overall mean age at warfarin initiation was 71.6 (9.4) years and South-Asian patients were 
significantly younger than Whites and Afro-Caribbeans (p=<0.05 for group comparison); half 
the population were male (55.3%) (see Table 3.3). Overall, hypertension was the most 
common co-morbidity (79.2%), followed by chronic kidney disease (37.3%) and diabetes 
mellitus (20.6%). There was a significant difference in prevalence of diabetes (p<0.001), 
anaemia (p<0.001), and vascular disease (p=0.007) between ethnic groups. Diabetes mellitus 
and anaemia were significantly more prevalent among South-Asians and Afro-Caribbeans 
(p<0.05 for group comparison) compared to Whites and vascular disease was significantly 
more prevalent among South-Asian compared to Whites and Afro-Caribbeans (p<0.05 for 
group comparison).  Smoking status was only available in 72.4% patients. Smoking (current 
or ex-smoker within 2 years) appeared to be more prevalent among Whites (51.6%) compared 
to South-Asian (14.6%) and Afro-Caribbeans (25.9%; p<0.05 group comparison). Type of AF 
differed by ethnicity (p=0.004), with a greater proportion of Afro-Caribbeans (40.2%) found to 
be in persistent AF compared to South-Asians and Whites. The only overall significant 
difference (p<0.001) in medications was calcium channel blocker prescription with a greater 
prevalence among Afro-Caribbeans compared to South-Asians and Whites. 
The overall mean (SD) CHA2DS2-VASc score was 3.4 (1.6) and was significantly higher among 
Afro-Caribbeans compared to Whites and South-Asians [3.9 (1.7) vs. 3.3 (1.6) vs. 3.6 (1.7), 
respectively; p<0.05 for group comparison]. The overall mean (SD) HAS-BLED score was 1.5 
(0.9) and was significantly higher in both South-Asians and Afro-Caribbeans compared to 
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Whites [mean (SD) HAS-BLED score of 1.8 (0.9) vs. 1.7 (1.0) vs. 1.5 (0.9) respectively; p<0.05 
for group comparison].  The SAMe-TT2R2 score, was significantly higher among South-Asians 
and Afro-Caribbeans compared to Whites (p<0.05 for group comparison) (see Table 3.3). 
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 Table 3.3: Baseline characteristics of the study population overall and stratified by ethnicity and age (≥80 vs. <80 years) 
 
Total, 
N=991 
White, 
N=807 
South-Asian, 
N=102 
Afro-Caribbean, 
N=82 
Age ≥80 
years, 
N=205 
Age <80 
years, 
N=786 
Overall 
p-value 
ethnicity 
Overall 
p-value 
age 
Mean (SD) age  71.6 (9.4) 71.9 (9.3) 68.2 (9.9) a 72.9 (9.3) c - - <0.001 - 
<65 209 (21.1) 166 (20.6) 29 (28.4) 14 (17.1) - - 0.004 - 
65-74 355 (35.8) 287 (35.6) 45 (44.1) 23 (28.0) - -  - 
≥75 427 (43.1) 354 (43.9) 28 (27.5) a, c 45 (54.9) c - -  - 
Female 443 (44.7) 343 (42.5) 46 (45.1) c 54 (66.0) b, c 120 (58.5) 323 (41.1) <0.001 
<0.001 
Male  548 (55.3) 464 (57.5) 56 (54.9) 28 (34.1) 85 (41.5) 463 (58.9)  
White - - - - 176 (85.9) 631 (80.3) - 
0.016 South-Asian - - - - 10 (4.9) 92 (11.7) - 
Afro-Caribbean - - - - 19 (9.3) 63 (8.0) - 
Heart failure 138 (13.9) 109 (13.5) 14 (13.7) 15 (18.3) 31 (15.1) 107 (13.6) 0.49 0.66 
Hypertension 785 (79.2) 631 (78.2) 82 (80.4) 72 (87.8) 176 (85.9) 609 (77.5) 0.12 0.011 
Diabetes 204 (20.6) 132 (16.4) 44 (43.1) a 28 (34.1) b 38 (18.5) 166 (21.1) <0.001 0.47 
Stroke/TIA 179 (18.1) 145 (18.0) 23 (22.5) 11 (13.4) 40 (19.5) 139 (17.7) 0.27 0.61 
VTE  38 (3.8) 32 (4.0) 3 (2.9) 3 (3.7) 7 (3.4) 31 (3.9) 0.88 0.88 
PAD 26 (2.6) 24 (3.0) 1 (1.0) 1 (1.2) 8 (3.9) 18 (2.3) 0.35 0.30 
Vascular disease* 163 (16.4) 123 (15.2) 28 (27.5) a 12 (14.6) b 37 (18.0) 126 (16.0) 0.007 0.56 
Lung disease# 196 (19.8) 165 (20.4) 12 (11.8) 19 (23.2) 34 (16.6) 162 (20.6) 0.08 0.23 
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Table 3.3 continued 
 Total,  
N=991 
White, 
 N=807 
South-Asian,  
N=102 
Afro-
Caribbean, 
N=82 
Age ≥80 years,  
N=205 
Age <80 
years, 
N=786 
Overall p-
value 
ethnicity 
Overall p-
value 
age 
Cardiomyopathy‡ 30 (3.0) 25 (3.1) 2 (2.0) 3 (3.7) 4 (2.0) 26 (3.3) 0.77 0.44 
Kidney disease† 370 (37.3) 308 (38.2) 40 (39.2) 22 (26.8) 103 (50.2) 267 (34.0) 0.12 <0.001 
Anaemia 145 (14.6) 101 (12.5) 28 (27.5)a 16 (19.5)b 34 (16.6) 111 (14.1) <0.001 0.44 
Smoker/ex-smoker 
(N=717) 
326 (45.5) 300 (51.6) 12 (14.6)a 14 (25.9)b 49 (33.8) 277 (48.4) <0.001 0.002 
Paroxysmal  274 (27.6) 225 (27.9) 31 (30.4) 18 (22.0) 48 (23.4) 226 (28.8) 
0.004 0.26 Persistent  229 (23.1) 174 (21.6) 22 (21.6)
c 33 (40.2)b, c 47 (22.9) 182 (23.2) 
Permanent  488 (49.2) 408 (50.6) 49 (48.0) 31 (37.8) 110 (53.7) 378 (48.1) 
ACEI/ARB 561 (56.6) 449 (55.6) 62 (60.8) 50 (61.0) 115 (56.1) 446 (56.7) 0.43 0.93 
Beta-blocker 455 (45.9) 360 (44.6) 57 (55.9) 38 (46.3) 87 (42.4) 368 (46.8) 0.10 0.30 
CCB 350 (35.3) 264 (32.7) 39 (38.2)c 47 (57.3)b, c 82 (40.0) 268 (34.1) <0.001 0.14 
Digoxin 226 (22.8) 194 (24.0) 18 (17.6) 14 (17.1) 43 (21.0) 183 (23.3) 0.15 0.54 
Diuretics  439 (44.3) 351 (43.5) 42 (41.2) 46 (56.1) 120 (58.8) 319 (40.6) 0.07 <0.001 
Amiodarone 58 (5.9) 52 (6.4) 3 (2.9) 3 (3.7) 7 (3.4) 51 (6.5) 0.25 0.13 
Concurrent 
antiplatelet 
46 (4.6) 38 (4.7) 6 (5.9) 2 (2.4) 10 (4.9) 36 (4.6) 0.53 1.00 
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Table 3.3 continued 
 Total, 
N=991 
White, 
N=807 
South-Asian, 
N=102 
Afro-
Caribbean, 
N=82 
Age ≥80 years,  
N=205 
Age <80 years, 
N=786 
Overall p-
value 
ethnicity 
Overall 
p-value 
age 
Mean (SD) CHA2DS2-
VASc  
3.4 (1.6) 3.3 (1.6) 3.6 (1.7) 3.9 (1.7)b 4.4 (1.3) 3.1 (1.6) 0.002 <0.001 
0 29 (2.9) 25 (3.1) 2 (2.0) 2 (2.4) 0 29 (3.7) 
0.001 <0.001 
1 81 (8.2) 72 (8.9) 5 (4.9) 4 (4.9) 0 81 (10.3) 
2 185 (18.7) 150 (18.6) 27 (26.5) 8 (9.8) 12 (5.9) 173 (22.0) 
3 238 (24.0) 200 (24.8) 20 19.6) 18 (22.0) 37 (18.0) 201 (25.6) 
4 225 (22.7) 183 (22.7) 17 (16.7) 25 (30.5) 68 (33.2) 157 (20.0) 
5 124 (12.5) 101 (12.5) 12 (11.8) 11 (13.4) 46 (22.4) 78 (9.9) 
6 82 (8.3) 62 (7.7) 13 (12.7) 7 (8.5) 28 (13.7) 54 (6.9) 
7 22 (2.2) 11 (1.4) 6 (5.9) 5 (6.1) 12 (5.9) 10 (1.3) 
8 4 (0.4) 2 (0.2) 0 2 (2.4) 1 (0.5) 3 (0.4) 
9 1 (0.1) 1 (0.1) 0 0 1 (0.5) 0 
CHA2DS2-VASc 
categories: Low risk 
39 (3.9) 32 (4.0) 3 (2.9) 4 (4.9) 0  39 (5.0) 
0.214 <0.001 Intermediate  71 (7.2) 65 (8.1) 4 (3.9) 2 (2.4) 0 71 (9.0) 
High risk  881 (88.9) 710 (88.0) 95 (93.1) 76 (92.7) 205 (100) 676 (86.0) 
Mean (SD) HAS-BLED  1.5 (0.9) 1.5 (0.9) 1.8 (0.9)a 1.7 (1.0)b 1.8 (0.8) 1.5 (0.9) <0.001 <0.001 
0 93 (9.4) 79 (9.8) 8 (7.8) 6 (7.3) 0 93 (11.8) 
<0.001 <0.001 
1 443 (44.7) 379 (47.0) 34 (33.3) 30 (36.6) 97 (47.3) 346 (44.0) 
2 326 (32.9) 263 (32.6) 32 (31.4) 31 (37.8) 68 (33.2) 258 (32.8) 
3 107 (10.8) 71 (8.8) 25 (24.5) 11 (13.4) 32 (15.6) 75 (9.5) 
4 20 (2.0) 13 (1.6) 3 (2.9) 4 (4.9) 7 (3.4) 13 (1.7) 
5 2 (0.2) 2 (0.2) 0 0 1 (0.5) 1 (0.1) 
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Table 3.3 continued  
 Total, 
N=991 
White, 
N=807 
South-Asian, 
N=102 
Afro-
Caribbean, 
N=82 
Age ≥80 years,  
N=205 
Age <80 years, 
N=786 
Overall p-
value 
ethnicity 
Overall 
p-value 
age 
HAS-BLED categories 
Low risk  
862 (87.0) 721 (89.3) 74 (72.5)a 67 (81.7) 165 (80.5) 697 (88.7) 
<0.001 0.003 
High risk 129 (13.0) 86 (10.7) 28 (27.5)a, c 15 (18.3)b, c 40 (19.5) 89 (11.3) 
Mean SAMe-TT2R2 
score 
2.3 (1.4) 2.0 (1.2) 3.7 (0.9)a 3.8 (0.9)b 2.2 (1.2) 2.4 (1.4) <0.001 0.04 
0 74 (7.5) 74 (9.2) 0 0 14 (6.8) 60 (7.6) 
<0.001 0.004 
1 231 (28.6) 0 0 0 49 (23.9) 182 (23.2) 
2 246 (24.8) 236 (29.2) 6 (5.9) 4 (4.9) 72 (35.1) 174 (22.1) 
3 235 (23.7) 167 (20.7) 42 (41.2) 26 (31.7) 36 (17.6) 199 (25.3) 
4 162 (16.3) 87 (10.8) 37 (36.3) 38 (46.3) 31 (15.1) 131 (16.7) 
5 35 (3.5) 12 (1.5) 13 (12.7) 10 (12.2) 3 (1.5) 32 (4.1) 
6 6 (0.6) 0 3 (2.9) 3 (3.7) 0 6 (0.8) 
7 2 (0.2) 0 1 (1.0) 1 (1.2) 0 2 (0.3) 
SAMe-TT2R2 
categories 0-2 
551 (55.6) 541 (67.0) 6 (5.9)a 4 (4.9)b 135 (65.9) 416 (52.9) <0.001 0.001 
>2 440 (44.4) 266 (33.0) 96 (94.1)a 78 (95.1)b 70 (34.1) 370 (47.1)  
 
ACEI/ARB: angiotensin converting enzyme inhibitor/ angiotensin receptor blockade; CCB: calcium channel blocker; CHA2DS2-VASc score - Congestive heart failure/left ventricular dysfunction, 
Hypertension, Age ≥75years [2 points], Diabetes, Stroke [2 points], Vascular disease, Age 65–74 years, and Sex category (female). Total scores range between 0-9; low risk CHA2DS2-VASc score:  0, 
intermediate: 1, high risk CHA2DS2-VASc score: ≥2; TIA: transient ischemic attack; TE: thromboembolism; HAS-BLED score – uncontrolled Hypertension: systolic ≥160 mmHg, Abnormal renal/liver 
function, Stroke, Bleeding history or predisposition, Labile INR ratio/TTR <60, Drugs/alcohol concomitantly. Total scores range between 0-9; low risk of bleeding range between 0-2 and high risk of 
bleeding ≥3; SAMe-TT2R2 score – Sex female, Age<60, Medical history (more than two comorbidities), Treatment (interacting drug, e.g. Amiodarone), Tobacco use (doubled) and Race (non-white, 
doubled). Total scores ranged from 0-8; probable good response to VKA therapy range between 0-2 and probable poor response to VKA therapy ranged from ≥3.  
* Vascular disease: prior myocardial infarction, peripheral artery disease or aortic plaque; † Kidney disease: eGFR<60 ml/min; ‡ Cardiomyopathy: dilated, restrictive and obstructive myocardial conditions; 
# Lung disease Includes obstructive and restrictive diagnosed lung conditions; 
a significant difference between White and South-Asian groups (p<0.05); b significant difference between White and Afro-Caribbean groups (p<0.05); c significant difference between South-Asian and 
Afro-Caribbean groups (p<0.05) 
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3.4.1.2 By age (≥80 years and <80 years) 
Baseline characteristics of the population grouped by ≥80 years and <80 years are also shown 
in Table 3.3. There were 205 patients (20.6%) who were ≥80 years old and the majority were 
female (58.5%; p<0.001) and of white ethnicity (85.9%; p=0.016). Hypertension (85.9%; 
p=0.011) and chronic kidney disease (50.2%; p=<0.001) were significantly more prevalent 
among elderly patients, whereas smoking history (48.4%; p=0.002) was significantly more 
prevalent in patients aged <80 years.  As expected, the mean (SD) CHA2DS2-VASc [4.4 (1.3); 
p<0.001] and HAS-BLED score [1.8 (0.8); <0.001] were significantly higher among elderly 
patients, whereas the mean SAMe-TT2R2 score was significantly higher in the younger 
population.  
3.4.1 By kidney disease categories 
There were 974 patients with eGFR results available at baseline. The distribution of patients 
according to the classification of the kidney disease is shown in Table 3.4. These categories 
were further dichotomised into normal kidney function with eGFR ≥90 ml/min/1.73m2; mildly 
decreased with eGFR 60-89 ml/min/1.73m2 and combination of group 3a, 3b, 4 and 5 (mild-
moderately-severe and kidney failure) with eGFR ≤59 ml/min/1.73m2. 
 Table 3.4: Distribution of patients in the current cohort according to the categories of 
kidney disease, N=974 
GFR category GFR 
(ml/min/1.73m2) 
N (%) New dichotomised group in this 
cohort, eGFR (ml/min/1.73m2)  
N (%) 
G1 ≥90 133 (13.7) Normal (≥90) 133 (13.7) 
G2 60-89 491 (50.4) Mild (60-89) 491 (50.4) 
G3a 45-59 225 (23.1) Mild-moderate-severe and kidney 
failure (≤59) 
350 (35.9) 
G3b 30-44 98 (10.1) 
G4 15-29 24 (2.5)   
G5 <15 3 (0.3) 
GFR: glomerular filtration rate 
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For the purpose of the thesis, the description of the different kidney function groups will be 
patients with eGFR ≥90, eGFR 60-89 and eGFR ≤59. The median (IQR) eGFR at baseline 
was 66.0 (54.0-79.0) ml/min/1.73m2. Half of the population had eGFR 60-89 ml/min/1.73m2, 
while 35.9% had an eGFR ≤59 ml/min/1.73m2. 
Compared to patients with normal kidney function, AF patients with eGFR 60-89 and eGFR 
≤59 were significantly older (p<0.05 for group comparison). There were significantly more 
females and those of white ethnicity in patients with eGFR ≤59 compared to eGFR ≥90 (p<0.05 
for group comparison) (Table 3.5). Heart failure, hypertension and anaemia were significantly 
more prevalent in patients with eGFR ≤59 compared to eGFR ≥90 and eGFR 60-89 (p<0.05 
for group comparison). Meanwhile, stroke/TIA was significantly more prevalent in patients with 
eGFR ≥90 and eGFR ≤59 compared to eGFR 60-89 (p<0.05 for group comparison). A 
significant proportion of AF patients with eGFR ≥90 had concomitant lung disease and also 
smoked (or used to smoke within 2 years) compared eGFR 60-89 and eGFR ≤59 (p<0.05 for 
group comparison) (Table 3.5). 
In addition, the use of ACE/ARB and diuretics were significantly more prevalent in patients 
with eGFR ≤59 (p<0.05 for group comparison) while the use of beta blockers (p<0.05 for group 
comparison) was significantly more prevalent in patients with eGFR ≥90. Mean (SD) CHA2DS2-
VASc score [3.9 (1.6); p<0.05 group comparison] and HAS-BLED score [1.7 (0.9); p<0.05 for 
group comparison] was significantly higher in patients with eGFR ≤59 while mean SAMe-TT2R2 
score was significantly higher in patients with eGFR ≥90 (Table 3.5). 
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 Table 3.5: Baseline characteristics of overall population with eGFR results and according to three categories of kidney disease 
N (%)  
Total, 
N=974 
eGFR≥90 ml/min 
N=133 
eGFR 60-89 ml/min 
N=491 
eGFR ≤59 ml/min 
N=350 
Overall  
p-value  
Age  
Mean (SD) 71.6 (9.4) 67.5 (10.1) 70.7 (9.4)a 74.4 (8.4)b, c <0.001 
<65 205 (21.0) 46 (34.6) 116 (23.6) 43 (12.3)b 
<0.001 65-74 351 (36.0) 49 (36.8) 191 (38.9) 111 (31.7) 
≥75 418 (42.9) 38 (28.6) 184 (37.5) 196 (56.0)b 
Sex 
Female 437 (44.9) 47 (35.3) 209 (42.6) 181 (51.7) b 
0.002 
Male  537 (55.1) 86 (64.7) 282 (57.4) 169 (48.3) b 
Ethnic groups 
White  792 (81.3) 89 (66.9) 403 (82.1)a 300 (85.7)b 
<0.001 South-Asian  102 (10.5) 13 (9.8) 52 (10.6) 37 (10.6) 
Afro-Caribbean 80 (8.2) 31 (23.3) 36 (7.3)a 13 (3.7)b 
Medical history 
  
Heart failure 135 (13.9) 15 (11.1) 55 (11.2) 65 (18.6)b,c 0.006 
Hypertension 774 (79.5) 101 (75.9) 376 (76.6) 297 (84.9)b,c 0.008 
Diabetes 202 (20.7) 26 (19.5) 100 (20.4) 76 (21.7) 0.84 
Stroke/TIA 175 (18.0) 26 (19.5) 70 (14.3)a 79 (22.6)b,c 0.007 
VTE  36 (3.7) 4 (3.0) 22 (4.5) 10 (2.9) 0.42 
PAD 26 (2.7) 3 (2.3) 8 (1.6) 15 (4.3) 0.06 
Vascular disease* 160 (16.4) 16 (12.0) 76 (15.5) 68 (19.4) 0.11 
Lung disease# 194 (19.9) 36 (27.1) 101 (20.6)a 57 (16.3)b,c 0.03 
Cardiomyopathy‡ 29 (3.0) 4 (3.0) 16 (3.3) 9 (2.6) 0.85 
Anaemia 145 (14.9) 17 (12.8) 62 (12.6) 66 (18.9)b,c 0.03 
Smoker/ex-smoker 
(N=708) 
319 (45.1) 54 (51.9) 169 (47.5) 96 (38.7) 0.03 
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Table 3.5 continued 
 
 Total, 
N=974 
eGFR≥90 ml/min 
N=133 
eGFR 60-89 ml/min 
N=491 
eGFR ≤59 ml/min 
N=350 
Overall  
p-value 
 
Types of AF 
 
Paroxysmal  274 (28.1) 37 (27.8) 143 (29.1) 94 (26.9) 
0.59 Persistent  228 (23.4) 37 (27.8) 114 (23.2) 179 (51.1) 
Permanent 472 (48.5) 59 (44.4) 234 (47.7) 77 (22.0) 
Medications  
ACEI/ARB 553 (56.8) 67 (50.4) 270 (55.0) 216 (61.7) 0.04 
Beta-blocker 454 (46.6) 69 (51.9) 207 (42.2)a 178 (50.9)c 0.02 
CCB 347 (35.6) 45 (33.8) 175 (35.6) 127 (36.3) 0.88 
Digoxin 223 (22.9) 25 (18.8) 108 (22.0) 90 (25.7) 0.22 
Diuretics  433 (44.5) 42 (31.6) 192 (39.1) 199 (56.9)b,c <0.001 
Amiodarone 58 (6.0) 6 (4.5) 27 (5.5) 25 (7.1) 0.46 
Concurrent 
antiplatelet 
44 (4.5) 6 (4.5) 19 (3.9) 19 (5.4) 0.56 
CHA2DS2-VASc 
score 
Mean (SD) 3.4 (1.6) 2.9 (1.5) 3.2 (1.6) 3.9 (1.6) b,c <0.001 
0 27 (2.8) 9 (6.8) 16 (3.3) 2 (0.6) 
<0.001 
1 80 (8.2) 14 (10.5) 51 (10.4) 15 (4.3) 
2 183 (18.8) 29 (21.8) 104 (21.2) 50 (14.3) 
3 235 (24.1) 35 (26.3) 125 (25.5) 75 (21.4) 
4 222 (22.8) 25 (18.8) 101 (20.6) 96 (27.4) 
5 120 (12.3) 14 (10.5) 55 (11.2) 51 (14.6) 
6 81 (8.3) 6 (4.5) 30 (6.1) 45 (12.9) 
7 21 (2.2) 1 (0.8) 8 (1.6) 12 (3.4) 
8 4 (0.4) 0 1 (0.2) 3 (0.9) 
9 1 (0.1) 0 0 1 (0.1) 
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Table 3.5 continued 
  Total, 
N=974 
eGFR≥9 ml/min 
N=133 
eGFR 60-89 ml/min 
N=491 
eGFR ≤59 ml/min 
N=350 
Overall  
p-value 
CHA2DS2-VASc 
score categories 
Low risk (0) 37 (3.8) 11 (8.3) 23 (4.7) 3 (0.9)b 
<0.001 Intermediate (1) 70 (7.2) 12 (9.0) 44 (9.0) 14 (4.0)b,c 
High risk (≥2) 867 (89.0) 110 (82.7) 424 (86.4) 333 (95.1)b 
HAS-BLED score Mean 1.5 (0.9) 1.5 (0.9) 1.4 (0.8) 1.7 (0.9)c <0.001 
 
0 91 (9.3) 14 (10.5) 61 (12.4) 16 (9.3) 
<0.001 
1 434 (44.6) 56 (42.1) 236 (48.1) 142 (40.6) 
2 322 (33.1) 46 (34.6) 148 (30.1) 128 (36.6) 
3 106 (10.9) 14 (10.5) 41 (8.4) 51 (14.6) 
4 19 (2.0) 2 (1.5) 5 (1.0) 12 (3.4) 
5 2 (0.2) 1 (0.8) 0 1 (0.3) 
HAS-BLED score 
categories 
Low risk (0-2) 847 (87.0) 116 (87.2) 445 (90.6) 286 (81.7) 
0.001 
High risk (≥3) 127 (13.0) 17 (12.8) 46 (9.4) 64 (18.3) 
SAMe-TT2R2 
score 
Mean  2.3 (1.3) 2.7 (1.5) 2.2 (1.3)a 2.4 (1.2)c <0.001 
0  69 (7.1) 12 (9.0) 51 (10.4) 6 (1.7) 
<0.001 
1 230 (23.6) 20 (15.0) 123 (25.1) 87 (24.9) 
2 244 (25.1) 24 (18.0) 114 (23.2) 106 (30.3) 
3 228 (23.4) 36 (27.1) 119 (34.2) 73 (20.9) 
4 160 (16.4) 29 (21.8) 65 (13.2) 66 (18.9) 
5 35 (3.6) 9 (6.8) 16 (3.3) 10 (2.9) 
6 6 (0.6) 2 (1.5) 3 (0.6) 1 (0.3) 
7 2 (0.2) 1 (0.8) 0 1 (0.3) 
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Table 3.5 continued 
 
 
eGFR ≥90ml/min/1.73m2- normal kidney function; eGFR 60-89 ml/min/1.73m2- mild kidney disease; eGFR ≤59 ml/min/1.73m2- mild-moderate-severe and kidney failure 
 
ACEI/ARB: angiotensin converting enzyme inhibitor/ angiotensin receptor blockade; CCB: calcium channel blocker; CHA2DS2-VASc score - Congestive heart failure/left ventricular dysfunction, 
Hypertension, Age ≥75years [2 points], Diabetes, Stroke [2 points], Vascular disease, Age 65–74 years, and Sex category (female). Total scores range between 0-9; low risk CHA2DS2-VASc score:  
0, intermediate 1, high risk CHA2DS2-VASc score: ≥2; TIA: transient ischemic attack; TE: thromboembolism; eGFR: estimated glomerular filtration rate, ml/min/1.73 m2; HAS-BLED score – uncontrolled 
Hypertension: systolic ≥160 mmHg, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR ratio/TTR <60, Drugs/alcohol concomitantly. Total scores range between 0-9; 
low risk of bleeding range between 0-2 and high risk of bleeding ≥3; SAMe-TT2R2 score – Sex female, Age<60, Medical history (more than two comorbidities), Treatment (interacting drug, e.g. 
Amiodarone), Tobacco use (doubled) and Race (non-white, doubled). Total scores ranged from 0-8; probable good response to VKA therapy range between 0-2 and probable poor response to VKA 
therapy ranged from ≥3. 
* Vascular disease: prior myocardial infarction, peripheral artery disease or aortic plaque; ‡ Cardiomyopathy: dilated, restrictive and obstructive myocardial conditions; # Lung disease: obstructive and 
restrictive diagnosed lung conditions; 
 
a: significant difference between eGFR≥90 and eGFR 60-89, p<0.05 
b: significant difference between eGFR≥90 and eGFR ≤59; p<0.05 
c: significant difference between eGFR 60-89, and eGFR ≤59; p<0.05 
 
 Total, 
N=974 
eGFR≥90 ml/min 
N=133 
eGFR 60-89 ml/min 
N=491 
eGFR ≤59 ml/min 
N=350 
Overall  
p-value 
SAMe-TT2R2 
score categories 
0-2 543 (55.7) 56 (42.1) 288 (58.7) 199 (56.9) 
0.003 
>2 431 (44.3) 77 (57.9) 203 (41.3) 151 (43.1) 
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3.4.2 Measures of anticoagulation control  
3.4.2.1 By ethnicity 
In this cohort, 96% of patients were VKA naïve. Table 3.6 presents the measures of 
anticoagulation control in the overall population and by ethnic group. Overall mean (SD) TTR 
and PINRR values were 66.6% (13.3) and 57.6% (11.2) respectively. TTR significantly 
correlated with PINRR (r=0.773, p<0.001). White patients had significantly higher mean TTR 
values compared to Afro-Caribbean and South-Asian patients, based on both mean TTR (by 
Rosendaal method; p<0.05 group comparison) and PINRR (p<0.05 for group comparison) 
(Figure 3.2). When TTR and PINRR was dichotomised (<70% vs. ≥70%) the same trend was 
observed (Figure 3.3). The mean (SD) number of INR tests used to calculate TTR was 58.7 
(25.5) and was similar across ethnic groups.  The proportion of sub-therapeutic INRs (<2.0) 
was significantly greater among South-Asians and Afro-Caribbeans, with no differences in the 
proportion of supra-therapeutic INRs by ethnicity (Figure 3.4). Overall, 29.6% and 4.1% of the 
population had at least one INR value above 5.0 and 8.0, respectively (Figure 3.5). 
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 Table 3.6: Measures of anticoagulation control overall and by ethnic group 
Measures of anticoagulation control, N (%) Total, N=991 White, N=807 
South-Asian, 
N=102 
Afro-Caribbean, 
N=82 
F-
value 
X2 
value 
p-
value 
Mean (SD) TTR Rosendaal 66.6 (13.2) 67.9 (12.8) 60.5 (12.8)a 61.3 (14.2)b 22.7 - <0.001 
TTR<70% 550 (55.5) 417 (51.7) 75 (73.5) 58 (70.7)  
25.9 
<0.001 
TTR≥70% 441 (44.5) 390 (48.3) 27 (26.5)a 24 (29.3)b  
TTR<65% 400 (40.4) 294 (36.4) 59 (57.8) 47 (57.3)  
27.9 
<0.001 
TTR≥65% 591 (59.6) 513 (63.6) 43 (42.2)a 35 (42.7)b  
Mean (SD) PINRR 57.6 (11.2) 58.8 (10.8) 51.6 (10.9)a 53.1 (11.6)b 27.3 - <0.001 
PINRR<70% 851 (85.9) 677 (83.9) 99 (97.1) 75 (91.5)  
 
<0.001 
PINRR ≥70% 140 (14.1) 130 (16.1) 3 (2.9)a, c 7 (8.5)b,c 15.3 
PINRR <65% 736 (74.3) 576 (71.4) 91 (89.2) 69 (84.1)  
19.6 
<0.001 
PINRR ≥65% 255 (25.7) 231 (28.6) 11 (10.8)a 13 (15.9)b  
Mean (SD) number of INR tests 58.7 (25.5) 59.4 (24.6) 55.0 (24.6) 56.5 (33.7) 1.7 - 0.18 
Mean (SD) percentage INRs<2 25.7 (10.0) 24.7 (9.5) 30.1 (11.2)a 30.2 (10.9)b 23.8 - <0.001 
Mean (SD) percentage INRs>3 16.6 (7.2) 16.5 (7.3) 17.9 (7.1) 16.5 (6.2) 1.9 - 0.16 
INR>5 293 (29.6) 239 (29.6) 31 (30.4) 23 (28.0) - 0.125 0.94 
INR>8 41 (4.1) 36 (4.5) 3 (2.9) 2 (2.4) - 1.177 0.56 
Median (IQR) years of follow-up 5.2 (3.2-7.0) 5.5 (3.4-7.0) 4.3 (2.6-6.7)a 4.0 (2.4-6.1)b - - <0.001 
 
TTR: Time in therapeutic range; PINRR: Percentage of INRs within range; INR: international Normalised Ratio; SD: standard deviation; IQR: interquartile range 
 
a significant difference between White and South-Asian groups (p<0.05); b significant difference between White and Afro-Caribbean groups (p<0.05); c significant difference between South-Asian and Afro-Caribbean 
groups (p<0.05) 
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 Figure 3.2: Measures of anticoagulation control (including TTR by Rosendaal and PINRR method) by 
ethnicity  
 Figure 3.3: Percentage of patients by ethnic group with a therapeutic (TTR≥70%) TTR by the 
Rosendaal and PINRR method 
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Measures of anticoagulation control continued 
3.4.2.2 By age (≥80 and <80 years) 
Table 3.7 presents the measures of anticoagulation control when patients were grouped 
according to age ≥80 and <80 years. The quality of anticoagulation control by both measures, 
TTR (Rosendaal method) [66.6% in ≥80 and <80 years age group] and PINRR [57.1% in the 
≥80 years old vs. 57.7% in <80 years old] were similar between the two age categories. Elderly 
patients had significantly fewer INR visits (mean 51 vs. 61 visits; p<0.001 for ≥80 vs. <80 
years, respectively) and a lower duration of follow up (Figure 3.6). Good TTR (defined as TTR 
and PINRR ≥70%) was 44% and 14% in those aged ≥80 years and <80 years, respectively; 
over half of the elderly population did not achieve the optimal percentage TTR advocated by 
clinical guidelines. No significant differences in sub-therapeutic or supra-therapeutic INRs 
were observed by age (≥80 and <80 years).  
 Table 3.7: Measures of anticoagulation control among overall population and in 
patients aged ≥80 and <80 years 
N, (%) Age ≥80, 
N=205 
Age <80, 
N=786 p-value 
Mean TTR (SD) 66.6 (13.8) 66.6 (13.1) 1.00 
TTR<70 114 (55.6) 436 (55.5) 
1.00 
TTR≥70 91 (44.4) 350 (44.5) 
Mean PINRR (SD) 57.1 (11.6) 57.7 (11.1) 0.54 
PINRR<70 176 (85.9) 675 (85.9) 
1.00 
PINRR≥70 29 (14.1) 111 (14.1) 
Mean (SD) number of visits 51.2 (22.7) 60.7 (25.8) <0.001 
Mean (SD) percentage of 
INRs<2 
26.6 (9.8) 25.5 (24.5) 0.17 
Mean (SD) percentage of 
INRs>3 
16.4 (15.6) 16.7 (7.1) 0.60 
INR>5 70 (34.1) 223 (28.4) 0.13 
INR>8 10 (4.9) 31 (3.9) 0.69 
Median (IQR) years follow up 4.4 (2.6-6.2) 5.7 (3.3-7.1) <0.001 
TTR: Time in therapeutic range, PINRR: Percentage of INRs within range; INR: international Normalised Ratio; SD: standard 
deviation; IQR: interquartile range 
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Quality of anticoagulation control continued 
3.4.2.3 By categories of kidney disease  
Table 3.8 presents the measures of anticoagulation control according to the different 
categories of kidney disease. Overall, there was no statistically significant difference in the 
quality of anticoagulation control, measured by TTR (Rosendaal’s method), by kidney disease 
groups, although TTR was higher in patients with eGFR 60-89 and eGFR ≤59 (67% in both 
groups) compared to those in with eGFR ≥90 (64%; overall p=0.053) (Figure 3.7). There was 
a significant trend in higher PINRR in patients with eGFR 60-89 and eGFR ≤59 (PINRR 58% 
in both groups) compared to those with eGFR ≥90 (PINRR 55%; all p<0.05 for group 
comparison) (Table 3.8 and Figure 3.7).  
Higher proportions of patients with eGFR 60-89 and eGFR ≤59 achieved good TTR compared 
to eGFR ≥90 (p<0.05 for group comparison). Sub-therapeutic INRs (INR <2.0) (Table 3.8 and 
Figure 3.8) and the proportion of patients with at least one INR >8.0 were significantly more 
prevalent in patients with eGFR ≥90 compared to eGFR 60-89 (p<0.05 for group comparison). 
Meanwhile, the proportion of supra-therapeutic INRS >3.0 did not differ by kidney function 
groups (Table 3.8 and Figure 3.8).  
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 Table 3.8: Measures of anticoagulation control among different categories of kidney disease, N=974 
N, (%) All 
(n=974) 
eGFR≥90 ml/min 
N=133 
eGFR 60-89 ml/min 
N=491 
eGFR ≤59 ml/min 
N=350 
Overall  
p-value 
Mean TTR (SD) 66.5 (13.2) 64.0 (14.1) 66.9 (12.7) 67.0 (13.4) 0.053 
TTR<70 542 (55.6) 87 (65.4) 263 (53.6)a 192 (54.9)b 
0.05 
TTR≥70 432 (44.4) 46 (34.6) 228 (46.4) a 158 (45.1)b 
Mean PINRR (SD) 57.4 (11.1) 55.0 (11.5)  57.8 (10.6)a 57.8 (11.7)b 0.02 
PINRR<70 842 (86.4) 120 (90.2) 427 (87.0) 295 (84.3) 
0.21 
PINRR≥70 132 (13.6) 13 (9.8) 64 (13.0) 55 (15.7) 
Median (IQR) number 
visits* 
59.0 (41.0-74.0) 61.0 (39.5-78.5) 60.0 (42.0-74.0) 57.5 (41.0-72.0) 0.37 
Mean (SD) percentage of 
INRs<2 
25.9 (9.9) 27.8 (9.9)  25.4 (9.8)a 25.7 (10.2) 0.05 
Mean (SD) percentage of 
INRs>3 
16.6 (7.2) 17.0 (8.3) 16.6 (7.0) 16.6 (7.1) 0.84 
INR>5 287 (29.5) 41 (30.8) 129 (26.3) 117 (33.4) 0.08 
INR>8 40 (4.1) 11 (8.3) 14 (2.9)a 15 (4.3)b,c 0.02 
Median (IQR) years follow 
up* 
5.2 (3.2-7.0) 5.0 (2.9-7.0) 5.6 (3.3-7.1) 5.0 (3.2-6.9) 0.18 
 
eGFR ≥90ml/min/1.73m2- normal kidney function; eGFR 60-89 ml/min/1.73m2 - Mild kidney disease; eGFR ≤59 ml/min/1.73m2- mild-moderate-severe and kidney failure 
 
eGFR: estimated glomerular filtration rate, ml/min/1.73 m2; INR: international normalised ratio; IQR: interquartile range; SD: standard deviation; TTR: time in therapeutic range; PINRR: percentage of 
INRs in range; *Kruskal-Wallis test was utilised to compare median across the groups 
 
a: significant difference between eGFR≥90 and eGFR 60-89; p<0.05 
b: significant difference between eGFR≥90 and eGFR ≤59; p<0.05 
c: significant difference between eGFR 60-89 and eGFR ≤59, p<0.05  
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 Figure 3.7: Measures of anticoagulation control in different categories of kidney disease 
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3.4.3 Predictors of time in therapeutic range (TTR) by the Rosendaal and 
PINRR methods 
 
In the unadjusted analyses for predictors of TTR and PINRR (as continuous variables), non-
white ethnicity, heart failure, vascular disease, anaemia, and bleeding history, with the addition 
of diabetes for PINRR, negatively predicted TTR and PINRR (Table 3.9 and 3.11).  
After adjusting for demographic and clinical variables, smoking history, non-white ethnicity, 
bleeding history, and heart failure were independent predictors of TTR (Table 3.10), with the 
addition of vascular disease as an independent predictor of PINRR (Table 3.12). 
When TTR and PINRR were dichotomised to TTR<70% and PINRR<70%, unadjusted 
analyses revealed that non-white ethnicity and anaemia significantly predicted poor TTR and 
PINRR (TTR<70%). Further factors predicting poor TTR (TTR<70%) were vascular disease 
and heart failure (Appendix 4, Table A4.2 and A4.3 for full model). However, after adjusting 
for demographic and clinical variables, non-white ethnicity and anaemia remained as 
independent predictors of poor TTR (TTR<70%) and PINRR (PINRR<70%), with vascular 
disease as an additional factor for predicting poor TTR (Table 3.13).  
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Table 3.9: Unadjusted demographic and clinical predictors of time in therapeutic range (TTR) by the Rosendaal method (linear 
regression) 
Variables  Contribution to 
R2 
Unstandardized 
B 
Standardized 
coefficient Beta 
95% CI for B F Significance p-value 
Age at first INR¥ 0.002 0.07 0.05 -0.02 to 0.15 2.15 0.14 
Female sex 0.00 0.30 0.01 -1.36 to 1.95 0.12 0.73 
Smoking history 0.01 -0.93 -0.04 -2.91 to 1.05 0.86 0.36 
Ethnicity (non-white) 0.04 -7.09 -0.21 -9.17 to -5.02 45.10 <0.001 
Hypertension  0.001 0.84 0.03 -1.19 to 2.87 0.66 0.42 
Stroke/TIA  0.001 1.33 0.04 -0.82 to 3.47 1.48 0.23 
Heart failure 0.007 -3.29 -0.09 -5.67 to -0.92 7.42 0.007 
Diabetes  0.002 -1.43 -0.04 -3.47 to 0.60 1.90 0.17 
Vascular disease 0.004 -2.33 -0.07 -4.55 to -0.11 4.24 0.040 
Kidney disease 0.00 0.01 0 -1.70 to 1.71 0 0.10 
Anaemia 0.014 -4.42 -0.12 -6.74 to -2.11 14.06 <0.001 
Bleeding history 0.008 -4.42 -0.09 -7.45 to -1.39 8.19 0.004 
 
¥ Continuous variable 
INR: international Normalised Ratio; TIA: transient ischemic attack; TTR: Time in therapeutic range 
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 Table 3.10: Adjusted demographic and clinical predictors of time in therapeutic range (TTR) by the Rosendaal method (linear 
regression) 
Variables Contribution to 
R2 
Unstandardized 
B 
Standardized 
coefficient Beta 
95% CI for B F Significance p-
value 
Overall model 0.086 - - - 5.51 - 
Age at first INR¥  0.06 0.04 -0.05 to 0.17  0.27 
Female sex -0.25 -0.01 -2.30 to 1.79 0.81 
Smoking history -2.49 -0.09 -4.55 to -0.42 0.02 
Ethnicity (non-white) -8.09 -0.24 -10.69 to -5.49 <0.001 
Hypertension  1.94 0.06 -0.52 to 4.37 0.12 
Stroke/TIA  0.91 0.03 -1.56 to 3.38 0.47 
Heart failure -3.18 -0.09 -5.81 to -0.54 0.02 
Diabetes  1.73 0.05 -0.73 to 4.18 0.17 
Vascular disease -1.19 -0.03 -3.87 to 1.49 0.38 
Kidney disease -0.30 -0.01 -2.39 to 1.78 0.78 
Anaemia -2.62 -0.07 -5.56 to 0.32 0.08 
Bleeding history -3.83 -0.08 -7.39 to -0.27 0.04 
¥ Continuous variable 
INR: international Normalised Ratio; TIA: transient ischemic attack TTR: Time in therapeutic range 
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 Table 3.11: Unadjusted demographic and clinical predictors of percentage of INRs in range using the PINRR method (linear 
regression) 
Variables Contribution 
to R2 
Unstandardized 
B 
Standardized 
coefficient Beta 
95% CI for B F Significance 
p-value 
Age at first INR¥ 0.00 0.02 0.01 -0.06 to 0.09 0.15 0.70 
Female sex 0.00 0.06 0.00 -1.35 to 1.46 0.01 0.94 
Smoking history 0.001 -0.70 -0.03 -2.35 to 0.95 0.69 0.41 
Ethnicity (non-white) 0.05 -6.54 -0.23 -8.29 to -4.79 53.75 <0.001 
Hypertension  0.001 1.06 0.04 -0.66 to 2.78 1.47 0.23 
Stroke/TIA  0.001 0.72 0.03 -1.09 to 2.54 0.61 0.44 
Heart failure 0.006 -2.60 -0.08 -4.61 to -0.59 6.42 0.011 
Diabetes  0.008 -2.49 -0.09 -4.21 to -0.77 8.06 0.005 
Vascular disease 0.011 -3.24 -0.11 -5.11 to -1.36 11.48 0.001 
Kidney disease 0.00 -0.15 -0.01 -1.59 to 1.30 0.04 0.84 
Anaemia 0.02 -4.12 -0.13 -6.08 to -2.16 17.03 <0.001 
Bleeding history 0.02 -5.13 -0.12 -7.69 to -2.57 15.45 <0.001 
¥ Continuous variable 
INR: international Normalised Ratio; TIA: transient ischemic attack; PINRR: Percentage of INRs within range  
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 Table 3.12: Adjusted demographic and clinical predictors of percentage of INRs in range using the PINRR method (linear regression) 
Variables Contribution 
to R2 
Unstandardized 
B 
Standardized 
coefficient Beta 
95% CI for B F Significance 
p-value 
Overall model 0.10    6.55  
Age at first INR¥ 
 
0.01 0.01 -0.08 to 0.10 
 
0.89 
Female sex -0.25 -0.01 -1.94 to 1.44 0.77 
Smoking history -1.99 -0.09 -3.70 to -0.28 0.02 
Ethnicity (non-white) -6.83 -0.24 -8.98 to -4.67 <0.001 
Hypertension  2.48 0.09 0.46 to 4.51 0.02 
Stroke/TIA  0.91 0.03 -1.14 to 2.95 0.38 
Heart failure -2.16 -0.07 -4.34 to 0.02 0.05 
Diabetes  -0.18 0.01 -2.21 to 1.86 0.86 
Vascular disease -2.26 -0.08 -4.48 to- 0.04 0.05 
Kidney disease 0.48 0.02 -1.25 to 2.20 0.59 
Anaemia -1.77 -0.06 -4.20 to 0.66 0.15 
Bleeding history -4.34 -0.11 -7.29 to -1.39 0.004 
¥ Continuous variable 
INR: international Normalised Ratio; TIA: transient ischemic attack; PINRR: Percentage of INRs within range 
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 Table 3.13: Logistic regression for significant predictors of TTR<70% and PINRR 
<70% (using Rosendaal and PINRR methods) 
 Adjusted OR  
(95% CI) TTR<70%  
(Rosendaal method) 
p-value Adjusted OR  
(95% CI) PINRR<70%  
(PINRR method) 
p-value 
Ethnicity (non- white)  2.62 (1.67-4.10) <0.001 3.47 (1.44-8.34) 0.005 
Vascular disease  1.81 (1.16-2.83) 0.01 -  
Anaemia  1.65 (1.00-2.70) 0.05 6.27 (1.89-20.94) 0.003 
3.4.4 Major adverse clinical outcomes 
During a median follow-up of 5.2 years, 50 (5.0%) patients had thromboembolic events (46 
patients with stroke/TIA, 4 systemic embolisms), 78 (7.9%) experienced bleeding events [18 
patients with major bleed and 62 patients with CRNMB], 226 (22.8%) were hospitalised for 
cardiovascular reasons, and 23 (2.3%) patients died. Three hundred and twenty-nine patients 
(33.2%) presented with ≥1 major adverse clinical event. The overall major adverse clinical 
outcomes for entire population and by ethnic group are presented in Table 3.14. 
In terms of the number of events, there were 48 (9.3%) stroke/TIA events, 4 (0.7%) systemic 
embolism, 91(17.5%) bleeding events [23 (4.4%) major bleed and 68 (13.1%) CRNMB], 353 
(68%) CV hospitalisations, and 23 (4.4%) deaths.  
3.4.4.1 By ethnicity 
There was no significant difference in the rate of major adverse clinical outcomes among the 
three ethnic groups except for CV hospitalisations, where the rate was significantly higher 
among South Asians compared to Whites (32.3% vs.  21.3%, respectively; p<0.05 for group 
difference) and Afro-Caribbeans [32.3% vs. 25.6%, respectively; p<0.05 for group difference] 
(Table 3.14). 
When events were stratified by TTR (Table 3.15), patients with CV hospitalisations and ≥1 
MACE events were more likely to have poor TTR (TTR<70% and TTR<65%) (CV 
hospitalisations: 26.5% vs. 18.1%; p=0.002 and 27.3% vs. 19.8%; p=0.008 respectively; and 
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≥1 MACE events: 37.8% vs. 27.4%; p=0.001 and 37.8% vs. 30.1%; p=0.015 respectively). 
There were no significant differences in thromboembolic, bleeding events and death when 
TTR was dichotomised into TTR<70% and TTR<65% by either the Rosendaal or PINNR 
methods. (Table 3.15) CV hospitalisations were also significantly higher when PINRR was 
<70% (24.4%; p=0.004) but not with PINRR<65%. (Table 3.16) Hospitalisations due to non-
cardiac causes were significantly higher when TTR<70% or TTR<65% by both the Rosendaal 
(Table 3.15) and PINRR methods. (Table 3.16) 
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Table 3.14: Major adverse clinical outcomes among patients receiving warfarin for stroke prevention for AF overall and by ethnic 
group 
Outcomes, N 
(%) 
Total, N=991 White, N=807 
South-Asian, 
N=102 
Afro-Caribbean, 
N=82 
p-
value 
Stroke/TIA 46 (4.6) 36 (4.5) 5 (4.9) 5 (6.1) 0.79 
SE 4 (0.4) 3 (0.4) 0 1 (0.1) 0.41 
Stroke/TIA/SE 50 (5.0) 39 (4.8) 5 (4.9) 6 (7.3) 0.62 
Bleeding* 78 (7.9) 64 (7.9) 6 (5.9) 8 (9.8) 0.62 
Cardiovascular 
hospitalisation 
226 (22.8) 172 (21.3) a 33 (32.3) a 21 (25.6) 0.036 
Death 23 (2.3) 20 (2.5) 2 (2.0) 1 (1.2) 0.75 
≥1 MACE 329 (33.2) 258 (32.0) 40 (39.2) 31 (37.8) 0.22 
 
Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, ventricular arrhythmia,  uncontrolled AF/atrial flutter, 
supraventricular arrhythmia,  ii) valve surgery, CABG surgery, PTCA surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb amputation AND as recorded in 
patient’s medical documents; DVT – Deep Vein Thrombosis ; Major Bleeding – ISTH Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, 
or leading to transfusion of two or more units of whole blood or red cells; Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding but meet 
at least one of the 3 criteria: i) leading to hospitalisation or increased level of care, ii) requiring medical intervention by healthcare professional and iii) prompting face to face evaluation.; PE – Pulmonary 
Embolism; SE: systemic embolism; TIA: transient ischemic attack; VTE: venous thromboembolism.* Bleeding ISTH is combination of major bleed ISTH and clinically relevant non-major bleed (CRNMB); 
MACE: major adverse clinical events. 
a significant difference between White and South-Asian groups (p<0.05) 
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 Table 3.15: Patients experiencing a major adverse clinical event stratified by TTR (<70% vs. ≥70% and <65% and ≥65%) 
N (%) TTR<70% TTR≥70% p-value TTR<65% TTR≥65% p-value 
CV hospitalisation 146 (26.5) 80 (18.1) 0.002 109 (27.3) 117 (19.8) 0.008 
Stroke/TIA 29 (5.3) 17 (3.9) 0.37 18 (4.5) 28 (4.7) 0.98 
SE 3 (0.5) 1 (0.2) 0.78 3 (0.8) 1 (0.2) 0.37 
Stroke/TIA/SE 32 (5.8) 18 (4.1) 0.27 21 (5.3) 29 (4.9) 0.93 
Bleeding* 50 (9.1) 28 (6.3) 0.14 36 (9.0) 42 (7.1) 0.33 
Death 16 (2.9) 7 (1.6) 0.25 14 (3.5) 9 (1.5) 0.07 
≥1 MACE 208 (37.8) 121 (27.4) 0.001 151 (37.8) 178 (30.1) 0.015 
Other hospitalisations 247 (44.9) 155 (35.1) 0.002 179 (44.8) 223 (37.7) 0.032 
 
Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, ventricular arrhythmia,  uncontrolled AF/atrial flutter, 
supraventricular arrhythmia,  ii) valve surgery, CABG surgery, PTCA surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb amputation AND as recorded in 
patient’s medical documents; DVT – Deep Vein Thrombosis ; Major Bleeding – ISTH Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, 
or leading to transfusion of two or more units of whole blood or red cells; Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding but meet 
at least one of the 3 criteria: i) leading to hospitalisation or increased level of care, ii) requiring medical intervention by healthcare professional and iii) prompting face to face evaluation.; PE – Pulmonary 
Embolism; SE: systemic embolism; TIA: transient ischemic attack; VTE: venous thromboembolism.*Bleeding ISTH is combination of major bleed ISTH and clinically relevant non-major bleed (CRNMB); 
MACE: major adverse clinical events. 
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 Table 3.16: Patients experiencing a major adverse clinical event stratified by PINRR (<70% vs. ≥70% and <65% and ≥65%) 
N (%) PINRR<70% PINRR≥70% p-value PINRR<65% PINRR≥65% p-value 
CV hospitalisation 208 (24.4) 18 (12.9) 0.004 179 (24.3) 47 (18.4) 0.07 
Stroke/TIA 40 (4.7) 6 (4.3) 1.00 35 (4.8) 11 (4.3) 0.91 
SE 3 (0.4) 1 (0.7) 1.00 3 (0.4) 1 (0.4) 1.000 
Stroke/TIA/SE 43 (5.1) 7 (5.0) 1.00 38 (5.2) 12 (4.7) 0.90 
Bleeding* 71 (8.3) 7 (5.0) 0.23 63 (8.6) 15 (5.9) 0.22 
Death 20 (2.4) 3 (2.1) 1.00 19 (2.6) 4 (1.6) 0.49 
≥1 MACE 298 (35.0) 31 (22.1) 0.004 259 (35.2) 70 (27.5) 0.029 
Other 
hospitalisations 
360 (42.3) 42 (30.0) 0.008 320 (43.5) 82 (32.2) 0.002 
 
Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, ventricular arrhythmia,  uncontrolled AF/atrial flutter, 
supraventricular arrhythmia,  ii) valve surgery, CABG surgery, PTCA surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb amputation AND as recorded in 
patient’s medical documents; DVT – Deep Vein Thrombosis ; Major Bleeding – ISTH Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, 
or leading to transfusion of two or more units of whole blood or red cells; Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding and that 
led to hospitalisation, physician medical or surgical treatment, or a change in antithrombotic therapy; PE – Pulmonary Embolism; SE: systemic embolism; TIA: transient ischemic attack; VTE: venous 
thromboembolism.* Bleeding ISTH is combination of major bleed ISTH and clinically relevant non-major bleed (CRNMB). 
 
 
215 
3.4.4.1.1 Predictors of adverse clinical outcomes 
In this exploratory analysis, unadjusted Cox proportional hazard regression analyses revealed 
that only prior stroke/TIA [HR 2.40 (95% CI 1.33-4.30); p=0.003] and diabetes [HR 2.01 (95% 
CI 1.11-3.65); p=0.021] predicted thromboembolic (stroke/TIA/ systemic embolism) events 
(see Appendix 4, Table A4.4). However, only prior stroke/TIA history [HR 2.29 (95% CI 1.12-
4.68); p=0.02] remained as independent predictor of thromboembolic events, after adjusting 
for demographic and clinical variables (Table 3.17).  
For bleeding events (major bleed and CRNMB), increasing age, TTR and PINRR (as 
continuous variables) predicted bleeding events (see Appendix 4, Table A4.5) but after 
adjustment, only TTR <70%, [HR 1.78 (95% CI 1.01-3.13); p=0.05] independently predicted 
bleeding events (Table 3.17). 
In unadjusted Cox proportional hazard regression analyses, non-white ethnicity, heart failure, 
diabetes, vascular disease, anaemia, TTR and PINRR (both continuous and categorical 
variable) predicted CV hospitalisation (see Appendix 4, Table A4.6). However, after 
adjustment, only heart failure [HR 1.46 (95% CI 1.02-2.11); p=0.04], vascular disease [HR 
1.62 (95% CI 1.11-2.34); p=0.01] and TTR<70% [HR 1.38 (95% CI 1.00-1.89) p=0.05] were 
independent predictors of CV hospitalisations (Table 3.17). Figure 3.9 shows the Kaplan-
Meier curve illustrating the event free rate for CV hospitalisation by TTR <70% and ≥70%. The 
rate of CV hospitalisation was significantly higher in patients with poor TTR (6.0/100 pt-yrs) 
(Log rank test: 11.90; p=0.001) compared to patients with optimal TTR (TTR≥70%; 3.7/100 
pt-yrs).   
Only increasing age and anaemia predicted all-cause mortality in the unadjusted Cox 
proportional hazard regression model, however after adjustment, none of the factors were 
significant predictors of all-cause mortality (see Appendix 4, Table A4.7).  
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When all adverse clinical outcomes were combined as composite events (MACE) in an 
unadjusted model, non-white ethnic group, hypertension, stroke/TIA, heart failure, diabetes, 
vascular disease, anaemia and both measures of quality of anticoagulation (TTR and PINNR 
as continuous and categorical variable) predicted composite events (see Appendix 4, Table 
A4.8). However, after adjusting for demographic and clinical variables, only prior stroke/TIA, 
vascular disease and TTR<70% predicted ≥1 MACE (Table 3.17). Kaplan-Meier analysis 
(Figure 3.10) shows the higher rate of ≥1 MACE in patients with poor TTR (9.1/100 pt-yrs) 
(Log rank test: 14.25; p<0.001) compared to patients with TTR≥70% (5.9/100 pt-yrs). 
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 Table 3.17: Cox proportional hazard regression analysis for thromboembolic, bleeding events, CV hospitalisations and composite 
outcomes of thromboembolic events, major bleed and clinically relevant non-major bleeding, cardiovascular hospitalisation and all-
cause mortality (≥1 MACE) 
 
 
 
 
 
 
 
 
 
Multivariate HR (95% CI) Thromboembolic events Bleeding events CV hospitalisations ≥1 MACE 
Stroke/TIA 2.29 (1.12-4.68) - - 1.38 (1.03-1.85) 
Heart failure - - 1.46 (1.02-2.11) - 
Vascular disease - - 1.62 (1.11-2.34) 1.67 (1.21-2.30) 
TTR <70% - 1.78 (1.01-3.13) 1.38 (1.00-1.89) 1.45 (1.11-1.89) 
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p=0.001 
 Figure 3.10: Impact of TTR on composite endpoints of thromboembolic 
events, major and clinically relevant non-major bleeding events, 
cardiovascular hospitalisation and all-cause mortality (≥1 MACE) 
 Figure 3.9: Impact of TTR on cardiovascular hospitalization 
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3.4.4.2 Adverse outcomes by age (≥80 years and <80 years) 
Only twelve (6%) of the elderly (≥80 years) patients experienced thromboembolic events; 21 
(10.2%) had a bleeding event and eight (4.0%) died. The proportion of bleeding (10.2% vs. 
7.3% for ≥80 years and <80 years respectively) and fatal (3.9% vs. 1.9% respectively) events 
were higher among elderly patients. However, cardiovascular hospitalisations (23.9% vs. 
18.5%) and the composite of adverse clinical outcome (≥1MACE) (33.7% vs. 31.2%) were 
proportionally higher in the younger age category (Table 3.18).  
The Kaplan-Meier curve illustrates the rate of bleeding events which were significantly higher 
in the elderly group compared to those aged <80 years (2.4% vs. 1.3%, respectively) (Log 
Rank-test: 6.73; p=0.009 Figure 3.11). Univariate Cox regression analysis (see Appendix 4, 
Table A4.9 for full model) showed that only age ≥80 years [HR 1.93 (1.16-3.20); p=0.01] was 
associated with bleeding risk and this relationship persisted after adjusting for demographic 
and clinical variables [≥80 years: HR 1.90 (1.01-3.56); p=0.047] (Table 3.19). History of 
stroke/TIA [HR 1.37 (1.02-1.85); p=0.04], vascular disease [HR1.53 (1.10-2.14); p=0.01] and 
poor TTR (TTR<70%) [HR 1.47 (1.13-1.91); p=0.004] were associated with an increased risk 
of the composite outcomes (≥1MACE) (Table 3.19), however, age ≥80 years was not (see 
Appendix 4, Table A4.10 for full model). 
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 Table 3.18: Major adverse clinical outcomes among patients receiving warfarin for stroke 
prevention in AF overall and in patients ≥80 and <80 years 
Outcomes, N 
(%) 
Age ≥80, 
N=205 
Event 
rate/100 
pt-yrs 
Age <80, 
N=786 
Event 
rate/100 pt-
yrs 
P value for 
proportions  
≥1 MACE 64 (31.2) 8.4 265 (33.7) 7.4 0.55 
Stroke/TIA/SE 12 (5.9) 1.4 38 (4.8) 0.9 0.68 
Bleeding* 21 (10.2) 2.4 57 (7.3) 1.3 0.16 
Cardiovascular 
hospitalisation‡ 
38 (18.5) 4.7 188 (23.9) 5.0 0.12 
Death 8 (3.9) 0.9 15 (1.9) 0.3 0.15 
 
* Bleeding is combination of major bleed according to International Society on Thrombosis and Haemostasis (ISTH) 
and clinically relevant non-major bleed (CRNMB). 
‡Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, myocardial infarction, 
new angina, non-fatal cardiac arrest, ventricular arrhythmia, uncontrolled atrial fibrillation/atrial flutter, supraventricular 
arrhythmia, ii) valve surgery, coronary artery bypass graft surgery (CABG), percutaneous transluminal coronary 
angioplasty (PTCA) surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb 
amputation AND as recorded in patient’s medical documents; DVT – Deep Vein Thrombosis; Major Bleeding – ISTH 
major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or bleeding 
causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of 
whole blood or red cells; Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the 
criteria for major bleeding and that led to hospitalisation, physician medical or surgical treatment, or a change in 
antithrombotic therapy; PE – pulmonary embolism; SE: systemic embolism; TIA: transient ischemic attack; VTE: venous 
thromboembolism. 
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 Table 3.19: Cox proportional hazard regression analysis for the impact of age (≥80 years) 
on all bleeding events, including major bleeding and clinically relevant non-major 
bleeding and ≥1 MACE 
Multivariate HR (95% CI) Bleeding events 
(95% CI) 
≥1 MACE 
(95% CI) 
Age ≥80 years 1.90 (1.01-3.56) 1.00 (0.72-1.39) 
Stroke/TIA - 1.37 (1.02-1.85) 
Vascular disease - 1.53 (1.10-2.14) 
TTR <70% - 1.47 (1.13-1.91) 
  
CI: confidence interval; HR: hazard ratio; TIA: transient ischemic attack; TTR: time in therapeutic range 
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 Figure 3.11: Kaplan-Meier curve of bleeding events among patients age ≥80 and <80 years 
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3.4.4.3 Adverse outcomes by kidney disease 
After a median (IQR) of 5.2 (3.2-2.7) years of follow up, 326 patients (33.5%) experienced ≥1 
MACE. There is no statistically significant difference in TE, bleeding, CV hospitalisation, death 
and ≥1 MACE with eGFR ≥90, eGFR 60-89 and eGFR ≤59 ml/min/1.73m2 respectively (Table 
3.20).  
 Table 3.20: Major adverse clinical outcomes among patients receiving warfarin for stroke 
prevention in AF overall and by different categories of kidney disease 
Outcomes 
All 
(N=974) 
eGFR≥90 
ml/min 
N=133 
eGFR 60-89 
ml/min 
N=491 
eGFR ≤59 
ml/min 
N=350 
p-value 
≥1 MACE 326 (33.5) 52 (39.1) 153 (31.2) 121 (34.6) 0.20 
Stroke/TIA/SE 50 (5.1) 7 (5.3) 21 (4.3) 22 (6.3) 0.43 
Bleeding* 76 (7.8) 11 (8.3) 39 (7.9) 26 (7.4) 0.94 
Cardiovascular 
hospitalisation 
224 (23.0) 37 (27.8) 109 (22.2) 78 (22.3) 0.36 
Death 22 (2.3) 3 (2.3) 9 (1.8) 10 (2.9) 0.62 
 
eGFR ≥90ml/min/1.73m2- normal kidney function; eGFR 60-89 ml/min/1.73m2- mild kidney disease; eGFR ≤59 ml/min/1.73m2- mild-
moderate-severe and kidney failure 
 
Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, 
ventricular arrhythmia,  uncontrolled AF/atrial flutter, supraventricular arrhythmia,  ii) valve surgery, CABG surgery, PTCA surgery, 
pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb amputation AND as recorded in patient’s 
medical documents; Major Bleeding – ISTH Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, 
such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome 
and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of 
whole blood or red cells; Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major 
bleeding but meet at least one of the 3 criteria: i) leading to hospitalisation or increased level of care, ii) requiring medical intervention 
by healthcare professional and iii) prompting face to face evaluation.; SE: systemic embolism; TIA: transient ischemic attack; VTE: 
venous thromboembolism. 
* Bleeding ISTH is combination of major bleed ISTH and clinically relevant non-major bleed (CRNMB). 
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3.5 Discussion 
This study found that anticoagulation control, evidenced by TTR and PINRR, was significantly 
lower in South-Asian and Afro-Caribbean patients compared to White patients, despite similar 
INR monitoring intensity. In contrast, no significant differences in TTR was evident when the 
cohort was grouped by age (≥80 vs. <80 years) or kidney disease at baseline. Further, non-
white ethnicity was the strongest independent predictor of poor TTR after adjustment for 
demographic and clinical variables.  
 
3.5.1 Anticoagulation control in the overall cohort 
 
In this study, the overall mean TTR by both methods (Rosendaal and PINRR) and across all 
ethnic groups was below 70%, which reflects sub-optimal anticoagulation control in this 
population, according to European guidelines (3). When the PINRR method was used, the 
overall percentage of time in the therapeutic range was 55.2%, indicating even poorer 
anticoagulation control. In addition, one third of the patients had at least one INR value above 
5, with 4.1% reporting an INR> 8.0, indicative of deranged INR control, associated with higher 
risk of bleeding (276, 426, 427).  These results are in line with the warfarin arms of the recent 
four landmark NOAC trials [RELY(132), ROCKET-AF (133), ARISTOTLE (134) and ENGAGE-
AF (135); mean TTR 64, 58, 66 and 68 respectively] which also showed sub-optimal 
anticoagulation control despite strict patient inclusion and follow ups. In clinical practice, 
obtaining a good TTR can be difficult as anticoagulation control is affected by many factors 
(see Section 1.5.1 pages 78-100 for more details). The SAMe-TT2R2 score (199) could be 
used to identify common clinical factors that might predict good/poor anticoagulation and aid 
physicians to choose the best anticoagulation treatment in this setting.  
 
 
224 
 
3.5.1.1 Anticoagulation control in different ethnic groups 
Despite similar INR monitoring intensity, it is evident that patients from ethnic minority groups 
obtained significantly lower quality of anticoagulation control than white patients. 
Previous studies by Yong (209) and Golwala et al (210) in the United States have also reported 
similar findings where Black patients had poorer anticoagulation control compared to Whites, 
Hispanics, Native Americans and other ethnic minority groups however, no studies to date are 
available examining anticoagulation control among South-Asian patients. Rao and colleagues 
(198) investigated patient-level and site-level factors that might influence the differences in 
anticoagulation control among 9572 Black and 88,481 White patients in the United States. 
Their findings suggest that greater proportion of the differences may be attributed to non-
modifiable factors such as young age, region and poverty level, distance to anticoagulation 
clinic and presence of co-morbid conditions (198). Although it is not certain, it could be 
possible that some of these factors (demographics and clinical) might also contribute to ethnic 
disparities in the quality of anticoagulation control in the current cohort. Younger patients were 
more commonly seen among South-Asian patients and could perhaps reflect hectic lifestyle 
resulting in difficulties attending INR appointments. In addition, the presence of vascular 
disease, diabetes and anaemia were also more commonly seen among patients in the non-
white ethnic groups suggesting greater burden of illness among them (see section 1.5.1.1.4 
for more explanation). 
 
Secondly, although pharmacogenetic factors were not investigated in this study, warfarin 
metabolism and dose response might differ between ethnic groups. Studies have shown that 
warfarin dosage requirement is lower in Asians and Whites but higher in Blacks partly due to 
racial differences in genotype frequencies (428). Patients who inherit one or two copies of 
CYP2C9*2 or CYP2C9*3 allele are more sensitive to warfarin compared to normal 
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metabolisers since they impair S-warfarin metabolism by 30-40% and ~80-90% respectively. 
They are at a higher risk of bleeding during warfarin initiation thus requiring lower doses of 
warfarin (429-432). The frequencies of the CYP2C9 alleles differ between ethnic groups (433-
435). More Caucasians (10-20%) were found to have the *2 allele compared to Asian (1-3%) 
or African (0-6%) populations (216) and less *3 allele were seen among the African-Americans 
(209, 216). Moreover, African Americans were also found to have additional CYP2C9 alleles 
(CYP2C9*5, *6, *8, and *11; the less common ones) which are also associated with reduced 
function of the CYP2C9 enzyme and contribute to dose variability (436). Thus warfarin dosage 
can be tailor- made accordingly, if needed, as per guidelines (216, 436).  
 
The role of pharmacogenetics testing and dosing of warfarin patients remains a controversial 
topic. Two randomized trials examining the impact of genotype dosing towards improving TTR 
have been contradictory. The EU-PACT trial  (437) (N=455) which included participants from 
European (98.6%), African (0.9%) ancestries and others (0.5%) showed that TTR was 
significantly higher in the genotype-guided therapy group compared to standard care at 12 
weeks (TTR 67.4% vs. 60.3%; p<0.001) (437). In contrast, the COAG trial (438) (N=1015) 
which included more African Americans (27%), 67% European American and 6% Hispanic 
showed no difference in the mean TTR in patients with genotype-guided dosing compared to 
clinical-guided dosing of warfarin (TTR 45.2% vs. 45.5% respectively) at 4 weeks. However, 
TTR improvement by genotype-guided dosing can only be seen among European Americans 
(2.8%; p=0.15) but not among African Americans. Instead worsening TTR was seen among 
the latter (-8.3%; p=0.01). The differences in the results of these two trials could be attributed 
to heterogeneity in racial diversity, CY2C9*2 and *3, VKORC1 frequency and warfarin 
indication among the participants. It was also demonstrated (439) that warfarin dosing 
variability was affected by both clinical and genetic factors in another study (N=1357) 
comprising of more African Americans (43%).  Nevertheless, in African Americans, clinical 
factors (such as age, CKD, body surface area, and amiodarone) account for higher proportion 
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of dose variability than genetic factors. Hence, a pharmacogenetic algorithm for warfarin 
dosing that is race-specific; rather than race-adjusted was suggested. 
 
Third, although this was not investigated in this cohort, previous studies have shown that many 
AF patients have little knowledge of their condition and lack understanding of the risk and 
benefit of anticoagulant therapy, in particular among ethnic minority patients (383, 384). This 
may also contribute to poor adherence to medication and may (or may not) result in poor 
anticoagulation control. Interventions such as more frequent follow up visits and reviews, 
educational interventions and counselling are needed (219). For example, discussions about 
specific food types and health supplements that may interact with warfarin (herbal remedies, 
vegetarianism, or inconsistent amount of food rich with vitamin K, for example, green leafy 
vegetables) or specific cultural differences (for example the impact of fasting or excess alcohol 
on the quality of anticoagulation control) that may affect their understanding are required 
especially to the ethnic minority groups to ensure that their TTR can be improved in order to 
achieve the best outcomes and prevent treatment complications (316). Materials for the 
education intervention should be available in different languages and in different media 
(booklets, video-clips etc.) so patients who do not speak English but is able to read in their 
own language can also benefit. Interpreters may also be required so that information shared 
between the healthcare professional and patient during the counselling session can be 
effectively understood. Patients should also be encouraged to be actively involved during 
sessions and to raise any concerns regarding warfarin treatment so that any barriers to 
adherence can be discussed and overcome. Recently, the TREAT intervention (a one-off 
educational behavioral session) delivered by a health psychologist demonstrated a significant 
improvement of TTR compared to patients receiving usual care alone (TTR 76.2% vs. 73.1%, 
p=0.035) (219). The design of this behavior-change intervention package (consist of DVD 
delivered by ‘expert patient’ narratives and consultant cardiologist, educational booklet, diary 
and patient worksheet) was based on theoretical models (Common Sense Model and 
Necessity-Concerns Framework), clinical guidelines, relevant literature and AF patient 
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feedback. This intervention not only resulted in improvement of the quality of anticoagulation 
control and a greater understanding of AF and its treatment; it also changed patients’ belief 
surrounding their treatment necessity and potential harm (293).  
3.5.1.2 Anticoagulation control in in elderly patients 
The quality of anticoagulation control was similar among those aged ≥80 and <80 years 
despite fewer INR visits and shorter follow up among the very elderly patients. Moreover, less 
than half (44%) of the elderly patients had optimal TTR (TTR≥70%).  
These results are consistent with the data obtained from the BAFTA (250) and WASPO (251) 
trials, with mean TTR comparable to the current elderly cohort (mean TTR 67% and 69% 
respectively vs. 67% in current elderly cohort). Two other Italian studies (247, 252) reported 
slightly higher TTR in their cohort (mean TTR 71% in both studies vs. 67% in current elderly 
cohort) while TTR was lower in another study by Hylek et al (241) among the elderly (≥80 
years; mean TTR 58%). This may be explained by the inclusion of an inception cohort by 
Hylek et al (241), whereas the current study included patients throughout the entire period of 
treatment (median duration of VKA treatment 5.2 years reflecting long term VKA 
management). Low TTR (mean TTR 48%) has also been reported in another inception cohort 
study (200) suggesting the difficulties in achieving good control with VKA therapy especially 
during the inception period (200).    
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3.5.1.3 Anticoagulation control in different categories of kidney disease 
 
There was no significant difference in TTR when calculated using the Rosendaal method 
among AF patients with different categories of kidney disease at baseline. However, when the 
PINRR method was utilised, a higher percentage of INRs within range was seen among AF 
patients in with eGFR 60-89 ml/min/1.73m2 and eGFR ≤59 ml/min/1.73m2 compared to 
patients with normal kidney function (eGFR ≥90 ml/min/1.73m2).  
Despite the challenges faced in managing AF patients with CKD, many studies have shown 
the benefits of VKA therapy in AF and CKD patients in reducing TE, bleeding, cardiovascular 
hospitalisation and all-cause death (263-265, 269, 440). As mentioned in the literature review, 
eight (263-270) studies reported TTR data and seven (263-265, 267-270) have shown a 
significant trend of worsening TTR as the kidney disease worsened (see section 1.5.1.1.5, 
pages 81-82 for more information). For example, in the SPORTIF III and IV trials, the mean 
TTR among AF patients with eGFR < 60 ml/min was significantly lower than those with eGFR 
≥60 ml/min  (mean TTR 66.6% vs. 69.6%; p<0.001 respectively) (264). In a retrospective 
analysis of the Swedish health registers of 307,351 AF patients comprising 13,435 patients 
with renal disease (diagnosis based on ICD-10 codes), the mean TTR for those with renal 
disease was also significantly lower than those without renal disease (mean TTR 66.7% vs. 
74.6%; p<0.001 respectively) (265).  
In contrast, this study did not show a similar trend, instead a non-significant higher TTR was 
observed in patients with eGFR 60-89 ml/min/1.73m2 and eGFR ≤59 ml/min/1.73m2 compared 
to patients with eGFR ≥90 ml/min/1.73m2 and this trend was statistically significant when the 
PINRR method was utilised. Also, sub-therapeutic INRs (INR <2.0) and the presence of at 
least one INR >8.0 was significantly more prevalent among AF patients with normal kidney 
function. Similarly, when investigating the influence of kidney disease towards anticoagulation 
control in linear and logistic regression analyses, the presence of kidney disease (eGFR ≤59 
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ml/min/1.73m2) at baseline did not influence sub-optimal anticoagulation control during follow 
up. This finding is also similar to a study among 724 non-dialysis dependent chronic kidney 
disease on VKA therapy (266). TTR was significantly higher (75.1%) in patients with moderate 
kidney disease (eGFR 30-60 ml/min) compared to patients without CKD (eGFR>60 ml/min: 
TTR 67.0%; p<0.01). There was also a non-significant trend towards higher TTR in the severe 
CKD group (eGFR <30 ml/min: TTR 70.3%; p=0.41) compared to those without kidney 
disease.  Similar to the current cohort, renal function was assessed at the start of VKA therapy 
and TTR was calculated throughout the entire treatment period, although the categorisations 
of kidney disease were different compared to the current cohort. Despite that, one common 
finding seen was that the quality of VKA therapy seemed to be better in patients with moderate 
kidney disease than with normal kidney function.    
There are several potential explanations for these contradictory findings. First of all, perhaps 
in this cohort, AF patients with concomitant kidney disease are well managed by a dedicated 
anticoagulant service thus resulting in similar or better anticoagulation control compared to 
patients without kidney disease. It could also be that the presence of concomitant ‘kidney 
disease’ serves as a ‘flag’ to the anticoagulant services so that extra care and attention is 
given throughout the entire monitoring period. This is because patients with concomitant 
kidney disease are considered to be a ‘vulnerable’ group of patients and are at higher risk of 
adverse events including thromboembolism and bleeding. Indeed in the SPORTIF III and IV 
trials (264), the presence of CKD was significantly associated with an increased risk of stroke 
and high TTR (TTR ≥70%) was significantly associated with a reduction in the risk of stroke 
[HR 0.63 (95% CI 0.41-0.98)], major bleeding [HR 0.58 (0.42-0.80)], and mortality [HR 0.63 
(0.47-0.84)].  Likewise, a study (266) in The Netherlands of 724 AF patients with VKA therapy 
and CKD also showed that patients with eGFR <30ml/min were at increased risk of major 
bleeding and stroke/TIA compared to those with eGFR 30-60 ml/min [HR 1.86 (95% CI 1.08-
3.21) and HR 3.93 (95% CI 1.71-9.00) respectively] and this was mediated when the 
anticoagulation control was sub-optimal. Lastly, better anticoagulation control among patients 
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with eGFR 60-89 and eGFR ≤59 may be driven by the significantly higher proportion of white 
patients with eGFR 60-89 and eGFR ≤59. Results from the main analysis have shown that a 
greater proportion of optimised TTR was seen among white patients compared to non-white 
patients. Furthermore, logistic regression analysis has shown that non-white ethnicity is an 
independent predictor of poor TTR. So, this might indirectly influence the TTR results among 
the CKD patients. 
3.5.2 Predictors of anticoagulation control in the whole cohort  
This study demonstrates that slightly more than half of the cohort experienced difficulties 
achieving optimal quality of anticoagulation and therefore further investigation on the 
predictors of poor anticoagulation control was conducted. Interestingly, non-white ethnicity 
emerged as the strongest predictor (in both univariate and multivariate linear and logistic 
regression analyses) of poor quality of anticoagulation control when TTR was calculated via 
both the Rosendaal and the PINRR methods. Possible explanations towards this finding have 
been described in section 3.5.1.2. 
 
Other significant patient factors related to anticoagulation control evident from this cohort is 
smoking history, although information on smoking status is only available for 72.4% of 
patients. It is an independent predictor of poor TTR and PINRR on linear regression analysis 
and was more prevalent among the Whites compared to South-Asian and Afro-Caribbean 
patients. This is consistent with three other studies demonstrating smoking as a predictor of 
poor TTR (199, 205, 208). The relationship of how smoking can influence anticoagulation 
control is unclear but may reflect less interest in maintaining good health that may translate 
into poorer adherence to OACs, thus resulting in poor TTR (199). 
 
Clinical factors such as comorbid diseases were shown to have an impact in the quality of 
anticoagulation control. In linear regression analyses, heart failure and bleeding history 
negatively predicted both TTR and PINRR, with vascular disease also predicting PINRR.  
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Meanwhile, in logistic regression analyses, anaemia was an independent predictor of poor 
anticoagulation control for both TTR<70% and PINRR<70% followed by vascular disease for 
TTR<70%.  
 
Other studies have also shown an association of poor anticoagulation control with a variety of 
comorbid conditions such as heart failure (197-202, 253-255), diabetes (197-200, 202, 205, 
256), kidney disease (198, 199, 201, 213, 257), liver disease (198, 199, 254, 257), lung 
disease (199, 201, 204, 205), coronary artery disease (199, 201), peripheral vascular disease 
(199, 201), stroke (199, 204) and previous bleeding (213).  The exact mechanism of this 
relationship is unclear but perhaps this reflects greater illness burden and complexity including 
more medications prescribed for each of the conditions thus increasing the potential of drug 
interaction with warfarin and nonadherence leading to poorer anticoagulation control (201). 
3.5.3 Adverse clinical outcomes in the whole cohort 
 
At least 30% of the patients experienced ≥1 MACE and there was no significant difference in 
terms of the rate of thromboembolic, bleeding events and mortality across the three ethnic 
groups except for CV hospitalizations, where it was highest among the South-Asians. In this 
cohort of patients, Afro-Caribbeans had the highest risk of stroke. Although underpowered, 
there was no significant difference in terms of TE events across different ethnic groups 
although proportionally, TE and bleeding events were highest among Afro-Caribbeans.  
 
Previous epidemiological studies have shown that black and Hispanic individuals have a two-
fold higher annual risk of stroke compared to Whites (441, 442). However, this was not evident 
in the present study, a finding consistent with the ORBIT-AF registry, that showed no 
difference in stroke or all-cause mortality among white, black and Hispanic participants where 
anticoagulation use was high (210). In a subgroup analysis of the AFFIRM trial, there was no 
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difference in overall survival at 5 year follow up among White, Black and Hispanic participants 
(443). 
 
Independent predictors of the composite outcome were prior stoke/TIA, vascular disease and 
poor TTR.  Other studies have shown that poor TTR is related to thromboembolic and bleeding 
events (119, 444) and in this cohort poor TTR (<70%) independently predicted composites of 
TE, bleeding events, CV hospitalizations and all-cause mortality.  
3.5.3.1 Adverse clinical outcomes in elderly  
Exploratory analyses of the elderly showed no significant differences in the composite 
endpoints (≥1 MACE) between the elderly (age ≥80 years) and those aged <80 years. 
However, age ≥80 years was significantly associated with higher bleeding risk even after 
adjustment for demographics and clinical variables.  
Previous studies have reported conflicting results regarding the increased risk of bleeding 
among elderly patients on OAC therapy. The absolute rate of major bleeding was 2.5 vs. 0.9 
per patient years among ≥80 vs. <80 year old AF patients, respectively receiving warfarin 
therapy in one Italian study (247). Conversely, a 5-fold increase in incidence rate of bleeding 
was reported in those aged ≥80 years compared to <80 years (13.1 vs. 4.8 per 100 patients 
years respectively) in another study (241). Age ≥80 years was associated with increased risk 
of bleeding events in both studies (241, 247). The difference in bleeding rate between these 
studies might be explained by the higher proportion of patients experiencing CAD (35% vs. 
20%) who were prescribed concomitant aspirin therapy (40% vs. 3.5%) in the latter (241) 
compared to the former (247) respectively; both of which are factors known to increase risk of 
bleeding.  
In the current cohort, when investigating the factors associated with bleeding events during 
the entire period of warfarin exposure, age ≥80 years was the only significant factor associated 
with bleeding events, similar to previous studies (241, 247). Indeed, very close attention needs 
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to be paid to the very elderly patients who are on OAC therapy to prevent bleeding 
complications. Various bleeding scores are available to assess bleeding risk in AF patients (3, 
176). These scores can be used to guide physicians to ‘flag up’ factors that may predispose 
patients to bleeding events. Any modifiable risk factors for bleeding, such as uncontrolled 
hypertension in the ‘H’ component of the HAS-BLED score (180) should be addressed by 
controlling patient’s blood pressure. The risk of bleeding is not static thus needs to be 
evaluated periodically (3, 242). 
3.5.3.2 Adverse clinical outcomes in different categories of kidney disease 
There were no significant differences in thromboembolic, bleeding, CV hospitalisations, all-
cause mortality and ≥1 MACE according to kidney disease though this analysis was purely 
exploratory. This result must be interpreted with caution as this investigation was not powered 
to detect any significant difference in any of the adverse clinical outcomes.  
Nevertheless, other studies have shown increased risk of thromboembolism, bleeding and 
mortality in patients with concomitant AF and CKD (264, 445-448). One Swedish AF cohort 
study from the health registers (265) reported a higher annual rate of stroke (3.9% vs. 2.9% 
respectively), any bleeding (9.8% vs. 4.1% respectively) and mortality (36.0% vs. 11.5% 
respectively) in patients with renal failure (definition obtained from the ICD-10 codes N17-19 
or by local Swedish procedure codes for haemodialysis, peritoneal dialysis or renal 
transplantation) compared to those without renal failure (265). In this Swedish cohort, renal 
failure independently predicted intracranial bleeding [adjusted HR 1.27 (95% CI 1.09-1.49)]. 
However, despite the high risk of bleeding, the use of warfarin compared to no warfarin therapy 
was beneficial in renal failure patients in the composite endpoint of ischaemic stroke, 
intracranial bleed or death [adjusted HR 0.76 (95% CI 0.72-0.80)] (265). Similarly, in the 
SPAF-III trial, (440) use of warfarin reduced the risk of ischemic stroke and systemic embolism 
by 76% (95% CI 42%-90%; p<0.001) among high risk AF patients with CKD stage 3 (eGFR 
30-59 ml/min) compared to the combination of low dose warfarin and aspirin (440).   
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3.5.4 Strengths and limitations 
This is the first study to assess anticoagulation control and adverse clinical outcomes in 
different ethnic groups in the UK. Other studies looking at the differences in anticoagulation 
control between ethnic minority groups were conducted in the United States comparing 
Whites, African-American, Hispanic and Native Americans (198, 210). In addition, two further 
ancillary analyses were undertaken among elderly and patients with different categories of 
kidney disease to give insights into the quality of warfarin control in these two sub-groups, 
managed by one anticoagulation clinic in this Trust. 
 
Furthermore, two methods of calculating TTR were utilised, with both methods correlating with 
each other and demonstrating similar results. Researchers recommend that ≥2 VKA control 
measures are reported per study as the quality of anticoagulation control can vary depending 
on the method of TTR reported (347, 449, 450). Further, TTR was also calculated using a 
large number of INR results [mean (SD) 58.7 (25.5)] for a median of 5.2 (3.2-7.0) years of 
follow up reflecting the long-term quality of anticoagulation control in this centre.  
 
The cohort comprised 991 patients but this was only 43 % of the available cohort and thus it 
is possible that the results are not representative of the whole (N=2478) cohort.  Nonetheless, 
the proportion of patients from each ethnic group included was representative of the total 
cohort in this Trust. Furthermore, Afro-Caribbean and South-Asian patients constituted about 
10% each from the whole population included in the study; similar to the ethnic composition 
of studies of anticoagulation control by Yong et al and Golwala et al (8.3% and 5% Blacks 
respectively) (198, 210). However, in general, AF is more prevalent among Whites (8.0%) 
than Asians (3.9%) and Blacks (3.8%)(35).  
 
In addition, the retrospective review from medical records means that some information was 
not readily available, including the patient’s ethnic group, medical history and medication 
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history, and thus a small number (3.2%) of patients had to be excluded. Also, recording of 
adverse clinical events were based on the events occurring in this Trust, thus any events 
occurring outside this Trust were not captured thus might lead to underestimation of the events 
of interest.   
 
Finally, this study assessed anticoagulant control by looking at objective measures available 
on clinical databases. Other variables that could influence anticoagulation control such as 
distance to anticoagulation clinic, education level, history of employment, quality of life of AF 
patients (414), magnitude of drug and food interaction, CYP2C9 or VKORC1 genotype (329) 
were not taken into account in the current analyses. 
 
3.5.5 Clinical implications  
The most clinically relevant finding of this study is that achieving optimal quality of 
anticoagulation control with warfarin is more challenging among non-whites but that being very 
elderly or having impaired renal function does not independently predict TTR in a setting with 
a well-managed anticoagulant clinic. This work highlights the importance of good TTR and 
that there is considerable room for improvement given that less than half the cohort achieved 
optimal TTR, especially Afro-Caribbean and South-Asian patients. This suggests the need to 
focus on individual reasons for poor INR control and to develop strategies to improve 
anticoagulation control where required. For example, more frequent follow up via phone call 
or face-to-face could be arranged so that more attention can be given to these patients. During 
the follow ups, factors that can influence anticoagulation control and the importance of being 
adherent to the anticoagulant should be emphasized. In addition, patients should also be 
encouraged to inform healthcare professionals if they encounter any problems with VKA 
therapy so that appropriate remedial action can be taken, and the patient should be reviewed.  
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3.5.6 Future research 
Further prospective, multicenter, observational studies with larger sample sizes (>1000 
patients) especially within ethnic minority groups are required to confirm these findings. 
Perhaps this study can be extended into a multi-national registry including other ethnically 
diverse countries for example in South-East Asian countries like Malaysia, Thailand, Vietnam, 
Myanmar, Cambodia and Laos which still uses VKA as the OAC of choice for stroke prevention 
in AF and in other thrombotic diseases (VTE/PE). It would be of interest to investigate TTR, 
determinants of TTR (including ethnicity) and its impact on predicting TE and bleeding events 
in Asian countries. Regional comparison of TTR and adverse clinical outcomes could be 
undertaken within each country where data in this area is lacking.  
 
Asian populations (451, 452) still rely heavily on herbal preparations for treating medical 
ailments. For example, ‘tongkat ali’ (Eurycoma longifolia), originating from Malaysia and 
Indonesia is used as an alternative for testosterone replacement therapy or treatment of 
impotence (451). Meanwhile, Withania somnifera, an Indian ginseng was shown to have 
potential for cancer-related fatigue and improvement of quality of life in a non-randomised 
comparative trial of 100 patients (N= 50 chemotherapy + WH vs. N=50 chemotherapy alone) 
with breast cancer (451, 453). Hence, it would be interesting to investigate the impact of herbal 
products on INR control as VKA-herb interaction have major safety concerns and more data 
is required in this field.  
3.6 Conclusions 
Ethnic disparities in the quality of anticoagulation control are evident but not among the very 
elderly and patients with different categories of kidney disease. South-Asians and Afro-
Caribbeans had poorer INR control compared to Whites, despite similar intensity INR-
monitoring. After adjustment, non-white ethnicity and anaemia remained the strongest 
independent predictor of poor TTR and PINRR. Meanwhile, CV hospitalisations were more 
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prevalent among the South-Asians. Closer attention needs to be given to patients from non-
white ethnic groups to understand the reasons of poor anticoagulation control so that effective 
strategies can be developed and implemented by healthcare providers to improve outcomes.  
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Chapter 4. Anticoagulation control in operated valvular heart 
disease patients with and without atrial fibrillation receiving vitamin 
K antagonist 
 
4.1 Abstract 
Introduction: Good quality anticoagulation control among patients with operated valvular 
heart disease (VHD) is needed to reduce ischaemic complications. There is limited evidence 
on factors affecting anticoagulation control among this patient population. 
Objective:  To investigate the quality of VKA control (TTR), predictors of anticoagulation 
control and the prevalence of adverse clinical outcomes [thromboembolic (stroke/TIA and 
systemic embolism), bleeding events, cardiovascular hospitalisation and all-cause mortality 
and ≥1 composite endpoints (MACE)] in operated VHD patients at one acute Trust in the West 
Midlands, United Kingdom. Exploratory analyses investigated the relationship between INR 
control and adverse clinical outcomes. 
Methods: Retrospective data collection from the electronic medical record database were 
undertaken to collect all demographics and clinical information. The Rosendaal and 
percentage INRs in range (PINRR) methods were used to calculate TTR among 456 operated 
VHD patients of whom 164 (36%) with AF and 292 (64%) without AF. Patient’s demographics, 
comorbidities and other clinical data were used as predictors of TTR and were examined by 
logistic regression analysis. Chi-squared tests were utilised to explore the relationship 
between INR control and adverse clinical outcomes. 
Results: The mean (SD) age was 51 (14.7), 64.5% were male, 96.1% had a mechanical 
prosthesis and 64% had aortic valve replacement. Operated VHD patients with AF had lower 
mean TTR and PINRR [mean (SD) TTR 55.7% (14.2) vs. 60.1% (14.6); p=0.002 respectively; 
mean PINRR 47.4% (13.5) vs. 51.6% (13.7); p=0.002 respectively], lower proportions with 
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optimal anticoagulation control (TTR ≥70%) (14.0% vs. 25.7%; p=0.004) and higher 
proportions with sub-therapeutic INRs (28.4% vs. 23.4%; p<0.001) despite a similar number 
of INR tests compared to operated VHD patients without AF. Independent factors predicting 
poor TTR after adjustment for demographic and clinical variables were: female, the presence 
of AF at baseline, anaemia/bleeding history and HAS-BLED score. Significantly higher 
proportions of patients with operated VHD and AF died [all-cause mortality (20.7% vs. 5.8%; 
p<0.001)]. Similarly, more deaths (13.1% vs. 4.1%; p=0.011) and ≥1 MACE (42.7% vs. 27.6%; 
p=0.006) were seen in patients with TTR <70% compared to TTR≥70% respectively. 
Conclusion: Operated VHD patients with AF at baseline have poorer anticoagulation control 
compared to those without AF at baseline. The presence of concomitant AF, 
anaemia/bleeding history, as well as female gender, independently predicted poor TTR and 
the rate of all-cause mortality was significantly higher among operated VHD patients with AF. 
These findings suggest closer INR monitoring among operated VHD patients especially those 
with AF to improve anticoagulation control and prevent adverse clinical outcomes. 
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4.2 Introduction 
VKAs are the only anticoagulant of choice in patients undergoing heart valve replacement, 
especially with mechanical prosthesis (358). The target INR for AF is 2.0-3.0, (349, 351, 358) 
whereas the INR targets for patients with VHD post-surgery varies depending on factors such 
as patient risk factors, (example: mitral/tricuspid valve replacement, previous TE, AF, mitral 
stenosis and LVEF <35%) type of valve, and the thrombogenicity of the prosthesis (349, 351, 
358). The 2017 ESC guidelines on the management of valvular heart disease (358) 
recommend a median INR value be maintained in place of a range to prevent extreme values 
within the target range. They also recommend a higher median INR value for patients with ≥1 
risk factor than those without any of these risk factors (358)(More details in section 1.7.2.1 
page 116). The newer types of valve used more commonly now, such as Carbomedics, St 
Jude or Medtronic have low valve thrombogenicity with limited data on the rate of valves 
thrombogenicity as they are also influenced by patient related risk factor and study design 
(454); however one review reported HR 1.06 (0.05-0.56) for valve thrombosis among St Jude 
and Carbomedics valves (455). Patients with risk factors receiving newer types of valves are 
recommended to achieve a median target INR of 3.0 compared to those without risk factors, 
where the target INR is lower at 2.5 (349, 351, 358). 
4.2.1 Study objectives  
To date, only five (377-381) studies, conducted between 2002 and 2018, have investigated 
anticoagulation control after valve replacement; two (380, 381) used anticoagulation variability 
while the others (377-380) used TTR. Therefore, the objective of this study was to investigate 
anticoagulation control measured using TTR (Rosendaal method) and the PINRR method 
among operated VHD patients, comparing patients with and without AF. Second, to investigate 
the predictors for poor anticoagulation control, and finally to investigate the prevalence of 
adverse clinical outcomes including stroke/TIA, bleeding, CV hospitalisations, death and the 
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composites of ≥1 MACE. Exploratory analyses investigated the relationship between INR 
control and adverse clinical outcomes. 
4.3 Methods 
4.3.1 Study design 
This is a single centre, retrospective analysis of patients with VHD receiving VKA therapy after 
valve replacement therapy at one acute Trust in the West Midlands, United Kingdom (SWBH 
NHS Trust). Data was collected from 1st November 2017 to 31st March 2018. VHD patients 
receiving VKA therapy were identified from the DAWN AC® anticoagulation management 
software (described in section 3.3.1, pages 174-175).  
This study was considered as service evaluation by the SWBH Research and Development 
department and therefore did not require REC approval.  However, local R&D approval was 
obtained (see email confirmation from SWBH R&D Department, Appendix 5). 
4.3.1.1 Patient selection 
A list of patients with VHD receiving VKA therapy (N=604) was generated from the DAWN AC 
management software.  However, 148 patients were excluded due to: i) VHD but without 
surgical intervention [N=38; mitral stenosis (N=22), aortic stenosis (N=2), mitral regurgitation 
(N=2), mitral valve repair (N=4), valvuloplasty (N= 6), and valvulotomy (N= 2)]; ii) incomplete 
INR results (N=3) and iii) incomplete medical information (N=107). The final cohort consists of 
456 VHD patients who had surgical intervention of the affected valve(s) and were prescribed 
VKA therapy post-surgery.  They were stratified into those with and without AF (Figure 4.1).   
4.3.1.2 Procedure  
All baseline characteristics and clinical information including medical history, medication, and 
laboratory tests were collected from the point that VKA was initiated after surgical replacement 
 
 
242 
of the valves (i.e., mechanical and tissue valve repair). Information on outcomes i.e., INR 
results and adverse clinical outcomes occurring after this point were collected using a 
proforma (see Appendix 4, Table A4.1).   
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CDA: clinical data archive; CV: cardiovascular; INR: international normalised ratio; TTR: time in therapeutic range; 
PINRR: percentage of INRs in range; SWBH: Sandwell and West Birmingham Hospitals; VHD: valvular heart 
disease; VKA: vitamin K antagonist 
VHD patients on VKA therapy selected from 
SWBH DAWN AC® Database (N=604) 
Patient’s baseline demographic characteristics, medical and 
medication history recorded from CDA and information on INRs 
from DAWN AC® databases 
Final cohort, N=456 
Operated VHD with AF (N=164) and without AF 
(N=292) 
 
Patients excluded N=148:  
-VHD without surgical intervention, N=38 
• Mitral stenosis, N=22; aortic stenosis, 
N=2; mitral regurgitation, N=2; mitral 
valve repair, N=4; valvuloplasty, N=6; 
valvulotomy; N=2 
-Insufficient INR result, N=3  
-Insufficient medical information, N=107 
 
Measures of 
anticoagulation 
control 
Adverse clinical 
outcomes 
Time to therapeutic 
range (TTR) by 
Rosendaal 
Percentage of INR 
within range (PINRR) 
Thromboembolic and 
bleeding events, CV 
hospitalization, death 
Predictors of 
anticoagulation 
control 
 Figure 4.1: Study design and patient selection flow chart 
Outcomes 
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Dependent/outcome variable  
4.3.1.2.1 Time in therapeutic range, TTR 
INR values for VKA therapy were collected from CDA and DAWN databases from SWBH NHS 
Trust for patients with at least three INR values in a year starting from February 2009 until 31 
January 2018. The year 2009 is the period where INR readings were consistently available in 
the hospital databases. Prior to this, another system was utilised and is no longer currently 
active to allow complete INR data collection resulting in wide gaps between the dates of each 
INR reading. The quality of anticoagulation control was calculated using the Rosendaal and 
the PINRR methods (421)(see section 2.3 for definition and description). TTR and PINRR 
were calculated based on each patient’s individual target INR range determined by the 
surgeon; thus, INR ranges differ between patients. TTR and PINRR were further dichotomised 
into TTR ≥70% and <70% and PINRR ≥70% and <70%, with TTR and PINRR ≥70% reflecting 
optimal anticoagulation control based on the ESC guideline (3). The proportions of sub-
therapeutic INRs (INRs below the target range), supra-therapeutic (INRs above target range) 
and patients with at least one INR >5.0 or >8.0 were also collected. The follow-up period was 
defined as the duration of VKA monitoring i.e., from the start date of INR collection until 31st 
January 2018.  
4.3.1.2.2 Definition of Atrial fibrillation 
The diagnosis of AF at baseline was obtained directly from the CDA. This was defined as the 
presence of AF as part of the concomitant diseases at the time of surgery or was diagnosed 
after the surgery (post-operative). Types of AF including paroxysmal, persistent, long standing 
and permanent were recorded.  If this information was not available, an assumption was made 
based on the length of time since AF diagnosis and the pattern of ECG recordings available, 
with confirmation of AF from a medical doctor, according to ESC AF guidelines (3).   
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4.3.1.3 Predictors: Patient demographics and clinical factors 
Patient’s age was calculated based on the date of their first valve surgery (ranging from 1972-
2017). Other demographic information such as gender, ethnicity, information regarding 
smoking status and alcohol intake, and other comorbidities, medication history and laboratory 
parameters were obtained as near to the date (or within one month) of VKA initiation after the 
first valve surgery, from the CDA. Information on smoking status was available for 372 patients 
(82%); data on alcohol intake was only available for 353 patients (77%).  This information was 
used to calculate the individual HAS-BLED and SAMe-TT2R2 scores. Assumptions were also 
made for chronic kidney disease, liver disease and anaemia based on the laboratory results 
(see page 181 for details). The calculation of the CHA2DS2-VASc, HAS-BLED and SAMe-
TT2R2 scores were made on the basis of baseline information (see section 3.3.3, page 177 
for more details). 
4.3.1.4 Adverse clinical outcome 
Information on adverse clinical outcomes were collected from the CDA covering the same time 
frame to that of the INR collection i.e., from the point/date where INR was consistently 
available in the system until 31 January 2018. Adverse clinical outcomes of interest were 
stroke/TIA/systemic embolism, bleeding (combination of major bleed and CRNMB), CV 
hospitalisation, death and a composite (≥ 1) of these MACE events. Definitions of each 
outcome are described in section 2.3.3. In this study, the cause of death was specified as CV 
death when specific information was available.  Where cause of death was unavailable, death 
was classified as all-cause mortality. 
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4.3.2 Statistical analysis  
 
After performing normality tests, by the histogram plot method and the Kolmogorov-Smirnov 
test where a bell-shaped distribution in the former and p-values >0.05 in the latter were 
indicative of normally distributed data, all normally distributed data were expressed as mean 
(SD), and non-normally distributed data as median (IQR). Demographic and clinical 
characteristics of patients with categorical data were compared with chi-square or Fisher’s 
exact test when appropriate and are reported as counts and percentage. Independent t-tests 
were used to compare the means of continuous data for normally distributed data; the Mann-
Whitney tests were used for data that was not normally distributed. Univariate and multivariate 
logistic regression analyses were performed to investigate the predictors of poor TTR 
(TTR<70%). The relationship between TTR and adverse clinical outcomes were investigated 
(exploratory) using the chi-squared test and are reported as counts and percentage. A Log-
Rank test was performed for AF categories and TTR categories and Kaplan-Meier Curves 
were used to report the differences in survival and ≥1 MACE between the subgroups. All 
analyses were conducted using SPSS version 23.0 (406), with p-values <0.05 considered 
statistically significant. 
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4.4 Results  
4.4.1 Baseline characteristics 
Among the 456 patients with operated VHD, only 164 (36.0%) had AF at baseline. The overall 
mean (SD) age was 51 (14.7), the majority were male (64.5%), of white ethnicity (65.2%), with 
a mechanical prosthesis (96.1%), and the most common operation was aortic valve 
replacement (64%) (Table 4.1). Patients with operated VHD with AF were significantly older 
[mean (SD) age 56.6 (13.3); p<0.001], more likely to be female (48.2%; p<0.001), to receive 
a tissue prosthesis (8.5%; p<0.001), to have had the mitral valve (41.5%; p<0.001) or both 
mitral and aortic (20.7%; p<0.001) valves replaced.  In addition, patients with operated VHD 
and AF were also more likely to have concomitant heart failure (21.3%; p<0.001), hypertension 
(72.0%; p=0.007), and pulmonary disease (25.6%; p=0.014) and were likely to be prescribed 
diuretics (70.1%; p<0.001), amiodarone (22.6%; p<0.001) and digoxin (36.0%; p<0.001), and 
had higher mean (SD) CHA2DS2-VASc [2.6 (1.5); p<0.001] and HAS-BLED scores [1.8 (1.1); 
p=0.014] compared to patients with operated VHD without AF (Table 4.1).  
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 Table 4.1: Baseline characteristics of patients with operated valvular heart disease, with and without AF 
N (%)  
Total,  
N=456 
AF 
N=164  
No AF 
N=292   
p-value 
Age at implantation Mean age (SD) 51.1 (14.7) 56.6 (13.3) 48.0 (15.0) <0.001 
Age groups 
≤64 382 (83.8) 117 (71.3) 265 (90.8) 
<0.001 65-74 59 (12.9) 35 (21.3) 24 (8.2) 
≥75 15 (3.3) 12 (7.3) 3 (1.0) 
Sex 
Female 162 (35.5) 79 (48.2) 83 (28.4) 
<0.001 
Male  294 (64.5) 85 (51.8) 209 (71.6) 
Ethnic groups‡ (N=454) 
White  296 (65.2) 114 (69.9) 182 (62.5) 
0.20 South-Asian  120 (26.4) 35 (29.2) 85 (29.2) 
Afro-Caribbean 38 (8.4) 14 (8.6) 24 (8.2) 
Alcohol intake Alcohol >14unit/day (N=353) 
32 (9.1) 9 (6.8) 23 (10.4) 0.26 
Smoking status 
Smoking/ex-smoker 
(N=372) 
83 (22.3) 27 (19.1) 56 (24.2) 
0.25 
Site(s) of prosthesis  
Mitral  110 (24.1) 68 (41.5) 42 (14.4) <0.001 
Aortic  292 (64.0) 62 (37.8) 230 (78.8) <0.001 
Both mitral and aortic 54 (11.8) 34 (20.7) 20 (6.8) <0.001 
Types of valve 
replacement  
Mechanical valve 438 (96.1) 150 (91.5) 288 (98.6) <0.001 
Tissue valve  18 (3.9) 14 (8.5) 4 (1.4) <0.001 
Past medical history  
Heart failure 53 (11.6) 35 (21.3) 18 (6.2) <0.001 
Hypertension 291 (63.8) 118 (72.0) 173 (59.2) 0.007 
Diabetes 71 (15.6) 32 (19.5) 39 (13.4) 0.08 
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Table 4.1 continued      
Past medical history 
 
 Total,  
N=456 
AF 
N=164  
No AF 
N=292  
p-value 
Stroke/TIA 66 (14.5) 30 (18.3) 36 (12.3) 0.08 
Vascular disease* 118 (25.9) 35 (21.3) 83 (28.4) 0.10 
Lung disease# 89 (19.5) 42 (25.6) 47 (16.1) 0.014 
Kidney disease† 17 (3.7) 7 (4.3) 10 (3.4) 0.65 
Anaemia/previous 
bleeding 
189 (41.4) 70 (42.7) 119 (40.8) 0.69 
Current medications 
Beta-blocker 177 (38.8) 62 (37.8) 115 (39.4) 0.74 
ACEI/ARB 247 (54.2) 94 (57.3) 153 (52.4) 0.31 
Diuretics  233 (51.1) 115 (70.1) 118 (40.4) <0.001 
Amiodarone 50 (11.0) 37 (22.6) 13 (4.5) <0.001 
Concurrent antiplatelet 79 (17.3) 21 (12.8) 58 (19.9) 0.06 
Digoxin  69 (15.1) 59 (36.0) 10 (3.4) <0.001 
Calcium channel blocker  54 (11.8) 20 (12.2) 34 (11.6) 0.86 
CHA2DS2-VASc score Mean (SD) 2.0 (1.4) 2.6 (1.5) 1.7 (1.3) <0.001 
CHA2DS2-VASc score 
categories 
Low risk  102 (22.4) 21 (12.8) 81 (27.7) 
<0.001 Intermediate  134 (29.4) 45 (27.4) 89 (30.5) 
High risk  220 (48.2) 98 (59.8) 122 (41.8) 
HAS-BLED score Mean 1.6 (1.2) 1.8 (1.1) 1.5 (1.2) 0.014 
HAS-BLED score 
categories 
Low risk (0-2) 359 (78.7) 127 (77.4) 232 (79.5) 
0.61 
High risk (≥3) 97 (21.3) 37 (22.6) 60 (20.5) 
 
  
 
 
250 
 
Table 4.1 continued      
  
Total,  
N=456 
AF 
N=164  
No AF 
N=292  
p-value 
SAMe-TT2R2 score Mean  2.7 (1.4) 2.7 (1.4) 2.7 (1.4) 0.53 
SAMe-TT2R2 score 
categories 
0-2 200 (43.9) 71 (43.3) 129 (44.2) 
0.86 
>2 256 (56.1) 93 (56.7) 163 (55.8) 
 
ACEI/ARB: angiotensin converting enzyme inhibitor/ angiotensin receptor blockade; AF: atrial fibrillation; CHA2DS2-VASc score - Congestive heart failure/left ventricular dysfunction, Hypertension, 
Age ≥75years [2 points], Diabetes, Stroke [2 points], Vascular disease, Age 65–74 years, and Sex category (female). Total scores range between 0-9; low risk CHA2DS2-VASc score:  0 male; 1 female, 
intermediate: 1male, ≥2 female, high risk CHA2DS2-VASc score: ≥2 male; ≥3 female; TIA: transient ischemic attack; eGFR: estimated glomerular filtration rate, ml/min/1.73 m2; HAS-BLED score – 
uncontrolled Hypertension: systolic ≥160 mmHg, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR ratio/TTR <60, Drugs/alcohol concomitantly. Total scores range 
between 0-9; low risk of bleeding range between 0-2 and high risk of bleeding ≥3; SAMe-TT2R2 score – Sex female, Age<60, Medical history (more than two comorbidities), Treatment (interacting 
drug, e.g. Amiodarone), Tobacco use (doubled) and Race (non-white, doubled). Total scores ranged from 0-8; probable good response to VKA therapy range between 0-2 and probable poor response 
to VKA therapy ranged from ≥3; SD: standard deviation 
* Vascular disease: prior myocardial infarction, peripheral artery disease or aortic plaque; # Lung disease: obstructive and restrictive diagnosed lung conditions; †eGFR <60ml/min or as noted in 
medical notes; ‡:2 missing information on ethnicity 
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4.4.2 Quality of anticoagulation control of patients with operated valvular 
heart disease, with and without AF 
 
As shown in Table 4.2, higher INR target ranges [INR 3.0-4.0; 41.4%] were used more often 
to maintain effectiveness and safety of VKA therapy in the overall population of patients with 
operated VHD. The overall mean (SD) TTR and PINRR for the cohort was 58.5 (14.6) and 
50.1 (13.8) respectively; only 98 patients (21.5%) achieved the optimal TTR target (TTR≥70%) 
during a median (IQR) of 6.2 (3.3-8.5) years of follow up.  
 
Operated VHD patients with AF had a significantly higher INR target range (3.5, 49.4%; 
p=0.03), lower mean TTR and PINRR [mean (SD) TTR 55.7 (14.2) vs. 60.1 (14.6); p=0.002 
respectively; mean PINRR 47.4 (13.5) vs. 51.6 (13.7); p=0.002 respectively] (Figure 4.2), 
lower proportions with optimal anticoagulation control (TTR ≥70%) (14.0% vs. 25.7%; 
p=0.004) and higher proportions with sub-therapeutic INRs (28.4% vs. 23.4%; p<0.001) 
(Figure 4.3) despite a similar number of INR tests compared to operated VHD patients without 
AF. There was no significant difference in INRs above the therapeutic range or the proportions 
of patients with one or more INR >5.0 or >8.0 (Table 4.2 and Figure 4.4).  
 
In exploratory analyses (Table 4.3), with measures of anticoagulation control stratified 
according to the different target INR ranges, patients with a higher TTR target (INR 3.5) had 
a significantly lower mean (SD) TTR and PINRR [mean (SD) TTR 51.7% (11.8); p<0.001; 
mean PINRR 42.6% (10.9); p<0.001 respectively], higher mean (SD) number of INR test 
[122.3 (59.6); p<0.001], higher sub-therapeutic [30.1 (10.2); p<0.001] and supra-therapeutic 
[26.8 (7.7); p=0.001] INRs and a significantly longer duration of VKA treatment compared to 
those with target ranges of 2.5 and 3.0. In contrast, a significantly higher proportion of patients 
with ≥1 INR >5.0 (95.8%; p<0.001) or >8.0 (22.2%; p<0.001) was evident among those with a 
target INR of 3.0 (Table 4.3). 
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 Table 4.2: Measures of anticoagulation control of patients with operated valvular heart disease, with and without AF 
Measures of anticoagulation control, N (%) Total,  N=456 
AF 
N=164  
No AF 
N=292 
F-
value 
X2 value p-value 
Median target INR 2.5‡ 110 (24.1) 33 (20.1) 77 (26.4) - 
6.76 0.034 3.0 157 (34.4) 50 (30.5) 107 (36.6) - 
3.5 189 (41.4) 81 (49.4) 108 (37.0) - 
Mean (SD) TTR Rosendaal* 58.5 (14.6) 55.7 (14.2) 60.1 (14.6) 0.09 - 0.002 
TTR<70% 358 (78.5) 141 (86.0) 217 (74.3) - 
8.46 0.004 
TTR≥70% 98 (21.5) 23 (14.0) 75 (25.7) - 
TTR<65% 310 (68.0) 126 (76.8) 184 (63.0) - 
9.21 0.002 
TTR≥65% 146 (32.0) 38 (23.2) 108 (37.0) - 
Mean (SD) PINRR* 50.1 (13.8) 47.4 (13.5) 51.6 (13.7) 0.60 - 0.002 
PINRR<70% 417 (91.4) 154 (93.9) 263 (90.1) - 
1.97 0.16 
PINRR ≥70% 39 (8.6) 10 (6.1) 29 (9.9) - 
PINRR <65% 398 (87.3) 150 (91.5) 248 (84.9) - 
4.04 0.05 
PINRR ≥65% 58 (12.7) 14 (8.5) 44 (15.1)  
Mean (SD) number of INR tests 96.2 (55.3) 100.7 (58.8) 93.7 (53.1) 0.60 - 0.19 
Mean (SD) percentage INRs below the range 25.2 (12.1) 28.4 (12.5) 23.4 (11.6) 0.85 - <0.001 
Mean (SD) percentage above the range 24.9 (9.5) 24.1 (8.6) 25.3 (9.9) 0.64 - 0.22 
INR>5 312 (68.4) 118 (72.0) 194 (66.4) 1.48 - 0.22 
INR>8 64 (14.0) 26 (15.9) 38 (13.1) - 0.70 0.40 
Median (IQR) years of follow-up 6.24 (3.3-8.5) 5.7 (3.7-8.5) 5.7 (3.1-8.5) - - 0.87 
AF: atrial fibrillation; INR: international normalized ratio; IQR: interquartile range; PINRR: percentage of INRs within range; SD: standard deviation; TTR: time in therapeutic range; *TTR and PINRR 
were calculated based on the INR ranges obtained from the anticoagulation clinic; †Median target INR ranges for each patient were different depending on indication and type of surgery and valve 
used which was set by the operating surgeon. 
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 Figure 4.2: Percentage of patients with optimal TTR/PINRR among operated valvular heart 
disease patients with and without AF 
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 Figure 4.3: Percentage of INRs within range, below the range and above the range among operated 
valvular heart disease, with and without AF 
 Figure 4.4: Percentage of patients with INRs>5.0 and INRs >8.0 among operated valvular heart 
disease, with and without AF 
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 Table 4.3: Measures of anticoagulation control of patients according to different target INRs 
Measures of anticoagulation control, N (%) 
Median INR  
2.5  
N=110 
Median INR  
3.0 
N=157 
Median INR  
3.5 
N=189 
X2 value p-value 
Mean (SD) TTR Rosendaal* 68.4 (14.4) 59.8 (13.3)a 51.7 (11.8)b, c - <0.001 
TTR<70% 53 (48.2) 124 (79.0) a 181 (95.8) b, c 
93.3 <0.001 
TTR≥70% 57 (51.8) 33 (21.0) a 8 (4.2) b, c 
TTR<65% 37 (33.6) 100 (63.7) a 173 (91.5) b, c 
109.1 <0.001 
TTR≥65% 73 (66.4) 57 (36.3) a 16 (8.5) b, c 
Mean (SD) PINRR* 61.4 (12.5) 51.1 (11.8)a 42.6 (10.9)b, c - <0.001 
PINRR<70% 79 (71.8) 187 (98.9) a 151 (96.2)b 
72.3 <0.001 
PINRR ≥70% 31 (28.2) 2 (1.1)a 6 (3.8) b 
PINRR <65% 67 (60.9) 145 (92.4) a 186 (98.4) b, c 
93.7 <0.001 
PINRR ≥65% 43 (39.1) 12 (7.6) a 3 (1.6) b, c 
Mean (SD) number of INR tests 71.2 (41.7) 82.3 (44.1) 122.3 (59.6)b,c  <0.001 
Mean (SD) percentage INRs below the range 15.1 (10.1) 26.4 (11.4) a 30.1 (10.2) b, c - <0.001 
Mean (SD) percentage above the range 24.0 (11.5) 23.1 (9.4) 26.8 (7.7)b, c - 0.001 
INR>5 35 (31.8) 181 (95.8) a 96 (61.1) b, c 137.5 <0.001 
INR>8 3 (2.7) 42 (22.2) a 19 (12.1) b, c 22.6 <0.001 
Median (IQR) years of follow-up 5.2 (2.0-8.3) 5.7 (3.0-8.5) 6.5 (5.0-8.6)b, c - <0.001 
AF: atrial fibrillation; INR: international normalized ratio; IQR: interquartile range; PINRR: percentage of INRs within range; SD: standard deviation; TTR: time in therapeutic range; *TTR and PINRR 
were calculated based on the INR ranges obtained from the anticoagulation clinic; †INR ranges for each patient were different depending on indication and type of surgery and this was set by the 
operating surgeon; a: significant difference between median target INR 2.5 to 3.0; b: significant difference between median target INR 2.5 to 3.5; c: significant difference between median target INR 
3.0 to 3.5 
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4.4.3 Predictors of poor anticoagulation control, TTR <70% 
Table 4.4 presents the results obtained from univariate logistic regression analyses 
investigating the predictors of poor anticoagulation control. Being female [OR 2.2 (95% CI 
1.32-3.73)], having an operated mitral valve [OR 1.8 (95% CI 1.02-3.28)] or both mitral and 
aortic valves [OR 3.0 (95% CI 1.14-7.62)], AF [2.12 (95% CI 1.27-3.54)], anaemia/bleeding 
history [OR 1.8 (95% CI 1.12-2.92)], digoxin [OR 5.2 (95% CI 1.85-14.69), increasing 
CHA2DS2-VASc [OR 1.2 (95% CI 1.02-1.43) and HAS-BLED [OR 2.7 (95% CI 2.01-3.48)] 
scores predicted poor TTR among patients with operated VHD with and without AF.  
Models 1-6 in Table 4.5 present the independent factors predicting poor TTR after adjustment 
for demographic and clinical variables. Being female, the presence of AF at baseline, and 
anaemia/bleeding history, were consistently present in 4 of the 6 models predicting poor TTR. 
The HAS-BLED score, which also contains anaemia/bleeding history, also predicted poor TTR 
in 2 of the 6 models (models 4 and 6).  
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 Table 4.4: Demographics and clinical characteristics associated with predictors of poor TTR (<70%), in univariate analysis among 
patients with operated valvular heart disease, with and without AF 
N (%)  Odds ratio (95% CI) p-value 
Age at implantation Age 1.00 (0.99-1.02) 0.36 
Sex Female 2.22 (1.32-3.73) 0.003 
Ethnicity‡  
White (ref) - - 
Non-White 1.22 (0.76-1.96) 0.42 
Social history 
Alcohol >14unit/day (N=353) 2.41 (0.71-8.15) 0.16 
Smoking/ex-smoker (N=372) 0.72 (0.40-1.30) 0.28 
Sites of prosthesis 
Mitral only 1.83 (1.02-3.28) 0.044 
Aortic only 0.41 (0.24-0.69) 0.001 
Mitral and aortic 2.95 (1.14-7.62) 0.025 
Types of valve 
replacement 
Mechanical valve 0.72 (0.21-2.55) 0.61 
Tissue valve  1.39 (0.39-4.88) 0.61 
Past medical history 
 
Atrial fibrillation 2.12 (1.27-3.54) 0.004 
Heart failure 1.20 (0.58-2.49) 0.62 
Hypertension 0.97 (0.61-1.55) 0.91 
Diabetes 1.26 (0.66-2.42) 0.48 
Stroke/TIA 1.14 (0.59-2.18) 0.70 
Vascular disease* 1.10 (0.66-1.84) 0.72 
Lung disease# 1.44 (0.79-2.64) 0.24 
Kidney disease† 0.89 (0.28-2.78) 0.84 
Anaemia/bleeding history 1.81 (1.12-2.92) 0.015 
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Table 4.4 continued    
  Odds ratio (95% CI) p-value 
Current medications 
Beta-blocker 0.77 (0.49-1.20) 0.25 
ACEI/ARB 0.66 (0.42-1.04) 0.07 
Diuretics 1.11 (0.71-1.74) 0.64 
Amiodarone 1.50 (0.68-3.30) 0.32 
Concurrent antiplatelet 1.21 (0.65-2.22) 0.55 
Digoxin 5.21 (1.85-14.69) 0.002 
Calcium channel blocker 1.08 (0.53-2.18) 0.83 
CHA2DS2-VASc score Mean (SD) 1.21 (1.02-1.43) 0.028 
HAS-BLED score Mean 2.65 (2.01-3.48) <0.001 
SAMe-TT2R2 score Mean 1.11 (0.94-1.30) 0.21 
 
ACEI/ARB: angiotensin converting enzyme inhibitor/ angiotensin receptor blockade; AF: atrial fibrillation; CI: confidence interval; CHA2DS2-VASc score - Congestive heart failure/left ventricular 
dysfunction, Hypertension, Age ≥75years [2 points], Diabetes, Stroke [2 points], Vascular disease, Age 65–74 years, and Sex category (female). Total scores range between 0-9; low risk CHA2DS2-
VASc score:  0 male; 1 female, intermediate: 1male, ≥2 female, high risk CHA2DS2-VASc score: ≥2 male; ≥3 female; TIA: transient ischemic attack; eGFR: estimated glomerular filtration rate, 
ml/min/1.73 m2; HAS-BLED score – uncontrolled Hypertension: systolic ≥160 mmHg, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR ratio/TTR <60, Drugs/alcohol 
concomitantly. Total scores range between 0-9; low risk of bleeding range between 0-2 and high risk of bleeding ≥3; SAMe-TT2R2 score – Sex female, Age<60, Medical history (more than two 
comorbidities), Treatment (interacting drug, e.g. Amiodarone), Tobacco use (doubled) and Race (non-white, doubled). Total scores ranged from 0-8; probable good response to VKA therapy range 
between 0-2 and probable poor response to VKA therapy ranged from ≥3; SD: standard deviation 
* Vascular disease: prior myocardial infarction, peripheral artery disease or aortic plaque; # Lung disease: obstructive and restrictive diagnosed lung conditions; †eGFR <60ml/min or as noted in 
medical notes; ‡ 2 missing information on ethnicity 
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 Table 4.5: Models of predictors of poor TTR (<70%) in the overall cohort of patients with operated valvular heart disease 
Predictors Model 1α 
(OR 95% CI) 
Model 2† Model 3‡ Model 4¥ Model 5§ Model 6¶ 
Age (continuous) 1.00 (0.98-1.02); 
p=0.98 
1.00 (0.98-1.02); 
p=0.96 1.12 (0.94-1.34); 
p=0.21 ‡ 
- 
1.12 (0.93-1.34); 
p=0.23§ 
- 
Female sex 1.93 (1.13-3.30); 
p=0.016 
2.05 (1.21-3.50); 
p=0.008 
2.28 (1.29-4.02); 
p=0.004 
2.51 (1.42-4.44); 
p=0.002 
Site of replacement  
(2 valves vs. 1 valve)* 
2.06 (0.77-5.48); 
p=0.15 
1.15 (0.30-4.35); 
p=0.84† 
2.45 (0.93-6.44); 
p=0.07 
2.02 (0.73-5.58); 
p=0.17 
1.16 (0.31-4.36); 
p=0.83§ 
1.99 (0.50-7.90); 
p=0.33¶ 
Atrial fibrillation  1.75 (1.01-3.03); 
p=0.045 
1.89 (1.10-3.27); 
p=0.022 
1.74 (1.01-3.00); 
p=0.047 
1.38 (0.78-2.43); 
p=0.26 
1.94 (1.13-3.33); 
p=0.016 
1.51 (0.86-2.65); 
p=0.16 
Anaemia/bleeding 
history  
1.84 (1.13-3.00); 
p=0.014 
1.86 (1.14-3.03); 
p=0.012 
1.72 (1.06-2.80); 
p=0.028 
2.60 (1.98-3.43); 
p=<0.001¥ 
1.75 (1.08-2.84); 
p=0.024 
2.65 (2.01-3.49); 
p=<0.001¶ 
 
 
*2 valves: aortic AND mitral valve vs. 1 valve: aortic OR mitral valve 
α Model 1 includes age, female, site or replacement (2 vs. 1 valve), AF, anaemia/bleeding history 
† Model 2 includes age; female, type of valve (mechanical vs. tissue), AF, anaemia/bleeding history 
‡ Model 3 includes CHA2DS2-VASc score, site or replacement (2 vs. 1 valve), AF, anaemia/bleeding history 
¥ Model 4 includes HAS-BLED score, female, site or replacement (2 vs. 1 valve), AF 
§ Model 5 includes CHA2DS2-VASc score, type of valve (mechanical vs. tissue), AF, anaemia/bleeding history 
¶ Model 6 includes female, type of valve (mechanical vs. tissue), AF and HAS-BLED score 
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4.4.4 Adverse clinical outcome  
Table 4.6 shows the proportions of patients with adverse clinical outcomes. Overall there were 
31 TE events, 113 bleeding events, 123 CV hospitalisations, 51 deaths and 316 experiences 
≥1 MACE. There were no significant differences in TE, bleeding, CV hospitalisation and ≥1 
MACE between those with and without AF. However, significantly higher proportions of 
patients with operated VHD and AF died [all-cause mortality (20.7% vs. 5.8%; p<0.001); CV 
mortality (7.3% vs. none; p<0.001) and non-CV mortality (13.4% vs. 5.8%; p=0.009)] 
compared to those operated without AF. In survival analyses, operated VHD patients with AF 
had a significantly higher risk of all-cause mortality compared to those without AF (Log-Rank: 
21.570; p<0.001; Figure 4.5) 
Table 4.7 compares the adverse clinical outcomes by TTR ≥70% and <70% and TTR≥65% 
and TTR <65%. Higher proportions of patients died (13.1% vs. 4.1%; p=0.011) and 
experienced ≥1 MACE (42.7% vs. 27.6%; p=0.006) when their TTR was <70% compared to 
those with TTR≥70%. In survival analyses, patients with TTR <70% had a significantly higher 
risk of all-cause mortality (Log-Rank: 5.845, p=0.016; Figure 4.6) and ≥1 MACE. (Log-Rank: 
7.541, p=0.006; Figure 4.7) A similar pattern emerged when TTR was stratified as <65%; a 
significantly higher proportion of patients with TTR <65% died (14.2% vs. 4.8%; p=0.003) or 
experienced ≥1 MACE (44.5% vs. 28.8%; p=0.001). 
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 Table 4.6: Adverse clinical outcome among patients with operated valvular heart disease, with and without AF 
Outcomes, N (%) 
Total,  
N=456 
Event 
rate/100 pt 
yrs 
AF 
N=164  
Event 
rate/100 pt 
yrs 
No AF 
N=292   
Event 
rate/100 pt 
yrs 
p-value* 
Stroke/TIA/SE 25 (5.5) 1.0 8 (4.9) 0.9 17 (5.8) 1.1 0.67 
Bleeding* 85 (18.6) 3.6 30 (18.3) 3.6 55 (18.8) 3.6 0.89 
CV hospitalisation 78 (17.1) 3.4 31 (18.9) 3.8 47 (16.1) 3.2 0.45 
All-cause death 51 (11.2) 1.9 34 (20.7) 3.6 17 (5.8) 1.0 <0.001 
CV death 12 (2.6) 0.5 12 (7.3) 1.3 0 - <0.001 
Non-CV death 39 (8.6) 1.5 22 (13.4) 2.3 17 (5.8) 1.0 0.009 
≥1 MACE† 180 (39.5) 8.7 75 (45.7) 10.1 105 (36.0) 7.8 0.051 
 
 
*p-value for proportion; Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, ventricular arrhythmia,  uncontrolled 
AF/atrial flutter, supraventricular arrhythmia,  ii) valve surgery, CABG surgery, PTCA surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb amputation AND 
as recorded in patient’s medical documents; DVT – Deep Vein Thrombosis ; * Bleeding ISTH is combination of major bleed ISTH and clinically relevant non-major bleed (CRNMB); Major Bleeding – 
ISTH Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular 
with compartment syndrome and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells; Clinically 
relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding but meet at least one of the 3 criteria: i) leading to hospitalisation or increased level of care, 
ii) requiring medical intervention by healthcare professional and iii) prompting face to face evaluation; SE: systemic embolism; TIA: transient ischemic attack; VTE: venous thromboembolism. 
 
† ≥1MACE: major adverse clinical event defined a composite of TE, bleeding, CV hospitalisation and all-cause death 
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Number 
at risk 
No AF 292 253 214 188 140 107 
AF 164 143 128 103 77 55 
 
  Figure 4.5: Kaplan-Meier curves among operated VHD patients 
stratified by the presence of AF for all-cause mortality  
 
No AF 
AF 
p<0.001 
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 Table 4.7: Adverse clinical outcome vs. TTR among patients with operated valvular heart disease, with and without AF 
N (%) 
TTR<70% 
N=358 
TTR≥70% 
N=98 
p-value 
TTR<65% 
N=310 
TTR≥65% 
N=146 
p-value 
Stroke/TIA/SE 23 (6.4) 2 (2.0) 0.13 20 (6.5) 5 (3.4) 0.19 
Bleeding* 72 (20.1) 13 (13.3) 0.12 65 (21.0) 20 (13.7) 0.06 
CV hospitalisation 65 (18.2) 13 (13.3) 0.26 58 (18.7) 20 (13.7) 0.19 
All-cause death 47 (13.1) 4 (4.1) 0.011 44 (14.2) 7 (4.8) 0.003 
≥1 MACE† 153 (42.7) 27 (27.6) 0.006 138 (44.5) 42 (28.8) 0.001 
 
 
Cardiovascular hospitalisation: a hospitalisation with a cardiovascular cause: i) heart failure, MI, new angina, non-fatal cardiac arrest, ventricular arrhythmia, uncontrolled AF/atrial flutter, 
supraventricular arrhythmia, ii) valve surgery, CABG surgery, PTCA surgery, pacemaker/ICD insertion, carotid endarterectomy, peripheral angioplasty/surgery, limb amputation AND as recorded in 
patient’s medical documents; DVT – Deep Vein Thrombosis; Major Bleeding – ISTH Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, 
intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, 
or leading to transfusion of two or more units of whole blood or red cells; Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding but meet 
at least one of the 3 criteria: i) leading to hospitalisation or increased level of care, ii) requiring medical intervention by healthcare professional and iii) prompting face to face evaluation; SE: systemic 
embolism; TIA: transient ischemic attack; VTE: venous thromboembolism. 
 
 
* Bleeding ISTH is combination of major bleed ISTH and clinically relevant non-major bleed (CRNMB); †≥1 MACE: major adverse clinical event defined a composite TE, bleeding, CV hospitalisation 
and all cause death 
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p=0.016 
TTR <70% 
TTR ≥70% 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
TTR <70% 358 317 272 233 171 123 
TTR⩾70% 98 84 70 58 46 39 
TTR <70% 358 275 207 160 108 67 
TTR⩾70% 98 78 64 47 36 27 
 Figure 4.6: Kaplan-Meier curves among operated VHD 
patients stratified by categories of TTR (TTR <70% vs. 
TTR≥70%) for all-cause mortality 
 Figure 4.7: Kaplan-Meier curves among operated VHD patients 
stratified by categories of TTR (TTR <70% vs. TTR≥70%) for 
composites of thromboembolic, bleeding event, cardiovascular 
hospitalisation and all-cause mortality (≥1 MACE) 
Number at risk Number at risk 
TTR <70% 
TTR ⩾70% 
p=0.006  
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4.5 Discussion 
This study has three main findings. First, the quality of anticoagulation control was significantly 
lower in operated VHD patients with AF at baseline compared to those without AF, using both 
the Rosendaal and PINRR methods. Second, females, the presence of AF, and 
anaemia/bleeding history significantly predicted poorer anticoagulation control in the overall 
cohort. Third, the rate of death was significantly higher in those with operated VHD with AF 
compared to operated VHD patients without AF. To date, this is the first study assessing the 
quality of anticoagulation control among operated VHD patients stratified by the presence of 
AF at baseline. 
Mechanical heart valves are more thrombogenic but more long-lasting compared to tissue 
valves (377). Due to this reason, patients with mechanical valve prosthesis require lifelong 
anticoagulation therapy with a VKA compared to those with tissue valves (without other 
indication for OAC therapy; for example, AF) who only require anticoagulation therapy for at 
least the first 3 months following surgery(349, 351, 358).  In this cohort of operated VHD 
patients, 36.0% of the population had concomitant AF, a proportion consistent with two 
recently published studies (377, 379). In the present cohort, AF patients were also significantly 
older and more likely to have additional stroke risk factors such as hypertension and heart 
failure and a greater proportion with AF received mitral or both mitral and aortic valve 
replacement, compared to patients without AF. Moreover, operated VHD patients with AF 
have significantly higher mean CHA2DS2-VASc and HAS-BLED scores than those without AF 
at baseline, indicating their higher risk of TE and bleeding events.    
In terms of anticoagulation management, the majority of the operated VHD patients with AF 
had a higher target INR (i.e., INR 3.5) compared to those without AF. In the recent ESC 
guidelines (358), a target INR of 3.5 is recommended for those patients with ≥1 risk factor (for 
example AF) and with medium prosthesis thrombogenicity. In this operated VHD cohort, there 
is insufficient information about the type of valve used thus it was not possible to ascertain the 
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valves’ thrombogenicity and explain the reasons behind the high target range. One possibility 
is that patients who had their valves replaced from as early as the 1970’s were perhaps treated 
based on recommendations from previous guidelines which suggested a target range of 3.0-
4.5 for all patients with prosthetic heart valves (regardless of type) (381). When examining 
anticoagulation control among patients with different target INRs in an exploratory analysis, 
TTR and PINRR were significantly lower among patients with a high target INR (INR 3.5) 
compared to those with target INRs of 2.5 and 3.0, respectively. Furthermore, other markers 
of poor anticoagulation control (sub-therapeutic INRs, supra-therapeutic INRs, INRs >5.0 and 
INRS >8.0) were also significantly more prevalent among those with higher INR targets (INR 
3.5) compared to those with lower INR targets (INR 2.5 and INR 3.0). The PLECTRUM study 
(377), a retrospective observational multi-centre study among patients with mechanical heart 
valves also investigated TTR according to different INR targets and showed consistent results 
with the current study; lower median TTR among patients with a higher INR target (INR 3.5) 
[TTR 71.5% vs. 58.6% vs. 46%; p=0.0001 for INR targets of 2.5, 3.0 and 3.5 respectively] 
(377). Similarly, in the PLECTRUM cohort and the present cohort, TTR was better when the 
intended INR target was kept at 2.5. These findings may imply the difficulties in achieving 
INRs within the therapeutic range when a more intense anticoagulation regimen is adopted.  
Overall in the present study, the mean (SD) TTR is 58.5% (14.6) and less than a quarter of 
the cohort achieved optimal TTR (TTR ≥70%), reflecting poor anticoagulation control among 
operated VHD patients. There is a paucity of literature on the quality of anticoagulation control 
among operated VHD patients, especially those with AF. Only four studies are available 
assessing TTR among VHD patients (377-380). The Swedish groups (379) examined TTR 
among 534 patients (379) and 4687 patients (380) with mechanical heart valves and reported 
a mean TTR of 71.3% (379) and 72.5% (380) respectively; higher than the mean TTR in the 
present study. In contrast, two recent studies (377, 378), conducted in Italy (N=2357) (377) 
and Denmark (N=659) (378), reported a median (IQR) TTR of 60% (47-74%) and 54.9% (39.0-
72.9%), respectively; comparable to the TTR in the current study. The findings of the Italian 
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and Danish studies (377, 378) and the current study show sub-optimal quality of 
anticoagulation control among operated VHD patients. In contrast, the two Swedish study 
(379, 380) showed optimal anticoagulation control among operated VHD patients although 
this could be explained by the fact that generally, Sweden (379) is known to have excellent 
anticoagulation management resulting in better TTR compared to other countries (206, 456). 
This again reinforces one important message; the difficulties in maintaining INR levels at the 
therapeutic range among anticoagulated operated VHD patients. This is more worrying in 
patients with concomitant AF, as AF patients with VHD carry an even higher risk of TE 
complications (5-62%)(457) than patients with NVAF (0-18%) (457).  
In logistic regression analyses, after adjusting for demographics and clinical variables, being 
female, the presence of AF and anaemia/bleeding history consistently predicted poor TTR in 
four of the six models. In addition, the HAS-BLED (which also consist of anaemia/bleeding 
history) score also predicted poor TTR (<70%) in two of six models. The finding that being 
female predicts poor TTR is consistent with other non-valvular AF studies (197-203) and is 
difficult to explain but could be influenced by several factors. The mean age of the overall VHD 
population was 51 years which is working age. It could be that working women have more 
hectic lifestyles with household, work and family responsibilities that makes them prone to 
being non-adherent to medication in general including towards anticoagulation therapy thus 
leading to poor anticoagulation control. One large American study (458) evaluating medication 
use and adherence among 16.0 million women and 13.5 million men showed that women 
were more likely to be non-adherent to their diabetic (35.4% vs. 32.5%; p<0.0001) and 
antihypertensive (25.8% vs. 24.8; p<0.0001) medications compared to men respectively and 
also speculated due to more complex medications regime, more side effects and more 
responsibilities resulting in self neglect compared to men (458). Furthermore, in this study, the 
majority of the operated VHD females also had AF at baseline which is also a predictor of poor 
TTR. Operated VHD patients with AF are older and had multiple comorbidities with complex 
disease management which might contribute to the lower quality of anticoagulation control 
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(197, 199, 201, 253). Lastly, history of anaemia/bleeding among operated VHD patients was 
also an independent predictor of poor TTR consistent with another study among non-valvular 
AF patients (213). It may be that these patients were managed more cautiously in terms of 
dosing of VKA. Although information on the dosage of VKAs used was not available, perhaps 
a lower dosage was used in this group of patients due to the fear of bleeding complications 
thus leading to the risk of suboptimal anticoagulation control in this population. No other 
studies have investigated the predictors of TTR specifically among operated VHD patients so 
comparison with other studies regarding the predictors of poor TTR among operated VHD 
patients could not be undertaken. However, Poli et al (377) has investigated predictors of TE 
among mechanical heart valves patients and showed that AF, history of TE and prosthesis at 
mitral position were associated with TE complications (377).  
During a median follow up of 6.2 years, at least two-fifths of all operated VHD patients had ≥1 
MACE.  The rate of TE was 1.0/100 pt-yrs, which is comparable with that reported by 
Cannegieter et al (362) (1.0 /100 pt-yrs) but slightly higher than the rate reported by Poli et al 
(377) (0.67/100 pt-yrs), although the latter acknowledged the low rate of TE events in their 
cohort despite an overall suboptimal TTR compared to other studies (362). Perhaps the higher 
TE rate in the current cohort, compared to Poli et al (377), is driven by the higher proportion 
of patients with history of stroke/TIA prior to valve surgery in the current study compared to 
Poli et al (377) (14.5% vs. 8.3%).  
The rate of bleeding events was 3.7/100 pt-yrs in the current study, higher than Cannegieter 
et al (362) and Poli et al (377), with 1.4/100 pt-yrs (362) and 1.0/100 patient-years, 
respectively. (377) The higher bleeding rate in the present cohort might be influenced by the 
higher target INR rate used (target INR 3.5), although further analyses on predictors of 
bleeding events (and all the other events) was not undertaken due to lack of power for these 
analyses.  
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Additionally, in this cohort, 11% of the patients died which was also higher than that reported 
from Poli et al (377) (7.4% deaths); this might be explained by differences in the demographic 
and clinical characteristics of the cohorts. There were more males, patients from ethnic 
minority groups, smokers/ex-smokers and a higher disease burden (stroke/TIA, diabetes, 
vascular disease and anaemia) in the present study which could potentially contribute to the 
differences in the mortality rate.  
The proportions of operated VHD patients who had a TE, bleeding event, CV hospitalisation 
and ≥1 MACE was similar among those with and without AF at baseline. Nevertheless, all-
cause mortality (including CV and non-CV related death) was significantly higher among those 
with AF compared to those without AF indicating that in this cohort, patients with operated 
VHD and AF have a worse prognosis than those without AF.  
When investigating the impact of TTR on adverse clinical outcomes, significantly higher 
proportions of deaths (all-cause mortality) and patients with ≥1 MACE were seen in the 
suboptimal TTR category (TTR<70%). This suggests an increased risk of adverse clinical 
outcomes among operated VHD patients in this cohort when TTR is not optimised. In contrast, 
two other studies (377, 379) investigating the impact of TTR on TE events among mechanical 
heart valve patients reported contrasting results. The PLECTRUM (377) study and the 
Swedish registry (379) showed no relationship between poor TTR and TE events but poor 
TTR (<61.6%) was associated with bleeding events in the Swedish study (adjusted OR 2.9; 
p=0.011)(379). However, another study in 2002 (381) showed that mortality was significantly 
increased in patients with high anticoagulation variability (381). These studies vary in some 
aspects compared to the present study, especially the target INR used among the patients 
(high INR target vs. normal INR target vs. patient-specific target), the method of calculating 
the quality of anticoagulation control (TTR vs. anticoagulation variability), the study design 
(prospective vs. retrospective), the settings (high TTR setting vs. normal TTR setting), the 
year of study (2002 vs. 2018) and the sample size included, which could affect the results.  
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More studies regarding TTR and adverse clinical outcomes among operated VHD patients are 
needed to confirm these findings.  
4.5.1 Strengths and Limitations  
This is the first study investigating anticoagulation control in the UK among operated VHD 
patients stratified by the presence of AF at baseline (obtained from the post-operative notes). 
Although it is limited by the relatively small sample size, it provides some insights on 
anticoagulation control among operated VHD patients, with and without AF. Studies 
investigating anticoagulation control among VHD patients are lacking thus the information 
gained from this study adds to the limited current literature. In addition, anticoagulation control 
was assessed for 6.2 years reflecting long term anticoagulation control among VHD patients. 
This study is limited by its retrospective, single centre design and the small number of operated 
VHD patients included, so caution must be applied as the findings might not be transferable 
to other settings. There is no information on the proportion of pregnancies, the doses of VKAs 
and type of valve inserted in the patients; if patients were offered PSM or home monitoring 
service, distance to anticoagulation clinic, level of education, drugs and food interaction and 
genetic information which could impact the quality of anticoagulation control. Additionally, this 
study is not powered for adverse clinical outcomes so analyses pertaining to outcomes were 
exploratory in nature.  
4.5.2 Clinical implications  
The findings of this study suggest that operated VHD patients with AF at baseline need closer 
attention and a more robust support system than those without AF. For example, more 
frequent follow up for closer INR monitoring should be arranged if patients INRs are not within 
the therapeutic range. During these follow ups, knowledge regarding the need for 
anticoagulation and the importance of keeping INR within the therapeutic range, the 
importance of being adherent to medication and avoiding or minimising food and drug 
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interactions should be reinforced from time to time. Perhaps barriers to medication adherence 
and persistence should be identified and addressed to improve adherence if this is identified 
as a cause of poor TTR.   
In addition, patient self-monitoring (PSM) of INR could be offered to patients who have 
difficulties in coming for frequent INR visits provided that appropriate training was given in 
advance and patients’ suitability for PSM has been assessed by the anticoagulant experts. 
One meta-analysis (459) of eleven trials comparing self-monitoring (self-testing) or self-
management (self-testing and self-dosage) versus usual care (dosed by physician or 
anticoagulation clinic) among anticoagulated patients with VKA therapy for AF, mechanical 
heart valve and others showed that TE was significantly reduced in patients who were in the 
PSM group compared to control [HR 0.51; 95% CI 0.31-0.85)] but there was no difference 
between groups on bleeding and mortality (459). Also, patients with a mechanical heart valve 
benefited from the PSM with a significant reduction in thrombotic events [HR 0.52; 95% CI 
0.35-0.77)] (459).   
There may be a role for pharmacogenetic testing in VHD patients with difficulties achieving 
therapeutic INRs or if they are complicated with multiple strokes or bleeding events after 
receiving VKA therapy. This could potentially investigate any polymorphism to the CYP2C9 or 
the VKORCI enzymes which are responsible for warfarin metabolism thus affecting their 
response to therapy. As NOAC is contraindicated in operated VHD patients with mechanical 
heart prosthesis, every effort should be made to ensure treatment with VKA is optimal to 
prevent serious adverse clinical event. 
4.5.3 Future work 
Future studies with more focus on the quality of anticoagulation in operated VHD patients with 
AF is recommended as less attention has been paid to this population despite them having 
higher risk of TE complications than NVAF patients. As more studies are utilising INR 
variability as another method of measuring quality of anticoagulation control, perhaps future 
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work could include this method alongside with the TTR via the Rosendaal and PINRR methods 
and investigate the correlation between these methods. While TTR measures anticoagulation 
intensity, INR variability measures anticoagulation stability and both methods have been 
shown to predict warfarin related adverse outcomes (460). However, to date, insufficient 
evidence exist regarding which method is better in predicting adverse events, thus this would 
be an area for future research.  
Guidelines on antithrombotic management in operated VHD were based on observational 
studies with small sample sizes and expert opinions. For example, there is as yet no 
agreement about the optimal level of anticoagulation intensity (INR targets) in different patient 
populations in order to have the net-clinical benefit of avoiding stroke and bleeding 
complications. Thus, future work with larger sample sizes (>1000) and prospective study 
designs is needed to provide greater insights into this population so that better management 
strategies can be provided to patients.  
4.6 Conclusion 
Operated VHD patients with AF at baseline have poorer anticoagulation control compared to 
those without AF at baseline. The presence of concomitant AF, anaemia/bleeding history, as 
well as female gender, independently predicted poor TTR.  The rate of all-cause mortality was 
significantly higher among operated VHD patients with AF. These findings suggest closer INR 
monitoring among operated VHD patients, especially those with AF is warranted, to improve 
anticoagulation and prevent adverse clinical outcomes.  
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Chapter 5. General discussion and conclusions 
 
Overall, this thesis included prospective (TREAT-2 study) and retrospective (study 2 and 3) 
studies primarily based on one acute Trust in the West Midlands.  
 
Study 1 (TREAT-2 study) included newly anticoagulated AF patients (warfarin or NOACs) 
whereas studies 2 and 3 comprised AF and operated VHD patients on long term VKA therapy 
for the prevention of thromboembolic complications. The TREAT-2 study examined self-
reported assessment of psychological measures, knowledge, beliefs and quality of life in AF 
patients new to OAC therapy. In contrast, studies 2 and 3 investigated objective measures of 
anticoagulation control (TTR) in AF patients in a multi ethnic population, inclusive of the elderly 
and patients with different categories of chronic kidney disease and operated VHD patients 
with and without AF. In addition, the prevalence of adverse clinical outcomes was also 
explored in studies 2 and 3. These studies were conducted in separate cohorts in order to 
achieve the objectives stated in section 1.8. However, for Study 1, due to a change in clinical 
practice regarding the prescription of a NOAC instead of warfarin since 2016, there were 
insufficient patients initiated on warfarin therapy within the Trust.  Therefore, the comparison 
of the impact of the TREAT-2 intervention on TTR among warfarin-treated patients could not 
be examined.  The main findings of the studies are summarised below:  
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Study 1 (TREAT-2) main findings: 
• Newly anticoagulated AF patients did not appear to be depressed or anxious, had poor 
knowledge of AF and its treatment and poor quality of life. Despite this, they had a 
positive perception regarding their medication 
• These findings remained unchanged during follow up at six months. However, more 
patients were aware of the consequences of AF and for some, AF symptoms had 
improved over time 
Study 2 (TTR vs. ethnicity) main findings: 
• Differences in the quality of anticoagulation control were evident amongst different 
ethnic groups but not within elderly populations and patients with different categories 
of kidney disease 
• Despite similar intensity INR-monitoring, South-Asians and Afro-Caribbeans had 
poorer INR control compared to Whites 
• Non-white ethnicity and anaemia remained the strongest independent predictor of poor 
TTR and PINRR after adjustment of demographic and clinical factors 
• CV hospitalisations were more prevalent amongst the South-Asians compared to Afro-
Caribbeans and Whites 
 
Study 3 (TTR in VHD) main findings: 
• Poorer anticoagulation control was seen in operated VHD patients with AF compared 
to those without AF 
• Independent predictors of poor TTR included AF, anaemia/bleeding history and female 
gender 
• Operated VHD patients with AF had higher rates of death compared to those without 
AF 
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Clinical implications 
Results from the TREAT-2 study highlighted some positive aspects and identified areas for 
continued development for newly anticoagulated AF patients. Reassuringly, most patients did 
not report significant levels of depression or anxiety and most patients understood the 
importance of taking OAC. However, there was room for improvement in terms of increasing 
knowledge of AF as a chronic condition and enhancing quality of life.  
 
Findings from Study 2 and 3 suggests that achieving good anticoagulation control is more 
challenging and the prevalence of adverse clinical outcomes is more commonly seen in AF 
patients from ethnic minority groups (Afro-Caribbeans and South-Asians) and among 
operated VHD patients with AF.  In Study 2, non-white ethnicity was a significant independent 
predictor of poor-quality anticoagulation control, while Study 3 identified AF, anaemia/bleeding 
history and female sex as independent predictors of poor TTR among operated VHD patients. 
Therefore, in future, more efforts need be made to engage with patients from these 
populations so that we can fully explore their behaviours and factors contributing to poor INR 
control and develop strategies to optimise TTR and reduce adverse clinical outcomes. 
 
Future research 
 
To date, many countries still use VKA (rather than NOAC) for stroke prevention in AF 
especially within Asian countries and therefore the TREAT-2 study could be conducted in 
these countries. Malaysia, a multi-ethnic country consists of 67.4% Bumiputra (Malays and 
Indigenous Bumiputra), 24.6% Chinese, 7.3% Indians and 0.7% others (461) still uses warfarin 
as the main OAC of choice for stroke prevention in AF as well as the treatment of other 
conditions like venous thromboembolism, pulmonary embolism, mechanical heart valves 
transplantation.  
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A further prospective study/registry in a Malaysian cohort (N>1000 including data from the 
warfarin Medication Therapy Adherence Clinic at regional public hospitals) might further help 
fill the knowledge gap in understanding the impact of ethnicity on quality of anticoagulation 
control and adverse clinical outcomes. Adult AF patients who are newly prescribed with OAC 
therapy (warfarin or NOACs) for:  i) stroke prevention in AF ii) prevention of TE complications 
among operated VHD patients can be included and followed up for 2 years. Demographics 
and clinical determinants of TTR among the Malaysian population can be investigated. 
Furthermore, it would be of interest to examine the impact of herbal medications/products on 
TTR as its usage is extensive among Malaysians due to aggressive promotions by promoters 
of herbal medicines. As mentioned in section 1.5.1.2.1 page 91-92, concomitant use of herbal 
medicines/products with warfarin therapy has resulted in a major safety concern due to 
warfarin-herbal interaction which might potentially increase the risk of thrombosis and bleeding 
complications. Thus, future work in this area is needed. Ancillary analyses might also include 
validation of the SAMe-TT2R2 score in the Malaysian cohort as the score includes non-white 
ethnicity as one of the predictors of anticoagulation control. Exploratory analysis can 
additionally investigate TE and bleeding outcomes in relation to TTR cut off values of ≥70% 
and <70%. Moreover, the incidence of TE, bleeding and mortality between patients prescribed 
with warfarin vs. NOAC could also be investigated at a population level. These analyses can 
be investigated separately among AF and operated VHD patients as data on both cohorts are 
limited in Malaysia. 
 
Studies focusing on patient knowledge, psychological aspects and quality of life in 
anticoagulated patients in Malaysia are lacking. Thus, it would be of essence to investigate 
these elements and extend the TREAT-2 study to the Malaysian anticoagulated AF patients 
managed by the warfarin Medication Therapy Adherence Clinic (more details can be found 
in section 2.5.2, pages 169-170). A similar study (TREATS-AF study) is also being planned 
in Thailand with additional aims of investigating the cost-effectiveness of educational-
behavioural intervention, cross cultural adaptation, acceptance and satisfaction of this 
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intervention among Thai AF patients (MRC grant number: MR/ R020892/1 and personal 
communication with Dr Lane and Professor Lip). 
 
Some patients prescribed long term warfarin therapy may experience worsening or 
improvements of TTR over time as there are likely to be changes in their comorbidities, drug 
therapy, anticoagulation management system, etc. that can influence anticoagulation control 
as stated in section 1.5.1. One recent Italian study (462) has shown that about 20% of their 
NVAF patients (N=1341) showed a worsening in TTR over time (mean follow up 37.7 months) 
and this was associated with increased risk of cardiovascular events [HR 2.1 (95% CI 1.06-
4.14); p=0.03].  Hence, another retrospective longitudinal study could also be designed to 
examine temporal trends in TTR among NVAF patients receiving long-term warfarin therapy 
in a Malaysian cohort. It would be of value to build on this area of interest and determine if 
worsening TTR predicts worse CV outcomes as no study to date has investigated this in a 
Malaysian population.  
 
The information gained from the proposed future research could then be conveyed to key 
stakeholders managing patients on anticoagulation therapy so that appropriate actions can be 
taken to improve their services for the benefits of the patients. Apart from that, these results 
could add to the current body of knowledge in the field of anticoagulation among Asian patients 
as this information is currently limited  
 
Conclusions 
Among newly anticoagulated AF patients, improvements are needed in AF knowledge. 
Although quality of life was reduced, most patients were not significantly anxious or depressed 
and they hold positive beliefs about their medication. Meanwhile, good anticoagulation control 
is more difficult to achieve in non-white AF patients and operated VHD patients with AF. 
Predictors of poor TTR include non-white ethnicity and anaemia in the former and the 
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presence of AF, anaemia and female sex in the latter. Lastly, the prevalence of CV 
hospitalisation was more common in South-Asian patients while mortality rates were higher 
among operated VHD patients with AF.  
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Appendix 1  
Table A1.1 Proforma  
 
RXK number:____________ DOB:___/___/____ 
Age: ____________ 
SEX:          Male           Female   
 
Weight:_______Height:_______ BMI:_____________ BP:  _______                    HR:_________ 
 
Group:        
                    1 AF (warfarin + usual care) 
                    2 AF (NOAC control)  
                    3 AF (warfarin + TREAT) 
                    4 AF (NOAC+ usual care) 
   
 
AF date diagnosed:  ___/____/___OAC type and start date:_____________ 
Paroxysmal 
Persistent 
Long-standing persistent 
Permanent  
 
1. Ethnic origin:____________________ 
2. Education level   
 Primary school  Secondary school  College/university 
   
3. Age of leaving formal education__________________________ 
4. Marital status 
 Married   Separated   Widowed  
 Single    Divorced   
   
5. Past Medical History  
 Hypertension   Diabetes mellitus (DM)  Coronary artery 
disease/myocardial 
infarction/heart 
attack 
 Peripheral arterial disease 
(PAD) 
 Gastritis   Previous 
stroke/transient 
ischemic attack 
(TIA) 
 Asthma   Renal disease, eGFR______  Hepatic disease 
 COPD  DVT/PE  Bleeding event 
 Congestive heart failure 
(CHF), NYHA class_____ 
 EHRA class 
 I(no symptoms) 
 II(mild symptoms-normal activity x affected) 
 III(severe symptoms-NA affected) 
 IV(disabling symptoms) 
 Thyroid disease 
 Others: 
6. Current smoking status  
 Yes   No   Stopped smoking 
past 2 yrs 
   
7. Alcohol use:______________   
8. Medications: 
 
 
 
 
 
 
 
The TREAT-2 study 
  
 
Date of study entry: __________ 
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9. HAS-BLEED score: _____________           
Hypertension 
Abnormal liver/renal(1/2)      
Stroke  
Bleeding             
Labile INR 
Elderly >65     
Drugs/alcohol (1/2)                            
10. CHA2DS2-VASc score:_________ 
CHF 
Hypertension 
Age ≥75 (2)   
Diabetes      
Stroke/TIA/TE (2)     
Vascular Disease     
Age 65-74  
Female      
11. SAMe-TT2R2 score 
Sex (female)  
Age (<60y) 
Medical history  
Treatment 
Tobacco use (within 2 yrs) (2) 
Race (not white) (2) 
Total score 
 
 
 
 
 
 
12. Inclusion criteria  
Adult (>18 years old) 
Women CHA2DS2-VASc score of ≥2 
Men CHA2DS2-VASc score of ≥1 
NVAF 
OAC-naïve 
 
 
 
 
 
 
13. Follow up event and dates 
Stroke 
TIA 
Systemic embolism (PE/DVT) 
Major bleeding ISTH 
CRNMB bleeding ISTH 
CV hospitalisation 
Death  
 
 
 
 
 
 
 
 
14. Pill count NOAC at 6 months  
received all boxes                      not received all boxes      pills left in the box________________ 
 
15. VKA RESULTS 
Anticoagulant used: _____________ 
Start date: _______________End date: __________ 
TTR (Rosendaal): _______________PINRR: __________ 
Days on therapy: _______________Total INR: ___________ 
16. INR<2: ___________INR>3: ___________INR>5: __________INR>8: ________ 
17. Lab results 
 
HB   
Creatinine   
eGFR (ml/min)  
 
ALT/ALP  
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Baseline and 6 months questionnaire 
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BASELINE QUESTIONNAIRE	
 
TREAT-2: Oral anticoagulation in AF 
stratified by SAMe-TT2R2 score 
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This questionnaire asks about your personal knowledge of atrial fibrillation, your beliefs about 
medication, how you feel generally and about your quality of life after being diagnosed with atrial 
fibrillation. 
Please read all the questions or statement carefully. If you are unsure about which response to 
give to a question or statement, please choose the one that appears most appropriate. This is 
often your first response. After you have answered ALL questions, please return them in the pre-
paid envelope given to you with the questionnaires. 
Thank you in advance for your kind cooperation.  
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Today’s date:   
Date of birth:  Age: 
Sex: Male  Female  
Part 1: Background 
For each of the following questions please tick (√) one response. 
 1. Ethnic origin (please tick (√) only one box within one ethnic group) 
White  
 White British 
 Irish  
 Gypsy or Irish Traveller  Other white 
Mixed /multiple ethnic groups 
 White and Black Caribbean  
 Others 
 White and Asians  White and Black 
African 
Asian/Asian British 
 Indian   Bangladeshi   Other Asian 
 Pakistani   Chinese   
Black/African/Caribbean/Black British 
 African   Caribbean   Other Black 
Other ethnic group   
 Arab   Other ethnic group  
   
2. Education level   
 Primary school  Secondary school  College/university 
 What age did you leave full-time education? (please write in age)  
_________________   
3. Marital status: Are you currently (tick (√) one response only) 
 Married   Separated   Widowed  
 Single    Divorced   
   
4.Do you currently smoke? 
 Yes   No   
If no, have you stopped smoking in the last 2 years? Yes    No 
 
Study ID: 
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PART 2:  
This section asks about how you have felt generally over the last 2 weeks. Please read each 
of the statements below.  Please circle one answer for each statement.   
 
 
Over the last 2 weeks, how often have you been 
bothered by any of the following problems? 
 
 
 
Not at  
all 
 
 
 
Several 
days 
 
More 
than half 
the days 
 
 
Nearly       
every 
 day 
1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3. Trouble falling or staying asleep, or sleeping too much 0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself — or that you are a failure   or 
have let yourself or your family down 
0 1 2 3 
7. Trouble concentrating on things, such as reading the 
newspaper or watching television 
0 1 2 3 
8. Moving or speaking so slowly that other people could have 
noticed?  Or the opposite — being so fidgety or restless 
that you have been moving around a lot more than usual 
0 1 2 3 
9. Thoughts that you would be better off dead or of hurting 
yourself in some way 
0 1 2 3 
 
If you have experienced any problems, how difficult have these problems made it for you 
to do your work, take care of things at home, or get along with other people? Please tick 
(√) one of the responses below. 
 
  
Not difficult  
at all 
Somewhat 
 difficult 
Very 
difficult 
Extremely 
difficult      
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This section asks about how you have felt generally over the last 2 weeks. Please read each 
of the statements below.  Please circle one answer for each statement.   
 
 
Over the last 2 weeks, how often have you been 
bothered by any of the following problems? 
 
 
 
Not at  
all 
 
 
 
Several 
days 
 
More 
than half 
the days 
 
 
Nearly       
every 
 day 
1. Feeling nervous, anxious or on edge 0 1 2 3 
2. Not being able to stop or control worrying 0 1 2 3 
3. Worrying too much about different things 0 1 2 3 
4. Trouble relaxing 0 1 2 3 
5. Being so restless that it is hard to sit still 0 1 2 3 
6. Becoming easily annoyed or irritable 0 1 2 3 
7. Feeling afraid as if something awful  
might happen 
0 1 2 3 
 
 
If you have experienced any problems, how difficult have these problems made it for you 
to do your work, take care of things at home, or get along with other people? Please tick 
(√) one of the responses below. 
 
  
Not difficult  
at all 
Somewhat 
 difficult 
Very 
difficult 
Extremely 
difficult  
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This section asks about your knowledge of atrial fibrillation. Please read each of the 
questions below.  Tick (√) one answer for each question.  
  
1. What are the trigger factors for atrial fibrillation?  
 Allergy to grass, animals or house dust   
 Alcohol, coffee or spicy food   
 Noise or loud sounds   
2. Why is it important to take my medication for atrial fibrillation properly?  
 Because the doctor wants me to   
 To prevent severe consequences of the arrhythmia   
 To prevent the possibility of a heart attack or sudden death   
3. If atrial fibrillation is identified without the patient experiencing any complaints, the 
patient should immediately visit the hospital. 
 
 True   
 False   
 Don’t know   
4. What is atrial fibrillation?  
 A heart disease in which the heart is not able to pump a sufficient amount of blood through 
the body 
  
 A blood disorder causing blood clots in the heart   
 An electric disorder in the atria of the heart which results in the heart contracting too fast 
and irregularly 
  
5. Why is oral anticoagulation medication prescribed in certain patients with atrial 
fibrillation? 
 
 To prevent the risk of blood clots which can cause a stroke   
 To make the blood flow more easily through the body   
 To prevent fluid retention in the body   
6. Why should a person using anticoagulation medication be careful with the use of 
alcohol? 
 
 Alcohol increases the retention of fluid in the body resulting in the blood becoming too thin   
 Alcohol causes a blockage of the blood vessels which in turn, slows blood flow to the heart   
 Alcohol influences the effect of the medication and this effects the clotting ability of the 
blood 
  
7. Atrial fibrillation is a rare condition.  
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 True   
 False   
 Don’t know   
   
8. It is particularly risky if a person does not feel his/her atrial fibrillation.  
 True   
 False   
 Don’t know   
9. Which statement with regard to physical exercise is true of patients with atrial 
fibrillation? 
 
 It is important for patients to rest in order to maintain normal heart activity   
 Patients with chronic atrial fibrillation cannot work fulltime   
 It is important to exercise normally within personal limitations   
10. Which statement is true?  
 Atrial fibrillation is life endangering because it can result in a heart attack   
 Atrial fibrillation is completely harmless   
 Atrial fibrillation is harmless if the right medication is taken   
11. What is the function of the anticoagulation clinic?  
 To monitor blood clotting and the number of tablets taken each day   
 To determine if the arrhythmia is present   
 To determine if the patient needs to continue taking oral anticoagulation   
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This section asks about your views on medicines prescribed to you. Please read each of 
the statements and indicate the extent to which you agree or disagree by circling one 
response.  
 Strongly 
disagree 
Disagree Uncertain Agree Strongly 
agree 
1. My health, at present, depends on 
my medicines 1 2 3 4 5 
2. Having to take medicines worries 
me 1 2 3 4 5 
3. My life would be impossible without 
my medicines 1 2 3 4 5 
4. Without my medicines I would be 
very ill 1 2 3 4 5 
5. I sometimes worry about long-term 
effects of my medicines 1 2 3 4 5 
6. My medicines are a mystery to me 1 2 3 4 5 
7. My health in the future will depends 
on my medicines 1 2 3 4 5 
8. My medicines disrupt my life 1 2 3 4 5 
9. I sometimes worry about becoming 
too dependent on my medicines 1 2 3 4 5 
10. My medicines protect me from 
becoming worse 1 2 3 4 5 
11. Doctors use too many medicines 1 2 3 4 5 
12. People who take medicines should 
stop their treatment for a while 
every now and again 
1 2 3 4 5 
13. Most medicines are addictive 1 2 3 4 5 
14. Natural remedies are safer than 
medicines 1 2 3 4 5 
15. Medicines do more harm than good 1 2 3 4 5 
16. All medicines are poisons 1 2 3 4 5 
17. Doctors place too much trust on 
medicines 1 2 3 4 5 
18. If doctors had more time with 
patients they would prescribe fewer 
medicines. 
1 2 3 4 5 
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This section refers to how atrial fibrillation affects your quality of life. Please read each of 
the statements below.  Tick (√) one answer for each statement.  
Are you currently in atrial fibrillation?    Yes    No 
If No, when was the last time you were aware of having had an episode of atrial fibrillation? 
Please tick (√) one answer, which best describes your situation: 
Earlier today 
Within the past week 
Within the past month 
1 month to 1 year ago 
More than 1 year ago 
I was never aware of having atrial fibrillation 
On a scale of 1 to 7, over the past 4 weeks, as a result of your atrial fibrillation, how much were you 
bothered by: (Please circle one number which best describes your situation) 
 
 Not at all 
bothered 
or I did not 
have this 
symptoms 
Hardly 
bothered 
A little 
bothered 
Moderately 
bothered 
Quite a 
bit 
bothered 
 
Very 
bothered 
Extremely 
bothered 
1. Palpitations: 
Heart fluttering, 
skipping or 
racing 
1 2 3 4 5 6 7 
2. Irregular heart 
beat 
1 2 3 4 5 6 7 
3. A pause in heart 
activity 
1 2 3 4 5 6 7 
4. Lightheadedness 
or dizziness 
1 2 3 4 5 6 7 
 Not at all 
limited 
Hardly 
limited 
A little 
limited 
Moderately 
limited 
Quite a 
bit 
limited 
Very 
limited 
Extremely 
limited 
5. Ability to have 
recreational 
pastimes, sports, 
and hobbies 
1 2 3 4 5 6 7 
6. Ability to have a 
relationship and 
do things with 
friends and 
family 
1 2 3 4 5 6 7 
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 No 
difficulty 
at all 
Hardly 
any 
difficulty 
A little 
difficulty 
Moderate 
difficulty  
Quite a 
bit of 
difficulty 
A lot of 
difficulty 
Extreme 
difficulty 
7. Doing any activity 
because you felt 
tired, fatigued, or 
low on energy 
1 2 3 4 5 6 7 
8. Doing physical 
activity because of 
shortness of breath 
1 2 3 4 5 6 7 
9. Exercising 1 2 3 4 5 6 7 
10. Walking briskly 1 2 3 4 5 6 7 
11. Walking briskly 
uphill or carrying 
groceries or other 
items, up a flight of 
stairs without 
stopping 
1 2 3 4 5 6 7 
12. Doing vigorous 
activities such as 
lifting or moving 
heavy furniture, 
running, or 
participating in 
strenuous sports 
like tennis or 
racquetball 
1 2 3 4 5 6 7 
 Not at all 
bothered  
Hardly 
bothered 
A little 
bothered 
Moderately 
bothered 
Quite a 
bit 
bothered 
Very 
bothered 
Extremely 
bothered 
13. Feeling worried or 
anxious that your 
atrial fibrillation can 
start anytime 
1 2 3 4 5 6 7 
14. Feeling worried that 
atrial fibrillation may 
worsen other medical 
conditions in the long 
run 
1 2 3 4 5 6 7 
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 Not at all 
bothered  
Hardly 
bothere
d 
A little 
bothered 
Moderately 
bothered 
Quite a bit 
bothered 
Very 
bothered 
Extremely 
bothered 
15. Worrying about 
the treatment 
side effects from 
medications 
1 2 3 4 5 6 7 
16. Worrying about 
complications or 
side effects from 
procedures like 
catheter 
ablation, 
surgery, or 
pacemakers 
therapy 
1 2 3 4 5 6 7 
17. Worrying about 
side effects of 
blood thinners 
such as 
nosebleeds, 
bleeding gums 
when brushing 
teeth, heavy 
bleeding from 
cuts, or bruising. 
1 2 3 4 5 6 7 
18. Worrying or 
feeling anxious 
that your 
treatment 
interferes with 
your daily 
activities 
1 2 3 4 5 6 7 
 Extremely 
satisfied 
Very 
satisfied 
Somewha
t  
satisfied 
Mixed with 
satisfied 
and 
dissatisfie
d 
Somewha
t 
dissatisfi
ed 
Very 
dissatisfi
ed 
Extremely 
dissatisfi
ed 
19. How well your 
current 
treatment 
controls your 
atrial fibrillation? 
1 2 3 4 5 6 7 
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20. The extent to 
which treatment 
has relieved 
your symptoms 
of atrial 
fibrillation? 
1 2 3 4 5 6 7 
 
 
 
Thank you for completing the questionnaires.  Please return them in the stamped-
addressed envelope provided. 
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Appendix 3  
 Table A3.1: Baseline psychological measures, knowledge and beliefs about medication of AF patients overall and in Group 
1, 2, 3 and 4 
 SAMe-TT2R2 0-2 SAMe-TT2R2 >2 
Baseline measures Overall, 
N=139 
Group 1 
N=9 
Group 2 
N=102 
Group 3 
N=4 
Group 4 
N=24 
PHQ-9 (9 items; scores range from 0-27) 
Median (IQR) score 4.0 (1.0-8.0) 2.0 (0.5-4.0) 4.0 (1.0-8.0) 2.5 (0-16.3) 5.0 (2-11) 
Minimal 0-4, (%)  80 (57.6) 8 (88.9) 59 (57.8) 2 (50.0) 11 (45.8) 
Mild 5-9, (%) 31 (22.3) 1 (11.1) 24 (23.5) 1 (25.0) 5 (20.8) 
Moderate 10-14, (%) 20 (14.4) 0 13 (12.7) 0 7 (29.2) 
Moderately severe 
15-19, (%) 
5 (3.6) 0 5 (4.9) 0 0 
Severe depression 
20-27, (%) 
3 (2.2) 0 1 (1.0) 1 (25.0) 1 (4.2) 
GAD-7 (7 items; scores range from 0-21) 
Median (IQR) score  1.0 (0-5) 0 1.0 (0-2.5) 3.0 (0.3-20.3) 1.0 (0-7.8) 
Minimal 0-4, (%) 100 (71.9) 8 (88.9) 74 (72.5) 2 (50.0) 16 (66.7) 
Mild 5-9, (%) 23 (16.5) 0 18 (17.6) 1 (25.0) 4 (16.7) 
Moderate 10-14, (%) 8 (5.8) 1 (11.1) 5 (4.9) 1 (25.0) 1 (4.2) 
Severe anxiety 15-
21, (%) 
8 (5.8) 0 5 (4.9) 0 3 (12.5) 
AF knowledge scale (11 items; scores range from 0-11) 
Total scores, mean 
(SD) (min-max: 0-11) 
5.7 (1.7) 6.8 (1.4) 5.5 (1.7) 6.8 (1.0) 6.0 (1.6) 
Total scores, 0-100% 52.0 (15.4) 61.6 (12.7) 50.2 (15.5) 61.4 (8.7) 54.5 (14.9) 
AF in general correct 
score, % (3 
questions) 
24.5 (22.9) 29.6 (33.3) 22.5 (22.6) 41.7 (16.7) 27.8 (23.4) 
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Baseline measures Overall, 
N=139 
Group 1 
N=9 
Group 2 
N=102 
Group 3 
N=4 
Group 4 
N=24 
AF symptoms 
recognition correct 
score, % (3 
questions) 
46.5 (32.0) 55.6 (33.3) 43.8 (32.5) 58.3 (31.9) 52.8 (29.4) 
AF treatment correct 
score, % (5 
questions) 
71.8 (20.5) 84.4 (16.7) 70.6 (21.0) 75.0 (25.2) 71.7 (18.6) 
Beliefs about medication (BMQ; 18 items) 
BMQ general (scores range from 4-20) 
General overuse  
(4-20) 
10.5 (2.9) 10.1 (3.1) 10.5 (2.9) 11.3 (2.5) 10.9 (3.1) 
General harm  
(4-20) 
8.6 (2.9) 6.7 (0.9) 8.6 (2.9) 9.0 (9.5) 9.1 (2.9) 
BMQ specific (scores range from 5-25) 
Specific necessity  
(5-25) 
19.0 (3.0) 19.1 (2.8) 18.9 (3.1) 19.3 (1.7) 19.3 (3.0) 
Specific concern  
(5-25)* 
13.3 (3.5) 12.4 (2.7) 13.1 (3.5) 11.8 (3.1) 14.5 (3.7) 
Necessity-concern 
differential 
5.7 (4.2) 6.7 (4.2) 5.8 (4.2) 7.5 (3.7) 4.9 (4.1) 
AFEQT (20 items; scores range from 0-100) 
Symptoms (0-100)* 79.2 (58.3-95.8) 58.3 (41.7-97.9) 83.3 (62.5-96.9) 62.5 (38.5-92.7) 62.5 (50.0-86.5) 
Daily activity (0-100)  60.4 (39.6-79.2) 68.8 (31.3-80.2)  60.4 (39.6-81.3) 35.5 (27.6-95.8) 59.4 (37.0-68.2) 
Treatment concern 
(0-100)* 
75.0 (52.8-86.1) 77.8 (72.2-84.7) 75.0 (55.6-91.7) 68.1 (50.0-75.7) 65.3 (25.0-83.3) 
Satisfaction (N=111) 
(0-100)* 
75.0 (66.7-83.3) 75.0 (60.4-89.6) 75.0 (66.7-83.3) 58.3 (50.0-) 70.8 (50.0-83.3) 
Overall global score 
(0-100)* 
 66.7 (53.7-77.8) 59.3 (50.9-80.1) 66.7 (54.4-83.3) 65.7 (38.7-87.3) 63.9 (39.1-74.8) 
*mean (SD); PHQ-9: Patient Health Questionnaire to measure depression; GAD-7: Generalised Anxiety Disorder to measure anxiety; AF knowledge scale to measure 
knowledge of atrial fibrillation; BMQ: beliefs about medication questionnaire; AFEQT: Atrial Fibrillation Effect on Quality of Life Questionnaire 
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 Table A3.2: Six month-follow up psychological measures, knowledge and beliefs about medication of AF patients overall 
and in Group 1, 2, 3 and 4 
 SAMe-TT2R2 0-2 SAMe-TT2R2 >2 
Follow up 
measures 
Overall, 
N=105 
Group 1 
N=7 
Group 2 
N=80 
Group 3 
N=2 
Group 4 
N=16 
PHQ-9 (9 items; scores range from 0-27) 
Median score (IQR) 4.0 (0.0-9.0) 3.0 (0-8.0) 4.0 (0-9.0) 2.0 (0-0) 5.0 (0.7-9.5) 
Minimal 0-4, (%)  56 (54.4) 5 (71.4) 44 (55.0) 2 (50.0) 7 (43.8) 
Mild 5-9, (%) 25 (24.3) 1 (14.3) 19 (23.8) 1 (25.0) 5 (31.3) 
Moderate 10-14, (%) 15 (14.6) 0 12 (15.0) 0  3 (18.8) 
Moderately severe 
15-19, (%) 
6 (5.8) 1 (14.3) 4 (5.0) 0 1 (6.3) 
Severe depression 
20-27, (%) 
1 (1.0) 0 1 (1.3) 1 (25.0) 0 
GAD-7 (7 items; scores range from 0-21) 
Median score (IQR) 1.0 (0-5.0) 0 (0-5) 1.0(0-5.8) 0 (0-5) 1.0 (0-4.8) 
Minimal 0-4, (%) 68 (66.0) 4 (57.1) 52 (65.0) 2 (50.0) 12 (75.0) 
Mild 5-9, (%) 25 (24.3) 2 (28.6) 21 (26.3) 1 (25.0) 2 (12.5) 
Moderate 10-14, (%) 6 (5.8) 0 5 (6.3) 1 (25.0) 1 (6.3) 
Severe anxiety 15-
21, (%) 
1.0 (1.0) 1 (14.3) 2 (2.5) 0 1 (6.3) 
AF knowledge scale (11 items; scores range from 1-11) 
Total scores, mean 
(SD) (min-max: 0-11) 
5.9 (1.9) 7.0 (1.3) 5.9 (1.8) 7.0 (1.4) 5.4 (2.1) 
Total scores, 0-100% 53.9 (16.9) 63.6 (11.7) 53.6 (16.6) 63.6 (12.9) 49.4 (19.3) 
AF in general correct 
score, % (3 
questions) 
 18.4 (22.6)  9.5 (16.3) 18.3 (22.4) 16.7 (23.6) 23.0 (26.4) 
AF symptoms 
recognition correct 
score, % (3 
questions) 
54.3 (31.4)  71.4 (40.5) 54.2 (31.5) 50.0 (23.6) 47.9 (27.1) 
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Follow up 
measures 
Overall, 
N=105 
Group 1 
N=7 
Group 2 
N=80 
Group 3 
N=2 
Group 4 
N=16 
AF treatment correct 
score, % (5 
questions) 
74.9 (24.2) 91.4 (15.7) 74.5 (22.5) 100  66.3 (31.6) 
BMQ (18 items) 
BMQ general (scores range from 5-25) 
General overuse  
 (4-20)* 
10.7 (2.9) 10.7 (1.1) 11.0 (2.9) 11.0 (2.8) 9.3 (3.0) 
General harm  
 (4-20)* 
8.2 (2.4) 8.4 (1.4) 8.3 (2.4) 8.5 (0.7) 7.8 (2.8) 
BMQ specific (scores range from 4-20) 
Specific necessity (5-
25)* 
19.1 (3.1) 18.6 (1.3) 19.0 (3.0) 19.5 (2.1) 19.5 (4.1) 
Specific concern  
(5-25)* 
12.9 (3.8) 14.0 (4.7) 12.8 (3.8) † 13.2 (3.7) 
Necessity-concern 
differential 
6.1 (4.4) 4.6 (4.3) 6.2 (4.2) 8.5 (2.1) 6.3 (5.3) 
AFEQT (20 items; scores range from 0-100) 
Symptoms*  
(0-100) 
 83.3 (64.6-100) 75.0 (50.0-95.8)  87.5 (66.7-100) 79.2 (58.3-.) 68.8 (53.1-79.2) 
Daily activity*  
(0-100) 
54.2 (34.4-77.1) 66.7 (20.8-85.4) 54.2 (35.4-80.7) 46.9 (22.9-.) 49.0 (29.2-69.8) 
Treatment concern * 
(0-100) 
72.2 (58.3-88.9) 72.2 (41.7-83.3) 72.2 (59.0-88.2) 81.9 (63.9-.) 69.4 (35.4-97.2) 
Satisfaction*   
(0-100) 
83.3 (66.7-91.7) 66.7 (66.7-83.3) 83.3 (66.7-91.7) 91.7 (91.7-91.7) 83.3 (68.8-83.3) 
Overall global score*  
(0-100) 
66.7 (49.1-81.9) 77.1 (38.0-83.3) 69.0 (50.9-83.1) 65.7 (56.5-.) 61.6 (43.9-70.0) 
 
*mean (SD); †Patients in Group 3 did not answer; PHQ-9: Patient Health Questionnaire to measure depression; GAD-7: Generalised Anxiety Disorder to measure 
anxiety; AF knowledge scale to measure knowledge of atrial fibrillation; BMQ: beliefs about medication questionnaire; AFEQT: Atrial Fibrillation Effect on Quality of 
Life Questionnaire 
 
 
299 
Appendix 4 
Table A4.1: Project proforma: Ethnic differences in anticoagulation control among atrial fibrillation patients 
receiving warfarin for stroke prevention 
Demographics 
RXK number: ______________ DOB:                  ____/___/____Ethnic origin: _______________ 
Patient number: ______________            Age: ____  Sex:       M □     F □ 
Clinical information        
AF date diagnosed: _________________            VKA naïve:   yes □  no □     
- Paroxysmal □       
- Persistent □        
- Long-standing persistent         □ 
- Permanent □       
Past Medical History Details:                      Date diagnosed 
Valvular heart disease □ Mitral stenosis   □ 
Valve 
replacement   □ Rheumatic  □         _____ 
Stroke   
 
□  Ischaemic   □  Haemorrhagic   □   
_____
_____ 
TIA 
 
□  Total_________      
_____
_____ 
History of TE 
 
□        
Coronary artery disease □ MI □ CABG □ PCI               □  
_____
_____ 
Heart failure □ HF-PEF  □ HF-REF  □ EF ______ %  
_____
_____ 
Hypertension □ Essential □ Secondary  □   
_____
_____ 
Diabetes □ Type 1    □ Type 2       □   
_____
_____ 
Lung disease □ Obstructive  □ Restrictive  □   
_____
_____ 
Vascular disease □ PAD □ Aortic Plaque □  MI                □  
_____
_____ 
Cardiomyopathy □ Dilated  □ Hypertrophic  □   
_____
_____ 
Kidney disease □ <60 ml/ml □ <30 ml/min □ Dialysis        □  
_____
_____ 
Hypercholesterolemia □       
_____
_____ 
Alcohol     yes □    no □ Current smoker □  Ex-smoker  □   Never smoked □ 
 
Lab results 
Hb 
Egfr 
Creatinine 
Alt 
Alp 
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Clinical Outcomes                      Details:  Yes □   Total________ No □ 
Stroke  □  Total______ Ischaemic  □ Haemorrhagic  □ 
 
__________ 
TIA □  Total______      __________ 
VTE DVT PE 
 
□ First    □ Recurrent   □  ________ 
Bleeding  □ Major  ISTH* □ CR Non-Major ** □ NCR □ ________ 
Hospitalisation □         
- CV cause 
□    ________________________ 
□     ________________________ 
□     ________________________ 
 Total__________   __________ 
- Bleeding cause  Total__________   __________ 
- Stroke/TIA cause  Total__________   __________ 
Other cause hospitalization □      __________________________________________________________________ 
Death  □ Cause: ______________________________Date: ____/____/____ 
Baseline medication list          Date: Most recent medication list     Date: 
1. 1. 
2. 2. 
3. 3. 
4. 4. 
5. 5. 
6. 6. 
7. 7. 
8. 8. 
9. 9. 
10. 10. 
VKA results         
Anticoagulant used:__________________ Start date: ____/____/____              End date: ____/____/____ 
Average dose: ________       
Target INR range: _______       
TTR Rosendaal:_________  %INR range:_____      
Days on therapy: ____________ Total INRs:_______      
INR<2:  _________   INR>3: ____________ INR>5:__________ INR>8:___________     
        
*Major Bleeding: fatal bleeding and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular 
with compartment syndrome and/or bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells; 
Clinically relevant non-major bleeding (CRNMB): clinically overt bleeding not satisfying the criteria for major bleeding and that led to hospitalisation, physician medical or surgical treatment, 
or a change in antithrombotic therapy 
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INR Recordings             Patient number _____________          Hospital number___________ 
 
DATE INR DOS
E 
 
DATE INR DOSE 
 
DATE INR DOSE 
1.    35.    69.    
2.    36.    70.    
3.    37.    71.    
4.    38.    72.    
5.    39.    73.    
6.    40.    74.    
7.    41.    75.    
8.    42.    76.    
9.    43.    77.    
10.    44.    78.    
11.    45.    79.    
12.    46.    80.    
13.    47.    81.    
14.    48.    82.    
15.    49.    83.    
16.    50.    84.    
17.    51.    85.    
18.    52.    86.    
19.    53.    87.    
20.    54.    88.    
21.    55.    89.    
22.    56.    90.    
23.    57.    91.    
24.    58.    92.    
25.    59.    93.    
26.    60.    94.    
27.    61.    95.    
28.    62.    96.    
29.    63.    97.    
30.    64.    98.    
31.    65.    99.    
32.    66.    100.    
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 Table A4.2: Logistic regression for TTR<70% (using Rosendaal method) in relation to demographic and clinical factors 
 Univariate OR (95% CI) p-value Multivariate OR (95% CI) p-value 
Age at first INR¥  0.99 (0.98-1.0) 0.11 0.99 (0.97-1.0) 0.12 
Female sex 1.05 (0.82-1.36) 0.69 1.21 (0.87-1.68) 0.26 
Smoking history 1.05 (0.78 -1.42) 0.73 1.27 (0.91-1.77) 0.16 
Ethnicity (non- white) 2.44 (1.72-3.47) <0.001 2.62 (1.67-4.10) <0.001 
Hypertension  0.85 (0.62-1.16) 0.29 0.83 (0.56-1.27) 0.35 
Stroke/TIA  0.69 (0.50-0.96) 0.027 0.82 (0.55-1.22) 0.33 
Heart failure 1.60 (1.10-2.33) 0.014 1.45 (0.94-2.24) 0.09 
Diabetes  1.10 (0.81-1.50) 0.55  0.76 (0.51-1.13) 0.17 
Vascular disease 1.83 (1.28-2.61) 0.001  1.81 (1.16-2.83) 0.01 
Kidney disease 1.01 (0.78-1.31) 0.93  0.97 (0.69-1.35) 0.85 
Anaemia 1.96 (1.34-2.85) <0.001  1.65 (1.00-2.70) 0.05 
Bleeding history 1.51 (0.93- 2.43) 0.09  1.51 (0.83-2.75) 0.17 
 
 
¥continuous variable 
INR: international Normalised Ratio; TIA: transient ischemic attack TTR: Time in therapeutic range 
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 Table A4.3: Logistic regression for PINRR <70% (using PINRR method) in relation to demographic and clinical factors 
 Univariate OR (95% CI) p-value Multivariate OR (95% CI) p-value 
Age at first INR¥  1.0 (0.98-1.02) 0.79 0.99 (0.97-1.02) 0.58 
Female sex 1.17 (0.81-1.68) 0.40 0.98 (0.62-1.56) 0.95 
Smoking history 0.79 (0.52-1.21) 0.28 0.94 (0.60-1.49) 0.80 
Ethnicity (non- white) 3.34 (1.72-6.49) <0.001 3.47 (1.44-8.34) 0.005 
Hypertension  0.90 (0.57-1.41) 0.64 0.80 (0.45-1.43) 0.45 
Stroke/TIA  1.21 (0.75-1.98) 0.44 1.17 (0.66-2.08) 0.59 
Heart failure 1.30 (0.75-2.26) 0.36 1.31 (0.70-2.45) 0.40 
Diabetes  1.55 (0.95-2.54) 0.08 0.98 (0.55-1.78) 0.96 
Vascular disease 1.07 (0.65-1.74) 0.80 0.87 (0.47-1.60) 0.65 
Kidney disease 0.79 (0.55-1.14) 0.21 0.66 (0.42-1.05) 0.08 
Anaemia 2.45 (1.26-4.79) 0.009 6.27 (1.89-20.94) 0.003 
Bleeding history 1.50 (0.71-3.19) 0.29 1.0 (0.40-2.54) 0.98 
¥continuous variable 
INR: international Normalised Ratio; TIA: transient ischemic attack; PINRR: Percentage of INRs within range 
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 Table A4.4: Cox proportional hazard regression analysis for the outcome of thromboembolic events (including stroke, 
transient ischaemic attack and pulmonary embolism) 
 Univariate HR (95% CI) p-value Multivariate p-value 
Age¥  0.99 (0.96-1.02) 0.51 0.97 (0.94-1.01) 0.16 
Female sex 0.82 (0.46-1.45) 0.50 0.59 (0.28-1.23) 0.16 
Smoking history 0.67 (0.33-1.33) 0.17 0.61 (0.28-1.30) 0.20 
Ethnicity (non- white) 1.43 (0.73-2.80) 0.29 1.14 (0.49-2.68) 0.76 
Hypertension  1.26 (0.61-2.60) 0.53 1.12 (0.44-2.85) 0.81 
Stroke/TIA history 2.40 (1.33-4.30) 0.003 2.29 (1.12-4.68) 0.02 
Heart failure 0.86 (0.37-2.01) 0.73 0.83 (0.31-2.19) 0.70 
Diabetes  2.01 (1.11-3.65) 0.021 1.85 (0.85-4.01) 0.12 
Vascular disease 1.08 (0.51-2.30) 0.84 1.33 (0.56-3.19) 0.52 
Kidney disease 1.54 (0.88-2.69) 0.13 1.42 (0.69-2.93) 0.34 
Anaemia 1.79 (0.89-3.58) 0.10 1.24 (0.47-3.30) 0.67 
Bleeding history 1.27 (0.46-3.52) 0.65 0.76 (0.17-3.36) 0.72 
TTR (continuous) 0.99 (0.97-1.01) 0.20 0.98 (0.96-1.01) 0.15 
TTR <70% 1.56 (0.88-2.79) 0.13 -  
PINRR (continuous) 0.98 (0.96-1.01) 0.19 -  
PINRR <70%  1.17 (0.52-2.60) 0.70 -  
¥ Continuous variable 
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 Table A4.5: Cox- proportional hazard regression analysis for all bleeding event, including major bleed and clinically 
relevant non-major bleed 
 Univariate HR (95% CI) p-value Multivariate HR  
(95% CI) (Model 1)* 
p-value Multivariate HR  
(95% CI) (Model 2)# 
p-value 
Age¥   1.03 (1.01-1.06) 0.016  1.02 (0.99-1.06) 0.14 1.02 (0.99-1.06) 0.13 
Female sex  0.92 (0.58-1.45) 0.71  0.85 (0.48-1.50) 0.58 0.82 (0.47-1.44) 0.49 
Smoking history  0.86 (0.51-1.45) 0.57  0.91 (0.52-1.61) 0.74 0.90 (0.51-1.59) 0.71 
Ethnicity (non- white)  1.13 (0.64-2.02) 0.67  0.96 (0.47-1.96) 0.90 0.97 (0.48-1.96) 0.93 
Hypertension   1.31 (0.73-2.33) 0.37  1.53 (0.71-3.31) 0.28 1.49 (0.69-3.21) 0.31 
Stroke/TIA history  1.10 (0.63-1.93) 0.74  1.09 (0.56-2.12) 0.80 1.10 (0.57-2.15) 0.77 
Heart failure  1.38 (0.78-2.47) 0.27  1.68 (0.89-3.19) 0.11 1.71 (0.90-3.22) 0.10 
Diabetes   1.18 (0.69-2.02) 0.54  0.95 (0.48-1.86) 0.87 0.93 (0.47-1.83) 0.84 
Vascular disease  0.97 (0.51-1.83) 0.92  0.83 (0.38-1.81) 0.63 0.78 (0.36-1.71) 0.53 
Kidney disease  0.92 (0.57-1.47) 0.72  0.63 (0.35-1.14) 0.12 0.63 (0.35-1.13) 0.12 
Anaemia  1.46 (0.80-2.65) 0.22  1.64 (0.77-3.52) 0.20 1.61 (0.75-3.46) 0.22 
Bleeding history  1.48 (0.68-3.23) 0.32  1.05 (0.40-2.79) 0.92 1.04 (0.39-2.75) 0.94 
TTR (continuous)  0.98 (0.97-0.998) 0.026  0.98 (0.97-1.00) 0.08 -  
TTR <70%  1.52 (0.95-2.42) 0.08 -  1.78 (1.01-3.13) 0.05 
PINRR (continuous)  0.97 (0.95-0.99) 0.003 -  -  
PINRR <70%  2.03 (0.93-4.42) 0.07 -  -  
¥continuous variable 
*Model 1: excluding PINRR continuous, TTR category and PINRR category, #Model 2: excluding TTR continuous, TTR category, PINRR category 
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 Table A4.6: Cox- proportional hazard regression analysis for cardiovascular hospitalisation 
  Univariate HR  
(95% CI) 
p-value Multivariate* HR  
(95% CI) (Model 1) 
p-value Multivariate# HR  
(95% CI) (Model 2) 
p-value 
Age ¥ 0.99 (0.98-1.01) 0.41  0.99 (0.97-1.01) 0.23  0.99 (0.97-1.01) 0.23 
Female sex 0.97 (0.74-1.26) 0.81  1.04 (0.76-1.44) 0.80  1.03 (0.75-1.41) 0.87 
Smoking history 0.88 (0.66-1.18) 0.40  0.88 (0.64-1.22) 0.45  0.89 (0.64-1.23) 0.48 
Ethnicity (non- white) 1.66 (1.22-2.25) 0.001  1.24 (0.85-1.81) 0.27  1.29 (0.89-1.89) 0.18 
Hypertension  1.31 (0.93-1.85) 0.12  0.95 (0.65-1.38) 0.77  0.93 (0.64-1.35) 0.68 
Stroke/TIA history 1.12 (0.80-1.55) 0.51  1.13 (0.78-1.63) 0.51  1.13 (0.78-1.63) 0.52 
Heart failure 1.76 (1.27-2.42) 0.001  1.45 (1.00-2.09) 0.05  1.46 (1.02-2.11) 0.04 
Diabetes  1.37 (1.01-1.86) 0.042  1.15 (0.80-1.65) 0.45  1.14 (0.79-1.63) 0.49 
Vascular disease 2.17 (1.61-2.93) <0.001  1.64 (1.12-2.38) 0.01  1.62 (1.11-2.34) 0.01 
Kidney disease 1.05 (0.80-1.38) 0.71  0.93 (0.67-1.28) 0.64  0.94 (0.68-1.29) 0.68 
Anaemia 1.64 (1.17-2.30) 0.004  1.26 (0.80-1.96) 0.32  1.23 (0.79-1.96) 0.36 
Bleeding history 1.09 (0.65-1.81) 0.75  1.17 (0.66-2.06) 0.50  1.18 (0.67-2.09) 0.56 
TTR (continuous) 0.98 (0.97-0.99) <0.001  0.99 (0.98-0.99) 0.01 -  
TTR <70% 1.61 (1.23-2.12) 0.001 -   1.38 (1.00-1.89) 0.05 
PINRR (continuous) 0.97 (0.96-0.98) <0.001 -  -  
PINRR <70%  2.31 (1.42-3.74) 0.001 -  -  
*TTR continuous; # TTR categorical 
¥continuous variable 
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 Table A4.7: Cox proportional hazard regression analysis for all-cause mortality 
 Univariate HR (95% CI) p-value Multivariate HR (95% CI) p-value 
Age¥  1.09 (1.03-1.14) 0.001  1.06 (0.99-1.13) 0.07 
Female sex 0.66 (0.27-1.61) 0.36  0.86 (0.26-2.86) 0.81 
Smoking history 2.13 (0.73-6.24) 0.17  2.87 (0.86-9.52) 0.09 
Ethnicity (non- white) 0.78 (0.23-2.63) 0.69  1.19 (0.25- 5.79) 0.83 
Hypertension  1.49 (0.51-4.39) 0.47  3.05 (0.39- 24.06) 0.29 
Stroke/TIA history 1.65 (0.65-4.18) 0.29  1.72 (0.52-5.69) 0.38 
Heart failure 0.94 (0.28-3.18) 0.93  0.99 (0.21-4.59) 0.99 
Diabetes  0.94 (0.32-2.76) 0.91  0.65 (0.13-3.21) 0.59 
Vascular disease 1.30 (0.44-3.82) 0.64  1.05 (0.26-4.15) 0.95 
Kidney disease 1.30 (0.56-3.02) 0.54  1.43 (0.48-4.21) 0.52 
Anaemia 2.86 (1.13-7.27) 0.027  3.39 (0.92-12.52) 0.07 
Bleeding history 1.68 (0.39-7.21) 0.48  0.60 (0.07-5.34) 0.65 
TTR (continuous) 0.98 (0.95-1.01) 0.13  0.98 (0.94-1.01) 0.20 
TTR <70% 1.79 (0.73-4.41) 0.21 -  
PINRR (continuous) 0.97 (0.93-1.01) 0.13 -  
PINRR <70%  1.39 (0.41-4.69) 0.60 -  
¥continuous variable 
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 Table A4.8: Cox proportional hazard regression analysis for composite outcome of thromboembolic events, major bleed 
and clinically relevant non-major bleeding, cardiovascular hospitalisation and all-cause mortality (incorporating TTR as 
continuous and categorical variables separately) 
 Univariate HR (95% CI) p-value Multivariate* HR 
(95% CI) (Model 1) 
p-value Multivariate† HR 
(95% CI) (Model 2) 
p-
value 
Age¥  1.0 (0.99-1.01) 0.91 0.99 (0.98-1.00) 0.17 0.99 (0.98-1.00) 0.20 
Female sex 0.92 (0.74-1.15) 0.48 0.93 (0.71-1.22) 0.62 0.91 (0.70-1.20) 0.51 
Smoking history 0.81 (0.63-1.03) 0.09 0.79 (0.60-1.04) 0.09 0.79 (0.60-1.04) 0.09 
Ethnicity (non- white) 1.47 (1.13-1.91) 0.004  1.15 (0.83-1.59) 0.40 1.20 (0.87-1.65) 0.26 
Hypertension  1.36 (1.02-1.81) 0.035  1.09 (0.78-1.52) 0.61 1.06 (0.76-1.48) 0.72 
Stroke/TIA history 1.39 (1.07-1.80) 0.014  1.39 (1.03-1.86) 0.03 1.38 (1.03-1.85) 0.03 
Heart failure 1.51 (1.14-1.99) 0.004  1.28 (0.93-1.76) 0.13 1.30 (0.94-1.78) 0.11 
Diabetes  1.41 (1.10-1.82) 0.008  1.24 (0.92-1.67) 0.16 1.22 (0.91-1.65) 0.19 
Vascular disease 1.93 (1.49-2.50) <0.001  1.69 (1.23-2.33) 0.001 1.67 (1.21-2.30) 0.002 
Kidney disease 1.18 (0.95-1.48) 0.14  0.99 (0.76-1.30) 0.96 1.00 (0.76-1.31) 0.99 
Anaemia 1.69 (1.27-2.24) <0.001  1.32 (0.91-1.91) 0.14 1.28 (0.88-1.85) 0.20 
Bleeding history 1.32 (0.89-1.96) 0.17  1.25 (0.78-1.99) 0.35 1.26 (0.79-2.01) 0.33 
TTR (continuous) 0.98 (0.98-0.99) <0.001  0.99 (0.98-0.99) 0.001 -  
TTR <70% 1.54 (1.23-1.92) <0.001 -  1.45 (1.11-1.89) 0.006 
PINRR (continuous) 0.97 (0.96-0.98) <0.001 -  -  
PINRR <70%  1.99 (1.37-2.88) <0.001 -  -  
*This model considers TTR as continuous variable; † This model considers TTR as categorical variable 
¥continuous variable 
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 Table A4.9: Cox proportional hazard regression analysis for all bleeding events, including major bleeding and clinically 
relevant non-major bleeding including age ≥80 years 
 Univariate Multivariate  
 HR (95% CI) p-value HR (95% CI) p-value 
Age ≥80 years 1.93 (1.16-3.20) 0.01 1.90 (1.01-3.56) 0.047 
Female sex 0.92 (0.58-1.45) 0.71 0.82 (0.47-1.44) 0.49 
Smoking history 0.86 (0.51-1.45) 0.57 0.91 (0.51-1.61) 0.75 
Ethnicity (non- white) 1.13 (0.64-2.02) 0.67 1.01 (0.49-2.05 0.98 
Hypertension  1.31 (0.73-2.33) 0.37 1.54 (0.72-3.31) 0.27 
Stroke/TIA history 1.10 (0.63-1.93) 0.74 1.09 (0.56-2.13) 0.80 
Heart failure 1.38 (0.78-2.47) 0.27 1.71 (0.91-3.24) 0.10 
Diabetes  1.18 (0.69-2.02) 0.54 0.93 (0.47-1.84) 0.84 
Vascular disease 0.97 (0.51-1.83) 0.92 0.78 (0.35-1.77) 0.56 
Kidney disease 0.92 (0.57-1.47) 0.73 0.65 (0.36-1.17) 0.15 
Anaemia 1.46 (0.80-2.65) 0.22 1.67 (0.78-3.61) 0.19 
Bleeding history 1.48 (0.68-3.23) 0.32 0.99 (0.37-2.64) 0.99 
Concomitant antiplatelet therapy 1.47 (0.54-4.03) 0.45 0.92 (0.21-44.06) 0.91 
TTR <70% 1.52 (0.95-2.42) 0.08 1.74 (0.99-3.05) 0.055 
CI: confidence interval; HR: hazard ratio; TIA: transient ischemic attack; TTR: time in therapeutic range 
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 Table A4.10: Cox- proportional hazard regression analysis for composite endpoints of thromboembolic event, bleeding 
event, cardiovascular hospitalisation and all-cause mortality including age ≥80 years 
 Univariate HR (95% CI) p-value Multivariate HR (95% CI) p-value 
Age ≥80 1.10 (0.84-1.45) 0.50 1.00 (0.72-1.39) 0.99 
Female sex 0.92 (0.74-1.15) 0.48 0.90 (0.69-1.18) 0.45 
Smoking history 0.81 (0.63-1.03) 0.09 0.82 (0.62-1.07) 0.14 
Ethnicity (non- white) 1.47 (1.13-1.91) 0.004 1.22 (0.89-1.68) 0.22 
Hypertension  1.36 (1.02-1.81) 0.04 1.05 (0.75-1.46) 0.78 
Stroke/TIA history 1.39 (1.07-1.80) 0.01 1.37 (1.02-1.85) 0.04 
Heart failure 1.51 (1.14-1.99) 0.004 1.32 (0.96-1.82) 0.09 
Diabetes  1.41 (1.10-1.82) 0.008 1.22 (0.91-1.65) 0.19 
Vascular disease 1.93 (1.49-2.50) <0.001 1.53 (1.10-2.14) 0.01 
Kidney disease 1.18 (0.95-1.48) 0.14 0.96 (0.73-1.25) 0.75 
Anaemia 1.69 (1.27-2.24) <0.001 1.27 (0.87-1.83) 0.21 
Bleeding history 1.32 (0.89-1.96) 0.17 1.25 (0.79-1.99) 0.35 
Concomitant antiplatelet therapy 2.50 (1.67-3.73) <0.001 1.36 (0.81-2.30) 0.24 
TTR <70% 1.54 (1.22-1.92) <0.001 1.47 (1.13-1.91) 0.004 
CI: confidence interval; HR: hazard ratio; TIA: transient ischemic attack; TTR: time in therapeutic range 
 
 
311 
 
Appendix 5 
List of ethical approvals: 
Study 1: TREAT-2 study 
1. South Birmingham Research Ethics Committee (REC) 
2. Health Research Authority (HRA)  
3. Confirmation of capacity and capability from Sandwell and West Birmingham 
Hospitals Research and Development (R&D) department 
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